
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM F-1
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933

Collect Biomed Ltd.

(Exact name of Registrant as specified in its charter)

State of Israel
(State or other jurisdiction of
incorporation or organization)

2836
(Primary standard industrial
classification code number)

Not Applicable
(I.R.S. employer
identification number)

**23 Hata'as Street
Kfar Saba, Israel 44425
(+972) (9) 974 1444**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Vcorp Services, LLC
25 Robert Pitt Drive, Suite 204
Monsey, New York 10952
888-528-2677**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

**Oded Har-Even, Esq.
Howard E. Berkenblit, Esq.
Shy S. Baranov, Esq.
Zysman, Aharoni, Gayer and
Sullivan & Worcester LLP
1633 Broadway
New York, NY 10019
Telephone: (212) 660-3000
Facsimilie: (212) 660-3001**

**Ronen Kantor, Esq.
Giora Gutman, Esq.
Eran Lasker, Esq.
Doron Tikotzky Kantor
Gutman Cederboun & Co
12 Abba Hillel Silver Rd.
Ramat Gan, Israel 52506
(+972) (3) 613-3371
(+972) (3) 613-3372
(facsimile)**

Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective. o

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, please check the following box. o

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Proposed maximum aggregate offering price	Amount of registration fee
	\$	\$

Ordinary shares, no par value⁽¹⁾⁽²⁾ (3) (4)

Total Registration Fee \$ _____ \$ _____

-
- (1) The ordinary shares will be represented by American Depositary Shares, or ADSs, each of which represents _____ ordinary shares. We intend to file a separate registration statement on Form F-6 to register the ADSs issuable upon deposit of the ordinary shares.
 - (2) Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the ordinary shares registered hereby also include an indeterminate number of additional ordinary shares as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions.
 - (3) Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. Includes the offering price of shares that the underwriters have the option to purchase to cover over-allotments, if any. Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
 - (4) Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the Securities and Exchange Commission declares our registration statement effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED [], 2016

American Depositary Shares

Each Representing Ordinary Shares



We are offering American Depositary Shares, or ADSs. Each ADS represents of our ordinary shares, no par value, or the ordinary shares. This is our initial public offering in the United States.

Our ordinary shares are currently traded on the Tel Aviv Stock Exchange, or the TASE, under the symbol "CLBD." The last reported sale price of our ordinary shares on the TASE on April 5, 2016 was NIS 1.364, or \$0.359, per share (based on the exchange rate reported by the Bank of Israel on that date, which was NIS 3.802 = \$1.00). There currently is no public market for the ADSs or ordinary shares in the United States. We intend to apply to list the ADSs on the NASDAQ Capital Market under the symbol " ." No assurance can be given that our application will be approved.

The expected public offering price of the ADSs is between \$ and \$ per ADS.

We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, we have elected to take advantage of certain reduced public company reporting requirements for this prospectus and future filings.

Investing in the ADSs involves certain significant risks. See "Risk Factors" beginning on page 10 of this prospectus. You should carefully consider these risk factors, as well as the information contained in this prospectus, before you invest.

None of the U.S. Securities and Exchange Commission, or the SEC, the Israeli Securities Authority, or the ISA, or any other state or foreign regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

	<u>Per ADS</u>	<u>Total</u>
Public offering price	\$	\$
Underwriting discounts and commissions	\$	\$
Proceeds, before expenses, to us	\$	\$

We have granted a -day option to the representative of the underwriters to purchase up to additional ADSs to cover over-allotments, if any.

The underwriters expect to deliver the ADSs to purchasers in the offering on or about , 2016.

Prospectus dated , 2016.

TABLE OF CONTENTS

TABLE OF CONTENTS

<u>PROSPECTUS SUMMARY</u>	<u>1</u>
<u>SUMMARY FINANCIAL DATA</u>	<u>8</u>
<u>RISK FACTORS</u>	<u>10</u>
<u>SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS</u>	<u>33</u>
<u>EXCHANGE RATE INFORMATION</u>	<u>35</u>
<u>PRICE RANGE OF OUR ORDINARY SHARES</u>	<u>36</u>
<u>USE OF PROCEEDS</u>	<u>37</u>
<u>DIVIDENDS AND DIVIDEND POLICY</u>	<u>38</u>
<u>CAPITALIZATION</u>	<u>39</u>
<u>DILUTION</u>	<u>41</u>
<u>SELECTED FINANCIAL DATA</u>	<u>43</u>
<u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	<u>44</u>
<u>BUSINESS</u>	<u>54</u>
<u>MANAGEMENT</u>	<u>77</u>
<u>BENEFICIAL OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT</u>	<u>100</u>
<u>RELATED PARTY TRANSACTIONS</u>	<u>102</u>
<u>DESCRIPTION OF SHARE CAPITAL</u>	<u>104</u>
<u>DESCRIPTION OF AMERICAN DEPOSITARY SHARES</u>	<u>110</u>
<u>SHARES ELIGIBLE FOR FUTURE SALE</u>	<u>117</u>
<u>TAXATION</u>	<u>119</u>
<u>UNDERWRITING</u>	<u>127</u>
<u>ENFORCEMENT OF FOREIGN JUDGMENTS</u>	<u>130</u>
<u>EXPENSES RELATING TO THIS OFFERING</u>	<u>131</u>
<u>LEGAL MATTERS</u>	<u>131</u>
<u>EXPERTS</u>	<u>131</u>
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	<u>131</u>
<u>INDEX TO FINANCIAL STATEMENTS</u>	<u>F-1</u>

About This Prospectus

You should rely only on the information contained in this prospectus and any free writing prospectus prepared by, or on behalf of, us or to which we have referred you. Neither we nor the underwriters have authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the underwriters are offering to sell these securities in any jurisdiction where their offer or sale is not permitted. This prospectus is not an offer to sell or the solicitation of an offer to buy the ADSs in any circumstances under which such offer or solicitation is unlawful. This document may only be used where it is legal to sell these securities. The information in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or when any sale of the ADSs occurs. Our business, financial condition, results of operations and prospects may have changed since that date. Neither we nor the underwriters take any responsibility for, nor do we provide any assurance as to the reliability of, any information other than the information in this prospectus and any free writing prospectus prepared by us or on our behalf. Neither the delivery of this prospectus nor the sale of the ADSs means that information contained in this prospectus is correct after the date of this prospectus.

Before you invest in the ADSs, you should read the registration statement (including the exhibits thereto) of which this prospectus forms a part.

Throughout this prospectus, unless otherwise designated, the terms “we”, “us”, “our”, “Collect”, “the Company” and “our Company” refer to Collect Biomed Ltd. References to “ordinary shares”, “ADSs” and “share capital” refer to the ordinary shares, ADSs and share capital, respectively, of Collect.

Market data and certain industry data and forecasts used throughout this prospectus were obtained from sources we believe to be reliable, including market research databases, publicly available information, reports of governmental agencies and industry publications and surveys. We have relied on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable based on our management’s knowledge of the industry. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the third-party forecasts we cite. Statements as to our market position are based on the most currently available data. While we are not aware of any misstatements regarding the industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading “Risk Factors” in this prospectus. Our financial statements are prepared and presented in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. Our historical results do not necessarily indicate our expected results for any future periods.

Certain figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them.

Unless derived from our financial statements or otherwise noted, the terms “shekels,” “Israeli shekels” and “NIS” refer to New Israeli Shekels, the lawful currency of the State of Israel, and the terms “dollar,” “U.S. dollar,” “US\$,” “USD” or “\$” refer to U.S. dollars, the lawful currency of the United States.

Collect Inside, Apotainer and ApoGraft are our registered trademarks.

[TABLE OF CONTENTS](#)

We have not taken any action to permit a public offering of the ADSs outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of the ADSs and the distribution of this prospectus outside of the United States.

Until _____, 2016 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as an underwriter and with respect to their unsold allotments or subscriptions.

PROSPECTUS SUMMARY

This summary highlights selected information presented in greater detail elsewhere in this prospectus. This summary does not include all the information you should consider before investing in the ADSs. Before investing in the ADSs, you should read this entire prospectus carefully for a more complete understanding of our business and this offering, including our audited and unaudited financial statements and related notes and the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Business Overview

Collect is an emerging biotechnology company that is developing a novel technology platform known as Collect Inside™ that functionally selects stem cells from a mixed population of cells in order to improve the safety and efficacy of regenerative medicine stem cell therapies. We aim to become the standard enabling technology for the enrichment of the stem cell population for companies developing stem cell therapies, physicians practicing regenerative medicine, and for researchers and academia engaged in stem cell research.

We believe our innovative technology platform represents a potential breakthrough in the field of regenerative medicine by using functional selection of stem cells. Efficient selection enables retention of most of the stem cells with few mature cells resulting in the near elimination of toxicity provoking cells coupled with the enrichment of the stem cell population.

Our Collect Inside technology platform takes advantage of a functional characteristic of stem cells relating to apoptosis. Apoptosis is the process of programmed cell death and is a vital part of physiological development and maintenance. Stem cells flourish in an environment where normal cells die. Because of their major role in the reconstitution of damaged tissue, stem cells are attracted to areas of cell death, areas typified by very high levels of apoptotic activity and apoptotic-inducing agents. Our research has demonstrated that stem cells are resistant to apoptotic stimulation by the physiological molecules that cause mature cells to self-destruct. We have chosen this *functional* characteristic of stem cells to use apoptosis-inducing proteins to more efficiently select stem cells while neutralizing harmful cells and their associated medical complications.

We are currently developing our first product based on our Collect Inside technology platform, the Apotainer™ selection kit. The Apotainer selection kit is an easy to use, cost effective, off the shelf stem cell selection kit. The kit is designed for clinical use with the aim of improving the results of human allogeneic (using stem cells from a donor) hematopoietic stem cell transplantation, or HSCT, for the treatment of hematological malignancies (blood cancers such as leukemia and lymphoma). HSCT, also known as bone marrow transplantation, has for decades been curative for many patients with hematological malignancies. Clinical trials have shown that that HSCT can also be used for other indications but is rarely used due to high toxicity. However, application of allogeneic HSCT is limited by graft-versus-host-disease, or GvHD, a condition in which the transplanted immune cells (populating the graft in much higher numbers than the stem cells) recognize the host cells and organs as foreign and attack them. GvHD does not resolve by itself and is the major cause of transplant-related morbidity and mortality. Despite improvements in the outcome of HSCT over recent years through improved supportive care, infection control and use of reduced intensity and reduced toxicity conditioning regimens, HSCT is still associated with significant morbidity and mortality mainly due to GvHD, and as such HSCT is restricted to patients with life threatening diseases. Due to non-efficient selection of stem cells for HSCT, the complex and expensive laboratory process, performed using technologies currently available, is able to reduce toxicity only at a significant tradeoff — graft rejection, cancer reoccurrence and high costs of treatment.

We have chosen allogeneic HSCT for the treatment of hematological malignancies as our first target indication for our Collect Inside technology platform in order to clinically validate that our technology can efficiently select stem cells while eliminating harmful cells and their associated medical complications. We believe that if we are able to demonstrate the clinical utility of our technology for this indication, it will open up the opportunity for the use of our Collect Inside technology platform for the treatment of other indications (e.g., solid organ transplantation and auto-immune diseases) and for the adoption of our Collect Inside technology platform by stem cell therapeutic companies, academia, researchers and others seeking to enrich their stem cell population.

TABLE OF CONTENTS

We plan to bring our Apotainer selection kits to market for HSCT as a combination product subject to the primary jurisdiction of the U.S. Food and Drug Administration's, or FDA, Center for Devices and Radiological Health, or CDRH, which is likely to result in the regulatory path usually followed for medical devices. We believe that this will result in cost savings and reduce time to market and further believe that such proof of concept will open up the opportunity for the licensing of our Collect Inside technology platform to allow for earlier revenues.

All of our research efforts to date have culminated in clinical trials that we plan to commence in 2016 related to a process we call ApoGraft. We plan to initiate the clinical development of ApoGraft with an open-label Phase I/II pilot study. The primary objective of this study is to evaluate the safety and tolerability of ApoGraft administered to subjects with hematological malignancies undergoing allogeneic HSCT. The secondary objective of this trial is to assess ApoGraft engraftment, the donor cells populating patients' hematological systems and prevention of GvHD. In addition, we plan on holding a pre-investigational new drug, or pre-IND, meeting with the FDA in the second half of 2016 using the Apotainer selection kit.

Our Strategy

We have developed a novel technology platform, the Collect Inside technology platform, for the functional selection of adult stem cells. This technology is expected to improve the safety and efficacy of regenerative medicine stem cell therapies and we aim to become the standard enabling technology for the enrichment of the stem cell population for companies developing stem cell therapies and for researchers and academia engaged in stem cell research.

Key elements of our strategy to accomplish this objective include the following:

- **Achieve relatively quick validation of the use of our Collect Inside technology platform in a clinical setting.** We have chosen allogeneic HSCT for the treatment of hematological malignancies as our first target indication for our Collect Inside technology platform in order to clinically validate that our technology can efficiently select stem cells while eliminating harmful cells and their associated medical complications caused by GvHD. While over one million HSCT procedures have been performed by the end of 2012, according to a study published in the Lancet, we believe hematopoietic cells administered to patients undergoing allogeneic HSCT can be therapeutically optimized. Based on our Collect Inside technology platform, we are currently developing the Apotainer, an off the shelf stem cell selection kit which we believe may significantly improve the curative potential of allogeneic HSCT by addressing major complications that currently contribute to the high morbidity and mortality of the procedure resulting from GvHD. We believe that the concomitant reduction of toxicity and increasing efficacy of allogeneic HSCT will allow clinicians to undertake HSCT earlier in the blood cancer treatment protocol.
- **Leverage our scientific, clinical and regulatory expertise to build and advance our Collect Inside technology platform beyond the allogeneic HSCT setting.** Based on the validation of our Apotainer selection kit for clinical use in the allogeneic HSCT setting, we intend to test the kit for solid organ transplantation and auto-immune system disorders (such as Type 1 diabetes, Crohn's disease, psoriasis and lupus). We also intend to develop our Collect Inside technology platform for other sources of stem cells (e.g., cord blood and fat) and other types of stem cells — most notably mesenchymal and neural. We believe that by expanding the various applications, sources and types of stem cells that can be used with our technology, we will establish broad use of our Collect Inside technology platform.
- **Build a diversified product portfolio.** Beginning with the development of our Apotainer selection kit as a combined product or medical device, which we believe will shorten the time to market, we intend to expand our product development and build a diversified product portfolio of Collect Inside products for a broad spectrum of market segments, up to and including all production and research processes for stem cell based products.
- **Selectively engage in strategic partnerships that establish our Collect Inside technology platform as the standard enabling technology for the enrichment of the stem cell population.** We ultimately seek to collaborate with other companies engaged in developing stem

TABLE OF CONTENTS

cell therapies and research by licensing our Collect Inside technology platform to improve their own stem cell expansion and purification processes. As we believe our Collect Inside technology platform will significantly increase the starting amount of stem cells, we believe stem cell therapy companies, as well as physicians, academics, researchers and others that are focused on stem cells, will have a major advantage if our selection process is integrated into their work protocol as the first step in their expansion process.

In the short term, we are currently focused on achieving the following critical milestones:

- **Pathway to first-in-human clinical trial:** We concluded preclinical studies in murines, including safety/toxicity tests as well as calibration and optimization of the materials and the process with a view to commencing a Phase I/II clinical trial in Israel and holding a pre-IND meeting with the FDA during the second half of 2016.
- **Pathway to product prototype:** We are engaged in developing prototypes of our Apotainer selection kit. Recently we demonstrated a proof of concept for the binding of the apoptotic protein to a polymer without impairing the protein's apoptotic activity. We tested a number of polymers and binding methods and selected the one best suited for manufacturing the stem cell selection kits. We aim to complete development of the prototype Apotainer selection kit by the end of 2016, subject to sufficient funding, including in this offering.
- **Patent portfolio enhancement:** We are currently expanding our patent coverage from five to eight patent families.

Our Competitive Strengths

We believe we are well positioned to achieve our corporate and strategic goals based on the following key strengths:

- Efficient, rapid and relatively cheap stem cell selection;
- Enriched stem cell population without depleting engraftment-enhancing and tumor-eradicating T-cells, thus reducing the risk of serious complications while not interfering with engraftment and anti-tumor activity;
- Lower costs per procedure, together with expected reduction in post-transplant treatment and simplified infrastructure needed, which is expected to support significant growth of HSCTs and expanded use in new indications;
- Regulatory strategy utilizing the FDA's medical device regulatory pathway for our initial product is expected to result in shorter development timelines and significantly less cash needed for development;
- Positioned as an enabling technology in the fast growing stem cell therapies market;
- Management team with significant drug development and commercial experience; and
- Strong company-owned IP portfolio.

Risk Factors

Our business is subject to numerous risks, as more fully described in the section titled "Risk Factors" immediately following this prospectus summary. You should read and carefully consider these risks and all of the other information in this prospectus, including the financial statements and the related notes included elsewhere in this prospectus, before deciding whether to invest in the ADSs. In particular, such risks include, but are not limited to, the following:

- We have a history of losses and can provide no assurance of our future operating results;
- We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts;

TABLE OF CONTENTS

- Our product development program is based on a novel functional stem cell selection technology platform and is inherently risky;
- Our Collect Inside technology platform is in an early stage of discovery and development, and we may fail to develop any commercially acceptable or profitable products;
- If the FDA classifies our Apotainer selection kits as a drug, biologic or a combination product subject to the primary jurisdiction of the FDA's Center for Drug Evaluation and Research or the FDA's Center for Biologics Evaluation and Research, we may not be able to obtain the necessary approval to market our Apotainer selection kits or other products based on our Collect Inside technology platform in a timely manner or at all. Even if we do obtain approval, the cost and delay could materially adversely affect our financial condition, results of operations and cash flows;
- Clinical trials necessary to support approval for our Apotainer selection kits or any future products based on Collect Inside technology platform would be expensive and could require the enrollment of large numbers of suitable patients, who could be difficult to identify and recruit. Delays or failures in any necessary clinical trials would prevent us from commercializing our Apotainer selection kits or any future product and could adversely affect our business, operating results and prospects;
- We might be unable to develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever;
- Disruptions in our supply chain could delay the commercial launch of our product candidates;
- We may encounter difficulties in managing our growth. Failure to manage our growth effectively will have a material adverse effect on our business, results of operations and financial condition;
- Our U.S. shareholders may suffer adverse tax consequences if we are characterized as a passive foreign investment company, or PFIC.

Implications of Being an Emerging Growth Company

We qualify as an "emerging growth company," as defined in the JOBS Act. For as long as we are deemed an emerging growth company, we are permitted to and intend to take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies, including:

- an exemption from the auditor attestation requirement in the assessment of our internal controls over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; and
- an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board, or the PCAOB, requiring mandatory audit firm rotation or a supplement to the auditor's report in which the auditor would be required to provide additional information about our audit and our financial statements.

We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth anniversary will occur in _____, 202 . However, if certain events occur prior to the end of such five year period, including if we become a "large accelerated filer," our annual gross revenues exceed \$1.0 billion or we issue more than \$1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

In addition, Section 107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we are choosing to "opt out" of such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is

TABLE OF CONTENTS

required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

Implications of being a Foreign Private Issuer

Upon completion of this offering, we will be subject to the information reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are applicable to “foreign private issuers,” and under those requirements we will file reports with the SEC. As a foreign private issuer, we will not be subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we will be subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, although we intend to report our financial results on a quarterly basis, we will not be required to issue quarterly reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting companies, or individual executive compensation information that is as detailed as that required of U.S. domestic reporting companies. We will also have four months after the end of each fiscal year to file our annual reports with the SEC and will not be required to file current reports as frequently or promptly as U.S. domestic reporting companies. We may also present financial statements pursuant to IFRS instead of pursuant to U.S. generally accepted accounting principles. Furthermore, although the members of our management and supervisory boards will be required to notify the ISA of certain transactions they may undertake, including with respect to our ordinary shares, our officers, directors and principal shareholders will be exempt from the requirements to report transactions in our equity securities and from the short-selling profit liability provisions contained in Section 16 of the Exchange Act. As a foreign private issuer, we will also not be subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In addition, as a foreign private issuer, we will be permitted, and intend, to follow certain home country corporate governance practices instead of those otherwise required under the listing rules of NASDAQ Capital Market, or NASDAQ, for domestic U.S. issuers (See “Risk Factors — Risks Related to the ADSs and the Offering.”) These exemptions and leniencies will reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting companies. We intend to take advantage of the exemptions available to us as a foreign private issuer during and after the period we qualify as an emerging growth company.

Our Corporate Information

Collect Biomed Ltd. was incorporated in Israel in 1986 under the name Montiger Ltd. Between 1986 and 2013, we underwent several name changes, most recently on August 28, 2013, when we changed our name to our current name. Since 1990, our shares have been traded on the TASE.

From October 25, 2012 until July 1, 2013, we did not have any business operations, excluding administrative management. On June 30, 2013, a general meeting of our shareholders approved our merger by way of share exchange with Collect Biotherapeutics Ltd. (renamed from Collect Biotechnology Ltd. during 2016, or Collect Biotherapeutics. As a result of the merger, which closed on July 1, 2013, Collect Biotherapeutics became our fully owned subsidiary and we issued to shareholders of Collect Biotherapeutics 44,887,373 ordinary shares, options (Series 1) exercisable for 227,358 ordinary shares until April 30, 2018 and options (Series 2) exercisable for 341,037 ordinary share (all of such 341,037 options were exercised into ordinary shares), which constituted 85% of our then outstanding share capital on a fully diluted basis.

Collect Biotherapeutics was incorporated in Israel in 2011 for the purpose of developing novel and unique technologies that allow the functional selection of stem cells through the substantial reduction of the complications that exist today in acceptable selection methods and increasing the chances of success of stem cell therapies.

Our principal executive offices are located at 23 Hata’as Street, Kfar Saba, Israel 44425, and our telephone number is (+972) (9) 974-1444. Our website is www.collectbio.com. Information contained on, or accessible through, our website is not incorporated by reference herein and shall not be considered part of this prospectus. Our agent for service of process in the United States is Vcorp Services, LLC, Monsey, New York 10952, and whose telephone number is 888-528-2677.

TABLE OF CONTENTS

THE OFFERING

Offering price	We currently estimate that the initial public offering price in this offering will be between \$ and \$ per ADS.
ADSs offered by us	Up to ordinary shares, represented by ADSs.
Option to purchase additional ADSs	We have granted to the underwriters an option, exercisable within days from the date of this prospectus, to purchase up to an aggregate of additional ADSs solely to cover over-allotments, if any.
Ordinary shares outstanding immediately after this offering	ordinary shares (or ordinary shares if the underwriters exercise their option to purchase additional ADSs in full).
Listing	We intend to apply to list the ADSs on NASDAQ under the symbol “ ”. No assurance can be given that our application will be approved. Our ordinary shares are listed on the TASE under the symbol “CLBD”.
Depository	The Bank of New York Mellon, Depository
The ADSs	Each ADS represents ordinary shares. The depository will hold the ordinary shares underlying your ADSs. You will have rights as provided in the deposit agreement. To better understand the terms of the ADSs, you should carefully read the “Description of American Depositary Shares” section of this prospectus. You should also read the deposit agreement, which is filed as an exhibit to the registration statement that includes this prospectus.
Use of proceeds	We expect that we will receive net proceeds of approximately \$ million from this offering, assuming an initial public offering price of \$ per ADS, which is the midpoint of the estimated range of the initial public offering price, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering for working capital and other general corporate purposes. See “Use of Proceeds”.
Lock-up	We, our directors and our executive officers will agree with the underwriters for this offering that we and they will not sell, transfer or otherwise dispose of any ADSs, ordinary shares or similar Company’s securities for a period of three months after the date of the closing of this offering. See “Shares Eligible for Future Sale” and “Underwriting.”
Risk Factors	You should read the “Risk Factors” section starting on page of this prospectus for a discussion of factors to consider before deciding to invest in our securities.

TABLE OF CONTENTS

The number of ordinary shares that will be outstanding immediately after this offering is based on 81,733,325 ordinary shares outstanding as of April 5, 2016, of which the issuance of 287,769 shares to our Chairman of the board of directors is subject to approval by our shareholders under Israeli law. This number excludes, as of such date:

- 2,686,693 ordinary shares held in treasury;
- 5,443,758 ordinary shares issuable upon the exercise of 5,443,758 options at a weighted average exercise price of NIS 1.39 (\$0.36) per share issuable under the Collect Biomed Ltd. 2014 Global Incentive Option Scheme, or the 2014 Collect Option Plan, and an additional 1,456,242 ordinary shares reserved for future issuance under our 2014 Collect Option Plan;
- 227,358 ordinary shares issuable upon the exercise of 227,358 options at exercise price of NIS 1.00 (\$0.26) per share issued to a consultant;
- 600,000 ordinary shares issuable upon the exercise of 600,000 options at exercise price of NIS 2.10 (\$0.56) per share issued to a consultant;
- 4,723,500 ordinary shares issuable upon the exercise of 4,723,500 options (Series 1) at an exercise price of NIS 1.85 (\$0.47) per share; and
- 1,927,801 ordinary shares issuable upon the exercise of 1,927,801 options (Series A) at an exercise price of NIS 2.1 (\$0.54) per share, of which the issuance of 95,923 options is subject to approval by our shareholders.

Unless otherwise indicated, all information in this prospectus assumes or gives effect to no exercise of outstanding options or warrants described above and the underwriters' over-allotment option.

[TABLE OF CONTENTS](#)**SUMMARY FINANCIAL DATA**

The following tables summarize our financial data. We have derived the summary statements of comprehensive loss data for the years ended 2015, 2014 and 2013 and the statement of financial position as of December 31, 2015 and 2014 from our audited financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future.

Our consolidated financial statements included in this prospectus were prepared in accordance with IFRS, as issued by the International Accounting Standards Board.

The following summary financial data should be read in conjunction with “Management's Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included elsewhere in this prospectus.

Statements of comprehensive loss data⁽¹⁾

	Year ended December 31,			
	2015	2015	2014	2013
	Convenience translation into USD in thousands ⁽²⁾	NIS in thousands		
Research and development expenses	1,510	5,893	3,058	1,062
General and administrative expenses	1,077	4,204	2,491	2,425
Operating loss	2,587	10,097	5,549	3,487
Financial income	(1)	(4)	(37)	(11)
Financial expenses	20	79	39	202
Financial expenses, net	19	75	2	191
Net loss	2,606	10,172	5,551	3,678
Comprehensive loss	2,606	10,172	5,551	3,678
Loss per ordinary share – basic and diluted	0.035	0.137	0.084	0.075
Weighted average number of shares outstanding used to compute basic and diluted loss per share	74,475,109	74,475,109	65,968,768	49,152,886

Statement of financial position

	Year ended December 31,		
	2015	2015	2014
	Convenience translation into USD in thousands ⁽²⁾	NIS in thousands	
Cash and cash equivalents	1,003	3,913	2,122
Marketable securities – short term	2,006	7,829	11,257
Other receivables	106	412	161
Restricted cash	5	20	20
Property, plant and equipment	304	1,187	234
Total assets	3,424	13,361	13,794
Trade payable	119	466	107
Other payables	614	2,394	728
Total liabilities	733	2,860	835
Total shareholders' equity	2,691	10,501	12,959

(1) Data on diluted loss per share were not presented in the financial statements because the effect of the exercise of the options and warrants is anti-dilutive.

(2) Calculated using the exchange rate reported by the Bank of Israel for December 31, 2015 at the rate of one U.S. dollar per NIS 3.902.

[TABLE OF CONTENTS](#)

We prepare our financial statements in NIS. This prospectus contains conversions of NIS amounts into U.S. dollars at specific rates solely for the convenience of the reader. Unless otherwise noted, for the purposes of the presentation of financial data for the period ended on December 31, 2015, all conversions from NIS to U.S. dollars and from U.S. dollars to NIS were made at a rate of 3.902 NIS to \$1.00 U.S. dollar, the daily representative rate in effect as of December 31, 2015. No representation is made that the NIS amounts referred to in this prospectus could have been or could be converted into U.S. dollars at any particular rate or at all.

RISK FACTORS

An investment in our ordinary shares and ADSs involves a high degree of risk. We operate in a dynamic industry that involves numerous risks and uncertainties. You should carefully consider the factors described below, together with all of the other information contained in this prospectus, including the audited financial statements and the related notes included elsewhere in this prospectus, before deciding whether to invest in the ADSs. The following risks may adversely affect our business, financial condition, operating results and cash flows and cause the trading price of the ADSs to decline, and you could lose all or part of your investment. The following risk factors are not the only risk factors facing our Company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

Risks Related to Our Financial Position and Capital Requirements

We are an early stage company with a limited operating history.

Our wholly owned subsidiary commenced operations developing our functional stem cell selection technology, which we refer to as Collect Inside, in 2011. As such, we have a limited operating history and our operations are subject to all of the risks inherent in the establishment of a new business enterprise, including a lack of operating history. We cannot be certain that our business strategy will be successful or that we will be solvent at any particular time. Our likelihood of success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with the establishment of any company. If we fail to address any of these risks or difficulties adequately, our business will likely suffer. Because of the numerous risks and uncertainties associated with developing and commercializing our Collect Inside technology platform, we are unable to predict the extent of any future losses or when we will become profitable, if ever. We may never become profitable and you may never receive a return on an investment in our securities. An investor in our securities must carefully consider the substantial challenges, risks and uncertainties inherent in the attempted development and commercialization of procedures and products in the medical, cell therapy, biotechnology and biopharmaceutical industries. We may never successfully commercialize Collect Inside, and our business may fail.

We have a history of losses and can provide no assurance of our future operating results.

Since 2011, we have been focused on research and development activities with a view to developing our Collect Inside technology platform. We have financed our operations primarily through the sale of equity securities (both in private placements and in public offerings on the TASE) and have incurred losses in each year since our inception. We have historically incurred substantial net losses, including net losses of approximately NIS 10,172,000 in 2015, NIS 5,551,000 in 2014, and NIS 3,678,000 in 2013. As of December 31, 2015, we had an accumulated deficit of approximately NIS 20,402,000. We do not know whether or when we will become profitable. To date, we have not commercialized our technology or generated any revenues and accordingly we do not have a revenue stream to support our cost structure. Our losses have resulted principally from costs incurred in development and discovery activities. The opinion of our independent registered public accounting firm on our audited financial statements as of and for the year ended December 31, 2015 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. We expect to continue to incur losses for the foreseeable future, and these losses will likely increase as we:

- initiate and manage preclinical development and clinical trials for our Apotainer kits;
- implement internal systems and infrastructures;
- seek to license additional technologies to develop;
- hire management and other personnel; and
- move towards commercialization.

TABLE OF CONTENTS

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.

As of December 31, 2015, we had approximately \$1,003,000 in cash and cash equivalents, a working capital of \$2,382,000 and an accumulated deficit of \$5,228,000. As of April 1, 2016, we had sufficient cash and cash deposits to fund operations through the end of the second quarter of 2017 if we do not raise additional capital including through this offering. Since our inception, most of our resources have been dedicated to the development of Collect Inside. In particular, we have expended and believe that we will continue to expend significant operating and capital expenditures for the foreseeable future developing our Collect Inside technology platform and our Apotainer collection kits. These expenditures will include, but are not limited to, costs associated with research and development, manufacturing, conducting preclinical experiments and clinical trials, contracting manufacturing organizations, hiring additional management and other personnel and obtaining regulatory approvals, as well as commercializing any products approved for sale. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company in the United States. Because the outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our Collect Inside technology platform, our Apotainer collection kits and any other future product. In addition, other unanticipated costs may arise. As a result of these and other factors currently unknown to us, upon closing of this offering, we will require additional funds through public or private equity or debt financings or other sources, such as strategic partnerships and alliances and licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. A failure to fund these activities may harm our growth strategy, competitive position, quality compliance and financial condition.

Our future capital requirements depend on many factors, including:

- the number and characteristics of products we develop from our Collect Inside technology platform;
- the scope, progress, results and costs of researching and developing our Collect Inside technology platform and any future products, and conducting preclinical and clinical trials;
- the timing of, and the costs involved in, obtaining regulatory approvals;
- the cost of commercialization activities if any products are approved for sale, including marketing, sales and distribution costs;
- the cost of manufacturing any future product we successfully commercialize;
- our ability to establish and maintain strategic partnerships, licensing, supply or other arrangements and the financial terms of such agreements;
- the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;
- the costs of in-licensing further patents and technologies;
- the cost of development of in-licensed technologies;
- the timing, receipt and amount of sales of, or royalties on, any future products;
- the expenses needed to attract and retain skilled personnel; and
- any product liability or other lawsuits related to any future products.

Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities for our Collect Inside technology platform or delay, limit, reduce or terminate our establishment of sales and marketing capabilities

TABLE OF CONTENTS

or other activities that may be necessary to commercialize our Collect Inside technology platform, our Apotainer collection kits or any future products.

Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

We may seek additional capital through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect shareholder rights and may cause the market price of our shares to decline. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or any products, or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market products that we would otherwise prefer to develop and market ourselves.

Risks Related to Product Development and Regulatory Approval

Our product development program is based on a novel functional stem cell selection technology platform and is inherently risky.

We are subject to the risks of failure inherent in the development of products based on new technologies. The novel nature of our Collect Inside technology platform creates significant challenges in regard to product development and optimization, manufacturing, government regulation, third-party reimbursement, and market acceptance, which makes it difficult to predict the time and cost of any product development and subsequently obtaining regulatory approval. These challenges may prevent us from developing and commercializing products on a timely or profitable basis or at all.

Our Collect Inside technology platform is in an early stage of discovery and development, and we may fail to develop any commercially acceptable or profitable products.

We are concentrating our efforts on developing our first line of products, our Apotainer collection kits, which is based on our Collect Inside technology platform, to improve the safety and efficacy of allogeneic HSCT. To date, we have conducted only in vitro and animal studies. As such, we have yet to develop any products that have been approved for marketing, and our future success depends on the successful development of our Apotainer selection kits for HSCT. There can be no assurance that any development problems we experience in the future related to our technology platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our Apotainer selection kits on a timely or profitable basis, if at all. Our Apotainer selection kits are not expected to be commercially available for several years, if at all.

If the FDA classifies our Apotainer selection kits as a drug, biologic or a combination product subject to the primary jurisdiction of the Center for Drug Evaluation and Research or Center for Biologics Evaluation and Research, we may not be able to obtain the necessary approval to market our Apotainer selection kits or other products based on our Collect Inside technology platform in a timely manner or at all. Even if we do obtain approval, the cost and delay could materially adversely affect our financial condition, results of operations and cash flows.

We plan to bring our Apotainer selection kits to market for HSCT as a combination product subject to the primary jurisdiction of the CDRH, which is likely to result in the regulatory path usually followed for medical devices, which generally has less burdensome and costly requirements than the requirements for approval of a drug or biologic. The classification of our Apotainer selection kits by the FDA as a drug, a

TABLE OF CONTENTS

medical device or a combination product depends upon, among other things, the regulatory definition of a drug and a device, their primary mode of action and the indications for use or product claims. While we have had informal discussions with the FDA concerning our regulatory plans, we cannot assure you that the FDA would classify our Apotainer selection kits as a combination product subject to the primary jurisdiction of the CDRH that may qualify for the medical devices approval pathway. If the FDA were to classify our Apotainer selection kits as drug, biologic or a combination product subject to the primary jurisdiction of the Center for Drug Evaluation and Research or Center for Biologics Evaluation and Research jurisdiction, or were to prospectively alter the requirements for obtaining approval, the FDA could require us to meet more burdensome and lengthy approval requirements. Even if such approval could be obtained, we would be subject to more stringent level of post-market regulation as well. If any of these events were to occur, our financial condition and results of operations and cash flows could be materially and adversely affected.

Clinical trials necessary to support approval for our Apotainer selection kits or any future products based on Collect Inside technology platform would be expensive and could require the enrollment of large numbers of suitable patients, who could be difficult to identify and recruit. Delays or failures in any necessary clinical trials would prevent us from commercializing our Apotainer selection kits or any future product and could adversely affect our business, operating results and prospects.

Initiating and completing clinical trials necessary to support approval for our Apotainer selection kits or any future products based on our Collect Inside technology platform that we may develop, or additional safety and efficacy data that the FDA may require for any new specific indications of our technology that we may seek, would be time consuming and expensive with an uncertain outcome. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product candidate we advance into clinical trials may not have favorable results in later clinical trials.

Conducting successful clinical trials could require the enrollment of large numbers of patients, and suitable patients could be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators and support staff, the proximity to clinical sites of patients that are able to comply with the eligibility and exclusion criteria for participation in the clinical trial, and patient compliance. For example, patients could be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our product candidates or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. In addition, patients participating in clinical trials may die before completion of the trial or suffer adverse medical events unrelated to our product candidates.

Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy will be required and we may not adequately develop such protocols to support clearance or approval. Further, the FDA could require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial could cause an increase in costs and delays in the approval and attempted commercialization of our product candidates or result in the failure of the clinical trial. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.

The results of our clinical trials may not support our product candidate claims or any additional claims we may seek for our products and our clinical trials may result in the discovery of adverse side effects.

Even if any clinical trial that we need to undertake is completed as planned, we cannot be certain that its results will support our product candidate claims or any new indications that we may seek for our products or that the FDA or foreign authorities will agree with our conclusions regarding the results of those trials. The clinical trial process may fail to demonstrate that our products or a product candidate is safe and effective for the proposed indicated use, which could cause us to stop seeking additional clearances or approvals for our Apotainer selection kits, abandon our Collect Inside technology platform or delay development of other product candidates. Any delay or termination of our clinical trials will delay the filing of our regulatory

TABLE OF CONTENTS

submissions and, ultimately, our ability to commercialize a product candidate. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate's profile.

We might be unable to develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever.

Even if regulatory authorities approve our Apotainer selection kits, they may not be commercially successful. Our Apotainer selection kits may not be commercially successful because government agencies and other third-party payors may not cover the product or the coverage may be too limited to be commercially successful; physicians, researchers and others may not use or recommend our products, even following regulatory approval. A product approval, assuming one issues, may limit the uses for which the product may be distributed thereby adversely affecting the commercial viability of the product. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate. Third parties may develop superior products or have proprietary rights that preclude us from marketing our products. We also expect that at least some of our product candidates will be expensive, if approved. Demand for any Apotainer selection kits for which we obtain regulatory approval or license will depend largely on many factors, including but not limited to the extent, if any, of reimbursement of costs by government agencies and other third-party payors, pricing, the effectiveness of our marketing and distribution efforts, the safety and effectiveness of alternative products, and the prevalence and severity of side effects associated with our products. If physicians, government agencies and other third-party payors do not accept our products, we will not be able to generate significant revenue.

If we fail to obtain regulatory approval in jurisdictions outside the United States, we will not be able to market our products in those jurisdictions.

We intend to seek regulatory approval for our Apotainer selection kits in a number of countries outside of the United States and expect that these countries will be important markets for our products, if approved. Marketing our products in these countries will require separate regulatory approvals in each market and compliance with numerous and varying regulatory requirements. The regulations that apply to the conduct of clinical trials and approval procedures vary from country to country and may require additional testing. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any foreign market.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Although we believe that our Collect Inside technology platform has broad application, because we have limited financial and managerial resources, we are currently focused on development of our Apotainer selection kits for HSCT in order to demonstrate commercial viability of our technology platform. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

TABLE OF CONTENTS

We will need to outsource and rely on third parties for the clinical development and manufacture, sales and marketing of our current product candidates or any future product candidates that we may develop, and our future success will be dependent on the timeliness and effectiveness of the efforts of these third parties.

We do not have the required financial and human resources to carry out on our own all the preclinical and clinical development for our Apotainer selection kits or any other or future product candidates that we may develop, and do not have the capability and resources to manufacture, market or sell our Apotainer selection kits or any future product candidates that we may develop. Our business model calls for the partial or full outsourcing of the clinical and other development and manufacturing, sales and marketing of our product candidates in order to reduce our capital and infrastructure costs as a means of potentially improving our financial position. Our success will depend on the performance of these outsourced providers. If such providers fail to perform adequately, our development of product candidates may be delayed and any delay in the development of our product candidates would have a material and adverse effect on our business prospects.

If we or our contractors or service providers fail to comply with regulatory laws and regulations, we or they could be subject to regulatory actions, which could affect our ability to develop, market and sell our product candidates and any other or future product candidates that we may develop and may harm our reputation.

If we or our manufacturers or other third-party contractors fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to regulatory actions, which could affect our ability to develop, market and sell our Apotainer selection kits or any future product candidates under development successfully and could harm our reputation and lead to reduced demand for or non-acceptance of our proposed product candidates by the market. Even technical recommendations or evidence by the FDA through letters, site visits, and overall recommendations to academia or biotechnology companies may make the manufacturing of a product extremely labor intensive or expensive, making the product candidate no longer viable to manufacture in a cost efficient manner. The mode of administration may make the product candidate not commercially viable. The required testing of the product candidate may make that candidate no longer commercially viable. The conduct of clinical trials may be critiqued by the FDA, or a clinical trial site's Institutional Review Board or Institutional Biosafety Committee, which may delay or make impossible clinical testing of a product candidate. The Institutional Review Board for a clinical trial may stop a trial or deem a product candidate unsafe to continue testing. This may have a material adverse effect on the value of the product candidate and our business prospects.

Disruptions in our supply chain could delay any preclinical or clinical trials and the commercial launch of our product candidates.

Any significant disruption in our supplier relationships could harm our business. We currently rely on a single source supplier for the apoptotic inducing signal, Fas ligand, or FasL, that we use, and we may rely on a limited number of suppliers for other raw material we use. We believe that we will be able to obtain a sufficient supply of FasL for our needs in the foreseeable future, although we do not have a supply agreement in place. If our current supplier or any other supplier suffers a major natural or man-made disaster at its manufacturing facility, or if they otherwise cease to supply to us, then we would not be able to manufacture our product candidates until a qualified alternative supplier is identified. Although alternative sources of supply exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers. Any significant delay in the supply of a product candidate or its key materials for a preclinical or clinical trial could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these key materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.

TABLE OF CONTENTS

Should our products be approved for commercialization, adverse changes in reimbursement policies and procedures by payors may impact our ability to market and sell our products.

Healthcare costs have risen significantly over the past decade, and there have been and continue to be proposals by legislators, regulators and third-party payors to decrease costs. Third-party payors are increasingly challenging the prices charged for medical products and services and instituting cost containment measures to control or significantly influence the purchase of medical products and services. For example, in the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, PPACA, among other things, reduced and/or limited Medicare reimbursement to certain providers. The Budget Control Act of 2011, as amended by subsequent legislation, further reduces Medicare's payments to providers by 2% through fiscal year 2024. These reductions may reduce providers' revenues or profits, which could affect their ability to purchase new technologies. Furthermore, the healthcare industry in the United States has experienced a trend toward cost containment as government and private insurers seek to control healthcare costs by imposing lower payment rates and negotiating reduced contract rates with service providers. Legislation could be adopted in the future that limits payments for our products from governmental payors. In addition, commercial payors, such as insurance companies, could adopt similar policies that limit reimbursement for medical device manufacturers' products. Therefore, we cannot be certain that our products or the procedures or patient care performed using our products will be reimbursed at a cost-effective level. We face similar risks relating to adverse changes in reimbursement procedures and policies in other countries where we may market our products. Reimbursement and healthcare payment systems vary significantly among international markets. Our inability to obtain international reimbursement approval, or any adverse changes in the reimbursement policies of foreign payors, could negatively affect our ability to sell our products and have a material adverse effect on our business and financial condition.

Should our products be approved for commercialization, our financial performance may be adversely affected by medical device tax provisions in the healthcare reform laws.

PPACA currently imposes, among other things, an excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States. Under these provisions, the Congressional Research Service predicts that the total cost to the medical device industry may be \$38 billion over the next decade. The Internal Revenue Service issued final regulations implementing the tax in December 2012, which requires, among other things, bi-monthly payments and quarterly reporting. Once we market products, we will be subject to this or any future excise tax on our sales of certain medical devices in the United States. To the extent our products are considered medical devices, we anticipate that primarily all of our sales, once commenced, of medical devices in the United States will be subject to this 2.3% excise tax.

Public perception of ethical and social issues surrounding the use of stem cell technology may limit or discourage the use of our technologies.

For social, ethical, or other reasons, governmental authorities in the United States and other countries may call for limits on, or regulation of the use of, stem cell technologies. Although our platform technology is designed to enrich the stem cell population as an enabling technology rather than manufacture stem cells, claims that stem cell technologies are ineffective, unethical or pose a danger to the environment may influence public attitudes. The subject of stem cell technologies in general has received negative publicity and aroused public debate in the United States and some other countries. Ethical and other concerns about our stem cell technology could materially hurt the market acceptance of our technologies.

The members of our management team and certain consultants are important to the efficient and effective operation of our business. Failure to retain our management and consulting team could have a material adverse effect on our business, financial condition or results of operations.

Our executive officers, our management team and technical personnel, as well as certain consultants, are important to the efficient and effective operation of our business, particularly Dr. Shai Yarkoni, our Chief Executive Officer, and Dr. Nadir Askenasy, our Chief Scientist. Our failure to retain the personnel that have developed much of the technology we utilize today, or any other key management and technical personnel, could have a material adverse effect on our future operations. Our success is also dependent on our ability to

TABLE OF CONTENTS

attract, retain and motivate highly trained technical and management personnel, among others, to continue the development and commercialization of our current and future products. As of the date of this prospectus, we do not have key-man insurance on any of our officers or consultants.

As such, our future success highly depends on our ability to attract, retain and motivate personnel, including contractors, required for the development, maintenance and expansion of our activities. There can be no assurance that we will be able to retain our existing personnel or attract additional qualified employees or consultants. The loss of personnel or the inability to hire and retain additional qualified personnel in the future could have a material adverse effect on our business, financial condition and results of operation.

We face significant competition. If we cannot successfully compete with new or existing products, our marketing and sales will suffer and we may never be profitable.

The field of regenerative medicine is expanding rapidly, mainly in uses of stem cells but also in the development of cell-based therapies and/or devices designed to isolate stem and progenitor cells from human tissues. As the field grows, we face, and will continue to face, increased competition from pharmaceutical, biopharmaceutical, medical device and biotechnology companies, as well as academic and research institutions and governmental agencies in the United States and abroad. In addition, many of these competitors, either alone or together with their collaborative partners, operate larger research and development programs than we do, and have substantially greater financial resources than we do, as well as significantly greater experience in:

- developing stem cell selection technology;
- undertaking preclinical testing and human clinical trials;
- obtaining FDA approvals and addressing various regulatory matters and obtaining other regulatory approvals;
- manufacturing medical devices; and
- launching, marketing and selling medical devices.

We are aware of two companies that lead the stem cell selection market with whom we directly compete. The first is Miltenyi Biotec, or Miltenyi, which dominates the stem cell selection market, using biomarkers to either enrich stem cells (positive selection by CD34) or deplete mature hematopoietic cells such as T cells from the biological sample (negative selection by monoclonal activity against T-cell receptor), resulting in the enrichment of stem and progenitor cells. The second is Cytori Therapeutics, or Cytori, which sells a medical device known as the Celution® System that enables bedside access to adult adipose-derived stem and regenerative cells, or ADRCs, by automating and standardizing the extraction, washing, and concentration of a patient's own ADRCs for present and future clinical use. We believe that both technologies result in less than optimal cell population both in terms of quantity and quality (purity) of the selected population of cells.

In addition, since we are developing our Apotainer selection kits to improve the safety and efficacy of allogeneic HSCT, we also compete with companies developing treatments for GvHD, a life-threatening condition associated with allogeneic HSCT.

In the general area of cell-based therapies, we may now or in the future compete on an indirect basis with a variety of companies, most of whom are specialty medical products or biotechnology companies that provide a finished stem cell product that has already undergone stem cell selection. We believe, however, that many of these companies have the potential to become customers in the future of our Collect Inside technology platform in order to improve and enhance their in-house processes.

If our competitors develop and commercialize products faster than we do, or develop and commercialize products that are superior to our Collect Inside technology platform or Apotainer selection kits, our commercial opportunities will be reduced or eliminated. Our competitors may succeed in developing and commercializing products earlier and obtaining regulatory approvals from the FDA and foreign regulatory authorities more rapidly than we do. Our competitors may also develop products or technologies that are superior to those we are developing, and render our product candidate obsolete or non-competitive. If we cannot successfully compete with new or existing products, our marketing and sales will suffer and we may never be profitable.

TABLE OF CONTENTS

The extent to which our product candidate achieves market acceptance will depend on competitive factors, many of which are beyond our control. Competition in the field of regenerative medicine is intense and has been accentuated by the rapid pace of technology development. Our competitors also compete with us to:

- attract parties for acquisitions, joint ventures or other collaboration;
- license proprietary technology that is competitive with Collect Inside technology platform or Apotainer selection kits;
- attract funding; and
- attract and hire scientific talent and other qualified personnel.

Product liability and other claims against us may in the future reduce demand for our products or result in substantial damages. We anticipate that we will need to obtain and maintain additional or increased insurance coverage, and we may not be able to obtain or maintain such coverage on commercially reasonable terms, if at all.

A product liability claim, a clinical trial liability claim or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business. Our business exposes us to potential liability risks that may arise from any future clinical testing of our product candidates in human clinical trials and the manufacture and sale of any approved products. Any clinical trial liability or product liability claim or series of claims or class actions brought against us, with or without merit, could result in:

- liabilities that substantially exceed any clinical trial liability or product liability insurance that we may obtain in the future, which we would then be required to pay from other sources, if available;
- an increase in the premiums we may pay for any clinical trial liability or product liability insurance we may obtain in the future or the inability to renew or obtain clinical trial liability or product liability insurance coverage in the future on acceptable terms, or at all;
- withdrawal of clinical trial volunteers or patients;
- damage to our reputation and the reputation of our products, including loss of any future market share;
- regulatory investigations that could require costly recalls or product modifications;
- litigation costs; and
- diversion of management's attention from managing our business.

We do not currently have clinical trial liability insurance or product liability insurance because we have not commenced clinical trials and none of our product candidates has yet been approved for commercialization. While we plan to seek clinical trial insurance and, if any of our product candidates are sold commercially, product liability insurance coverage, we cannot assure you that we will be able to obtain clinical trial and product liability insurance on commercially acceptable terms, if at all, or that we will be able to maintain such insurance at a reasonable cost or in sufficient amounts to protect against potential losses.

If our employees commit fraud or other misconduct, including noncompliance with regulatory standards and requirements and insider trading, our business may experience serious adverse consequences.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state health-care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee

TABLE OF CONTENTS

misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.

Our board of directors intends to adopt a Code of Ethics to be effective upon the listing of our ADSs on NASDAQ (subject to submission and approval of our listing application). However, it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

In addition, during the course of our operations, our directors, executives and employees may have access to material, nonpublic information regarding our business, our results of operations or potential transactions we are considering. If a director, executive or employee was to be investigated, or an action was to be brought against a director, executive or employee for insider trading, it could have a negative impact on our reputation and the market price of the ADSs. Such a claim, with or without merit, could also result in substantial expenditures of time and money, and divert attention of our management team from other tasks important to the success of our business.

We may encounter difficulties in managing our growth. Failure to manage our growth effectively will have a material adverse effect on our business, results of operations and financial condition.

We may not be able to successfully grow and expand. Successful implementation of our business plan will require management of growth, including potentially rapid and substantial growth, which will result in an increase in the level of responsibility for management personnel and place a strain on our human and capital resources. To manage growth effectively, we will be required to continue to implement and improve our operating and financial systems and controls to expand, train and manage our employee base. Our ability to manage our operations and growth effectively will require us to continue to expend funds to enhance our operational, financial and management controls, reporting systems and procedures and to attract and retain sufficient talented personnel. If we are unable to scale up and implement improvements to our control systems in an efficient or timely manner, or if we encounter deficiencies in existing systems and controls, then we will not be able to successfully commercialize our Collect Inside technology platform, our Apotainer selection kits or any future product candidate. Failure to attract and retain sufficient talented personnel will further strain our human resources and could impede our growth or result in ineffective growth. Moreover, the management, systems and controls currently in place or to be implemented may not be adequate for such growth, and the steps we have taken to hire personnel and to improve such systems and controls might not be sufficient. If we are unable to manage our growth effectively, it will have a material adverse effect on our business, results of operations and financial condition.

If we are unable to obtain adequate insurance, our financial condition could be adversely affected in the event of uninsured or inadequately insured loss or damage. Our ability to effectively recruit and retain qualified officers and directors could also be adversely affected if we experience difficulty in obtaining adequate directors' and officers' liability insurance.

Our business will expose us to potential liability that results from risks associated with conducting any future clinical trials of our Apotainer selection kits or any future product candidate. A successful clinical trial liability claim, if any, brought against us could have a material adverse effect on our business, prospects, financial condition and results of operations even though clinical trial insurance is successfully maintained or obtained. Our planned insurance coverage may only mitigate a small portion of a substantial claim against us. In addition, we may be unable to maintain sufficient insurance as a public company to cover liability claims made against our officers and directors. If we are unable to adequately insure our officers and directors, we may not be able to retain or recruit qualified officers and directors to manage us.

Recent disruptions in the financial markets and economic conditions could affect our ability to raise capital.

In recent years, the United States and global economies suffered dramatic downturns as the result of a deterioration in the credit markets and related financial crisis as well as a variety of other factors including, among other things, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations of others. The United States and certain foreign governments have taken unprecedented actions in an attempt to address and rectify these extreme market and economic conditions by providing liquidity and stability to the financial markets. If the actions taken by these governments are not successful, the return of adverse economic conditions may cause a significant impact on our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all.

Our current management team has no experience in managing and operating a publicly traded U.S. company. Any failure to comply or adequately comply with federal securities laws, rules or regulations could subject us to fines or regulatory actions, which may materially adversely affect our business, results of operations and financial condition.

Although our ordinary shares trade on the TASE and we file reports in Israel, our current management team has no experience managing and operating a publicly traded U.S. company. Failure to comply or adequately comply with any laws, rules or regulations applicable to our business may result in fines or regulatory actions, which may materially adversely affect our business, results of operation or financial condition, and could result in delays in achieving the development of an active and liquid trading market for the ADSs.

Risks Related to Our Intellectual Property

We rely upon patents to protect our technology.

The patent position of biotechnology firms is generally uncertain and involves complex legal and factual questions. We do not know whether any of our current or future patent applications will result in the issuance of any patents. Even issued patents may be challenged, invalidated or circumvented. Patents may not provide a competitive advantage or afford protection against competitors with similar technology. Competitors or potential competitors may have filed applications for, or may have received patents and may obtain additional and proprietary rights to compounds or processes used by or competitive with ours.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

Periodic maintenance fees on any issued patent are due to be paid to the U.S. Patent and Trademark Office, or USPTO, and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to office actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and ultimately unsuccessful.

Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent

TABLE OF CONTENTS

infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent's claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could adversely affect us.

Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

Our commercial success depends upon our ability to develop, manufacture, market and sell our platform technology without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the medical device and pharmaceutical industries. While no such litigation has been brought against us and we have not been held by any court to have infringed a third party's intellectual property rights, we cannot guarantee that our technology or use of our technology does not infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing, which is referred to as the priority date. Therefore, patent applications covering our technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our technology.

We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our technology, including inter parties review, interference, or derivation proceedings before the USPTO and similar bodies in other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future.

If we are found to infringe a third party's intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology. In addition, we could be found liable for monetary damages, including treble damages and attorneys' fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our technology or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States and Israel can be less extensive than those in the United States and Israel. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as laws in the United States and Israel. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States and Israel, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents, but enforcement is not as strong as that in the United States and Israel.

Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to medical devices and biopharmaceutical products, which could make it difficult for us to stop

TABLE OF CONTENTS

the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. To date, we have not sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

We rely on confidentiality agreements that could be breached and may be difficult to enforce, which could result in third parties using our intellectual property to compete against us.

Although we believe that we take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure of confidential information to third parties, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them, the agreements can be difficult and costly to enforce. Although we seek to enter into these types of agreements with our contractors, consultants, advisors and research collaborators, to the extent that employees and consultants utilize or independently develop intellectual property in connection with any of our projects, disputes may arise as to the intellectual property rights associated with our Collect Inside technology platform, our Apotainer selection kits or any future product candidate. If a dispute arises, a court may determine that the right belongs to a third party. In addition, enforcement of our rights can be costly and unpredictable. We also rely on trade secrets and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors or others. Despite the protective measures we employ, we still face the risk that:

- these agreements may be breached;
- these agreements may not provide adequate remedies for the applicable type of breach;
- our proprietary know-how will otherwise become known; or
- our competitors will independently develop similar technology or proprietary information.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:

- others may be able to develop technology that is similar to our Collect Inside technology platform, our Apotainer selection kits or any future product candidate, but that is not covered by the claims of the patents that we own;
- we or any future strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;
- we or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;
- others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
- it is possible that our pending patent applications will not lead to issued patents;

TABLE OF CONTENTS

- issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;
- our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
- we may not develop additional proprietary technologies that are patentable; and
- the patents of others may have an adverse effect on our business.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. In addition, the Israeli Supreme Court ruled in 2012 that an employee who receives a patent or contributes to an invention during his employment may be allowed to seek compensation for such contributions from his or her employer, even if the employee's contract of employment specifically states otherwise and the employee has transferred all intellectual property rights to the employer. The Israeli Supreme Court ruled that the fact that a contract revokes an employee's right for royalties and compensation does not rule out the right of the employee to claim their right for royalties. As a result, it is unclear whether and, if so, to what extent our employees may be able to claim compensation with respect to our future revenue. We may receive less revenue from future products if any of our employees successfully claim for compensation for their work in developing our intellectual property, which in turn could impact our future profitability.

Risks Related to Our Operations in Israel

Potential political, economic and military instability in the State of Israel, where our senior management, our head executive office, and research and development facilities are located, may adversely affect our results of operations.

Our head executive office, our research and development facilities, as well as some of our planned clinical sites, are or will be located in Israel. Our officers and most of our directors are residents of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly affect our business and operations. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. During the summer of 2006 and the fall of 2012, Israel was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite militia group and political party. In December 2008, January 2009, November 2012 and July 2014, there were escalations in violence between Israel, on the one hand, and Hamas, the Palestinian Authority and/or other groups, on the other hand, as well as extensive hostilities along Israel's border with the Gaza Strip, which resulted in missiles being fired from the Gaza Strip into Southern and central Israel, including near Tel Aviv and at areas surrounding Jerusalem. These conflicts involved missile strikes against civilian targets in various parts of Israel, including areas in which our employees and some of our consultants are located, and negatively affected business conditions in Israel. Our offices and laboratory, located in Kfar Saba, Israel, are within the range of the missiles and rockets that have been fired at Israeli cities and towns from Gaza sporadically since 2006, with escalations in violence (such as the recent escalation in July 2014) during which there were a substantially larger number of rocket and missile attacks aimed at Israel. In addition, since February 2011, Egypt has experienced political

TABLE OF CONTENTS

turbulence and an increase in terrorist activity in the Sinai Peninsula following the resignation of Hosni Mubarak as president. This turbulence included protests throughout Egypt, and the appointment of a military regime in his stead, followed by the elections to parliament which brought groups affiliated with the Muslim Brotherhood (which had been previously outlawed by Egypt), and the subsequent overthrow of this elected government by a military regime. Such political turbulence and violence may damage peaceful and diplomatic relations between Israel and Egypt, and could affect the region as a whole. Similar civil unrest and political turbulence has occurred in other countries in the region, including Syria, which shares a common border with Israel, and is affecting the political stability of those countries. Since April 2011, internal conflict in Syria has escalated, and evidence indicates that chemical weapons have been used in the region. This instability and any outside intervention may lead to deterioration of the political and economic relationships that exist between the State of Israel and some of these countries, and may have the potential for causing additional conflicts in the region. In addition, Iran has threatened to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, and various rebel militia groups in Syria. Additionally, a violent jihadist group named Islamic State of Iraq and Levant (ISIL) is involved in hostilities in Iraq and Syria and have been growing in influence. Although ISIL's activities have not directly affected the political and economic conditions in Israel, ISIL's stated purpose is to take control of the Middle East, including Israel. These situations may potentially escalate in the future to more violent events which may affect Israel and us. Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions and could harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business.

Investors may have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws, against us or our executive officers and directors, or asserting U.S. securities laws claims in Israel.

None of our directors or officers are residents of the United States. Most of our directors' and officers' assets and our assets are located outside the United States. Service of process upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us or our non-U.S. directors and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our officers and directors.

Moreover, among other reasons, including but not limited to fraud or absence of due process, or the existence of a judgment which is at variance with another judgment that was given in the same matter if a suit in the same matter between the same parties was pending before a court or tribunal in Israel, an Israeli court will not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel.

TABLE OF CONTENTS

Under applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective of their agreements with us, which in turn could impact our future profitability.

We generally enter into non-competition agreements with our employees and key consultants. These agreements prohibit our employees and key consultants, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict our competitors from benefiting from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company's confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees or consultants and our ability to remain competitive may be diminished.

In addition, Chapter 8 to the Israeli Patents Law, 5727-1967, or the Patents Law, deals with inventions made in the course of an employee's service and during his or her term of employment, whether or not the invention is patentable, or service inventions. Section 134 of the Patents Law sets forth that if there is no agreement which explicitly determines whether the employee is entitled to compensation for the service inventions and the extent and terms of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory committee of the Israeli Patents Office. The Israeli Supreme Court ruled in 2012 that an employee who contributes to a service invention during his or her employment may be allowed to seek compensation for such contributions from his employer, even if the employee's contract of employment specifically states otherwise and the employee has assigned all intellectual property rights to the employer. The Israeli Supreme Court ruled that the fact that a contract revokes the employee's right for royalties and compensation in connection with service inventions does not rule out the right of the employee to claim a right for royalties. Following such ruling, the Israeli Supreme Court remanded the proceedings to the District Court for further discussion and therefore the ultimate outcome has yet to be resolved. As a result, it is unclear if, and to what extent, our research and development employees may be able to claim compensation with respect to our future revenue. As a result, we may receive less revenue from future products if such claims are successful, which in turn could impact our future profitability.

Your rights and responsibilities as our shareholder will be governed by Israeli law, which may differ in some respects from the rights and responsibilities of shareholders of U.S. corporations.

Since we are incorporated under Israeli law, the rights and responsibilities of our shareholders are governed by our articles of association and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders of U.S.-based corporations. In particular, a shareholder of an Israeli company, such as us, has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards us and other shareholders and to refrain from abusing its power in us, including, among other things, in voting at the general meeting of shareholders on certain matters, such as an amendment to our articles of association, an increase of our authorized share capital, a merger and approval of related party transactions that require shareholder approval. A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder who knows that it possesses the power to determine the outcome of a shareholders vote or to appoint or prevent the appointment of an office holder of ours or other power towards us has a duty to act in fairness towards us. However, Israeli law does not define the substance of this duty of fairness. See "Management — Approval of Related Party Transactions under Israeli Law." Since Israeli corporate law underwent extensive revisions approximately 15 years ago, the parameters and implications of the provisions that govern shareholder behavior have not been clearly determined. These provisions may be interpreted to impose additional obligations and liabilities on our shareholders that are not typically imposed on shareholders of U.S. corporations.

TABLE OF CONTENTS

Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.

Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each merging company with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies approved the merger. In addition, the holder of a majority of each class of securities of the target company must approve a merger. Moreover, a full tender offer can only be completed if the acquirer receives at least 95% of the issued share capital (provided that a majority of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer, except that if the total votes to reject the tender offer represent less than 2% of the company's issued and outstanding share capital, in the aggregate, approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender offer), and the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder that accepts the offer may not seek appraisal rights).

Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to those of our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred.

These and other similar provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.

Because a certain portion of our expenses is incurred in currencies other than the U.S. dollar, our results of operations may be harmed by currency fluctuations and inflation.

Our reporting and functional currency is the NIS, but some portion of our clinical trials and operations expenses are in the U.S. dollar and Euro. As a result, we are exposed to some currency fluctuation risks. We may, in the future, decide to enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the currencies mentioned above in relation to the NIS. These measures, however, may not adequately protect us from adverse effects.

Our operations may be disrupted as a result of the obligation of Israeli citizens to perform military service.

Many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include the call-up of members of our management. Such disruption could materially adversely affect our business, financial condition and results of operations.

Risks Related to the ADSs and the Offering

The ADSs have no prior trading history in the United States, and an active market may not develop, which may limit the ability of our investors to sell the ADSs in the United States.

There is no public market for the ADSs or our ordinary shares in the United States. Although we intend to apply to list the ADSs on NASDAQ, such application may not be approved and, even if it is approved, an active trading market for the ADSs may never develop or may not be sustained if one develops. If an active market for the ADSs does not develop, it may be difficult for you to sell your ADSs.

We will incur significant additional increased costs as a result of the listing of the ADSs for trading on NASDAQ and thereby becoming a public company in the United States as well as in Israel, and our management will be required to devote substantial additional time to new compliance initiatives as well as to compliance with ongoing U.S. and Israeli reporting requirements.

Upon the successful completion of this offering and the listing of our ADSs on NASDAQ, we will become a publicly traded company in the United States. As a public company in the United States, we will incur additional significant accounting, legal and other expenses that we did not incur before the offering. We also anticipate that we will incur costs associated with corporate governance requirements of the SEC and NASDAQ, as well as requirements under Section 404 and other provisions of the Sarbanes-Oxley Act. We expect these rules and regulations to increase our legal and financial compliance costs, introduce new costs such as investor relations, stock exchange listing fees and shareholder reporting, and to make some activities more time consuming and costly. The implementation and testing of such processes and systems may require us to hire outside consultants and incur other significant costs. Any future changes in the laws and regulations affecting public companies in the United States, including Section 404 and other provisions of the Sarbanes-Oxley Act, and the rules and regulations adopted by the SEC and NASDAQ, for so long as they apply to us, will result in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, if any, or as executive officers.

If we were to be characterized as a PFIC for U.S. tax purposes, U.S. holders of our ADSs could have adverse U.S. income tax consequences.

If we were to be characterized as a PFIC under the U.S. Internal Revenue Code of 1986, as amended, or the Code, in any taxable year during which a U.S. taxpayer owns ADSs, such U.S. holder could be liable for additional taxes and interest charges upon certain distributions by us and any gain recognized on a sale, exchange or other disposition, including a pledge, of the ADSs, whether or not we continue to be a PFIC. Based on the nature of our business, the projected composition of our income and the projected composition and estimated fair market values of our assets, we believe that we may be deemed a PFIC. In particular, in light of the complexity of PFIC rules, we cannot assure you that we have not been a PFIC in prior years or are not a PFIC or will avoid becoming a PFIC in the future. Were we to be classified as a PFIC, a U.S. investor may be able to mitigate some of the adverse U.S. federal income tax consequences with respect to owning the ADSs for our taxable year ending December 31, 2016, provided that such U.S. investor is eligible to make, and successfully makes, a “mark-to-market” election. U.S. investors could also mitigate some of the adverse U.S. federal income tax consequences of us being classified as a PFIC by making a “qualified electing fund” election, provided that we provide the information necessary for a U.S. investor to make such an election. We intend to make available to U.S. investors upon request the information necessary for U.S. holders to make qualified electing fund elections. U.S. Holders are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences to them of making a “qualified electing fund” or “mark-to-market” election with respect to our ADSs in the event we that qualify as a PFIC. For more information see “Taxation — U.S. Federal Income Tax Considerations.”

TABLE OF CONTENTS

Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, results of operation or financial condition. In addition, current and potential shareholders could lose confidence in our financial reporting, which could have a material adverse effect on the price of the ADSs.

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. We will be required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which requires annual management assessments of the effectiveness of our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404. Disclosing deficiencies or weaknesses in our internal control, failing to remediate these deficiencies or weaknesses in a timely fashion or failing to achieve and maintain an effective internal control environment may cause investors to lose confidence in our reported financial information, which could have a material adverse effect on the price of the ADSs. If we cannot provide reliable financial reports or prevent fraud, our operating results could be harmed.

As an “emerging growth company” under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements, which could make the ADSs less attractive to investors.

For as long as we are deemed an emerging growth company, we are permitted to and intend to take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies, including:

- an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act; and
- an exemption from compliance with any new requirements adopted by the PCAOB, requiring mandatory audit firm rotation or a supplement to the auditor’s report in which the auditor would be required to provide additional information about our audit and our financial statements.

We will be an emerging growth company until the earliest of: (i) the last day of the fiscal year during which we had total annual gross revenues of \$1 billion or more, (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of the ADSs pursuant to an effective registration statement, (iii) the date on which we have, during the previous three-year period, issued more than \$1 billion in non-convertible debt or (iv) the date on which we are deemed a “large accelerated issuer” as defined in Regulation S-K under the Securities Act.

We cannot predict if investors will find the ADSs less attractive because we may rely on these exemptions. If some investors find the ADSs less attractive as a result, there may be a less active trading market for the ADSs and the market price of the ADSs may be more volatile.

We are a “foreign private issuer” and have disclosure obligations that are different from those of U.S. domestic reporting companies.

We are a foreign private issuer and are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we will be subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we will not be required to issue quarterly reports or proxy statements that comply with the requirements applicable to U.S. domestic reporting companies. Furthermore, although under a recent amendment to the regulations promulgated under the Israeli Companies Law, as amended, or the Companies Law, as an Israeli public company listed overseas we will be required to disclose the compensation of our five most highly compensated officers on an individual basis (rather than on an aggregate basis, as was previously permitted for Israeli public companies listed overseas prior to such amendment), this disclosure will not be as extensive as that required of U.S. domestic reporting companies. We will also have four months after the end of each fiscal year to file our annual reports with the SEC and will not be required to file current reports as frequently or promptly as U.S. domestic reporting companies. Furthermore, our officers, directors and principal shareholders will be exempt from the requirements to report transactions and short-swing profit

TABLE OF CONTENTS

recovery required by Section 16 of the Exchange Act. Also, as a “foreign private issuer,” we are not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies will reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting companies.

As a “foreign private issuer,” we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable SEC and NASDAQ requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.

As a “foreign private issuer,” we will be permitted, and intend, to follow certain home country corporate governance practices instead of those otherwise required under the listing rules of NASDAQ for domestic U.S. issuers. For instance, we intend to follow home country practice in Israel with regard to, among other things, board of directors independence requirements, director nomination procedures and quorum requirements. In addition, we may follow our home country law instead of the listing rules of NASDAQ that require that we obtain shareholder approval for certain dilutive events, such as the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change of control of us, certain transactions other than a public offering involving issuances of a 20% or greater interest in the company, and certain acquisitions of the stock or assets of another company. We also intend to follow our home country rules regarding the periodic approval of and changes to the formal charter for our compensation committee instead of the listing rules of NASDAQ. We may in the future elect to follow home country corporate governance practices in Israel with regard to other matters. Following our home country corporate governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on NASDAQ may provide less protection to you than what is accorded to investors under the listing rules of NASDAQ applicable to domestic U.S. issuers. See “Management — NASDAQ listing rules and Home Country Practices.”

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our traded securities, our securities price and trading volume could be negatively impacted.

The trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts, and we cannot provide any assurance that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding the ADSs, or provide more favorable relative recommendations about our competitors, the price of the ADSs would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could negatively impact the price of the ADSs or their trading volume.

The market price for the ADSs may be volatile.

The market price for the ADSs is likely to be highly volatile and subject to wide fluctuations in response to numerous factors including the following:

- our failure to obtain the approvals necessary to commence clinical trials;
- results of clinical and preclinical studies;
- announcements of regulatory approval or the failure to obtain it, or changes or delays in the regulatory review process;
- announcements of technological innovations, new products or product enhancements by us or others;
- adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;
- changes or developments in laws, regulations or decisions applicable to our product candidates or patents;

TABLE OF CONTENTS

- any adverse changes to our relationship with manufacturers or suppliers;
- announcements concerning our competitors or the regenerative medicine or healthcare industries in general;
- achievement of expected product sales and profitability or our failure to meet expectations;
- our commencement of or results of, or involvement in, litigation, including, but not limited to, any product liability actions or intellectual property infringement actions;
- any major changes in our board of directors, management or other key personnel;
- announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;
- expiration or terminations of licenses, research contracts or other collaboration agreements;
- public concern as to the safety of our products that we, our licensees or others develop;
- success of research and development projects;
- developments concerning intellectual property rights or regulatory approvals;
- variations in our and our competitors' results of operations;
- changes in earnings estimates or recommendations by securities analysts, if our ordinary shares or the ADSs are covered by analysts;
- future issuances of ordinary shares, ADSs or other securities;
- general market conditions, including the volatility of market prices for shares of healthcare companies generally, and other factors, including factors unrelated to our operating performance; and
- the other factors described in this "Risk Factors" section.

These factors and any corresponding price fluctuations may materially and adversely affect the market price of the ADSs, which would result in substantial losses by our investors. In addition, the securities market has from time to time experienced significant price and volume fluctuations that are not related to the operating performance of any particular company. These market fluctuations may also have a material adverse effect on the market price of the ADSs.

Our ordinary shares and the ADSs will be traded on different markets and this may result in price variations.

Our ordinary shares have been traded on the TASE since 1990. If our application is approved, we expect that the ADSs will be traded on NASDAQ following the completion of this offering. Trading in these securities on these markets will take place in different currencies (dollars on NASDAQ and NIS on the TASE), and at different times (resulting from different time zones, different trading days and different public holidays in the United States and Israel). The trading prices of our securities on these two markets may differ due to these and other factors.

Substantial future sales or perceived potential sales of our ordinary shares or ADSs in the public market could cause the price of our ordinary shares or the ADSs to decline.

Substantial sales of our ordinary shares or the ADSs, either on the TASE or on NASDAQ, as applicable, including in this offering, may cause the market price of our ordinary shares and ADSs to decline. Almost all of our outstanding ordinary shares are registered and available for sale in Israel. Sales by us or our security holders of substantial amounts of our ordinary shares or ADSs, or the perception that these sales may occur in the future, could cause a reduction in the market price of our ordinary shares or ADSs. The issuance of any additional ordinary shares or any additional ADSs, or any securities that are exercisable for or convertible into our ordinary shares or ADSs, may have an adverse effect on the market price of our ordinary shares or the ADSs and will have a dilutive effect on our existing shareholders and holders of ADSs.

TABLE OF CONTENTS

Furthermore, ordinary shares outstanding after this offering will be available for sale, upon the expiration of the [] day lock-up period applicable to our directors and executive officers (as described under “Underwriting-Lock-Up Agreements” below) beginning from the date of the final prospectus relating to this offering, subject to any other restrictions as applicable under Israeli Law. Any or all of these shares may be released prior to the expiration of the lock-up period at the discretion of the underwriter of this offering. To the extent shares are released before the expiration of the lock-up period and sold into the market, the market price of the ADSs could decline.

We have not paid, and do not intend to pay, dividends on our ordinary shares and, therefore, unless our traded securities appreciate in value, our investors may not benefit from holding our securities.

We have not paid any cash dividends on our ordinary shares since inception. We do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future. Moreover, the Companies Law imposes certain restrictions on our ability to declare and pay dividends. See “Description of Share Capital — Dividends” for additional information. As a result, investors in the ADSs or ordinary shares will not be able to benefit from owning these securities unless their market price becomes greater than the price paid by such investors and they are able to sell such securities. We cannot assure you that you will ever be able to resell our securities at a price in excess of the price paid.

You may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in some limited circumstances, you may not receive dividends or other distributions on our ordinary shares and you may not receive any value for them, if it is illegal or impractical to make them available to you.

The depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions, if any, in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act, but that are not properly registered or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars from foreign currency that was part of a dividend made in respect of deposited ordinary shares may require the approval or license of, or a filing with, any government or agency thereof, which may be unobtainable. In these cases, the depositary may determine not to distribute such property and hold it as “deposited securities” or may seek to effect a substitute dividend or distribution, including net cash proceeds from the sale of the dividends that the depositary deems an equitable and practicable substitute. We have no obligation to register under U.S. securities laws any ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. In addition, the depositary may withhold from such dividends or distributions its fees and an amount on account of taxes or other governmental charges to the extent the depositary believes it is required to make such withholding. This means that you may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in some limited circumstances, you may not receive any value for such distributions or dividends if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.

Holders of ADSs must act through the depositary to exercise their rights as our shareholders.

Holders of the ADSs do not have the same rights of our shareholders and may only exercise the voting rights with respect to the underlying ordinary shares in accordance with the provisions of the deposit agreement for the ADSs. Under Israeli law, the minimum notice period required to convene a shareholders meeting is no less than 35 or 21 calendar days, depending on the proposals on the agenda for the shareholders meeting. When a shareholder meeting is convened, holders of the ADSs may not receive sufficient notice of a shareholders meeting to permit them to withdraw their ordinary shares to allow them to cast their vote with respect to any specific matter. In addition, the depositary and its agents may not be able to send voting instructions to holders of the ADSs or carry out their voting instructions in a timely manner. We will make all

TABLE OF CONTENTS

reasonable efforts to cause the depository to extend voting rights to holders of the ADSs in a timely manner, but we cannot assure holders that they will receive the voting materials in time to ensure that they can instruct the depository to vote their ADSs. Furthermore, the depository and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of the ADSs may not be able to exercise their right to vote and they may lack recourse if their ADSs are not voted as they requested. In addition, in the capacity as a holder of ADSs, they will not be able to call a shareholders meeting.

You may be subject to limitations on transfer of your ADSs.

Your ADSs are transferable on the books of the depository. However, the depository may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depository may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depository are closed, or at any time if we or the depository deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement.

Your percentage ownership in us may be diluted by future issuances of share capital, which could reduce your influence over matters on which shareholders vote.

Following the completion of this offering, our board of directors will have the authority, in most cases without action or vote of our shareholders, to issue all or any part of our authorized but unissued shares, including ordinary shares issuable upon the exercise of outstanding warrants and options. Issuances of additional shares would reduce your influence over matters on which our shareholders vote.

You will experience immediate dilution in book value of any ADSs you purchase.

Because the price per ADS being offered is substantially higher than our net tangible book value per ADS, you will suffer substantial dilution in the net tangible book value of any ADS you purchase in this offering. If the underwriters exercise their over-allotment option, you may experience additional dilution. See "Dilution".

Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.

Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that you do not agree with or that do not improve our results of operations or enhance the value of ADSs (see "Use of Proceeds"). Our failure to apply these funds effectively could have a material adverse effect on our business and cause the price of the ADSs to decline.

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

This prospectus contains express or implied “forward-looking statements” within the meaning of U.S. Federal securities laws. These forward-looking statements include, but are not limited to:

- our expectations regarding the timing of commencing clinical trials with respect to our ApoGraft process and our Apotainer selection kit;
- our expectations regarding the progress of our clinical trials, including the duration, cost and whether such trials will be conducted at all;
- our intention to hold meetings with regulators and apply for regulatory approval for our product candidates, and the costs and timing of such regulatory approvals;
- the likelihood of regulatory approvals for our product candidates;
- the timing and cost of the developments of our prototype Apotainer selection kit;
- our expectation to obtain a sufficient supply of FasL for our needs in the foreseeable future;
- the market size and future sales of our product candidates or any other future products or product candidates;
- that our technology may potentially improve the safety and efficacy of regenerative medicine stem cell therapy and other potential advantages of our selection process for physicians, academics, researchers and others;
- our intention to expand our product development and build a diversified product portfolio of Collect Inside products for a broad spectrum of market segments; and
- our estimates regarding anticipated expenses, capital requirements and our needs for substantial additional financing.

In some cases, forward-looking statements are identified by terminology such as “believes”, “estimates”, “expects”, “intends”, “plans”, “potential”, “may”, “should”, “could”, “might”, “seeks”, “targets”, “will”, “would”, “projects”, “forecasts”, “continues” or “anticipates” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements may be included in, among other things, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements.

This prospectus identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements, particularly those set forth under the heading “Risk Factors.” In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or that historic results referred to in this prospectus would not be interpreted differently in light of additional research and clinical and preclinical trials results.

We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading “Risk Factors” and elsewhere in this prospectus. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events.

[TABLE OF CONTENTS](#)

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this prospectus. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law. In evaluating forward-looking statements, you should consider these risks and uncertainties.

EXCHANGE RATE INFORMATION

As of April 5, 2016, the daily representative exchange rate of NIS per U.S. dollars was 3.802. The following table sets forth information regarding the exchange rates of NIS per U.S. dollars for the periods indicated. Average rates are calculated by using the daily representative rates as reported by the Bank of Israel on the last day of each month during the periods presented.

<u>Year Ended December 31,</u>	<u>NIS per U.S. \$</u>			
	<u>High</u>	<u>Low</u>	<u>Average</u>	<u>Period End</u>
2015	4.053	3.761	3.887	3.902
2014	3.994	3.402	3.578	3.889
2013	3.791	3.471	3.611	3.471
2012	4.084	3.700	3.856	3.733
2011	3.821	3.363	3.578	3.821

<u>Month Ended</u>	<u>NIS per U.S. \$</u>			
	<u>High</u>	<u>Low</u>	<u>Average</u>	<u>Period End</u>
April 2016 (through April 5, 2016)	3.802	3.784	3.791	3.802
March 2016	3.912	3.766	3.868	3.766
February 2016	3.964	3.871	3.908	3.910
January 2016	3.983	3.913	3.951	3.951
December 2015	3.905	3.855	3.881	3.902
November 2015	3.921	3.868	3.889	3.877
October 2015	3.923	3.816	3.863	3.867

PRICE RANGE OF OUR ORDINARY SHARES

Our ordinary shares have been trading on the TASE under the symbol “CLBD” since September 13, 2013, before then our ordinary shares were traded on the TASE under the name TRF Capital Ltd. No trading market currently exists for our ordinary shares in the United States. We intend to apply to list the ADSs on NASDAQ under the symbol “[].” No assurance can be given that our application will be approved.

The following table sets forth, for the periods indicated, the reported high and low closing sale prices of our ordinary shares on the TASE in NIS and U.S. dollars.

	NIS		U.S. dollar (\$)	
	Price Per Ordinary Share		Price Per Ordinary Share ⁽¹⁾	
	High	Low	High	Low
Annual:				
2015	1.626	0.989	0.417	0.253
2014	1.531	0.705	0.392	0.181
2013	2.020	0.182	0.518	0.047
2012	1.706	0.169	0.437	0.043
2011	3.543	1.417	0.908	0.437
Quarterly:				
Second Quarter 2016 (through April 5, 2016)	1.398	1.364	0.358	0.350
First Quarter 2016	1.499	1.207	0.384	0.309
Fourth Quarter 2015	1.472	1.040	0.377	0.267
Third Quarter 2015	1.381	1.143	0.354	0.293
Second Quarter 2015	1.626	1.267	0.417	0.325
First Quarter 2015	1.501	0.989	0.385	0.253
Fourth Quarter 2014	1.102	0.961	0.282	0.246
Third Quarter 2014	1.531	1.008	0.392	0.258
Second Quarter 2014	1.481	0.970	0.380	0.249
First Quarter 2014	1.240	0.705	0.318	0.181
Most Recent Six Months:				
April 2016 (through April 5, 2016)	1.398	1.364	0.358	0.350
March 2016	1.480	1.308	0.379	0.335
February 2016	1.499	1.241	0.384	0.318
January 2016	1.364	1.207	0.350	0.309
December 2015	1.412	1.040	0.362	0.267
November 2015	1.390	1.221	0.356	0.313
October 2015	1.472	1.293	0.377	0.331

(1) Calculated using the exchange rate reported by the Bank of Israel for December 31, 2015 at the rate of one U.S. dollar per NIS 3.902.

As of April 5, 2016, there were 5 shareholders of record of our ordinary shares. The number of record holders is not representative of the number of beneficial holders of our ordinary shares, as the shares of most our shareholders who hold ordinary shares that are traded on the TASE are recorded in the name of our Israeli share registrar, Bank Leumi Registration Company Ltd. As of April 5, 2016, there were no record holders of our ordinary shares in the United States.

USE OF PROCEEDS

We estimate that our net proceeds from this offering will be approximately \$[] million (after deducting underwriting discounts and commissions and estimated offering expenses payable by us) or approximately \$[] million if the underwriters exercise their over-allotment option in full, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. These estimates are based upon an assumed initial public offering price of \$[] per ADS, which was the last reported price of our ordinary shares on the TASE on [], 2016 (based on the exchange rate reported by the Bank of Israel on that date). Each \$1.00 increase (decrease) in the assumed initial public offering price of \$[] per ADS would increase (decrease) the net proceeds to us from this offering by approximately \$[] million, or approximately \$[] million if the underwriter exercise their over-allotment option in full, assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

We currently intend to use the net proceeds from this offering for working capital expenditures and other general corporate purposes. The amounts and schedule of our actual expenditures will depend on multiple factors including the progress of our clinical development and regulatory efforts, the status and results of the clinical trials, the pace of our partnering efforts in regards to manufacturing and commercialization and the overall regulatory environment. Therefore, our management will retain broad discretion over the use of the proceeds from this offering. We may ultimately use the proceeds for different purposes than what we currently intend. Pending any ultimate use of any portion of the proceeds from this offering, if the anticipated proceeds will not be sufficient to fund all the proposed purposes, our management will determine the order of priority for using the proceeds, as well as the amount and sources of other funds needed.

DIVIDENDS AND DIVIDEND POLICY

We have never declared or paid cash dividends to our shareholders. Currently, we do not intend to pay cash dividends. We intend to reinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our board of directors and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, applicable Israeli law and other factors our board of directors may deem relevant. In addition, the distribution of dividends is limited by Israeli law, which permits the distribution of dividends only out of distributable profits. See “Description of Share Capital — Articles of Association — Dividends.” See “Taxation — Israeli Tax Considerations and Government Programs.”

If we pay any dividends, we will also pay such dividends to the ADS holders to the same extent as holders of our ordinary shares, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See “Description of American Depositary Shares.” Cash dividends on our ordinary shares, if any, will be paid to ADS holders in U.S. dollars.

CAPITALIZATION

The following table sets forth our cash and cash equivalents, total debt and capitalization as of December 31, 2015:

- on an actual basis; and
- on a pro forma, as adjusted, basis to also give effect to: our sale of [] ADSs in this offering at an assumed initial public offering price of \$[] per ADS, which was the last reported sale price of our ordinary shares on TASE on [], 2016 (based on the exchange rate reported by the Bank of Israel on that date). You should read this table in conjunction with “Selected Financial Data,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included elsewhere in this prospectus.

The data below based on the December 31, 2015 exchange rate of 3.902 = \$1.00

	As of December 31, 2015	
	Actual	As Adjusted
	In thousands, in \$	
Cash and cash equivalents, and marketable securities	3,009	
Shareholders’ equity:		
Ordinary shares	—	
Share Premium	9,365	
Options	923	
Capital fund from transaction with controlling interest	46	
Treasury shares	(2,415)	
Accumulated deficit	(5,228)	
Total shareholders’ equity	2,691	
Total capitalization	5,700	

A \$1.00 increase (decrease) in the assumed public offering price of \$[] per ADS, would increase (decrease) the as adjusted amount of each of cash and cash equivalents and total shareholders' equity by approximately \$[] million, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A [100,000] ADS increase in the number of ADSs offered by us together with a concomitant \$1.00 increase in the assumed public offering price of \$[] per ADS would increase our as adjusted cash and cash equivalents by approximately \$[] million after deducting estimated underwriting discounts and estimated offering expenses payable by us. Conversely, a [100,000] ADS decrease in the number of ADSs offered by us together with a concomitant \$1.00 decrease in the assumed public offering price of \$[] per ADS would decrease our as adjusted cash and cash equivalents by approximately \$[] million after deducting estimated underwriting discounts and estimated offering expenses payable by us.

The number of ordinary shares that will be outstanding immediately after this offering is based on 81,733,325 ordinary shares outstanding as of April 5, 2016, of which the issuance of 287,769 shares is subject to approval by our shareholders. This number excludes, as of such date:

- 2,686,693 ordinary shares held in treasury;
- 5,443,758 ordinary shares issuable upon the exercise of 5,443,758 options at a weighted average exercise price of NIS 1.39 (\$0.36) per share issuable under 2014 Collect Option Plan, and an additional 1,456,242 ordinary shares reserved for future issuance under our 2014 Collect Option Plan;
- 227,358 ordinary shares issuable upon the exercise of 227,358 options at exercise price of NIS 1.00 (\$0.26) per share issued to a consultant;

TABLE OF CONTENTS

- 600,000 ordinary shares issuable upon the exercise of 600,000 options at exercise price of NIS 2.10 (\$0.56) per share issued to a consultant;
- 4,723,500 ordinary shares issuable upon the exercise of 4,723,500 options (Series 1) at an exercise price of NIS 1.85 (\$0.47) per share; and
- 1,927,801 ordinary shares issuable upon the exercise of 1,927,801 options (Series A) at an exercise price of NIS 2.1 (\$0.54) per share, of which the issuance of 95,923 options is subject to approval by our shareholders.

DILUTION

If you purchase ADSs in this offering, your ownership interest in us will be diluted to the extent of the difference between the public offering price per ADSs you will pay in this offering and the pro forma net tangible book value per ADS after this offering. Dilution results from the fact that the per initial public offering price per ordinary shares is substantially in excess of the book value per ordinary share attributable to the existing shareholders for our presently outstanding ordinary shares.

Our historical net tangible book value as of December 31, 2015, was approximately NIS 10.5 million, or \$2.7 million, corresponding to a net tangible book value of NIS 0.14 or \$0.036 per ordinary share or \$[] per ADS (using the ratio of [] ordinary shares to one ADS), as of such date. We calculate our historical net tangible book value per share or per ADS by taking the amount of our total tangible assets, subtracting the amount of our total liabilities, and then dividing the difference by the actual total number of ordinary shares or ADSs outstanding, as applicable.

The pro forma as adjusted net tangible book value per share as of December 31, 2015 was NIS [] or \$[] per ordinary share or \$[] per ADS (using the ratio of [] ordinary shares to one ADS). The pro forma as adjusted net tangible book value per share gives effect to the sale and issuance of the ADSs in this offering at an offering price of \$[] per ADS, which reflects the last reported sale price of [] of our ordinary shares on the TASE on December 31, 2015, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted net tangible book value per share after the offering is calculated by dividing the pro forma net tangible book value of NIS [] or \$[], by [], which is equal to our pro forma issued and outstanding ordinary shares. The difference between the public offering price and the pro forma net tangible book value per share represents an immediate increase in the net tangible book value of NIS [], or \$[] per ordinary share or \$[] per ADS to existing shareholders and immediate dilution of NIS [], \$[], per share to new investors purchasing the ADSs in this offering.

The following table illustrates this dilution on a per share basis:

Assumed public offering price per ADS	NIS	\$
Actual net tangible book value per ADS as of December 31, 2015		
Increase in net tangible book value per share attributable to purchasers purchasing ADSs in this offering		
Pro forma net tangible book value per share of ADSs, as adjusted to give effect to this offering		
Dilution per ADS to purchasers in this offering	NIS	\$

A \$1.00 increase (decrease) in the assumed initial public offering price of \$[] per ADS would increase (decrease) our pro forma net tangible book value per ADS after this offering by \$[] and the dilution per ADS to new investors by \$[], assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ADSs we are offering.

The following table summarizes, on a pro forma as adjusted basis as of December 31, 2015, the differences between the number of ordinary shares purchased from us (treating each ADS as [] ordinary shares), the total consideration paid to us and the average price per ordinary share paid by existing holders of our ordinary shares and by investors in this offering (treating each ADS as [] ordinary shares) in purchases of the ADSs from us and by purchasers in this offering. As the table shows, new purchasers purchasing ADSs in this offering will pay an average price per ordinary share substantially higher than our existing shareholders paid. The table below is based on [] ordinary shares outstanding immediately after the consummation of this offering (including those represented by the ADSs) and does not give effect to the ordinary shares reserved for future issuance under our 2014 Collect Option Plan, or outstanding warrants. A total of [] ordinary shares have been reserved for future issuance under our 2014 Collect Option Plan, by which we have granted options to purchase [] shares thereunder as of December 31, 2015. We have also reserved for issuance [] ordinary shares for issuance upon the exercise of all outstanding options. The

TABLE OF CONTENTS

table below is based upon a public offering price of NIS [] or \$[], per ordinary share purchased in this offering (treating each ADS as [] ordinary shares), the last reported sales price of our ordinary shares on TASE, after excluding underwriting discounts and commissions and estimated offering expenses payable by us, and assuming no exercise of the underwriter's over-allotment option:

<u>Shares Purchased</u>		<u>Total Consideration</u>			<u>Average Price Per Share (NIS)</u>	<u>Average Price Per Share (USD)</u>
<u>Number</u>	<u>Percent</u>	<u>Amount</u> (thousands in NIS)	<u>Amount</u> (thousands in USD)	<u>Percent</u>		
Existing shareholders	%	\$		%		\$
Purchasers in this offering						
Total	%	\$		%		\$

To the extent that new options are granted under our 2014 Collect Option Plan and/or that any options are exercised, there will be further dilution to investors purchasing ordinary shares represented by the ADSs in this offering.

SELECTED FINANCIAL DATA

The following tables summarize our financial data. We have derived the selected statements of comprehensive loss data for the years ended December 31, 2015, 2014 and 2013 and the balance sheet data as of December 31, 2015 and 2014 from our audited financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future. The following selected financial data should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included elsewhere in this prospectus.

Our financial statements included in this prospectus were prepared in accordance with IFRS, as issued by the IASB, and reported in NIS.

Statements of comprehensive loss data⁽¹⁾

	Year ended December 31,			
	2015	2015	2014	2013
	Convenience translation into USD in thousands ⁽²⁾	NIS in thousands		
Research and development expenses	1,510	5,893	3,058	1,062
General and administrative expenses	1,077	4,204	2,491	2,425
Operating loss	2,587	10,097	5,549	3,487
Financial income	(1)	(4)	(37)	(11)
Financial expenses	20	79	39	202
Financial expenses, net	19	75	2	191
Net loss	2,606	10,172	5,551	3,678
Comprehensive loss	2,606	10,172	5,551	3,678
Loss per ordinary share – basic and diluted	0.035	0.137	0.084	0.075
Weighted average number of shares outstanding used to compute basic and diluted loss per share	74,475,109	74,475,109	65,968,768	49,152,886

Statement of financial position

	Year ended December 31,		
	2015	2015	2014
	Convenience translation into USD in thousands ⁽²⁾	NIS in thousands	
Cash and cash equivalents	1,003	3,913	2,122
Marketable securities – short term	2,006	7,829	11,257
Other receivables	106	412	161
Restricted cash	5	20	20
Property, plant and equipment	304	1,187	234
Total assets	3,424	13,361	13,794
Trade payables	119	466	107
Other payables	614	2,394	728
Total liabilities	733	2,860	835
Total shareholders’ equity	2,691	10,501	12,959

(1) Data on diluted loss per share were not presented in the financial statements because the effect of the exercise of the options and warrants is anti-dilutive.

(2) Calculated using the exchange rate reported by the Bank of Israel for December 31, 2015 at the rate of one U.S. dollar per NIS 3.902.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion along with our financial statements and the related notes included in this prospectus. The following discussion contains forward-looking statements that are subject to risks, uncertainties and assumptions, including those discussed under "Risk Factors." U.S. dollar amounts herein have been translated for the convenience of the reader from the original NIS amounts at the representative rate of exchange as of December 31, 2015 (NIS 3.902 = \$1.00) and as of December 31, 2014 (NIS 3.889 = \$1.00), as applicable. Our actual results, performance and achievements may differ materially from those expressed in, or implied by, these forward-looking statements. See "Special Note About Forward-Looking Statements." We have prepared our financial statements in accordance with IFRS, as issued by the IASB.

Overview

We are an emerging biotechnology company that is developing a novel technology platform known as Collect Inside that functionally selects stem cells in order to improve the safety and efficacy of regenerative medicine stem cell therapies. We aim to become the standard enabling technology for the enrichment of the stem cell population for companies developing stem cell therapies, physicians practicing regenerative medicine, and for researchers and academia engaged in stem cell research.

We believe our innovative technology platform represents a potential breakthrough in the field of regenerative medicine by using functional selection of stem cells. Efficient selection enables retention of most of the stem cells with few mature cells resulting in the near elimination of toxicity provoking cells coupled with the enrichment of the stem cell population.

Our Collect Inside technology platform takes advantage of a functional characteristic of stem cells relating to apoptosis. Apoptosis is the process of programmed cell death and is a vital part of physiological development and maintenance. Stem cells flourish in an environment where normal cells die. Because of their major role in the reconstitution of damaged tissue, stem cells are attracted to areas of cell death, areas typified by very high levels of apoptotic activity and apoptotic-inducing agents. Our research has demonstrated that stem cells are resistant to apoptotic stimulation by the physiological molecules that cause mature cells to self-destruct. We have chosen this *functional* characteristic of stem cells to use apoptosis-inducing proteins to more efficiently select stem cells while neutralizing harmful cells and their associated medical complications.

We are currently developing our first product based on our Collect Inside technology platform, the Apotainer selection kit. The Apotainer selection kit is an easy to use, cost effective, off the shelf stem cell selection kit. The kit is designed for clinical use with the aim of improving the results of human allogeneic (using stem cells from a donor) HSCT for the treatment of hematological malignancies (blood cancers such as leukemia and lymphoma). HSCT, also known as bone marrow transplantation, has for decades been curative for many patients with hematological malignancies. Clinical trials have shown that that HSCT can also be used for other indications but is rarely used due to high toxicity. However, application of allogeneic HSCT is limited by GvHD, a condition in which the transplanted immune cells (populating the graft in much higher numbers than the stem cells) recognize the host cells and organs as foreign and attack them. GvHD does not resolve by itself and is the major cause of transplant-related morbidity and mortality. Despite improvements in the outcome of HSCT over recent years through improved supportive care, infection control and use of reduced intensity and reduced toxicity conditioning regimens, HSCT is still associated with significant morbidity and mortality mainly due to GvHD and as such HSCT is restricted to patients with life threatening diseases. Due to non-efficient selection of stem cells for HSCT, the complex and expansive laboratory process performed using technologies currently available is able to reduce toxicity only at a significant tradeoff — graft rejection, cancer reoccurrence and high costs of treatment.

TABLE OF CONTENTS

We have chosen allogeneic HSCT for the treatment of hematological malignancies as our first target indication for our Collect Inside technology platform in order to clinically validate that our technology can efficiently select stem cells while neutralizing harmful cells and their associated medical complications. We believe that if we are able to demonstrate the clinical utility of our technology for this indication, it will open up the opportunity for the use of our Collect Inside technology platform for the treatment of other indications (e.g., solid organ transplantation and auto-immune diseases) and for the adoption of our Collect Inside technology platform by stem cell therapeutic companies, academia, researchers and others seeking to enrich their stem cell population.

We plan to bring our Apotainer selection kits to market for HSCT as a combination product subject to the primary jurisdiction of the CDRH, which is likely to result in the regulatory path usually followed for medical devices. We believe that this will result in cost savings and reduce time to market and further believe that such proof of concept will open up the opportunity for the licensing of our Collect Inside technology platform to allow for earlier revenues.

All of our research efforts to date have culminated in clinical trials that we plan to begin in 2016. We are currently preparing for a Phase I/II, single arm, open label clinical trial in Israel to evaluate the safety and tolerability and efficacy of functionally selected donor derived mobilized peripheral blood cells that undergo our ApoGraft process in the prevention of acute GvHD in patients suffering from hematological malignancies that are undergoing allogeneic HSCT. In addition, we plan on holding a pre-IND meeting with the FDA in the second half of 2016 using the Apotainer selection kit.

History of Losses

Since our inception, we have generated significant losses in connection with our research and development, including the development of our Collect Inside technology platform. As of December 31, 2015, we had an accumulated deficit of NIS 20.4 million (approximately \$5.2 million). We expect that we will incur additional losses in the near future as a result of our research and development activities. Such research and development activities will require us to obtain and expend further resources if we are to be successful. As a result, we expect to continue to incur operating losses, and we will need to obtain additional funds to further develop our research and development programs.

As a result of, among other things, our research and development activities, as well as our failure to generate revenues since our inception, for the years ended December 31, 2015 and December 31, 2014, our net loss was approximately NIS 10.2 million (approximately \$2.6 million) and NIS 5.6 million (approximately \$1.6 million), respectively.

We have funded our operations primarily through the sale of equity securities (both in private placements and in public offerings on the TASE). From our inception until our first public offering in Israel in April 2015, we raised approximately NIS 20.0 million in various private placements. We received approximately NIS 6.3 million from our first public offering in Israel. Recently, we received approximately NIS 8.0 million from our private offering in Israel in March 2016.

Operating Expenses

Our current operating expenses consist of two components, research and development expenses and general and administrative expenses.

Research and Development Expenses

Our research and development expenses consist primarily of salaries and related personnel expenses, share-based compensation, fees paid to consultants, patent-related legal fees, costs of preclinical studies, and costs for facilities and equipment. We charge all research and development expenses to operations as they are incurred. We expect our research and development expense to remain our primary expense in the near future as we continue to develop our Collect Inside technology platform. Increases or decreases in research and development expenditures are attributable to the number and/or duration of the studies that we conduct.

TABLE OF CONTENTS

During the years ended December 31, 2013, 2014 and 2015, we incurred NIS 1,062,000 (\$295,000), NIS 3,058,000 (\$855,000) and NIS 5,893,000 (\$1.5 million), respectively (based on the average of NIS/USD exchange rates reported by the Bank of Israel for each of the three years ended on these respective dates: 2013 – 3.611, 2014 – 3.578, 2015 – 3.887) in expenses on company-sponsored research and development activities.

We expect that a large percentage of our research and development expense in the future will be incurred in support of our future clinical development projects. Due to the inherently unpredictable nature of clinical development processes, we are unable to estimate with any certainty the costs we will incur in the continued development of Collect Inside technology platform for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations.

While we are currently focused on advancing our Collect Inside technology platform, our future research and development expenses will depend on the clinical success of our Apotainer selection kits and any future product candidates' commercial potential. As we obtain results from clinical studies, we may elect to discontinue or delay clinical studies for our Apotainer selection kits and any future product candidate in certain indications in order to focus our resources on more promising product candidates. Completion of clinical studies may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate.

We expect our research and development expenses to increase in the future from current levels as we continue the advancement of our Collect Inside technology platform. The lengthy process of completing clinical studies and seeking regulatory approval for Apotainer selection kits requires the expenditure of substantial resources. Any failure or delay in completing clinical studies, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.

General and Administrative Expenses

Our general and administrative expenses consist primarily of salaries and expenses related to employee benefits, including share-based compensation, for our general and administrative employees, which includes employees in executive and operational roles, including finance and human resources, as well as consulting, legal and professional services related to our general and administrative operations.

We expect our general and administrative expenses, such as accounting and legal fees, to increase after we become a public company in the United States.

Financial Income and Expenses

Financial income consists primarily of interest income on our cash and cash equivalents and foreign currency exchange income. Financial expenses consist primarily of expenses related to bank charges and foreign currency exchange expense.

[TABLE OF CONTENTS](#)**Results of Operations**

The table below provides our results of operations for the year ended December 31, 2015 as compared to the years ended December 31, 2014 and 2013.

Statements of comprehensive loss data⁽¹⁾

	Year ended December 31,			
	2015	2015	2014	2013
	Convenience translation into USD in thousands ⁽²⁾	NIS in thousands		
Research and development expenses	1,510	5,893	3,058	1,062
General and administrative expenses	1,077	4,204	2,491	2,425
Operating loss	2,587	10,097	5,549	3,487
Financial income	(1)	(4)	(37)	(11)
Financial expenses	20	79	39	202
Financial expenses, net	19	75	2	191
Net loss	2,606	10,172	5,551	3,678
Comprehensive loss	2,606	10,172	5,551	3,678
Loss per ordinary share – basic and diluted	0.035	0.137	0.084	0.075
Weighted average number of shares outstanding used to compute basic and diluted loss per share	74,475,109	74,475,109	65,968,768	49,152,886

Research and Development Expenses

	Year ended December 31,			
	2015	2015	2014	2013
	Convenience translation into USD in thousands ⁽²⁾	NIS in thousands		
Salaries and related fees	702	2,739	1,555	729
Professional services	191	746	400	147
Patents	84	326	169	164
Subcontractors*	335	1,308	354	—
Share-based payments	134	523	512	—
Other expenses	64	251	68	22
Total Research and Development	1,510	5,893	3,058	1,062

* Includes lab and clinical trial materials.

(1) Data on diluted loss per share were not presented in the financial statements because the effect of the exercise of the options and warrants is anti-dilutive.

(2) Calculated using the exchange rate reported by the Bank of Israel for December 31, 2015 at the rate of one U.S. dollar per NIS 3.902.

Year Ended December 31, 2015 Compared to Year Ended December 31, 2014**Research and Development Expenses**

Our research and development expenses for the year ended December 31, 2015 amounted to NIS 5.9 million (\$1.5 million) compared to NIS 3.1 million (approximately \$900,000) for the year ended December 31, 2014. The increase was primarily attributable to an increase of expenses related to third-party preclinical consultants and other expenses related to conducting preclinical trials in an amount of \$330,000 and to an increase of salaries and related personnel expenses in an amount of \$270,000 reflecting an increase in the number of employees engaged in research and development related activities from five to nine.

TABLE OF CONTENTS

General and Administrative Expenses

Our general and administrative expenses for the year ended December 31, 2015 amounted to NIS 4.2 million (\$1.1 million) compared to NIS 2.5 million (\$700,000) for the year ended December 31, 2014. The increase resulted primarily from an increase of \$130,000 in share-based compensation expenses, an increase of payroll in an amount of \$40,000 reflecting an increase of payroll to our employees, an increase of \$140,000 in professional services and an increase of \$52,000 in travel and conference expenses.

Financial Expense, Net

We recognized financial expenses, net of NIS 75,000 (\$19,000) for the year ended December 31, 2015 compared to financial expenses of NIS 2,000 (less than \$1,000) for the year ended December 31, 2014. Financial expenses, net in 2015 were derived mainly from revaluations of foreign-currency-linked cash balances.

Net Loss

As a result of the foregoing research and development, general and administrative expenses, and as we did not yet generate revenues since our inception, our net loss for the year ended December 31, 2015 was NIS 10.2 million (\$2.7 million), compared to our net loss for the year ended December 31, 2014 of NIS 5.6 million (\$1.6 million).

Year Ended December 31, 2014 Compared to Year Ended December 31, 2013

Research and Development Expenses

Our research and development expenses for the year ended December 31, 2014 amounted to NIS 3.1 million (approximately \$900,000) compared to NIS 1.1 million (\$300,000) for the year ended December 31, 2013. The increase was primarily attributable to an increase of expenses related to third-party preclinical consultants and other expenses related to conducting preclinical trials in an amount of \$170,000 and to an increase of salaries and related personnel expenses in an amount of \$200,000 reflecting an increase in the number of employees engaged in research and development related activities from one to five, in addition to an increase of share-based compensation expenses of \$140,000.

General and Administrative Expenses

Our general and administrative expenses for the year ended December 31, 2014 amounted to NIS 2.5 million (approximately \$700,000) compared to NIS 2.4 million (\$670,000) for the year ended December 31, 2013. This slight increase resulted primarily from an increase of payroll in an amount of \$145,000 reflecting an increase of payroll to our employees, offset mainly by a decrease of \$82,000 in share-based compensation expenses, and a decrease of \$77,000 in professional services.

Financial Expenses (Income), Net

We recognized financial expenses, net of \$1,000 for the year ended December 31, 2014, compared to financial expenses, net of \$53,000 for the year ended December 31, 2013. Financial expense in 2013 included interest accrued on loans received from a related party.

Net Loss

As a result of the foregoing research and development and general and administrative expenses, and as we have not yet generated revenues since our inception, our net loss for the year ended December 31, 2014 was NIS 5.6 million (\$1.6 million), compared to our net loss for the year ended December 31, 2013 of NIS 3.7 million (\$1.0 million).

Liquidity and Capital Resources

Since our inception, we have funded our operations primarily through public (in Israel) and private offerings of our equity securities in Israel.

As of December, 2014 and December 31, 2015, we had NIS 13.4 million (\$3.4 million) and NIS 11.7 million (\$3.0 million), respectively, in cash, cash equivalents and marketable securities. During

TABLE OF CONTENTS

the years ended December 31, 2014 and 2015, we incurred a net loss of NIS 5.6 million (\$1.6 million) and NIS 10.2 million (\$2.6 million), respectively, and had negative cash flows from operating activities of NIS 4.4 million (\$1.1 million) and NIS 7.4 million (\$1.9 million), respectively. In addition, on December 31, 2014 and 2015, we had an accumulated deficit of NIS 10.2 million (\$2.6 million) and NIS 20.4 million (\$5.2 million), respectively. In the year ended December 31, 2014, we raised NIS 14.5 million (\$3.7 million) net of issuance costs through the sale of our ordinary shares and in the year ended December 31, 2015, we raised approximately NIS 8.0 million (\$2.0 million) net of issuance costs through the sale of our ordinary shares and exercise of options.

Our activities since inception have consisted principally of raising capital and performing research and development activities. We are considered to be in the development stage as of December 31, 2015, as our principal commercial operations have not commenced. Successful completion of our development programs and, ultimately, the attainment of profitable operations, if any, are dependent on future events, including, among other things, our ability to obtain marketing approval from regulatory authorities and access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances. Although management believes that we will be able to successfully fund our operations, there can be no assurance that we will be able to do so or that we will ever operate profitably. We expect to continue to incur substantial losses over the next several years during our development phase.

In the opinion of our management and based on our current business plans, our balances of cash and cash equivalents will enable us to fund our activities through the end of the second quarter of 2017 if we do not raise additional capital including through this offering. The opinion of our independent registered public accounting firm on our audited financial statements as of and for the year ended December 31, 2015 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. We will require significant additional financing in the future to fund our operations. However, if we do not generate sufficient cash through this offering or otherwise, our cash on hand may not be sufficient to meet our anticipated cash needs.

Net cash used in operating activities was NIS 7.7 million (\$2.0 million) for the year ended December 31, 2015, compared with net cash used in operating activities of approximately NIS 4.4 million (\$1.1 million) for the year ended December 31, 2014, compared with net cash used in operating activities of NIS 2.6 million (\$700,000) for the year ended December 31, 2013. The increases in such periods are primarily due to increases in ongoing research costs.

Net cash provided by investing activities for the year ended December 31, 2015 was NIS 3.2 million (\$820,000), mainly from the sale of marketable securities. Net cash used in investing activities for the year ended December 31, 2014 was NIS 11.5 million (\$2.9 million) and primarily reflects net cash used for investments in marketable securities, in addition to purchases of fixed assets. Net cash used in investing activities for the year ended December 31, 2013 was NIS 100,000 (\$30,000) and primarily reflects changes in restricted cash, as well as purchases of fixed assets.

We had positive cash flow from financing activities of NIS 6.4 million (\$1.6 million) for the year ended December 31, 2015 as compared to positive cash flow of NIS 13.9 million (\$3.6 million) for the year ended December 31, 2014 as compared to positive cash flow of NIS 6.5 million (\$1.7 million) for the year ended December 31, 2013. The positive cash flow from financing activities for the years ended December 31, 2015, 2014 and 2013 was primarily due to public and private offerings in Israel.

Current Outlook

Developing medical devices, conducting clinical trials, obtaining commercial manufacturing capabilities and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. According to our estimates and based on our budget, we believe our existing cash resources and the net proceeds from the current offering will be sufficient to fund our projected cash requirements until the second quarter of 2017. Nevertheless, we will require significant additional financing in the future to fund our operations, including if and when we progress into clinical trials of our Apotainer selection kits, obtain regulatory approval, obtain commercial manufacturing capabilities and commercialize our Collect Inside technology platform. We currently anticipate that, assuming consummation of the current

TABLE OF CONTENTS

offering, we will utilize approximately \$[] million for clinical trial activities over the course of the next 12 months. Our future capital requirements will depend on many factors, including:

- the progress and costs of our clinical trials and other research and development activities;
- the scope, prioritization and number of our clinical trials and other research and development programs;
- the amount of revenues and contributions we receive under future licensing, collaboration, development and commercialization arrangements;
- the costs of the development and expansion of our operational infrastructure;
- the costs and timing of obtaining regulatory approval;
- the ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments;
- the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
- the costs and timing of securing manufacturing arrangements for clinical or commercial production;
- the costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves;
- the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or platforms;
- the magnitude of our general and administrative expenses; and
- any cost that we may incur under future in- and out-licensing arrangements.

Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through the net proceeds from the current offering, additional equity financings and, to the extent we are able to locate and utilize, non-dilutive resources. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to our Collect Inside technology platform, our Apotainer selection kits or any future product candidate. This may raise substantial doubts about our ability to continue as a going concern.

Contractual Obligations

Our significant contractual obligations as of December 31, 2015 included the following (in thousands):

	<u>Total</u>	<u>Less than 1 Year</u>	<u>1 – 3 Years</u>	<u>3 – 5 Years</u>	<u>More than 5 Years</u>
Operating Lease Obligations in NIS	1,207	474	733	—	—
Operating Lease Obligations in \$	309	121	188	—	—

We did not have any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment, as of December 31, 2015.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Quantitative and Qualitative Disclosure of Market Risk

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position, results of operations or cash flows due to adverse changes in financial market prices and rates, including interest rates and foreign exchange rates, of financial instruments. Our market risk exposure is primarily a result of interest rates and foreign currency exchange rates.

TABLE OF CONTENTS

Interest Rate Risk

Following the date of this prospectus, we do not anticipate undertaking any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents and financial assets at fair value. Following the date of this prospectus, we may invest in investment-grade marketable securities with maturities of up to three years, including commercial paper, money market funds, and government/non-government debt securities. The primary objective of our investment activities is to preserve principal while maximizing the income that we receive from our investments without significantly increasing risk and loss. Our investments are exposed to market risk due to fluctuation in interest rates, which may affect our interest income and the fair market value of our investments, if any. We manage this exposure by performing ongoing evaluations of our investments. Due to the short-term maturities, if any, of our investments to date, their carrying value has always approximated their fair value. If we decide to invest in investments other than cash and cash equivalents, it will be our policy to hold such investments to maturity in order to limit our exposure to interest rate fluctuations.

Foreign Currency Exchange Risk

Our foreign currency exposures give rise to market risk associated with exchange rate movements of the NIS, our functional and reporting currency, mainly against the U.S. dollar. Although the NIS is currently our functional currency, a small portion of our expenses are denominated in U.S. dollars. Our U.S. dollar expenses consist principally of payments made to sub-contractors and consultants for clinical trials and other research and development activities as well as payments made to purchase new equipment. We anticipate that our expenses in U.S. dollar will increase in the future. If the NIS fluctuates significantly against the U.S. dollar, it may have a negative impact on our results of operations. To date, fluctuations in the exchange rates have not materially affected our results of operations or financial condition.

To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.

Trend Information

We are a preclinical stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research and development efforts. As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause financial information to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are described in this "Management's Discussion and Analysis of Financial Condition and Results of Operations."

Application of Critical Accounting Policies and Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with IFRS as issued by the IASB. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to our audited financial statements appearing elsewhere in this prospectus, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.

Share-based payment transactions

From time to time we grant to our employees and other service providers remuneration in the form of equity-settled share-based instruments, such as options to purchase ordinary shares.

The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model.

TABLE OF CONTENTS

As for other service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured by reference to the fair value of the equity instruments granted.

The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period in which the performance or service conditions are satisfied, and ending on the date on which the relevant employees become fully entitled to the award.

No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vested irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.

When we change the conditions of the award of equity-settled instruments, an additional expense is recognized beyond the original expense, calculated in respect of a change that increases the total fair value of the remuneration granted or benefits the other service provider according to the fair value on date of change.

Cancellation of the award of equity-settled instruments is accounted for as having vested at the cancellation date and the expense not yet recognized in respect of the award is recognized immediately. However, if the cancelled grant is replaced by a new grant, and is intended as an alternate grant at the date awarded, the cancelled and new awards will both be accounted for as a change to the original award, as described above.

Option Valuations

The determination of the grant date fair value of options using an option pricing model (we utilize the Black-Scholes model) is affected by estimates and assumptions regarding a number of complex and subjective variables. These variables include the expected volatility of our share price over the expected term of the options, share option exercise and cancellation behaviors, risk-free interest rates and expected dividends, which are estimated as follows:

- *Volatility.* The expected share price volatility is based on the historical volatility in the trading price of our ordinary shares as well as comparable companies on the TASE.
- *Expected Term.* The expected term of options granted is based upon historical experience and represents the period of time that options granted are expected to be outstanding.
- *Risk-Free Rate.* The risk-free interest rate is based on the yield from Israeli government bonds with a term equivalent to the contractual life of the options.
- *Expected Dividend Yield.* We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we use an expected dividend yield of zero.

Jumpstart Our Business Startups Act of 2012

We qualify as an “emerging growth company,” as defined in the JOBS Act. For as long as we are deemed an emerging growth company, we are permitted to and intend to take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies, including:

- an exemption from the auditor attestation requirement in the assessment of our internal controls over financial reporting required by Section 404 of the Sarbanes-Oxley Act; and
- an exemption from compliance with any new requirements adopted by the PCAOB, requiring mandatory audit firm rotation or a supplement to the auditor’s report in which the auditor would be required to provide additional information about our audit and our financial statements.

We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act, which such fifth anniversary will occur in 2021. However, if certain events occur prior to the end of such five year period, including if we become a “large accelerated filer,” our annual

[TABLE OF CONTENTS](#)

gross revenues exceed \$1.0 billion or we issue more than \$1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we are choosing to “opt out” of such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

Government Policies and Factors

We believe certain governmental policies and factors could materially affect, directly or indirectly, our operations or your investment. Please see “Risk Factors — Risks Related to Product Development and Regulatory Approval.”

BUSINESS

Business Overview

We are an emerging biotechnology company that has developed a novel technology platform known as Collect Inside that functionally selects stem cells in order to improve the safety and efficacy of regenerative medicine stem cell therapies. We aim to become the standard enabling technology for the enrichment of the stem cell population for companies developing stem cell therapies, physicians practicing regenerative medicine and for researchers and academia engaged in stem cell research.

We believe our innovative technology platform represents a potential breakthrough in the field of regenerative medicine through by using functional selection of stem cells. Efficient selection enables retention of most of the stem cells with few mature cells resulting in the near elimination of toxicity provoking cells coupled with the enrichment of the stem cell population.

Our Collect Inside technology platform takes advantage of a functional characteristic of stem cells relating to apoptosis. Apoptosis is the process of programmed cell death and is a vital part of physiological development and maintenance. Stem cells flourish in an environment where normal cells die. Because of their major role in the reconstitution of damaged tissue, stem cells are attracted to areas of cell death, areas typified by very high levels of apoptotic activity and apoptotic-inducing agents.

We are currently developing our first product based on our Collect Inside technology platform, the Apotainer selection kit. The Apotainer selection kit is an easy to use, cost effective, off the shelf stem cell selection kit. The kit is designed for clinical use with the aim of improving the results of human allogeneic (using stem cells from a donor) HSCT for the treatment of hematological malignancies (blood cancers such as leukemia and lymphoma). HSCT, also known as bone marrow transplantation, has for decades been curative for many patients with hematological malignancies. Clinical trials have shown that that HSCT can also be used for other indications but is rarely used due to high toxicity. However, application of allogeneic HSCT is limited by GvHD, a condition in which the transplanted immune cells (populating the graft in much higher numbers than the stem cells) recognize the host cells and organs as foreign and attack them. GvHD does not resolve by itself and is the major cause of transplant-related morbidity and mortality. Despite improvements in the outcome of HSCT over recent years through improved supportive care, infection control and use of reduced intensity and reduced toxicity conditioning regimens, HSCT is still associated with significant morbidity and mortality mainly due to GvHD, and as such HSCT is restricted to patients with life threatening diseases. Due to non-efficient selection of stem cells for HSCT, the complex and expansive laboratory process performed using technologies currently available is able to reduce toxicity only at a significant tradeoff — graft rejection, cancer reoccurrence and high costs of treatment.

We have chosen allogeneic HSCT for the treatment of hematological malignancies as our first target indication for our Collect Inside technology platform in order to clinically validate that our technology can efficiently select stem cells while neutralizing harmful cells and their associated medical complications. We believe that if we are able to demonstrate the clinical utility of our technology for this indication, it will open up the opportunity for the use of our Collect Inside technology platform for the treatment of other indications (e.g., solid organ transplantation and auto-immune diseases) and for the adoption of our Collect Inside technology platform by stem cell therapeutic companies, academia, researchers and others seeking to enrich their stem cell population.

We plan to bring our Apotainer selection kits to market for HSCT as a combination product subject to the primary jurisdiction of the CDRH, which is likely to result in the regulatory path usually followed for medical devices. We believe that this will result in cost savings and reduce time to market and further believe that such proof of concept will open up the opportunity for the licensing of our Collect Inside technology platform to allow for earlier revenues.

TABLE OF CONTENTS

All of our research efforts to date have culminated in clinical trials that we plan to begin in 2016. We are currently preparing for a Phase I/II, single arm, open label clinical trial in Israel to evaluate the safety and tolerability and efficacy of functionally selected donor derived mobilized peripheral blood cells that undergo our ApoGraft process in the prevention of acute GvHD in patients suffering from hematological malignancies that are undergoing allogeneic HSCT. In addition, we plan on holding a pre-IND meeting with the FDA in the second half of 2016 using the Apotainer selection kit.

Our Strategy

We have developed a novel technology platform, the Collect Inside™ technology platform, for the functional selection of adult stem cells. This technology is expected to improve the safety and efficacy of regenerative medicine stem cell therapies and we aim to become the standard enabling technology for the enrichment of the stem cell population for companies developing stem cell therapies and for researchers and academia engaged in stem cell research.

Key elements of our strategy to accomplish this objective include the following:

- **Achieve relatively quick validation of the use of our Collect Inside technology platform in a clinical setting.** We have chosen allogeneic HSCT for the treatment of hematological malignancies as our first target indication for our Collect Inside technology platform in order to clinically validate that our technology can efficiently select stem cells while eliminating harmful cells and their associated medical complications caused by GvHD. While over one million HSCT procedures have been performed by the end of 2012, according to a study published in the Lancet, we believe hematopoietic cells administered to patients undergoing allogeneic HSCT can be therapeutically optimized. Based on our Collect Inside technology platform, we are currently developing the Apotainer selection kit, an off the shelf stem cell collection kit, which we believe may significantly improve the curative potential of allogeneic HSCT by addressing major complications that currently contribute to the high morbidity and mortality of the procedure resulting from GvHD. We believe that the concomitant reduction of toxicity and increasing efficacy of allogeneic HSCT will allow clinicians to undertake HSCT earlier in the blood cancer treatment protocol.
- **Leverage our scientific, clinical and regulatory expertise to build and advance our Collect Inside technology platform beyond the allogeneic HSCT setting.** Based on the validation of our Apotainer selection kit for clinical use in the allogeneic HSCT setting, we intend to test the kit for solid organ transplantation and auto-immune system disorders (such as Type 1 diabetes, Crohn's disease, psoriasis and lupus). We also intend to develop our Collect Inside technology platform for other sources of stem cells (e.g., cord blood and fat) and other types of stem cells — most notably mesenchymal and neural. We believe that by expanding the various applications, sources and types of stem cells that can be used with our technology, we will establish broad use of our Collect Inside technology platform.
- **Build a diversified product portfolio.** Beginning with the development of our Apotainer selection kit as a combined product or medical device, which we believe will shorten the time to market, we intend to expand our product development and build a diversified product portfolio of Collect Inside products for a broad spectrum of market segments, up to and including all production and research processes for stem cell based products.
- **Selectively engage in strategic partnerships that establish our Collect Inside technology platform as the standard enabling technology for the enrichment of the stem cell population.** We ultimately seek to collaborate with other companies engaged in developing stem cell therapies and research by licensing our Collect Inside technology platform to improve their own stem cell expansion and purification processes. As we believe our Collect Inside technology platform will significantly increase the starting amount of stem cells, we believe stem cell therapy companies, as well as physicians, academics, researchers and others that are focused on stem cells, will have a major advantage if our selection process is integrated into their work protocol as the first step in their expansion process.

TABLE OF CONTENTS

In the short term, we are currently focused on achieving the following critical milestones:

- **Pathway to first-in-human clinical trial:** We are currently finalizing preclinical studies in murines, including safety/toxicity tests as well as calibration and optimization of the materials and the process with a view to commencing a clinical trial in Israel and holding a pre-IND meeting with the FDA during the second half of 2016.
- **Pathway to product prototype:** We are engaged in developing prototypes of our Apotainer selection kit. Recently, we demonstrated a proof of concept for the binding of the apoptotic protein to a polymer without impairing the protein's apoptotic activity. We tested a number of polymers and binding methods and selected the one best suited for manufacturing the stem cell selection kits. We aim to complete development of the prototype Apotainer selection kit by the end of 2016.
- **Patent portfolio enhancement:** We are currently expanding our patent coverage from five to eight patent families.

In the long term, we are focused on leveraging our key assets, including our intellectual property, our scientific team and our facilities, to advance our technologies and are pursuing strategic collaborations with members of academia and industry.

Regenerative Medicine and Cell Therapy

Our business focus is the development of technologies for the functional selection of stem cells in the field of regenerative medicine. According to Regenerative Medicine (2008, 3(1), 1-5 [47]), regenerative medicine is the “process of replacing or regenerating human cells, tissues or organs to restore or establish normal function”. Cell therapy as applied to regenerative medicine holds the promise of regenerating damaged tissues and organs in the body by rejuvenating damaged tissue and by stimulating the body's own repair mechanisms to heal previously irreparable tissues and organs.

Medical cell therapies are classified into two types: allogeneic (cells from a third-party donor) or autologous (cells from one's own body), with each offering its own distinct advantages. Allogeneic cells are beneficial when the patient's own cells, whether due to disease or degeneration, are not as viable as those from a healthy donor. The use of healthy donors' cells is severely limited by the immune system of the patient which rejects the transplanted cells. This rejection is limited to adult cells with stem cells generally evading such rejection. Separation of the immune rejection causing cells from the stem cells is therefore the bottle neck of all stem cell based therapies.

Regenerative medicine can be categorized into major subfields as follows:

Cell Therapy. Cell therapy involves the use of cells, whether derived from adults, children or embryos, third-party donors or patients, from various parts of the body, for the treatment of diseases or injuries. Therapeutic applications may include cancer vaccines, cell based immune-therapy, arthritis, heart disease, diabetes, Parkinson's and Alzheimer's diseases, vision impairments, orthopedic diseases and brain or spinal cord injuries. This subfield also includes the development of growth factors and serums and natural reagents that promote and guide cell development.

Tissue Engineering. This subfield involves using a combination of cells with biomaterials (also called “scaffolds”) to generate partially or fully functional tissues and organs, or using a mixture of technology in a bioprinting process. Some natural materials, like collagen, can be used as biomaterial, but advances in materials science have resulted in a variety of synthetic polymers with attributes that would make them uniquely attractive for certain applications. Therapeutic applications may include heart patch, bone re-growth, wound repair, replacement neo-urinary conduits, saphenous arterial grafts, inter-vertebral disc and spinal cord repair.

Diagnostics and Lab Services. This subfield involves the production and derivation of cell lines that may be used for the development of drugs and treatments for diseases or genetic defects. This sector also includes companies developing devices that are designed and optimized for regenerative medicine techniques, such as specialized catheters for the delivery of cells, tools for the extraction of stem cells and cell-based diagnostic tools.

TABLE OF CONTENTS

All living complex organisms start as a single cell that replicates, differentiates (into various tissues and organs) and perpetuates in an adult through its lifetime. Cell therapy is aimed at tapping into the power of cells to treat disease, regenerate damaged or aged tissue and provide functional as well as cosmetic applications. The most common type of cell therapy has been the replacement of mature, functioning cells such as through blood and platelet transfusions. Since the 1970s, bone marrow and then blood and umbilical cord-derived stem cells have been used to restore immune system cells mainly after chemotherapy and radiation used to treat many cancers. These types of cell therapies have been approved for use world-wide and are typically reimbursed by insurance.

Over the past number of years, cell therapies have been in clinical development to attempt to treat an array of human diseases. The use of autologous (self-derived) cells to create vaccines directed against tumor cells in the body has been demonstrated to be effective and safe in clinical trials. Dendreon Corporation's *Provenge* therapy for prostate cancer received FDA approval in early 2010. Researchers around the globe are evaluating the effectiveness of cell therapy as a form of replacement or regeneration of cells for the treatment of numerous organ diseases or injuries, including those of the brain and spinal cord. Cell therapies are also being evaluated for safety and effectiveness to treat heart disease, autoimmune diseases such as diabetes, inflammatory bowel disease and bone diseases. While no assurances can be given regarding future medical developments, we believe that the field of cell therapy is a subset of biotechnology that holds promise to improve human health, help eliminate disease and minimize or ameliorate the pain and suffering from many common degenerative diseases relating to aging.


Market for Cell-Based Therapies

According to a 2015 report by Visiongain, the world stem cell technologies market is expected to grow from \$7.2 billion in 2014 to \$12 billion in 2018, achieving high revenue growth from 2015 to 2025.

- **The global population is aging.** According to the United Nations Department of Economic and Social Affairs, 2 billion people will be aged 60 and older by 2050, which means an increased prevalence of age-related disease in general and chronic disease in particular. Heavily burdened healthcare systems are looking to regenerative medicine to provide therapies that treat the root causes of chronic diseases rather than just their symptoms.
- **Expansion of stem cell therapies.** Stem cell therapies are being extended to new and prevalent indications such as cardiovascular diseases, neurodegenerative diseases, and autoimmune diseases. The number of cell therapy companies that are currently in Phase II and Phase III trials has been gathering momentum, and we anticipate that new cellular therapy products will appear on the market within the next several years.
- **Potential new source of stem cells.** The last decade has witnessed the emergence of umbilical cord cryopreservation for the storage of newborn blood for future medical use. This new market already affects the field of transplantations with a growing share of cord blood transplantations at the expense of autologous and allogeneic transplantations of hematopoietic cells. In addition, another source of stem cells is fat used for treatment of bone, cartilage and skeleton related diseases as well as for esthetic purposes.
- **Increasing government, strategic partner, and investor support for stem cell research and development.** According to the Alliance for Regenerative Medicine, the stem cell and progenitor therapy market raised \$2.6 billion in public and private funds in 2014, while according to the National Institutes of Health, or NIH, the level of annual support for stem cell research across the NIH is estimated to grow from \$1.179 billion in 2011 to \$1.436 billion in 2016.

TABLE OF CONTENTS

The following table from the 2015 Report of the Alliance for Regenerative Medicine illustrates the wide range of indications being targeted by the stem cell product pipeline:



Our Current Focus: Proof of Concept of our Collect Inside technology platform through the treatment of Haematological Malignancies

Haematological malignancies (blood cancers) comprise a variety of lymphomas and leukemias. A very important treatment protocol for these malignancies involves the use of HSCT. According to the Worldwide Network for Blood & Marrow Transplantation, more than 50,000 HSCTs are performed yearly worldwide, of which 53% are autologous (using stem cells from the patient) and 47% are allogeneic (using stem cells from a donor). In the treatment of leukemia, an allogeneic procedure is usually preferred over autologous due to a higher risk of recurrence of the underlying disease.

HSCT, also known as bone marrow transplantation, relies on the ability of infused hematopoietic stem cells to engraft in the patient's bone marrow, multiply and differentiate into mature blood cells. However, the success of allogeneic HSCT strongly depends upon the degree of immune compatibility between the donor and the host cells. In the majority of cases, the unavailability of fully matching donors results in complications due to rejection by the host.

GvHD is a complication that often develops after a bone marrow or stem cell transplant. GvHD happens when transplanted cells in the donated bone marrow or stem cells (graft) regard the transplant patient's native cells (host) as foreign and attack and destroy them. According to Cancer Research UK, GvHD affects between 20 – 80% of all patients undergoing bone marrow or stem cell transplants. GvHD can be acute or chronic. Acute GvHD, which usually occurs up to three months post transplantation, is associated with diarrhea, rash, liver damage and, in severe cases, can be life-threatening. Chronic GvHD, which usually appears later than three months post transplantation, is associated with skin damage, oral and/or vaginal mucositis, and liver damage. GvHD is treated by repressing the immune system using steroids and chemotherapy. The treatment's adverse effects include increased exposure to infections, recurrent hospital admissions, damage to vital organs and, in some cases, secondary cancers. Both quality of life and life expectancy are significantly decreased in these patients. Unfortunately, many patients are nonresponsive to steroids. The patients that do respond to

TABLE OF CONTENTS

steroids suffer from frequent infections leading to recurrent antibiotic treatments and hospitalizations. These complications are associated with high mortality and morbidity and are a meaningful limiting factor for what would otherwise be the most suitable therapy for cancer and autoimmune diseases.

GvHD can be prevented by depletion of the T-cell population from the donor graft prior to transplantation. Methods used to capture and purge T-cells out of the donor graft include using anti-thymocyte globulin or alemtuzumab, suicide gene therapy, cytotoxic agents and fusion proteins. However, T cells support HSCT engraftment and immune reconstitution and are potent initiators and mediators of graft versus tumor, or GvT, reactions. As such, purging T-cells can result in increased risks of graft failure or delayed immune reconstitution leading to life threatening infection and/or reduced GvT response, increasing the chances of cancer recurrence.

Due to these and other complications and due to the extremely aggressive pre-treatment chemotherapy and irradiation conditioning regimens, allogeneic HSCT is used only when the patient faces immediate life-threatening danger. If allogeneic HSCT could be made safer, it could be used far earlier and more frequently for even more effective treatment of blood cancers. There is widespread awareness of the need for improved immune-system management technologies for HSCT — both to improve outcomes of transplantations that have already taken place and to make transplantation safe enough to become appropriate for older patients and those with earlier-stage diseases.

The use of HSCT has been tested and found to be effective for autoimmune diseases such as juvenile diabetes, Crohn's disease and lupus with the inherent toxicity of HSCT being the major drawback from further use. A safer HSCT could be used for these indications as well as creating immune tolerance for organ transplantation.

We have therefore chosen allogeneic HSCT for the treatment of hematological malignancies as our first target indication for our Collect Inside technology platform in order to clinically validate that our technology can efficiently select stem cells while eliminating harmful cells and their associated medical complications caused by GvHD. However, while GvHD has a sizeable market share with an unmet clinical need that we seek to address, we consider the validation of our technology as an important driver of a much broader utility of our platform technology.

An Unmet Need: Efficient Stem Cell Selection

Typically, there is a very small number of stem cells in the source tissue (1 in 10,000 cells in bone marrow, the tissue with the highest stem cell concentration) and, once removed from the body, these cells have the propensity to differentiate and lose their "stemness". Generation of large quantities of stem cells is therefore very challenging. This scarcity of stem cells within the biological donor samples is a serious obstacle to regenerative medicine and stem cell companies, both in research and in production settings. In addition to stem cell scarcity, another critical problem is the presence in the donor sample of mature cells that trigger immune response and create the major adverse effects associated with transplantation.

There are currently two main methods for attaining a critical mass of stem cells:

- **Morphological stem cell selection:**

Negative selection approach: Elimination of the cells that contribute to engraftment failure, usually T cells. It uses T cell-specific antigens common to all T cells and therefore indiscriminately eliminates all T cells, including the ones responsible for engraftment support and combating tumors. The clinical outcome is reduced engraftment and reoccurrence of the tumor.

Positive selection approach: Retains the stem cells in the graft using only one of the determinants found on stem cells and progenitor cells and therefore a significant number of reconstituting capable cells are discarded. It has been clinically shown that the loss of reconstituting capable cells significantly reduces engraftment.

Both of these approaches have a poor efficacy/toxicity ratio.

TABLE OF CONTENTS

- **Stem cells population expansion:** Most companies expand stem cell numbers in a culture. However, expansion of the reconstituting capable cells while maintaining their level of differentiation is a major challenge. A high number of cells is required initially, as well as a very long culturing time (weeks) during which sterility must be maintained and differentiation avoided. The methodology is very expensive and requires specialized equipment that is not widely available. Moreover, the regulatory demands related to long-term culturing create a significant challenge for these companies.

In short, we believe the prevailing methodologies for stem cell enrichment/expansion in the graft do not adequately meet the need to enrich and purify the biological sample prior to transplantation. We believe our novel Collect Inside technology platform that quickly and effectively enriches the stem cell population while eliminating the unwanted cells in a biological sample will contribute significantly to the growth of the stem cell therapy market.

Our first target market for our Collect Inside technology platform is allogeneic HSCT for hematological malignancies. According to the Center for International Blood & Marrow Transplant Research, over 6,000 allogeneic HSCTs were performed in the United States in 2012 for these two diseases. A 2013 survey conducted by the European Group for Bone Marrow Transplantation in 48 countries (39 European and 9 affiliated) showed that over 10,500 allogeneic HSCTs were performed for leukemias and for lymphoma. We believe that beyond the value of proving and validating our platform technology, these numbers represent a substantial market opportunity for us to prove the benefits of our Collect Inside technology platform.

Our Proprietary Stem Cell Technology Platform

We believe our innovative Collect Inside technology platform represents a potential breakthrough in the field of regenerative medicine through the functional selection of stem cells.

Our technology is based on a decade of research in the field of stem cells in general and hematopoietic stem cells in particular conducted by Dr. Nadir Askenasy, our Chief Scientist. The concept of functional selection suggests that by using functional assays, which are based on the physiological features of stem cells, one can achieve dual goals: (i) the elimination of non stem cells that are responsible for the immune triggering and most of the clinical adverse effects, and (ii) the achievement of a larger and better population of stem cells. We believe this dual effect will allow for safer and improved clinical outcome of transplantations and enable the whole regenerative (transplantation) segment to achieve its full potential.

Stem cells flourish in an environment where there are signals of apoptosis. Apoptosis is the process of programmed cell death and is a vital part of physiological development and maintenance. Because of their major role in the reconstitution of damaged tissue, stem cells are attracted to what are often characterized as disaster areas in which there are very high levels of apoptotic activity and apoptotic-inducing agents. Our research has demonstrated that stem cells are resistant to apoptotic stimulation by the physiological molecules that cause mature cells to self-destruct. We have chosen this *functional* characteristic of stem cells to use apoptosis-inducing proteins to more efficiently select stem cells while eliminating harmful cells and their associated medical complications.

Our preclinical studies to date have shown that the differential sensitivity to the apoptosis signals allows functional selection of the stem cells while at the same time eliminating apoptosis sensitive mature immune cells. We believe this will result in a reduction of GvHD, improved graft acceptance and a dramatic reduction in treatment cost.


The ApoGraft Process

To achieve functional selection of stem cells utilizing our Collect Inside technology platform, we have developed the ApoGraft process, which is intended for the prevention of GvHD in patients with hematological malignancies receiving a transplant of allogeneic, mobilized peripheral blood hematopoietic stem and progenitor cells. Following collection of the cells from a matched related donor, the donor graft is immediately incubated for 2 – 6 hours in the presence of FasL, washed twice and transplanted via intravenous administration. FasL, also known as CD95L, is a type-II transmembrane protein that belongs to the tumor necrosis factor family. The binding of FasL with its receptor induces apoptosis (programmed cell death) that plays an important role in the development, homeostasis, and function of the immune system.

TABLE OF CONTENTS


The apoptotic inducer used in Collect's ApoGraft process is based on a FasL protein known by its commercial name Apo010. Apo010 is a recombinant, soluble, hexameric protein consisting of two trimers of human FasL extracellular domains fused to the dimer-forming collagen domain of human adiponectin. This soluble hexameric structure has been developed to mimic the natural occurring endogenous FasL clustering. Binding of clustered FasL activates its receptor, leading to caspase-dependent apoptosis in susceptible cell populations.

The ApoGraft process is illustrated below:



Apotainer Selection Kit

Our first product that we are developing, the Apotainer selection kit, is an easy to use, cost effective, off the shelf stem cell selection kit for clinical laboratories designed to improve the results of human allogeneic HSCT.



The Apotainer selection kit is a specialized infusion bag which is coated on the inside with FasL. The Apotainer selection kit is designed to create a microenvironment intended to induce apoptosis by creating an ex-vivo microenvironment that resembles the normal physiological conditions where stem cells can migrate to areas of destruction (where apoptotic triggering molecules are abundant) and, once there, proliferate and differentiate into the needed tissue and organ.

Our preclinical research has shown that FasL only appears to activate when immobilized, as in the case of its binding to the plastic film of the Apotainer selection kit. This immobilization to the kit also creates another advantage by eliminating the need to discard the FasL from the graft before transplantation.

The Apotainer selection kit is currently being designed to be used for allogeneic HSCT procedures for patients suffering leukemia in which the donor graft of cells is incubated in the infusion bag for a number of hours and expected to cause the mature GvHD-causing cells expressing the Fas receptor to bind to the bag surface-bound FasL and undergo apoptosis while the hematopoietic stem cells remain active. The Apotainer selection kit thus is expected to harness the differential effect of the apoptotic microenvironment on mature cell and stem cell populations, producing an enriched population of stem cells that are then transfused to the patient.

Preliminary studies conducted by us have shown that selective polymers coated with specific materials in a specific process create an optimal container enabling positive biological activity of FasL while tightly bound. We believe that this polymer-binder-FasL complex is the basis not only for the Apotainer selection kit as currently in development, but also for a line of containers with different designs and sizes to be used for different applications.

Preclinical Studies

As part of our in-vitro studies, and prior to animal studies, we performed studies to determine which apoptotic molecules have the best differential effect on stem and non-stem cells. We have also conducted nine animal studies including murine to murine and human cells to murine transplantation models, using the various sources of human hematopoietic cells (mobilized peripheral blood, bone marrow and umbilical cord blood), the relevant donor type (self, family and unrelated) and measuring the relevant effects (GvHD, mortality, engraftment and anti tumor effect).

TABLE OF CONTENTS

Major preliminary findings include the following:

- Resistance to receptor-mediated apoptosis is an inherent characteristic of stem and progenitor cells;
- Apoptosis-insensitive progenitors are privileged for engraftment through competitive advantage over the apoptosis-sensitive differentiated cells; and
- Using the most stringent conditions for GvHD, there was a statistically significant reduction in mortality rate.

We believe these preliminary findings support our product claim for:

- Selection of stem and progenitor cells based on insensitivity to receptor-mediated apoptosis from all sources;
- Ex vivo selective depletion of GvHD effector cells;
- Accelerated engraftment by ex vivo treatment of umbilical cord blood; and
- Induction of tolerance to grafts and suppression of autoimmunity.

During late 2014 and early 2015, we achieved an important milestone in the development of our stem cell selection kits: proof of feasibility that our apoptosis-inducing protein can be bound to plastic surfaces without compromising the biological activity of the protein. Trials that were conducted in cooperation with American and Israeli partners, including the University of Louisville, Bar-Ilan University and the Israel Center for Plastics and Rubber, showed that on some of the plastic surfaces tested, the bound protein induced apoptosis in the same manner as it had in previous experiments in which the protein was unbound.

In June 2015, we entered into a Joint Product Development Agreement with Entegris Inc., or Entegris (NASDAQ: ENTG), a provider of yield-enhancing materials and solutions for advanced manufacturing processes, or the Entegris Agreement. Under the Entegris Agreement, the parties are collaborating in the development of the polymer film that will be used for the manufacturing of the Apotainer selection kit. The Entegris Agreement contemplates that upon successful development of the polymer film, Entegris will supply the polymer film upon terms to be agreed to between the parties at such time. The parties agree that if Entegris defaults in this obligation, the Company may find an alternate party for manufacturing the polymer system, in which case Entegris would be entitled to 5% of final product sales up to the amount paid by Entegris.

In another collaborative effort, we initiated a line of studies aimed to assess the effect of FasL based selection on mesenchymal stem cells, or MSCs, derived from fat tissue. In collaboration with the Tel-Aviv Medical Center, we used human fat tissue aspirated from patients and performed selection and expansion of the MSCs. MSCs have almost no good markers and the only existing way to select them is based on long term culturing in an environment with a selective pressure. This process usually takes many weeks and is continuously subjected to disruptions caused by infection and maturation of the MSCs. In preliminary studies we showed that using FasL based selection, we can dramatically increase the yield of the MSCs and improve their capacities for repopulation.

In August 2015, we initiated a full preclinical Good Laboratory Practice safety study designed to test safety and engraftment outcome in a murine model ahead of our first planned clinical trial. Complete clinical, biochemical and histology evaluation is being performed by a contract research organization. In December 2015, we announced that results from this study showed that, while the control group had a 50% death rate, the group that was transplanted with bone marrow that underwent our ApoGraft process had no deaths. In addition, with respect to additional parameters, such as clinical signs, weight and histological analysis, no toxicity was found.

Future Studies

We are currently preparing for a Phase I/II, single arm, open label clinical trial to evaluate the safety, tolerability and efficacy of functionally selected donor derived mobilized peripheral blood cells that undergo our ApoGraft process in the prevention of acute GvHD in patients suffering from hematological malignancies that are undergoing allogeneic HSCT. In the study, we expect that the graft will be taken from the donor

TABLE OF CONTENTS

through regularly used apheresis and then the cells will be exposed to short incubation with FasL and then undergo washing and centrifugation to remove the FasL. The resulting cells will then be transfused to the patient according to routine myeloablative procedures. We expect to enroll up to 12 patients with various hematological malignancies in need of allogeneic HSCT. The primary endpoint is expected to be safety and the secondary endpoint is expected to be efficacy measures including incidence of acute GvHD at day 100.

The study is expected to be conducted in a tertiary bone marrow transplant center in Israel. To that end we entered into an agreement with the Rambam Medical Center in Haifa, Israel for the purpose of conducting a clinical trial under approval from the local Institutional Review Board and Israeli Ministry of Health at the medical center.

We intend to undertake the following actions during the following twelve months:

- Complete further preclinical studies, including safety/toxicity tests as well as calibration and optimization of the materials and the process;
- Commence our planned Phase I/II ApoGraft clinical trial;
- Complete the development of our Apotainer selection kits;
- Develop sterilization methods and Apotainer selection kits shelf life;
- Produce initial batches of the Apotainer selection kits for clinical trials; and
- Meet FDA and European regulatory authorities and submit a trial protocol for a clinical trial using the Apotainer selection kit.

Regulatory Status

Our stem cell kits are still under development, and to date we have conducted only animal studies and other preclinical work with respect to our technology platform. We have not made any filing with any regulatory authority seeking approval or clearance for our Collect Inside technology platform or our Apotainer selection kits.

Based on the views of our scientific advisors and following informal discussions with U.S. and European regulatory authorities, we intend to seek regulatory approval of our stem cell kits that we are developing in the United States, Europe and other countries as a combined therapy or Class III “medical device”. We believe that being classified as a medical device as opposed to a medicinal product will result in cost savings and reduce time to market.

Future Applications

Beyond the use of our Collect Inside technology platform in the allogeneic HSCT setting for the treatment of hematological malignancies as currently contemplated, we believe that our technology platform has the potential for a much broader set of usages:

- **Use of HSCT earlier in the blood cancer treatment protocol.** By reducing HSCT toxicity and other complications while increasing efficacy, we believe that our stem cell selection kits will allow clinicians to undertake HSCT earlier in the blood cancer treatment protocol.
- **Broadened use of HSCT to non-life threatening autoimmune disorders.** We intend to initiate clinical trials in autoimmune conditions where HSCT was proven to be beneficial but it was seldom used because of the inherent toxicity. We believe that if we are able to demonstrate significant reduction of inherent toxicity, this will help make HSCT eligible for treatment of diseases such as diabetes (Type i), lupus, Crohn's disease and the like.
- **Broadened use of HSCT to organ transplants.** It has been known for some time that allogeneic HSCT taken from the same donor enhances transplantation tolerance. This phenomenon has been observed not only in numerous animal models, but in humans as well. For example, several clinical trials have reported that kidney transplantation accompanied by a previous HSCT from the same donor was tolerated by the recipient's immune system. We believe that our products could become the major adjunct therapy in any solid organ transplantation to allow tolerance.

TABLE OF CONTENTS

- **Functional selection of cord blood.** Stem cells from the cord blood of newborns can be collected immediately after birth and preserved frozen. Currently, the main impediment of HSCT based on stem cells from cord blood is that the amount of cord blood is very limited. In combination with inefficient selection methods, the quantity of the collected stem cells is minimal. Therefore, the treatment is usually limited to children having low body mass. Physicians have tried using double cord blood and other methods which have resulted in new immune related adverse effects. Under ethical review board approval, we examined more than 150 samples of cord blood and showed that we can achieve approximately 400 times more stem and progenitor cells from any given samples. We believe this may open up the use of cord blood for adult patients in the future.
- **Stem cell expansion.** We already have preliminary indications that our Collect Inside technology platform greatly improves the efficiency of the stem cell expansion process by increasing the initial number of cells that undergoes expansion. Therefore, we believe that companies that currently use stem cell expansion will have a major advantage if our selection process is integrated as the first step in their manufacturing process.
- **Tissue and organ engineering.** One of the objectives of regenerative medicine is to enable the use of stem cells as a reservoir for organ and tissue engineering and, ultimately, transplantation. The goal is that the patient will be able to accept organs or tissues engineered from foreign stem cells. These emerging technologies rely on a sufficient number of stem cells from the donor and the separation of those cells from the donor's immune system in order to avoid rejection. We believe that our functional stem cell selection process can be the optimal solution for such needs.

Research and Development

Our core technology was originally derived from research conducted by the research group of Dr. Nadir Askenasy. Our research and development activities are focused on additional animal models of a variety of diseases, experiments to determine the mechanism of action of our Collect Inside technology platform, and toxicology testing. Once these preliminary preclinical programs have been completed, we expect to begin clinical trials to test the use of products based on our Collect Inside technology platform in humans. During the years ended December 31, 2013, 2014 and 2015, we incurred \$300,000, \$900,000 and \$1.5 million, respectively (based on the average of NIS/USD exchange rates reported by the Bank of Israel for each of the three years ended on these respective dates: 2013 – 3.609, 2014 – 3.578, 2015 – 3.887) in expenses on company-sponsored research and development activities.

Raw Materials and Suppliers

Although most raw materials for the Apotainer selection kits we are developing are readily obtainable from multiple sources, we know of only two manufacturers of FasL, the apoptotic inducing signal. We currently rely on a single source supplier for FasL. We believe that we will be able to obtain a sufficient supply of FasL for our needs in the foreseeable future, although we do not have a supply agreement in place. Although alternative sources of supply exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers.

Any significant delay in the supply of key materials for a preclinical or clinical trial could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these key materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.

Manufacturing

We do not own or operate, and currently have no current plans to establish, any manufacturing facilities. We rely on third-party outsourcing arrangements for our Apotainer selection kits that we are developing as well as other preclinical testing activities. For clinical testing purposes, we intend to rely on third-party outsourcing arrangements as well. Upon completion of development, we may either continue to rely on

TABLE OF CONTENTS

third-party outsourcing arrangements or build a manufacturing facility either on our own or together with a strategic partner. We are currently working with Entegris to jointly develop the polymer film that will be used for the manufacturing of the Apotainer selection kit and may engage Entegris in the future to manufacture the Apotainer selection kits for clinical and/or commercial purposes.

Competition

The field of regenerative medicine is expanding rapidly, in large part through the development of cell-based therapies and/or devices designed to isolate cells from human tissues. As the field grows, we face, and will continue to face, increased competition from pharmaceutical, biopharmaceutical, medical device and biotechnology companies, as well as academic and research institutions and governmental agencies in the United States and abroad. Most regenerative medicine efforts involve sourcing adult stem and regenerative cells from tissues such as bone marrow, placental tissue, umbilical cord and peripheral blood. However, a growing number of companies are using adipose tissue as a cell source.

With the growing number of companies working in the cell therapy field, we, either now or in the future, will be forced to compete across several areas, including equity and capital, clinical trial sites, enrollment of patients in clinical trials, corporate partnerships, skilled and experienced personnel and commercial market share. Many of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We cannot with any accuracy forecast when or if these companies are likely to bring cell therapies to market for indications such as bone marrow transplants which we are also pursuing.

There are currently two companies that lead the stem cell selection market with whom we directly compete. The first is Miltenyi, which dominates the hematopoietic stem cell selection market, using biomarkers to either enrich stem cells (positive selection by CD34) or deplete mature hematopoietic cells such as T cells from the biological sample (negative selection by monoclonal activity against T-cell receptor $\alpha\beta$), resulting in the enrichment of stem and progenitor cells. The second is Cytori, which sells a medical device known as the Celution® System that enables bedside access to adult ADRCs by automating and standardizing the extraction, washing, and concentration of a patient's own ADRCs for present and future clinical use. While Miltenyi is using morphological markers of stem cells to enrich the stem cell population, Cytori is using the physical properties of cells (in general) through centrifugal force for separation. We believe that both technologies result in less than optimal cell population both in terms of quantity and quality (purity) of the selected population of cells.

In addition, since we are developing our Apotainer selection kits to improve the safety and efficacy of allogeneic HSCT, we also compete with companies developing treatments for GvHD. These companies include Athersys, Inc., or Athersys, Bellicum Pharmaceuticals Inc., Erytech Pharma SA, Fate Therapeutics Inc., Fortress Biotech Inc., (formerly Coronado Biosciences), Gamida Cell Ltd., or Gamida, Kiadis Pharma N.V., or Kiadis, MEDIPOST Co., Ltd., Mesoblast Ltd., or Mesoblast, MolMed S.p.A., and Pluristem Therapeutics Inc., or Pluristem.

In the general area of cell-based therapies, we may now or in the future compete on an indirect basis with a variety of companies, most of whom are specialty medical products or biotechnology companies that provide a finished stem cell product that has already undergone stem cell selection including, among others, Advanced Cell Technology, Inc., Arteriocyte Medical Systems Inc., Athersys, Baxter International Inc., Bioheart Inc., Caladarius Biosciences Inc., Nuo Therapeutics, Inc., Fibrocell Science Inc., Gamida, Genzyme Corporation, Harvest Technologies Corporation, In vivo Therapeutics Holdings Corp., Johnson & Johnson, Kiadis, Mesoblast, Neuralstem Inc., Ocata Therapeutics Inc., Osiris Therapeutics, Inc., Pluristem, Tigenix NV, and others. We believe, however, that many of these companies have the potential to become customers in the future of our Collect Inside technology platform in order to improve and enhance their in-house processes.

Intellectual Property

Our success depends in large part on our ability to protect our proprietary technology and to operate without infringing on the proprietary rights of third parties. We rely on a combination of patent, trade secret, copyright and trademark laws, as well as confidentiality agreements, licensing agreements and other agreements, to establish and protect our proprietary rights. Our success also depends, in part, on our ability to avoid infringing patents issued to others. If we were judicially determined to be infringing on any third-party patent, we could be required to pay damages, alter our products or processes, obtain licenses or cease certain activities.

To protect our proprietary functional cell selection technology platform and other scientific discoveries, we have a wide family of patents and patent applications. These patents cover other stem cell related inventions but mainly our functional selection methodology, products and methods of use. The full published domain is further described below:

- A patent entitled “Method of Inducing Immune Tolerance via Blood/Lymph Flow-Restricted Bone Marrow Transplantation” was granted in the United States. If the appropriate maintenance fees are paid, the patent is expected to expire in April 2024 (including a 571 day patent term adjustment granted by the USPTO).
- A patent entitled “Methods of Selecting Stem Cells and Uses Thereof” was granted in the United States, Israel, India and Europe (validated in Denmark, France, Germany, Ireland, Netherlands, Switzerland and the United Kingdom), and is under examination in Canada. If the appropriate maintenance fees are paid, the patent is expected to expire in May 2027 in Israel, India and Europe and in September 2029 in the United States (including an 829 day patent term adjustment granted by the USPTO).
- A patent application entitled “Regulatory Immune Cells with Enhanced Targeted Cell Death Effect” was filed as a Patent Cooperation Treaty, or PCT, application and is now in national phase in the United States, Europe and Israel. If patents are issued from these applications, and if the appropriate maintenance fees are paid, these patents are currently expected to expire in July, 2031.
- A patent application entitled “Devices and Methods for Selecting Apoptosis-Signaling Resistant Cells and Uses Thereof” was filed as a PCT application and is now in national phase in Australia, Brazil, Canada, China, Europe, India, Japan, Korea, Russia, USA and Israel. If patents are issued from these applications, and if the appropriate maintenance fees are paid, these patents are currently expected to expire in March, 2033.
- A patent application entitled “Activation of Hematopoietic Progenitors by Pretransplant Exposure to Death Ligands” was filed as a PCT application and is now in national phase in April, 2016. If patents are issued from these applications, and if the appropriate maintenance fees are paid, these patents are currently expected to expire in October, 2034.

We cannot assure that any of our pending patent applications will be issued, that we will develop additional proprietary products that are patentable, that any patents issued to us will provide us with competitive advantages or will not be challenged by any third parties, or that the patents of others will not prevent the commercialization of products incorporating our technology. Furthermore, we cannot assure that others will not independently develop similar products, duplicate any of our products, or design around our patents. U.S. patent applications are not immediately made public, so we might be surprised by the grant to someone else of a patent on a technology we are actively using.

There is a risk that any patent applications that we file and any patents that we hold or later obtain could be challenged by third parties and declared invalid or infringing of third-party claims. For many of our pending applications, patent interference proceedings may be instituted with the USPTO when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validity of an issued patent. At the completion of the interference proceeding, the USPTO will determine which competing applicant is entitled to the patent, or whether an issued patent is valid. Patent interference proceedings are complex and highly contested, and the USPTO’s decision is subject to appeal. This means that if an interference proceeding arises with respect to any of our patent applications, we may experience

TABLE OF CONTENTS

significant expenses and delay in obtaining a patent, and if the outcome of the proceeding is unfavorable to us, the patent could be issued to a competitor rather than to us. Third parties can file post-grant proceedings in the USPTO, seeking to have issued patent invalidated, within nine months of issuance. This means that patents undergoing post-grant proceedings may be lost, or some or all claims may require amendment or cancellation, if the outcome of the proceedings is unfavorable to us. Post-grant proceedings are complex and could result in a reduction or loss of patent rights.

Patent law outside the United States and Israel is uncertain and in many countries is currently undergoing review and revisions. The laws of some countries may not protect our proprietary rights to the same extent as the laws of the United States and Israel. Third parties may attempt to oppose the issuance of patents to us in foreign countries by initiating opposition proceedings. Opposition proceedings against any of our patent filings in a foreign country could have an adverse effect on our corresponding patents that are issued or pending in the United States or Israel. It may be necessary or useful for us to participate in proceedings to determine the validity of our patents or our competitors' patents that have been issued in countries other than the United States and Israel. This could result in substantial costs, divert our efforts and attention from other aspects of our business, and could have a material adverse effect on our results of operations and financial condition.

In addition to patent protection, we rely on unpatented trade secrets and proprietary technological expertise. We cannot assure you that others will not independently develop or otherwise acquire substantially equivalent techniques, somehow gain access to our trade secrets and proprietary technological expertise or disclose such trade secrets, or that we can ultimately protect our rights to such unpatented trade secrets and proprietary technological expertise. We rely, in part, on confidentiality agreements with our marketing partners, employees, advisors, vendors and consultants to protect our trade secrets and proprietary technological expertise. We cannot assure you that these agreements will not be breached, that we will have adequate remedies for any breach or that our unpatented trade secrets and proprietary technological expertise will not otherwise become known or be independently discovered by competitors.

Environmental Matters

We are subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. We believe that our business, operations and facilities are being operated in compliance in all material respects with applicable environmental and health and safety laws and regulations. Based on information currently available to us, we do not expect environmental costs and contingencies to have a material adverse effect on us. The operation of our testing facilities, however, entails risks in these areas. Significant expenditures could be required in the future if these facilities are required to comply with new or more stringent environmental or health and safety laws, regulations or requirements.

Government Regulation

Any products we may develop and our research and development activities are subject to stringent government regulation. In the United States, these regulations include the Food Drug and Cosmetic Act, or FDCA, and other federal and state statutes and regulations that govern the clinical and preclinical testing, manufacture, safety, effectiveness, approval, labeling, distribution, sale, import, export, storage, record-keeping, reporting, advertising, and promotion of our products. Product development and approval within this regulatory framework, if successful, will take many years and involve the expenditure of substantial resources. Violations of regulatory requirements at any stage may result in various adverse consequences, including the FDA's and other health authorities' delay in approving or refusal to approve a product. Violations of regulatory requirements also may result in enforcement actions.

We are currently in the preclinical stage of development and none of our products have been approved for sale in any market.

United States Regulatory Requirements

Regulation of Combination Products

The FDA has specified a definition for the term “combination product,” which includes: (1) a product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; (2) two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; (3) a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or (4) any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.

The FDA is divided into various “centers” by product type such as the Center for Drug Evaluation and Research, or CDER, the Center for Biologics Evaluation and Research, or CBER, or the CDRH. Different Centers typically review drug, biologic, or device applications. In order to review an application for a combination product, the FDA must decide which center should be the center with primary jurisdiction or the lead center for the review. FDA regulations require that the FDA determine the combination product’s primary mode of action which is the single mode of a combination product that provides the most important therapeutic action of the combination product. The center that regulates that portion of the product that generates the primary mode of action becomes the lead evaluator. If there are two independent modes of action, neither of which is subordinate to the other, the FDA makes a determination as to which center to assign the product based on consistency with other combination products raising similar types of safety and effectiveness questions or to the center with the most expertise in evaluating the most significant safety and effectiveness questions raised by the combination product. When evaluating an application, a lead center may consult other centers but still retain complete reviewing authority, or it may collaborate with another center, by which the center assigns review of a specific section of the application to another center, delegating its review authority for that section. Typically, the FDA requires a single marketing application submitted to the center selected to be the lead evaluator, although the agency has the discretion to require separate applications to more than one center. One reason to submit multiple evaluations is if the applicant wishes to receive some benefit that accrues only from approval under a particular type of application, like new drug product exclusivity. If multiple applications are submitted, each may be evaluated by a different lead center.

Because we believe the primary mode of action for our Apotainer selection kits for HSCT is that of a medical device, we anticipate that when, and if, we apply for approval in the United States, our Apotainer selection kits will be reviewed by the FDA with CDRH having primary jurisdiction for review and regulation, which is likely to result in the regulatory path usually followed for medical devices. While we have had informal discussions with the FDA concerning our regulatory plans, we cannot assure you that the FDA would classify our Apotainer selection kits as a combination product primarily regulated by the CDRH that may qualify for the medical devices approval pathway. If the FDA were to classify our Apotainer selection kits as a drug, biologic or a combination product primarily subject to CDER or CBER jurisdiction, or were to prospectively alter the requirements for obtaining approval, the FDA could require us to meet more burdensome and lengthy approval requirements. Even if such approval could be obtained, we would be subject to more stringent level of post-market regulation as well.

FDA Approval Process

The FDA governs the following activities that we may perform or that may be performed on our behalf, to ensure that the medical devices we may in the future manufacture, promote and distribute domestically or export internationally are safe and effective for their intended uses:

- product design, preclinical and clinical development and manufacture;
- product premarket clearance and approval;

TABLE OF CONTENTS

- product safety, testing, labeling and storage;
- record keeping procedures;
- product marketing, sales and distribution; and
- post-marketing surveillance, complaint handling, medical device reporting, reporting of deaths, serious injuries or device malfunctions and repair or recall of products.

FDA Premarket Clearance and Approval Requirements

Unless an exemption applies, each medical device we wish to commercially distribute in the United States will require either premarket notification, or 510(k) clearance, or approval of a premarket approval application, or PMA, from the FDA. The FDA classifies medical devices into one of three classes. Class I devices, considered to have the lowest risk, are those for which safety and effectiveness can be assured by adherence to the FDA's general regulatory controls for medical devices, which include compliance with the applicable portions of the FDA's Quality System Regulation, or QSR, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials (General Controls). Class II devices are subject to the FDA's General Controls, and any other special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device (Special Controls). Manufacturers of most Class II and some Class I devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA, requesting permission to commercially distribute the device. This process is generally known as 510(k) clearance. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a PMA.

We believe our Apotainer selection kits are likely to be considered as a Class III medical device requiring FDA approval of a PMA.

510(k) Clearance Pathway

When a 510(k) clearance is required, we will be required to submit a 510(k) application demonstrating that our proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of PMAs. By regulation, the FDA is required to clear or deny a 510(k) premarket notification within 90 days of submission of the application. As a practical matter, clearance may take longer. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence.

Once filed, the FDA has 90 days in which to review the 510(k) application and respond. Typically, the FDA's response after reviewing a 510(k) application is a request for additional data or clarification. Depending on the complexity of the application and the amount of data required, the process may be lengthened by several months or more. If additional data, including clinical data, are needed to support our claims, the 510(k) application process may be significantly lengthened.

If the FDA issues an order declaring the device to be Not Substantially Equivalent, or NSE, the device is placed into a Class III or PMA category. At that time, a company can request a de novo classification of the product. De novo generally applies where there is no predicate device and the FDA believes the device is sufficiently safe so that no PMA should be required. The request must be in writing and sent within 30 days from the receipt of the NSE determination. The request should include a description of the device, labeling for the device, reasons for the recommended classification and information to support the recommendation. The de novo process has a 60-day review period. If the FDA classifies the device into Class II, a company will then receive an approval order to market the device. This device type can then be used as a predicate device for future 510(k) submissions. However, if the FDA subsequently determines that the device will remain in the Class III category, the device cannot be marketed until the company has obtained an approved PMA.

Any modification to a 510(k)-cleared device that would constitute a major change in its intended use, or any change that could significantly affect the safety or effectiveness of the device, requires a new 510(k) clearance and may even, in some circumstances, require a PMA if the change raises complex or novel scientific issues or the product has a new intended use. The FDA requires every manufacturer to make the

TABLE OF CONTENTS

determination regarding the need for a new 510(k) submission in the first instance, but the FDA may review any manufacturer's decision. If the FDA were to disagree with any of our determinations that changes did not require a new 510(k) submission, it could require us to cease marketing and distribution and/or recall the modified device until 510(k) clearance or PMA approval is obtained. If the FDA requires us to seek 510(k) clearance or PMA approval for any modifications, we may be required to cease marketing and/or recall the modified device, if already in distribution, until 510(k) clearance or PMA approval is obtained and we could be subject to significant regulatory fines or penalties.

PMA Approval Pathway

A PMA must be submitted to the FDA if the device cannot be cleared through the 510(k) process, or is not otherwise exempt from the FDA's premarket clearance and approval requirements. A PMA must generally be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling, to demonstrate to the FDA's satisfaction the safety and effectiveness of the device for its intended use. During the review period, the FDA will typically request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel's recommendation. In addition, the FDA will generally conduct a pre-approval inspection of our or our third-party manufacturers' or suppliers' manufacturing facility or facilities to ensure compliance with the QSR. Once a PMA is approved, the FDA may require that certain conditions of approval be met, such as conducting a post-market clinical trial.

New PMAs or PMA supplements are required for modifications that affect the safety or effectiveness of the device, including, for example, certain types of modifications to the device's indication for use, manufacturing process, labeling and design. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel.

Clinical trials are generally required to support a PMA application and are sometimes required for 510(k) clearance. Such trials generally require an application for an investigational device exemption, or IDE, which is approved in advance by the FDA for a specified number of patients and study sites, unless the product is deemed a non-significant risk device eligible for more abbreviated IDE requirements. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating, or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. Clinical trials are subject to extensive monitoring, recordkeeping and reporting requirements. Clinical trials must be conducted under the oversight of an institutional review board, or IRB, for the relevant clinical trial sites and must comply with FDA regulations, including, but not limited to, those relating to good clinical practices. To conduct a clinical trial, we also are required to obtain the patient's informed consent in a form and substance that complies with both FDA requirements and state and federal privacy and human subject protection regulations. We, the FDA or the IRB could suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA clearance or approval to market the product in the United States. Similarly, in Europe, the clinical study must be approved by a local ethics committee and in some cases, including studies with high-risk devices, by the ministry of health in the applicable country.

Pervasive and Continuing Regulation

After a device is placed on the market, numerous regulatory requirements continue to apply. In addition to the requirements below, the Medical Device Reporting regulations require that we report to the FDA any incident in which our product may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Additional regulatory requirements include:

- product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;
- QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;
- labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;
- clearance of product modifications that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices;
- approval of product modifications that affect the safety or effectiveness of one of our approved devices;
- post-approval restrictions or conditions, including post-approval study commitments;
- post-market surveillance regulations, which apply, when necessary, to protect the public health or to provide additional safety and effectiveness data for the device;
- the FDA's recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations;
- regulations pertaining to voluntary recalls; and
- notices of corrections or removals.

Advertising and promotion of medical devices, in addition to being regulated by the FDA, are also regulated by the U.S. Federal Trade Commission, or FTC, and by state regulatory and enforcement authorities. Promotional activities for FDA-regulated products of other companies have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. Furthermore, under the federal U.S. Lanham Act and similar state laws, competitors and others can initiate litigation relating to advertising claims. In addition, we are required to meet regulatory requirements in countries outside the United States, which can change rapidly with relatively short notice. If the FDA determines that our promotional materials or training constitutes promotion of an unapproved or uncleared use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.

Failure by us or by our third-party manufacturers and suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other regulatory authorities, which may result in sanctions including, but not limited to:

- untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
- customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;
- operating restrictions or partial suspension or total shutdown of production;
- refusing or delaying requests for 510(k) clearance or PMA approvals of new products or modified products;

TABLE OF CONTENTS

- withdrawing 510(k) clearances or PMA approvals that have already been granted;
- refusing to grant export approval for our products; or
- criminal prosecution.

Human Cells, Tissues, and Cellular and Tissue-Based Products Regulation

Under Section 361 of the U.S. Public Health Service Act, the FDA issued specific regulations governing the use of human cells, tissues and cellular and tissue-based products, or HCT/Ps, in humans. Pursuant to Part 1271 of Title 21 of the Code of Federal Regulations, or Part 1271, the FDA established a unified registration and listing system for establishments that manufacture and process HCT/Ps. The regulations also include provisions pertaining to donor eligibility determinations; current good tissue practices covering all stages of production, including harvesting, processing, manufacture, storage, labeling, packaging, and distribution; and other procedures to prevent the introduction, transmission, and spread of communicable diseases.

The HCT/P regulations strictly constrain the types of products that may be regulated solely under these regulations. Factors considered include the degree of manipulation, whether the product is intended for a homologous function, whether the product has been combined with noncellular or non-tissue components, and the product's effect or dependence on the body's metabolic function. In those instances where cells, tissues, and cellular and tissue-based products have been only minimally manipulated, are intended strictly for homologous use, have not been combined with noncellular or nontissue substances, and do not depend on or have any effect on the body's metabolism, the manufacturer is only required to register with the FDA, submit a list of manufactured products, and adopt and implement procedures for the control of communicable diseases. If one or more of the above factors has been exceeded, the product would be regulated as a drug, biological product, or medical device rather than an HCT/P.

While we do not currently intend to rely on the regulation of HCT/Ps under Part 1271, if we do so in the future, the FDA may disagree with this position or conclude that we do not meet the applicable definitions and exemptions to the regulation. If we are not regulated solely under the HCT/P provisions, we would need to expend significant resources to comply with the FDA's broad regulatory authority under the FDCA.

Pharmaceutical coverage, pricing and reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any products for which we obtain regulatory approval. Sales of any of our products, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the approved drugs for a particular indication.

In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Our products may not be considered medically necessary or cost-effective. A payor's decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development.

The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. The U.S. government, state legislatures and foreign governments

TABLE OF CONTENTS

have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as the drug candidates that we are developing and could adversely affect our net revenue and results.

Pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products.

The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular, the Patient Protection and Affordable Care Act was enacted in the United States in March 2010 and contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies' share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Anti-kickback and false claims laws

In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Violations of the anti-kickback statute are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor.

Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly

TABLE OF CONTENTS

providing free products to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

Other Regulations

We may from time to time become subject to various local, state and federal laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including chemicals, micro-organisms and various radioactive compounds used in connection with our research and development activities. These laws include, but are not limited to, the U.S. Occupational Safety and Health Act, the U.S. Toxic Test Substances Control Act and the U.S. Resource Conservation and Recovery Act. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by state and federal regulations, there can be no assurances that accidental contamination or injury to employees and third parties from these materials will not occur.

Foreign Regulatory Requirements

International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ.

In order to conduct clinical testing on humans in the State of Israel, special authorization must first be obtained from the ethics committee and general manager of the institution in which the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), as amended from time to time, and other applicable legislation. These regulations require authorization by the institutional ethics committee and general manager as well as from the Israeli Ministry of Health, except in certain circumstances, and in the case of genetic trials, special fertility trials and complex clinical trials, an additional authorization of the Ministry of Health's overseeing ethics committee. The institutional ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived from the project to determine if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must ensure that adequate protection exists for the rights and safety of the participants as well as the accuracy of the information gathered in the course of the clinical testing. Since we intend to perform a portion of our clinical studies in Israel, we are required to obtain authorization from the ethics committee and general manager of each institution in which we intend to conduct our clinical trials, and in most cases, from the Israeli Ministry of Health.

The European Union has adopted numerous directives and standards regulating the design, manufacture, clinical trials, labeling, and adverse event reporting for medical devices. Each European Union member state has implemented legislation applying these directives and standards at a national level. Other countries, such as Switzerland, have voluntarily adopted laws and regulations that mirror those of the European Union with respect to medical devices. Devices that comply with the requirements of the laws of the relevant member state applying the applicable European Union directive are entitled to bear a CE mark and, accordingly, can be distributed throughout the member states of the European Union as well as in other countries, such as Switzerland and Israel, that have mutual recognition agreements with the European Union or have adopted the European Union's regulatory standards.

The method of assessing conformity with applicable regulatory requirements varies depending on the classification of the medical device, which may be Class I, Class IIa, Class IIb or Class III. Normally, the method involves a combination of self-assessment by the manufacturer of the safety and performance of the device, and a third-party assessment by a Notified Body, usually of the design of the device and of the manufacturer's quality system. A Notified Body is a private commercial entity that is designated by the national government of a member state as being competent to make independent judgments about whether a device complies with applicable regulatory requirements. An assessment by a Notified Body in one country with the European Union is required in order for a manufacturer to commercially distribute the device

TABLE OF CONTENTS

throughout the European Union. In addition, compliance with ISO 13485 issued by the International Organization for Standardization, among other standards, establishes the presumption of conformity with the essential requirements for CE marking. Certification to the ISO 13485 standard demonstrates the presence of a quality management system that can be used by a manufacturer for design and development, production, installation and servicing of medical devices and the design, development and provision of related services.

Property and Facilities

Our headquarters is currently located in Kfar Saba, Israel and consists of approximately 4,360 square feet of leased office space under a lease until October 14, 2020, with an option to terminate the agreement on October 14, 2018. In addition, we hold options to extend the lease period until October 14, 2022 and until October 14, 2024. We may require additional space and facilities as our business expands.

Legal Proceedings

From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings and except as set forth below, are not aware of any pending or threatened material legal or administrative proceedings against us.

Employees

As of April 5, 2016, we had fourteen full-time employees. These employees are comprised of ten in research and development and four employees in management, finance and administration. From time to time, we also employ independent contractors to support our operations. Our employees are not represented by any collective bargaining agreements and we have never experienced an organized work stoppage.

Historical Background and Corporate Structure

Our legal and commercial name is Collect Biomed Ltd. We were established as a private company limited by shares under the laws of the State of Israel on August 4, 1986, under the name Montiger Ltd. Between 1986 and 2013, we underwent several name changes, most recently on August 28, 2013, when we changed our name from T.R.F. Capital Ltd. to our current name. Since 1990, our shares have been traded on the TASE in Israel.

From October 25, 2012 until July 1, 2013, we did not have any business operations, excluding administrative management. On June 30, 2013, a general meeting of our shareholders approved our merger by way of share exchange with Collect Biotherapeutics. As a result of the merger, which closed on July 1, 2013, Collect Biotherapeutics became a fully owned subsidiary and we issued to shareholders of Collect Biotherapeutics 44,887,373 ordinary shares, options (Series 1) exercisable for 227,358 ordinary shares, and options (Series 2) exercisable for 341,037 ordinary shares, which constituted approximately 85% of our then outstanding share capital and 85% of our then outstanding share capital on a fully diluted basis.

Collect Biotherapeutics was established as a private company limited by shares under the State of Israel on June 9, 2011 for the purpose of developing novel and unique technologies that allow the functional selection of stem cells through the substantial reduction of the complications that exist today in acceptable selection methods and increasing the chances of success of stem cell therapies.

Our principal offices are located at 23 HaTa'as St., Kfar Saba, Israel 44425, and our telephone number is +972-9-974-1444. Our primary internet address is www.collectbio.com. None of the information on our website is incorporated by reference herein.

MANAGEMENT

Executive Officers and Directors

We are managed by a board of directors, which is currently comprised of seven members, and our executive officers. Each of our executive officers is appointed by our board of directors. The table below sets forth our directors and executive officers. The business address for each of our executive officers and directors is c/o Collect Biomed Ltd. 23 Hata'as Street, Kfar Saba, Israel 44425.

<u>Name</u>	<u>Age</u>	<u>Position</u>
Nuriel Chirich Kasbian	57	Chairman of the Board of Directors
Dr. Shai Yarkoni	57	Chief Executive Officer and Director
Ronen Twito	41	Deputy Chief Executive Officer and Chief Financial Officer
Dr. Nadir Askenasy	57	Chief Scientist
Dr. Amotz Nechushtan	56	Vice President of Product Development
Dr. Moran Meiron	44	Vice President of Research and Development
Yaakov Goldman ⁽¹⁾⁽²⁾⁽³⁾	60	Director
Abraham Nahmias ⁽¹⁾	61	Director
Dr. Ruth Ben Yakar	46	Director
Yuval Berman ⁽¹⁾⁽²⁾⁽³⁾	49	External Director
David Grossman ⁽¹⁾⁽²⁾⁽³⁾	41	External Director

(1) Indicates independent director under NASDAQ rules.

(2) Member of our Audit Committee.

(3) Member of our Compensation Committee.

Nuriel Chirich Kasbian co-founded our subsidiary, Collect Biotherapeutics, in 2011 and has served as Chairman of our board of directors since 2013 and of our subsidiary since inception. Mr. Kasbian is an entrepreneur and businessman with extensive financial and business expertise with innovative ventures throughout East Africa and Israel. Mr. Kasbian is a real estate developer and was previously the founder and general manager of Leadcom Kasbian, which is credited, among other things, with establishing the national television of Tanzania and building the infrastructure of two cellular networks in Tanzania. Mr. Kasbian serves as the Honorary Consul of Tanzania in Israel.

Dr. Shai Yarkoni co-founded our subsidiary, Collect Biotherapeutics, in 2011, and has served as our Chief Executive Officer and a director since 2013 and of our subsidiary since inception. Dr. Yarkoni has over 15 years of clinical and management experience in the biopharmaceutical industry. Dr. Yarkoni is a founder of Sne, an Israeli technology transfer company established in 2013. Since 1999, Dr. Yarkoni has also been the Chief Executive Officer and Chairman of GASR Biotechnology, a life sciences consulting and investing firm. From 2009 until 2013, Dr. Yarkoni served as Chief Executive Officer of BioNegev, an international innovation center for biotechnology and life sciences in the Negev region. Prior to that he served as Chief Executive Officer of Target-In Ltd., a developer of therapeutic recombinant proteins for cancer treatment and as Chief Technology Officer and Vice President R&D of Collgard Biopharmaceutical, a tissue therapeutics company, and was an attending OB/GYN specialist practicing for approximately thirteen years. Dr. Yarkoni holds an M.D and Ph.D from the Hadassah Medical School, Jerusalem, Israel, and is a board certified OB/GYN. Dr. Yarkoni is the author of over 60 scientific papers and inventor of approximately 20 patents.

Ronen Twito has served as our Deputy Chief Executive Officer and Chief Financial Officer since November 2015. Prior to joining us, from 2014 to 2015, he served as the VP Finance of BioBlast Pharma Ltd. (NASDAQ: ORPN), a clinical-stage biotechnology development company for rare and ultra-rare genetic diseases. From 2009 to 2014, Mr. Twito served as Deputy Chief Executive Officer and Chief Financial Officer at XTL Biopharmaceuticals, or XTL (NASDAQ: XTLB, TASE: XTL), a late stage clinical development company. Mr. Twito served also as Chief Executive Officer of InterCure, a medical device company specializing in the development and marketing of FDA-cleared hypertension treatment device (a then subsidiary of XTL) (TASE: INCR), from 2012 to 2013. From 2004 to 2009, Mr. Twito served as Corporate Finance Director at Leadcom Integrated Solutions Ltd., an international telecommunications company,

TABLE OF CONTENTS

specializing in management and implementation of network deployment services (then listed on the AIM and TASE). Previously, he served as an Audit Manager at Ernst & Young Israel. Mr. Twito possesses over 15 years of finance and management experience. Mr. Twito is an Israeli Certified Public Accountant and is a member of the Institute of CPAs in Israel. He holds a BSc in Business & Management-Accounting, and a B.Ed in teaching of accounting, both from the Collman Management College in Israel.

Dr. Nadir Askenasy co-founded our subsidiary, Celect Biotherapeutics, in 2011 and has served as our Chief Scientist since 2013 and of our subsidiary since our inception. Since 2010, Dr. Askenasy has been an attending physician in private practice performing immunotherapies and specifically bone marrow transplants. Dr. Askenasy is a founder of the Frankel Laboratory of Experimental Bone Marrow Transplantation, Schneider Children's Medical Center of Israel. Dr. Askenasy is also the founder of the Israel Stem Cell Society. Previously, Dr. Askenasy has served as a senior researcher at John Hopkins University and Carnegie Mellon University. Dr. Askenasy is a physician whose specialty is Internal Medicine and he holds an M.D and Ph.D from Tel Aviv University. Dr. Askenasy is the author of over 100 scientific papers.

Dr. Amotz Nechushtan has served as Vice President of Product Development since March 2016. Prior to that, since July 2015 until March 2016, he served as Vice President of Research and Development Prior to joining the Company, Dr. Nechushtan served as Chief Executive Officer of Ilutem Ltd from 2010 until 2013. Before that he served as Vice President of Research and Development of Target-in Ltd., Pharmaseed Ltd. and Quantomix Ltd. in the years 2001 to 2004. Dr. Nechushtan holds B.Sc., M.Sc. and Ph.D in biochemistry, all from the Hebrew University followed by 5 years post-doc at the NIH Bethesda, Maryland.

Dr. Moran Meiron has served as Vice President of Research and Development since February 2014. Prior to joining the Company, Dr. Meiron served as a Director of Research and Pre-Clinical Affairs at TheraCoat Ltd. since 2012 until 2014; Director of Scientific and Pre-Clinical Affairs at Nephera Ltd. since 2011 until 2012 and as a Director of Research at Pluristem Therapeutics Inc. since 2006 until 2011. Dr. Moran Meiron has a Ph.D in Immunology from the Department of Immunology, Faculty of Medicine at the Institute of Technology, Technion, Israel.

Yaakov Goldman has served as a member of our board of directors since September 2006 and is a member of our audit committee, and compensation committee. Mr. Goldman provides consulting services to companies in strategic-financial areas, through his wholly owned company, Maanit-Goldman Management & Investments (2002) Ltd. Mr. Goldman also serves as a director of Golden House Ltd. (TASE: GOHO), Isrotel Ltd. (TASE: ISRO), Meitav Dash Investments Ltd. (TASE: MTDS), Medi Power (Overseas) Public Co. Limited, Mer Telemanagement Solutions Ltd. (NASDAQ: MTSL) and IceCure Medical Ltd. (TASE: ICCM). From 2003 to 2012, Mr. Goldman served as a director of Elron Electronic Industries Ltd. (TASE: ELRN) and from 2007 to 2012 as a director of Negev Ceramics Ltd. From 2003 to 2010, Mr. Goldman served as a director of Bank Leumi Le'Israel Ltd. and from 2007 to 2009 as Chairman of Amnis Therapeutics Ltd. (TASE: AMNS) (formerly ITGI Medical Ltd.). From 2013 to 2014, Mr. Goldman served as a director of Proteologics Ltd. (TASE: PRTL) and from 2006 to 2014 as a director of Renewable Resources Ltd. and its affiliated companies (private companies). Mr. Goldman served as the Professional Secretary of the Peer Review Institute of the Certified Public Accountants Institute in Israel from 2004 until 2008. Commencing in 1981, Mr. Goldman worked for Kesselman & Kesselman (Israeli member firm of PricewaterhouseCoopers) for 19 years, and from 1991 until 2000, as a partner and then senior partner of such firm. Mr. Goldman holds a B.A. degree in Economics and Accounting from Tel Aviv University and is a Certified Public Accountant (Israel).

Abraham Nahmias has served as a member of our board of directors since July 2014. Since 1985, Mr. Nahmias has served as a founding partner of Nahmias-Grinberg C.P.A., an accounting firm. Mr. Nahmias serves or has served as a member of the board of directors of several private and public companies including Rotshtein Real Estate (TASE: ROTS), Orad Ltd., Allium Medical Ltd. (TASE: ALMD) and Nano Dimension Ltd. (TASE: NNDM). Mr. Nahmias holds a B.A. degree in Economics and Accounting from Tel Aviv University, and has had a C.P.A. license since 1982.

Dr. Ruth Ben Yakar has served as a member of our board of directors since July 2014. She has over 22 years of experience in the biomedical field, including 14 years of management in the biotech industry, leading diverse corporate, business, operational, financial, clinical and regulatory development, and research activities. Dr. Ben Yakar currently serves as Chief Executive Officer of BioSight Ltd., a private Israeli drug

TABLE OF CONTENTS

development company active in the field of oncology as a director on the board of directors at SHL Telemedicine (SHLTN: SW), and as a consultant to several biotech companies. From 2012 until 2014, Dr. Ben Yakar served as the Chief Executive Officer of Procognia (TASE: PRCG), a public biotech company traded on the TASE, and from 2012 until 2015 as a director at Israel Advanced Technology Industries. Prior to that, from 2011 until 2012, Dr. Ben Yakar was the Chief Executive Officer of Thrombotech, a biotechnology company established around thrombotic research at Hadassah Medical Center, where she led a multi-center clinical trial and led the company towards acquisition by D-Pharm Ltd. (TASE: DPRM). Prior to that, from 2009 until 2011, she served as the Chief Business Officer of YEDA Research and Development, the technology transfer company of the Weizmann Institute of Science, or WIS, responsible for the commercialization of the WIS technologies, and a Vice President in several biotech companies. Dr. Ben Yakar holds a PhD cum laude in molecular cell biology from the WIS. Her research, in the field of oncology, yielded several prestigious publications and awards.

Yuval Berman has served as a member of our board of directors since 2009. Mr. Berman serves as one of our external directors and serves on our audit committee, and compensation committee. Mr. Berman is the founder and managing director of U.V.B Business Initiatives Ltd., a business consultancy firm based in Tel Aviv established in 2002. Previously, Mr. Berman worked in the investment banking and underwriting units of Poalim Capital Markets & Investments Ltd. and Omega Investments Ltd., a publicly traded financial services group. Preceding this, Mr. Berman practiced corporate law for four years. Mr. Berman previously served on the board of directors of Elbit Vision Systems Ltd. (Nasdaq: EVSNF), as well as several private companies. He holds an LL.B. and B.A. degrees in Law and Economics from Tel Aviv University and an MBA from the Solvay Business School, Université Libre De Bruxelles. Mr. Berman is a member of the Israeli bar.

David Grossman has served as a member of our board of directors since November 2014. Mr. Grossman serves as one of our external directors and serves on our audit committee, and compensation committee. Since 2015, Mr. Grossman has served on the board of directors of Amnis Therapeutics Ltd. (TASE: AMNS) (formerly ITGI Medical Ltd.) and since 2014 he is the Chairman of Algomizer Ltd. (TASE: ALMO). Mr. Grossman previously served as Chief Executive Officer at XTL from 2009 until 2014, and was also a member of the board of directors from 2009 until 2013. He served as a Vice President of Eurocom Investments LP, a private equity fund, from 2006 to 2009. Also during that time, Mr. Grossman served as Vice President of Sahar Investments Ltd. (TASE: ENLT; formerly SAIN), which focused on investments in the life sciences arena. Prior to that, Mr. Grossman was a Senior Analyst at Israel Health Care Ventures (IHCV), an Israeli healthcare venture capital fund. Mr. Grossman has previously served on a number of boards of public companies including Proteologics Ltd. (TASE: PRTL) and InterCure Ltd. (TASE: INCR) from 2012 to 2013, Rosetta Green Ltd. (TASE: RSTG) from 2011 to 2014, Bio Light Israeli Life Science Investments Ltd. (TASE: BOLT) from 2009 to 2011, and Gilat Satcom Ltd. (AIM: GLT) from 2007 to 2008. Mr. Grossman received a BA in Business Administration with a focus on information technology, from the Interdisciplinary Center Herzliya.

Our Scientific Advisory Team

Our Scientific Advisory Team includes specialists and experts in Israel, with experience in the fields of Biochemistry, infectious diseases and medical research. Our Scientific Advisory Team plays an active role in advising us with respect to our products, technology development, clinical trials and safety. Our Scientific Advisory Team members are entitled, according to their work and contribution to us, to either hourly or monthly consulting fees.

Our Scientific Advisory Team is comprised of the following members:

Professor Dov Zipori is the Director of the Helen and Martin Kimmel Institute for Stem Cell Research at the WIS. Pluristem's technology is based on Prof. Zipori's scientific research.

Dr. Susan Alpert has served as the Director of Medical Device Assessment in the FDA, as well as senior VP Regulatory at Medtronic Inc. (NYSE:MDT) and C. R. BARD Inc.

Professor Robert Negrin is the Medical Director of the Clinical Bone Marrow Transplantation Laboratory and the Division Chief of the Blood and Marrow Transplant Program at Stanford University.

TABLE OF CONTENTS

Professor John F. DiPersio is Chief of Oncology at the Washington University School of Medicine in St. Louis. He specializes in bone marrow transplantations, leukemia, gene therapy and GvHD.

Professor Francesco Dazzi is a specialist in Regenerative and Haematological Medicine and is KHP Lead for Cellular Therapies at King's College London. Professor Dazzi is also a member of editorial boards at leading scientific journals.

Family Relationships

There are no family relationships between any members of our executive management and our directors.

Arrangements for Election of Directors and Members of Management

There are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management or our directors were selected.

Compensation

The aggregate compensation expensed, including share-based compensation and other compensation expensed by us and our subsidiaries to our directors and executive officers with respect to the year ended December 31, 2015 was \$1,113 million.

The table below sets forth the compensation paid to our five most highly compensated senior office holders (as defined in the Companies Law) during or with respect to the year ended December 31, 2015, in the disclosure format of Regulation 21 of the Israeli Securities Regulations (Periodic and Immediate Reports), 1970. We refer to the five individuals for whom disclosure is provided herein as our "Covered Executives."

For purposes of the table and the summary below, and in accordance with the above mentioned securities regulations, "compensation" includes base salary, bonuses, equity-based compensation, retirement or termination payments, benefits and perquisites such as car, phone and social benefits and any undertaking to provide such compensation.

Name and Principal Position	Base Salary (NIS) (including social allowances)	Variable Compensation⁽¹⁾ (NIS)	Equity-Based Compensation⁽²⁾ (NIS)	Consulting fees⁽³⁾ (NIS)	Other (NIS)	Total⁽⁴⁾ (NIS)
Dr. Shai Yarkoni, Chief Executive Officer & Director	886,000	316,000	562,000		68,000	1,832,000
Nuriel Chirich Kasbian, Chairman of the Board of Directors	295,000	34,000	24,000			353,000
Ronen Twito, Deputy Chief Executive Officer & Chief Financial Officer ⁽⁵⁾	145,000		369,000		11,000	525,000
Yaron Diamant, Former Chief Financial Officer ⁽⁶⁾		35,000	11,000	350,000		396,000
Moran Meiron, Vice President of R&D	398,000	10,000	50,000		48,000	506,000
Dr. Amotz Nechushtan, Vice President Product Development	175,000		10,000		22,000	207,000

(1) Amounts reported in this column refer to variable compensation such as commission, incentive and bonus payments as recorded in our financial statements for the year ended December 31, 2015.

(2) Amounts reported in this column represent the expense recorded in our financial statements for the year ended December 31, 2015 with respect to equity-based compensation. Assumptions and key variables used in the calculation of such amounts are described in paragraph d of Note 14 to our audited consolidated financial statements, which are included in this prospectus.

TABLE OF CONTENTS

- (3) Represents consulting fees for persons providing services to us as independent contractors.
- (4) All amounts reported in the table are in terms of cost to our company, as recorded in our financial statements.
- (5) Mr. Twito has served as our Deputy Chief Executive Officer and Chief Financial Officer since November 2015.
- (6) On November 30, 2015, Mr. Diamant ceased to serve as Chief Financial Officer.

On August 26, 2015, we granted options to purchase 72,000 ordinary shares to each of our directors, Mr. Kasbian, Dr. Yarkoni, Mr. Goldman, Mr. Nahmias, Dr. Ben Yakar, Mr. Berman and Mr. Grossman. The options are exercisable at NIS 1.90 per share and expire on August 26, 2025. The options vest each quarter from the date of grant over three years in twelve equal installments.

On December 7, 2015, we granted options to purchase 2,658,246 ordinary shares to Mr. Twito, our Deputy Chief Executive Officer and Chief Financial Officer. The options are exercisable at NIS 1.286 per share and expire on December 7, 2025. The options vest each quarter from the date of grant over three years in twelve equal installments.

On March 8, 2016, as part of a private placement, we granted 23,980 options to purchase 23,980 ordinary shares to Mr. Twito, our Deputy Chief Executive Officer and Chief Financial Officer. The options are exercisable at NIS 2.1 per share and expire on March 7, 2016. The options vest each quarter from the date of grant over two years in eight equal installments.

Employment and Services Agreements

Our employees are employed under the terms prescribed in their respective personal contracts, in accordance with the decisions of our management. Under these employment contracts, the employees are entitled to the social benefits prescribed by law and as otherwise provided in their personal contracts. These employment contracts each contain provisions standard for a company in our industry regarding non-competition, confidentiality of information and assignment of inventions. Under current applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. See “Risk Factors — Risks Related to Our Operations in Israel” for a further description of the enforceability of non-competition clauses. We also provide certain of our employees with a company car, which is leased from a leasing company, and a mobile phone and additional benefits.

Our executive officers are also employed under the terms and conditions prescribed in personal contracts. These personal contracts provide for notice periods of varying duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer will continue to receive base salary and benefits. These agreements also contain customary provisions regarding non-competition, confidentiality of information and assignment of inventions. However, the enforceability of the non-competition and assignment of inventions provisions may be limited under applicable law. See “Risk Factors — Risks Related to Our Operations in Israel.”

Chairman of the Board of Directors Agreement with Nuriel Chirich Kasbian

On April 30, 2013, Collect Biotherapeutics, our subsidiary, entered into a Chairman of the board of directors agreement with Nuriel Chirich Kasbian employing him on a part-time basis as Chairman of the board of directors of the Company and Collect Biotherapeutics. Under the agreement, Mr. Kasbian is entitled to a salary of NIS 10,000 per month commencing July 1, 2013, and increasing in NIS 5,000 increments up to NIS 20,000 per month on each capital raise of over \$2 million. Mr. Kasbian is currently being paid a gross salary of NIS 20,000 per month. In addition, Mr. Kasbian is entitled to a one-time bonus of 0.75% of the amount received in a capital raise if such amount raised is between \$1 million and \$2 million or 1% of the amount received in a capital raise if such amount raised is over \$2 million. As a result of our capital raise of NIS 15,000,000 in May 2014, Mr. Kasbian was paid NIS 166,000 and as a result of our capital raise in 2015, Mr. Kasbian became entitled to NIS 34,000. Mr. Kasbian is entitled to an allocation to a manager’s insurance policy and study fund. Mr. Kasbian is also entitled to reimbursement for reasonable out-of-pocket expenses, including travel expenses. The agreement has a term of 36 months and will be renewable for additional terms of 36 months subject to any approvals that are required by law. The agreement is terminable by either party

TABLE OF CONTENTS

upon 180 days prior written notice and is terminable immediately by Collect Biotherapeutics for cause as such term is defined in the employment agreement.

On August 26, 2015, we granted options to purchase 72,000 ordinary shares to Mr. Kasbian for his service on the board of directors. The options are exercisable at NIS 1.90 per share and expire on August 26, 2025. The options vest each quarter from the date of grant over three years in twelve equal installments.

Employment Agreement with Shai Yarkoni

On April 30, 2013, Collect Biotherapeutics, our subsidiary, entered into an employment agreement with Dr. Shai Yarkoni employing him on full-time basis as Chief Executive Officer of the Company and Collect Biotherapeutics. Under the agreement, commencing May 1, 2013, Dr. Yarkoni is entitled to a salary of NIS 45,000 per month, subject to cost of living increases. In addition, Dr. Yarkoni's salary will increase by 10% on each capital raise of over \$2 million, up to a maximum increase of 20%. Dr. Yarkoni is currently being paid a monthly salary of NIS 54,450. In addition, under the agreement, upon the completion of the reverse merger that was completed on June 30, 2013, Dr. Yarkoni was entitled to a one-time bonus of NIS 100,000 which was paid to him during 2013. In addition, Dr. Yarkoni is entitled to a further one-time bonus of 0.75% of the amount received in a capital raise if such amount raised is between \$1 million and \$2 million or 1% of the amount received in a capital raise if such amount raised is over \$2 million. As a result of our capital raise of NIS 15,000,000 in May 2014, Dr. Yarkoni was paid NIS 166,000 and as a result of our capital raise in 2015, Mr. Yarkoni became entitled to NIS 216,000. Dr. Yarkoni is entitled to an allocation to a manager's insurance policy and study fund. Dr. Yarkoni is also entitled to reimbursement for reasonable out-of-pocket expenses, including travel expenses and a company car and mobile phone. The agreement has a term of 36 months and is terminable by either party upon 180 days prior written notice and terminable immediately by Collect Biotherapeutics for cause as such term is defined in the employment agreement.

On September 8, 2014, we granted options to purchase 1,200,000 ordinary shares to Dr. Yarkoni for his service on the board of directors. The options are exercisable at NIS 1.40 per share and expire on September 8, 2024. The options vest each quarter from the date of grant over three years in twelve equal installments.

On May 6, 2015, a special meeting of shareholders approved the payment of NIS 100,000 to Dr. Yarkoni for his activities in 2014. In addition, at the same meeting, our shareholders approved the targets for the payment of an annual bonus of up to five months' salary for the year 2015 to Dr. Yarkoni as follows: (1) if we raise \$3 million or over and up to \$4 million, Dr. Yarkoni will be entitled to a bonus of one month's salary, (2) if we raise between \$4 million and \$7 million, Dr. Yarkoni will be entitled to a bonus of two months' salary, (3) if we raise over \$7 million, Dr. Yarkoni will be entitled to a bonus of three months' salary, (4) if we stay within the 2015 budget as approved by the board of directors, as may be updated from time to time, Dr. Yarkoni will be entitled to one month's salary, and (v) if the Chairman of the board of directors determines based on an evaluation of the performance of Dr. Yarkoni, Dr. Yarkoni will be entitled to one month's salary.

On August 26, 2015, we granted options to purchase 72,000 ordinary shares to Dr. Yarkoni for his service on the board of directors. The options are exercisable at NIS 1.90 per share and expire on August 26, 2025. The options vest each quarter from the date of grant over three years in twelve equal installments.

Employment Agreement with Ronen Twito

On October 14, 2015, we entered into an employment agreement with Ronen Twito employing him on full-time basis as our Deputy Chief Executive Officer and Chief Financial Officer, effective as of November 3, 2015. Under the agreement, Mr. Twito is entitled to a salary of NIS 52,000 per month, increasing to NIS 60,000 per month upon a successful financing round of more than \$7.5 million or a merger, acquisition or joint venture at a valuation of at least \$10 million. In addition, Mr. Twito is entitled to an annual bonus of up to five months' salary commencing as of January 1, 2016, as determined by our compensation committee. In the case of a fundraising, the bonus payment will be as follows: (1) if we raise over \$4 million and up to \$5 million, Mr. Twito will be entitled to a bonus of two months' salary, (2) if we raise over \$5 million and up to \$7.5 million, Mr. Twito will be entitled to a bonus of three months' salary, (3) if we raise over \$7.5 million and up to \$12 million, Mr. Twito will be entitled to a bonus of four months' salary, and (4) if we raise over \$12 million, Mr. Twito will be entitled to a bonus of five months' salary. Mr. Twito is entitled to an allocation to a manager's insurance policy, pension plan, study fund and disability insurance. Mr. Twito is also entitled

TABLE OF CONTENTS

to reimbursement for reasonable out-of-pocket expenses, including travel expenses and a company car and mobile phone. The agreement will remain in effect unless earlier terminated and is terminable by either party upon four months' prior written notice and terminable immediately by us in the case of a material breach by Mr. Twito of the employment agreement.

Under the agreement, Mr. Twito is entitled to stock options equal to 3.5% of our issued and outstanding shares at an exercise price equal to the average of the trading price of our shares in the 30 trading days preceding the grant. On December 7, 2015, we granted to Mr. Twito options to purchase 2,658,246 ordinary shares at an exercise price of NIS 1.286 per share. The options vest on a quarterly basis in equal installments over 36 months and expire on December 26, 2025. Upon a merger or change of control, the unvested options will vest immediately.

Consulting Agreement with Dr. Nadir Askenasy

On April 30, 2013, Collect Biotherapeutics, our subsidiary, entered into a consulting agreement with Nadir Askenasy retaining him as a consultant of Collect Biotherapeutics. Under the agreement, Dr. Askenasy is entitled to NIS 400 per hour plus VAT. The agreement had an initial term of 12 months and is automatically renewable for additional terms of 12 months unless either party notifies the other that it does not wish to renew at least 60 days prior to the end of the then term. The agreement is terminable by either party upon 30 days prior written notice and is terminable immediately by Collect Biotherapeutics for cause as such term is defined in the employment agreement.

Services Agreement with Dr. Ruth Ben Yakar

In September 2014, a special meeting of shareholders approved entering into a services agreement with Dr. Ruth Ben Yakar under which Dr. Ben Yakar will provide up to 20 hours per month of assistance to our Chief Executive Officer in business development and raising money for a monthly fee of NIS 6,000. In April 2015, our shareholders approved an increase to Dr. Ben Yakar's monthly fee to NIS 14,000 for up to 40 hours per month of services, effective November 15, 2014.

In addition, in September 2014, we granted to Dr. Ben Yakar options to purchase 100,000 ordinary shares at an exercise price of NIS 1.40 per share. The options vest on a quarterly basis in equal installments over 36 months and expire on September 28, 2025.

On August 26, 2015, we granted options to purchase 72,000 ordinary shares to Dr. Ben Yakar for her service on the board of directors. The options are exercisable at NIS 1.90 per share and expire on August 26, 2025. The options vest each quarter from the date of grant over three years in twelve equal installments.

Equity Compensation Plan

We maintain our 2014 Collect Option Plan, which was originally adopted by our board of directors in February 2014 and is scheduled to expire in February 2024. The 2014 Collect Option Plan provides for the grant of options to our directors, officers, employees, consultants, advisers and service providers. The 2014 Collect Option Plan reserved for issuance 7,500,000 ordinary shares. As of April 5, 2016, options to purchase 6,043,758 ordinary shares were outstanding. Of such outstanding options, options to purchase 1,701,199 ordinary shares were vested as of April 5, 2016, with a weighted average exercise price of NIS 1.41 per share, and will expire 10 years from the date of grant, during the years 2024 – 2026.

The 2014 Collect Option Plan provides for options to be granted at the determination of our board of directors (which is entitled to delegate its powers under the 2014 Collect Option Plan to our compensation committee) in accordance with applicable laws. Upon termination of employment for any reason, other than in the event of death or disability or for cause, all unvested options will expire and all vested options at time of termination will generally be exercisable for 90 days following termination, subject to the terms of the 2014 Collect Option Plan and the governing option agreement. If we terminate a grantee for cause (as defined in the 2014 Collect Option Plan) the grantee's right to exercise all vested and unvested the options granted to him or her will expire immediately. Upon termination of employment due to death or disability, all the vested options at the time of termination will be exercisable for 12 months after date of termination, subject to the terms of the 2014 Collect Option Plan and the governing option agreement.

TABLE OF CONTENTS

Pursuant to the 2014 Collect Option Plan, we may award options pursuant to Section 102 of the Israeli Income Tax Ordinance, or the Ordinance, and section 3(I) of the Ordinance, based on entitlement and compliance with the terms for receiving options under these sections of the Ordinance. Section 102 of the Ordinance provides to employees, directors and officers who are not controlling shareholders (i.e., such persons are not deemed to hold 10% of our share capital, or to be entitled to 10% of our profits or to appoint a director to our board of directors) and are Israeli residents, favorable tax treatment for compensation in the form of shares or options issued or granted, as applicable, to a trustee under the “capital gains track” for the benefit of the applicable employee, director or officer and are (or were) to be held by the trustee for at least two years after the date of grant or issuance. Options granted under Section 102 of the Ordinance will be deposited with a trustee appointed by us in accordance with Section 102 of the Ordinance and the relevant income tax regulations and guidelines, and will be granted in the employee income track or the capital gains track.

Options granted under the 2014 Collect Option Plan are subject to applicable vesting schedules and generally expire ten years from the grant date.

In the event that options allocated under the 2014 Collect Option Plan expire or otherwise terminate in accordance with the provisions of the 2014 Collect Option Plan, such expired or terminated options will become available for future grant awards and allocations under the 2014 Collect Option Plan.

Corporate Governance Practices

Companies incorporated under the laws of the State of Israel whose shares are publicly traded, including companies with shares listed on NASDAQ, are considered public companies under Israeli law and are required to comply with various corporate governance requirements under Israeli law relating to such matters as external directors, the audit committee, the compensation committee and an internal auditor. These requirements are in addition to the corporate governance requirements imposed by the listing rules of NASDAQ and other applicable provisions of U.S. securities laws to which we will become subject (as a foreign private issuer) upon the closing of this offering and, subject to approval of our listing application, the listing of the ADSs on NASDAQ. Under the listing rules of NASDAQ, a foreign private issuer, such as us, may generally follow its home country rules of corporate governance in lieu of the comparable requirements of the listing rules of NASDAQ, except for certain matters including (among others) the composition and responsibilities of the audit committee and the independence of its members within the meaning of the rules and regulations of the SEC.

NASDAQ listing rules and Home Country Practices

In accordance with Israeli law and practice, and subject to the exemption set forth in Rule 5615 of the listing rules of NASDAQ, if we are approved for listing on NASDAQ we intend to follow the provisions of the Companies Law, rather than the listing rules of NASDAQ, with respect to the following requirements:

Distribution of certain reports to shareholders. As opposed to the listing rules of NASDAQ, which require listed issuers to make certain reports, such as annual reports, interim reports and quarterly reports, available to shareholders in one of a number of specific manners, Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders, but to make such reports available through a public website. In addition to making such reports available on a public website, we plan to make our audited financial statements available to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC’s proxy solicitation rules. See “Where You Can Find More Information” for a description of our Exchange Act reporting obligations.

Nomination of directors. With the exception of our external directors and directors elected by our board of directors due to vacancy, our directors are elected by an annual meeting of our shareholders to hold office until the next annual meeting following his or her election. See “Management — Board Practices.” The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of directors itself, in accordance with the provisions of our articles of association and the Companies Law. One or more shareholders of a company holding at least 1% of the voting power of the company may nominate a currently serving external director for an additional three year term. Nominations

TABLE OF CONTENTS

need not be made by a nominating committee of our board of directors consisting solely of independent directors or by independent directors constituting a majority of independent directors, as required under the listing rules of NASDAQ.

Compensation of officers. We follow the provisions of the Companies Law with respect to matters in connection with the composition and responsibilities of our compensation committee, office holder compensation and any required approval by the shareholders of such compensation. Israeli law and our articles of association do not require that the independent members of our board of directors, or a compensation committee composed solely of independent members of our board of directors, determine an executive officer's compensation, as is generally required under the listing rules of NASDAQ with respect to the Chief Executive Officer and all other executive officers of a company. However, Israeli law and our articles of association do require that our audit and compensation committees each contain two external directors (as defined in the Companies Law. See "Management — Board Practices — External Directors."). In addition, Israeli law requires that additional members of the compensation committee and the external directors be compensated equally. Our compensation committee has been established and conducts itself in accordance with the provisions governing the composition of and the responsibilities of a compensation committee as set forth in the Companies Law. Furthermore, compensation of office holders is determined and approved by our compensation committee, and in general, by our board of directors as well, and in certain circumstances by our shareholders, as detailed below under the caption "— Shareholder Approval." Thus, we will seek shareholder approval for all corporate actions with respect to office holder compensation (including the compensation required to be approved for our Chief Executive Officer) requiring such approval under the requirements of the Companies Law, including seeking prior approval of the shareholders for the compensation policy and for certain office holder compensation, rather than seeking approval for such corporate actions in accordance with listing rules of NASDAQ. See "— Compensation Committee and Compensation Policy" below.

Compensation Committee. Pursuant to the Companies Law, we established a compensation committee as detailed below. Prior to the consummation of this offering, our board of directors will have affirmatively determined that each member of our compensation committee qualifies as "independent" under applicable NASDAQ and SEC rules.

Independent directors. Israeli law does not require that a majority of the directors serving on our board of directors be "independent," as defined under NASDAQ Listing Rule 5605(a)(2), but rather requires we have at least two external directors who meet the requirements of the Companies Law, as described below under "Management — Board Practices — External Directors." We are required, however, to ensure that all members of our audit committee are "independent" under the Companies Law and the applicable NASDAQ and SEC criteria for independence, and under Israeli law, the audit committee and compensation committee must each include all external directors then serving on our board of directors. We must also ensure that a majority of the members of our audit committee are "unaffiliated directors" as defined in the Companies Law, as described below under the caption "— Audit Committee." However, while not required by Israeli law, as of the date of this prospectus, a majority of our directors are independent. Prior to the consummation of this offering, our board of directors will have affirmatively determined that each of: David Grossman, Yuval Berman, Yaakov Goldman, and Abraham Nahmias qualifies as "independent" under NASDAQ independence standards.

Shareholder approval. We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporate actions in accordance with NASDAQ Listing Rule 5635. In particular, under this NASDAQ rule, shareholder approval is generally required for: (i) an acquisition of shares or assets of another company that involves the issuance of 20% or more of the acquirer's shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption or material amendment of equity compensation arrangements; and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (or via sales by directors, officers or 5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Companies Law, shareholder approval is required for, among other things: (a) transactions

TABLE OF CONTENTS

with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, (b) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval described below under “Disclosure of personal interests of controlling shareholders and approval of certain transactions,” (c) terms of office and employment or other engagement of our controlling shareholder, if any, or such controlling shareholder’s relative, which require the special approval described below under “Disclosure of personal interests of controlling shareholders and approval of certain transactions,” (d) approval of transactions with company’s Chief Executive Officer with respect to his or her compensation, whether in accordance with the approved compensation policy of the company or not in accordance with the approved compensation policy of the company, or transactions with officers of the company not in accordance with the approved compensation policy, and (e) approval of the compensation policy of the company for office holders. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies. See also “Description of Share Capital — Acquisitions under Israeli Law — Merger” below.

Quorum for shareholders meetings. As permitted under the Companies Law, pursuant to our articles of association, the quorum required for a general meeting of shareholders will consist of two or more shareholders present in person, by proxy or by other voting instrument in accordance with the Companies Law, who hold, in the aggregate, at least 33 1/3% of the voting power of our shares (and in an adjourned meeting, any number of shareholders), instead of 33 1/3% of the issued share capital required under NASDAQ corporate governance rules.

Other than the foregoing home country practices, we otherwise intend to comply with the rules generally applicable to U.S. domestic companies listed on NASDAQ. We may in the future decide to use the foreign private issuer exemption with respect to some or all of the other NASDAQ corporate governance rules. Following our home country corporate governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on NASDAQ may provide less protection to you than what is accorded to investors under the listing rules of NASDAQ applicable to domestic U.S. issuers.

Board practices

Board of Directors

Under the Companies Law and our articles of association, our board of directors directs our policy and supervises the performance of our Chief Executive Officer. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors. All other executive officers are also appointed by our board of directors, and are subject to the terms of any applicable employment or services agreements that we may enter into with them or with certain entities through which we receive their services.

Prior to the consummation of this offering, our board of directors will have affirmatively determined that a majority of our directors are independent, and we will therefore be in compliance with NASDAQ rules. Prior to the consummation of this offering, our board of directors will have affirmatively that all of our directors other than Dr. Shai Yarkoni and Nuriel Chirich Kasbian are independent under such rules. The definition of independent director under the NASDAQ rules and external director under the Companies Law overlap to a significant degree such that we would generally expect the two directors serving as external directors to satisfy the requirements to be independent under NASDAQ rules. The definition of external director includes a set of statutory criteria that must be satisfied, including criteria whose aim is to ensure that there is no factor which would impair the ability of the external director to exercise independent judgment. The definition of independent director specifies similar, if slightly less stringent, requirements in addition to the requirement that the board of directors consider any factor which would impair the ability of the independent director to exercise independent judgment. In addition, our external directors each serve for a period of three years. However, external directors must be elected by a special majority of shareholders, while independent directors may be elected by an ordinary majority. See “— External Directors” below for a description of the requirements under the Companies Law for a director to serve as an external director.

TABLE OF CONTENTS

Under our articles of association, our board of directors must consist of at least five and not more than eight directors, including at least two external directors required to be appointed under the Companies Law. Our board of directors currently consists of seven members, including our non-executive Chairman of the board of directors.

Under a founders agreement among Nuriel Chirich Kasbian, our Chairman, Dr. Shai Yarkoni, our Chief Executive Officer and director, and Dr. Nadir Askenasy, our Chief Scientist, each founder holding at least 30% of our share capital shall be entitled to recommend the appointment of one director (and remove any director so appointed). See “Related Party Transactions” below. We are not a party to this founders agreement and are not bound by it. Other than our two external directors, our directors are elected by an ordinary resolution at the annual and/or special general meeting of our shareholders. Because our ordinary shares do not have cumulative voting rights in the election of directors, the holders of a majority of the voting power represented at a shareholders meeting have the power to elect all of our directors, subject to the special approval requirements for external directors. See “— External Directors” below. We have held elections for each of our non-external directors at each annual meeting of our shareholders since our initial public offering in Israel.

In addition, our articles of association allow our board of directors to appoint directors to fill vacancies on our board of directors, for a term of office ending on the earlier of the next annual general meeting of our shareholders, or the conclusion of the term of office in accordance with our articles of association or any applicable law, subject to the maximum number of directors allowed under the articles of association. External directors are elected for an initial term of three years and may be elected for up to two additional three-year terms, provided that, for Israeli companies traded on NASDAQ and certain other international exchanges, such term may be extended indefinitely in increments of additional three-year terms. External directors may be removed from office only under the limited circumstances set forth in the Companies Law. See “— External Directors” below.

Under the Companies Law, our board of directors must determine the minimum number of directors who are required to have accounting and financial expertise. See “— External Directors.” In determining the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of directors of our company who are required to have accounting and financial expertise is two. Our board of directors has determined that Yuval Berman and Yaakov Goldman have accounting and financial expertise and possess professional qualifications as required under the Companies Law.

Chairman of the Board

Our articles of association provide that the Chairman of the board of directors is appointed by the members of the board of directors and serves as Chairman of the board of directors throughout his term as a director, unless resolved otherwise by the board of directors. Under the Companies Law, the Chief Executive Officer or a relative of the Chief Executive Officer may not serve as the Chairman of the board of directors, and the Chairman or a relative of the Chairman may not be vested with authorities of the Chief Executive Officer without shareholder approval consisting of a majority vote of the shares present and voting at a shareholders meeting, provided that either:

- such majority includes at least 2/3 of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such appointment, present and voting at such meeting (not including abstaining shareholders); or
- the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such appointment voting against such appointment does not exceed 2% of the aggregate voting rights in the company.

TABLE OF CONTENTS

In addition, a person subordinated, directly or indirectly, to the Chief Executive Officer may not serve as the Chairman of the board of directors; the Chairman of the board of directors may not be vested with authorities that are granted to those subordinated to the Chief Executive Officer; and the Chairman of the board of directors may not serve in any other position in the company or a controlled company, except as a director or Chairman of a controlled company.

External Directors

Under the Companies Law, an Israeli company whose shares have been offered to the public or whose shares are listed for trading on a stock exchange in or outside of Israel is required to appoint at least two external directors to serve on its board of directors. External directors must meet stringent standards of independence.

According to regulations promulgated under the Companies law, at least one of the external directors is required to have “financial and accounting expertise,” unless another member of the audit committee, who is an independent director under the NASDAQ Stock Market rules, has “financial and accounting expertise,” and the other external director or directors are required to have “professional expertise”. An external director may not be appointed to an additional term unless: (1) such director has “accounting and financial expertise;” or (2) he or she has “professional expertise,” and on the date of appointment for another term there is another external director who has “accounting and financial expertise” and the number of “accounting and financial experts” on the board of directors is at least equal to the minimum number determined appropriate by the board of directors.

A director has “professional expertise” if he or she holds an academic degree in certain fields or has at least five years of experience in certain senior positions.

David Grossman and Yuval Berman have served as our external directors since 2014 and 2009 respectively, and both have the requisite accounting and financial expertise. David Grossman was elected to serve from November 9, 2014 to November 9, 2017. Yuval Berman was initially elected to serve from August 27, 2009 to August 27, 2012, reelected to serve an additional term from August 27, 2012 and until August 27, 2015 and reelected to serve a final term from August 27, 2015 until August 27, 2018. Our board of directors has determined that Yuval Berman has accounting and financial expertise.

The provisions of the Companies Law set forth special approval requirements for the election of external directors. External directors must be elected by a majority vote of the shares present and voting at a shareholders meeting, provided that either:

- such majority includes at least a majority of the shares held by all shareholders who are non-controlling shareholders and do not have a personal interest in the election of the external director (other than a personal interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding abstentions, to which we refer as a disinterested majority; or
- the total number of shares voted by non-controlling shareholders and by shareholders who do not have a personal interest in the election of the external director, against the election of the external director, does not exceed 2% of the aggregate voting rights in the company.

The term controlling shareholder is defined in the Companies Law as a shareholder with the ability to direct the activities of the company, excluding such ability deriving solely from his or her position as a director of the company or from any other position with the company. A shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in a company or has the right to appoint the majority of the directors of the company or its general manager. With respect to certain matters, a controlling shareholder is deemed to include a shareholder that holds 25% or more of the voting rights in a public company if no other shareholder holds more than 50% of the voting rights in the company.

TABLE OF CONTENTS

The initial term of an external director is three years. Thereafter, an external director may be reelected by shareholders to serve in that capacity for up to two additional three-year terms, except as provided below, provided that either:

- his or her service for each such additional term is recommended by one or more shareholders holding at least 1% of the company's voting rights and is approved at a shareholders meeting by a disinterested majority, where the total number of shares held by non-controlling, disinterested shareholders voting for such reelection exceeds 2% of the aggregate voting rights in the company. In such event, the external director so reappointed may not be a Related or Competing Shareholder, as defined below, or a relative of such shareholder, at the time of the appointment, and is not and has not had any affiliation with a Related or Competing Shareholder, at such time or during the two years preceding such person's reappointment to serve an additional term as external director. The term "Related or Competing Shareholder" means a shareholder proposing the reappointment or a shareholder holding 5% or more of the outstanding shares or voting rights of the company, provided, that at the time of the reappointment, such shareholder, the controlling shareholder of such shareholder, or a company controlled by such shareholder, have a business relationship with the company or are competitors of the company.

Additionally, the Israeli Minister of Justice, in consultation with the ISA, may determine matters that under certain conditions will not constitute a business relationship or competition with the company; or

- his or her service for each such additional term is recommended by the board of directors and is approved at a shareholders meeting by the same majority required for the initial election of an external director (as described above).

The term of office for external directors for Israeli companies traded on certain foreign stock exchanges, including NASDAQ, may be extended indefinitely in increments of additional three-year terms, in each case provided that the audit committee and the board of directors of the company confirm that, in light of the external director's expertise and special contribution to the work of the board of directors and its committees, the reelection for such additional period(s) is beneficial to the company, and provided that the external director is reelected subject to the same shareholder vote requirements as if elected for the first time (as described above). Prior to the approval of the reelection of the external director at a general shareholders meeting, the company's shareholders must be informed of the term previously served by him or her and of the reasons why the board of directors and audit committee recommended the extension of his or her term.

External directors may be removed from office by a special general meeting of shareholders called by the board of directors, which approves such dismissal by the same shareholder vote percentage required for their election, after receiving the board of directors arguments for such removal, or by a court, in each case, only under limited circumstances, including ceasing to meet the statutory qualifications for appointment, or violating their duty of loyalty to the company. If an external directorship becomes vacant and there are fewer than two external directors on the board of directors at the time, then the board of directors is required under the Companies Law to call a shareholders meeting as soon as practicable to appoint a replacement external director.

Each committee of the board of directors that is authorized to exercise the powers of the board of directors must include at least one external director, except that the audit committee and the compensation committee must include all external directors then serving on the board of directors.

External directors may be compensated only in accordance with regulations adopted under the Companies Law.

Committees of the Board of Directors

Our board of directors has established three standing committees, the audit committee, the financial statement examination committee the compensation committee.

Audit Committee

Our audit committee consists of Yaakov Goldman along with our two external directors, David Grossman and Yuval Berman. Mr. Berman serves as Chairman of the audit committee.

TABLE OF CONTENTS

Under the Companies Law, we are required to appoint an audit committee. The audit committee must be comprised of at least three directors, including all of the external directors, one of whom must serve as Chairman of the committee. Under the Companies Law, the audit committee may not include the Chairman of the board of directors, a controlling shareholder of the company or a relative of a controlling shareholder, a director employed by or providing services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling shareholder or a director most of whose livelihood depends on a controlling shareholder.

In addition, under the Companies Law, the audit committee of a publicly traded company must consist of a majority of unaffiliated directors. In general, an “unaffiliated director” under the Companies Law is defined as either an external director or as a director who meets the following criteria:

- he or she meets the qualifications for being appointed as an external director, except for the requirement that the director be an Israeli resident (which does not apply to companies whose securities have been offered outside of Israel or are listed outside of Israel); and
- he or she has not served as a director of the company for a period exceeding nine consecutive years, provided that, for this purpose, a break of less than two years in service shall not be deemed to interrupt the continuation of the service.

The Companies Law further requires that generally, any person who does not qualify to be a member of the audit committee may not attend the audit committee’s meetings and voting sessions, unless such person was invited by the chairperson of the committee for the purpose of presenting on a specific subject; provided, however, that an employee of the company who is not the controlling shareholder or a relative of a controlling shareholder may attend the discussions of the committee, provided that any resolutions approved at such meeting are voted on without his or her presence. A company’s legal advisor and company secretary who are not the controlling shareholder or a relative of a controlling shareholder may attend the meeting and voting sessions, if required by the committee.

The quorum required for the convening of meetings of the audit committee and for adopting resolutions by the audit committee is a majority of the members of the audit committee, provided such majority is comprised of a majority of independent directors, at least one of which is an external director.

Under the NASDAQ corporate governance rules, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise.

Upon the consummation of this offering, all members of our audit committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the NASDAQ corporate governance rules. Prior to the consummation of this offering, our board of directors will have affirmatively determined that Yuval Berman and Yaakov Goldman are audit committee financial experts as defined by the SEC rules and has the requisite financial experience as defined by the NASDAQ corporate governance rules.

Upon the consummation of this offering, each of the members of the audit committee will be deemed “independent” as such term is defined in Rule 10A-3(b)(1) under the Exchange Act, according to which an audit committee member is barred from accepting any consulting, advisory or other compensatory fee from the company or any subsidiary thereof, other than in the member's capacity as a member of the board of directors, and may not be an affiliated person of the company or any subsidiary of the company apart from his or her capacity as a member of the board of directors and any committee of the board of directors.

Our board of directors will adopt an audit committee charter to be effective upon the listing of our shares on NASDAQ that will set forth the responsibilities of the audit committee consistent with the rules of the SEC and the listing rules of NASDAQ, as well as the requirements for such committee under the Companies Law, including the following:

- oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law;

TABLE OF CONTENTS

- recommending the engagement or termination of the person filling the office of our internal auditor; and
- recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors.

Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the accountants are independent of management.

Under the Companies Law, our audit committee is responsible for:

- determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices;
- determining the approval process for transactions that are ‘non-negligible’ (i.e., transactions with a controlling shareholder that are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types of transactions would require the approval of the audit committee, optionally based on criteria which may be determined annually in advance by the audit committee;
- determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law) (see “— Approval of Related Party Transactions under Israeli Law”);
- where the board of directors approves the working plan of the internal auditor, to examine such working plan before its submission to our board of directors and proposing amendments thereto;
- examining our internal controls and internal auditor’s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities;
- examining the scope of our auditor’s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor; and
- establishing procedures for the handling of employees’ complaints as to the management of our business and the protection to be provided to such employees.

Our audit committee may not approve any actions requiring its approval (see “— Approval of Related Party Transactions under Israeli Law” below), unless at the time of the approval a majority of the committee’s members are present, which majority consists of unaffiliated directors including at least one external director.

Financial Statement Examination Committee

Under the Israeli Companies Law, the board of directors of a public company must appoint a financial statement examination committee, which consists of members with accounting and financial expertise or the ability to read and understand financial statements. According to a resolution of our board of directors, the audit committee has been assigned the responsibilities and duties of a financial statements examination committee, as permitted under relevant regulations promulgated under the Israeli Companies Law. From time to time as necessary and required to approve our financial statements, the audit committee holds separate meetings, prior to the scheduled meetings of the entire board of directors regarding financial statement approval. The function of a financial statements examination committee is to discuss and provide recommendations to its board of directors (including the report of any deficiency found) with respect to the following issues: (1) estimations and assessments made in connection with the preparation of financial statements; (2) internal controls related to the financial statements; (3) completeness and propriety of the disclosure in the financial statements; (4) the accounting policies adopted and the accounting treatments implemented in material matters of the company; (5) value evaluations, including the assumptions and

TABLE OF CONTENTS

assessments on which evaluations are based and the supporting data in the financial statements. Our independent auditors and our internal auditors are invited to attend all meetings of audit committee when it is acting in the role of the financial statements examination committee.

Compensation Committee and Compensation Policy

Our compensation committee consists of Yaakov Goldman along with our two external directors, David Grossman and Yuval Berman. Mr. Berman serves as Chairman of the compensation committee.

The duties of the compensation committee include the recommendation to the company's board of directors of a policy regarding the terms of engagement of office holders, to which we refer as a compensation policy. That policy must be adopted by the company's board of directors, after considering the recommendations of the compensation committee, and will need to be brought for approval by the company's shareholders, which approval requires a Special Approval for Compensation as described below under "— Approval of related party transactions under Israeli law — Fiduciary duties of directors and executive officers".

Under the Companies Law, the board of directors of a public company must appoint a compensation committee and adopt a compensation policy. The compensation committee must be comprised of at least three directors, including all of the external directors, who must constitute a majority of the members of the compensation committee, and one of the external directors must serve as Chairman of the committee. However, subject to certain exceptions, Israeli companies whose securities are traded on stock exchanges such as NASDAQ, and who do not have a controlling shareholder, do not have to meet this majority requirement; provided, however, that the compensation committee meets other Companies Law composition requirements, as well as the requirements of the jurisdiction where the company's securities are traded. Each compensation committee member that is not an external director must be a director whose compensation does not exceed an amount that may be paid to an external director. The compensation committee is subject to the same Companies Law restrictions as the audit committee as to who may not be a member of the committee.

The compensation policy must be based on certain considerations, must include certain provisions and needs to reference certain matters as set forth in the Companies Law. The compensation policy must be approved by the company's board of directors after considering the recommendations of the compensation committee. In addition, the compensation policy needs to be approved by the company's shareholders by a simple majority, provided that (1) such majority includes a majority of the votes cast by the shareholders who are not controlling shareholders and who do not have a personal interest in the matter, present and voting (abstentions are disregarded) or (2) the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the matter who were present and voted against the compensation policy, constitute two percent or less of the voting power of the company.

To the extent a compensation policy is not approved by shareholders at a duly convened shareholders meeting, the board of directors of a company may override the resolution of the shareholders following a re-discussion of the matter by the board of directors and the compensation committee and for specified reasons, and after determining that despite the rejection by the shareholders, the adoption of the compensation policy is for the benefit of the company.

A compensation policy that is for a period of more than three years must be approved in accordance with the above procedure every three years.

Notwithstanding the above, the amendment of existing terms of office and employment of office holders (other than directors or controlling shareholders and their relatives, who serve as office holders) requires the approval of only the compensation committee, if such committee determines that the amendment is not material in relation to its existing terms.

Pursuant to the Companies Law, following the recommendation of our compensation committee, our board of directors approved our compensation policy, and our shareholders, in turn, approved the compensation policy at our annual general meeting of shareholders that was held in January 2014.

TABLE OF CONTENTS

The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company's objectives, the company's business plan and its long-term strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company's risk management, size and the nature of its operations. The compensation policy must furthermore consider the following additional factors:

- the knowledge, skills, expertise and accomplishments of the relevant office holder;
- the office holder's roles and responsibilities and prior compensation agreements with him or her;
- the ratio between the cost of the terms of employment of an office holder and the cost of the compensation of the other employees of the company, including those employed through manpower companies, in particular the ratio between such cost and the average and median compensation of the other employees of the company, as well as the impact such disparities may have on the work relationships in the company;
- the possibility of reducing variable compensation, if any, at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and
- as to severance compensation, if any, the period of service of the office holder, the terms of his or her compensation during such service period, the company's performance during that period of service, the person's contribution towards the company's achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company.

The compensation policy must also include:

- a link between variable compensation and long-term performance and measurable criteria;
- the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation;
- the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company's financial statements;
- the minimum holding or vesting period for variable, equity-based compensation; and
- maximum limits for severance compensation.

The compensation committee is responsible for (a) recommending the compensation policy to a company's board of directors for its approval (and subsequent approval by its shareholders) and (b) duties related to the compensation policy and to the compensation of a company's office holders as well as functions previously fulfilled by a company's audit committee with respect to matters related to approval of the terms of engagement of office holders, including:

- recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);
- recommending to the board of directors periodic updates to the compensation policy;
- assessing implementation of the compensation policy; and
- determining whether the compensation terms of the Chief Executive Officer of the company need not be brought to approval of the shareholders.

TABLE OF CONTENTS

Our compensation committee's responsibilities include:

- reviewing and recommending overall compensation policies with respect to our Chief Executive Officer and other executive officers;
- reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers including evaluating their performance in light of such goals and objectives;
- reviewing and approving the granting of options and other incentive awards; and
- reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors.

Internal Auditor

Under the Companies Law, the board of directors of an Israeli public company must appoint an internal auditor in accordance with the recommendation of the audit committee. An internal auditor may not be:

- a person (or a relative of a person) who holds more than 5% of the company's outstanding shares or voting rights;
- a person (or a relative of a person) who has the power to appoint a director or the general manager of the company;
- an office holder (including a director) of the company (or a relative thereof); or
- a member of the company's independent accounting firm, or anyone on his or her behalf.

The role of the internal auditor is to examine, among other things, our compliance with applicable law and orderly business procedures. The audit committee is required to oversee the activities and to assess the performance of the internal auditor as well as to review the internal auditor's work plan. On November 30, 2008, we appointed Amit Gal as our internal auditor. Amit Gal is a certified internal auditor and a partner at Amit Halfon (PKF), a certified public accounting firm in Israel.

The Chairman of the board of directors will be the direct supervisor of the internal auditor, unless the board of directors shall determine otherwise, according to our articles of association and the Companies Law. The internal auditor is required to submit his or her findings to the audit committee, unless specified otherwise by the board of directors.

Approval of Related Party Transactions under Israeli Law

Fiduciary Duties of Directors and Executive Officers

The Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under "Management — Executive Officers and Directors" above is an office holder under the Companies Law.

An office holder's fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty requires that an office holder act in good faith and in the best interests of the company.

The duty of care includes a duty to use reasonable means to obtain:

- information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and
- all other important information pertaining to any such action.

TABLE OF CONTENTS

The duty of loyalty includes a duty to:

- refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs;
- refrain from any activity that is competitive with the company;
- refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and
- disclose to the company any information or documents relating to the company's affairs which the office holder received as a result of his or her position as an office holder.

Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions

The Companies Law requires that an office holder promptly disclose to the board of directors any personal interest that he or she may be aware of and all related material information or documents concerning any existing or proposed transaction with the company. An interested office holder's disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. A personal interest includes an interest of any person in an act or transaction of a company, including a personal interest of such person's relative or of a corporate body in which such person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest stemming from one's ownership of shares in the company. A personal interest furthermore includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such shareholder has no personal interest in the matter. An office holder is not, however, obligated to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction is defined as any of the following:

- a transaction other than in the ordinary course of business;
- a transaction that is not on market terms; or
- a transaction that may have a material impact on a company's profitability, assets or liabilities.

If it is determined that an office holder has a personal interest in a transaction, approval by the board of directors is required for the transaction, unless the company's articles of association provide for a different method of approval. Our articles of association do not provide otherwise. Further, so long as an office holder has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the office holder that would otherwise be deemed a breach of the duty of loyalty. However, a company may not approve a transaction or action that is adverse to the company's interest or that is not performed by the office holder in good faith. An extraordinary transaction in which an office holder has a personal interest requires approval first by the company's audit committee and subsequently by the board of directors. The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director requires approval first by the company's compensation committee, then by the company's board of directors, and, if such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company's stated compensation policy or if the office holder is the Chief Executive Officer (apart from a number of specific exceptions), then such arrangement is subject to the approval of a majority vote of the shares present and voting at a shareholders meeting, provided that either: (a) such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement (excluding abstaining shareholders); or (b) the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation arrangement and who vote against the arrangement does not exceed 2% of the company's aggregate voting rights. We refer to this as the Special Approval for Compensation. Arrangements regarding the compensation, indemnification or insurance of a director require the approval of the compensation committee, board of directors and shareholders by ordinary majority, in that order, and under certain circumstances, a Special Approval for Compensation.

TABLE OF CONTENTS

Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting or vote on that matter unless the Chairman of the relevant committee or board of directors, as applicable, determines that he or she should be present in order to present the transaction that is subject to approval. Generally, if a majority of the members of the audit committee or the board of directors, as applicable, has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee or the board of directors, as applicable. In the event a majority of the members of the board of directors have a personal interest in the approval of a transaction, then the approval thereof shall also require the approval of the shareholders.

Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions

Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder of a public company. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated. The approval of the audit committee or the compensation committee, as the case may be, the board of directors and the shareholders of the company, in that order, is required for (a) extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, (b) the engagement with a controlling shareholder or his or her relative, directly or indirectly, for the provision of services to the company, (c) the terms of engagement and compensation of a controlling shareholder or his or her relative who is not an office holder or (d) the employment of a controlling shareholder or his or her relative by the company, other than as an office holder (collectively referred to as a Transaction with a Controlling Shareholder). In addition, such shareholder approval requires one of the following, which we refer to as a Special Majority:

- at least a majority of the shares held by all shareholders who do not have a personal interest in the transaction and who are present and voting at the meeting approving the transaction, excluding abstentions; or
- the shares voted against the transaction by shareholders who have no personal interest in the transaction and who are present and voting at the meeting do not exceed 2% of the voting rights in the company.

To the extent that any such Transaction with a Controlling Shareholder is for a period extending beyond three years, approval is required once every three years, unless, with respect to certain transactions, the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto.

Arrangements regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an office holder require the approval of the compensation committee, board of directors and shareholders by a Special Majority and the terms thereof may not be inconsistent with the company's stated compensation policy.

Pursuant to regulations promulgated under the Companies Law, certain transactions with a controlling shareholder, a relative of a controlling shareholder, or a director that would otherwise require approval of a company's shareholders may be exempt from shareholder approval upon certain determinations of the audit committee and board of directors. Under these regulations, a shareholder holding at least 1% of the issued share capital of the company or the voting rights may require, within 14 days of the publication of such determinations, that despite such determinations by the audit committee and the board of directors, such transaction will require shareholder approval under the same majority requirements that would otherwise apply to such transactions.

Shareholder Duties

Pursuant to the Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at a general meeting and at shareholder class meetings with respect to the following matters:

- an amendment to the company's articles of association;
- an increase of the company's authorized share capital;
- a merger; or
- the approval of related party transactions and acts of office holders that require shareholder approval.

In addition, a shareholder also has a general duty to refrain from discriminating against other shareholders.

Certain shareholders also have a duty of fairness toward the company. These shareholders include any controlling shareholder, any shareholder who knows that he or she has the power to determine the outcome of a shareholder vote at a general meeting or a shareholder class meeting and any shareholder who has the power to appoint or to prevent the appointment of an office holder of the company or other power towards the company. The Companies Law does not define the substance of the duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness.

Exculpation, Insurance and Indemnification of Directors and Officers

Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our articles of association include such a provision. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.

Under the Companies Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification, which ours do:

- financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator's award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be reasonably foreseen based on the company's activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;
- reasonable litigation expenses, including attorneys' fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (a) no indictment was filed against such office holder as a result of such investigation or proceeding; and (b) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; and

TABLE OF CONTENTS

- reasonable litigation expenses, including attorneys' fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent.

Under the Companies Law and the Israeli Securities Law 5728-1968, or the Israeli Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company's articles of association:

- a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;
- a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and
- a financial liability imposed on the office holder in favor of a third party.

Under our articles of association, we may insure an office holder against the aforementioned liabilities as well as the following liabilities:

- a breach of duty of care to the company or to a third party;
- any other action against which we are permitted by law to insure an office holder;
- expenses incurred and/or paid by the office holder in connection with an administrative enforcement procedure under any applicable law including the Efficiency of Enforcement Procedures in the Securities Authority Law (legislation amendments), 5771-2011, or the Efficiency of Enforcement Procedures, and the Israeli Securities Law, which we refer to as an Administrative Enforcement Procedure, and including reasonable litigation expenses and attorney fees; and
- a financial liability in favor or a victim of a felony pursuant to Section 52ND of the Israeli Securities Law.

Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:

- a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;
- a breach of duty of care committed intentionally or recklessly, excluding a breach arising solely out of the negligent conduct of the office holder;
- an act or omission committed with intent to derive illegal personal benefit; or
- a fine, civil fine, administrative fine or ransom or levied against the office holder.

Under the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders. See "—Approval of Related Party Transactions under Israeli Law."

Our articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Companies Law and the Israeli Securities Law, including expenses incurred and/or paid by the office holder in connection with an Administrative Enforcement Procedure.

Prior to the closing of this offering, we intend to enter into agreements with each of our directors and executive officers exculpating them, to the fullest extent permitted by law and our articles of association, and undertaking to indemnify them to the fullest extent permitted by law and our articles of association. This indemnification will be limited to events determined as foreseeable by the board of directors based on our activities, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.

TABLE OF CONTENTS

The maximum indemnification amount set forth in such agreements is limited to an amount which shall not exceed 25% of our net assets based on our most recently audited or reviewed financial statements prior to actual payment of the indemnification amount. Such maximum amount is in addition to any amount paid (if paid) under insurance and/or by a third-party pursuant to an indemnification arrangement.

In the opinion of the SEC, indemnification of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and therefore unenforceable.

We have obtained directors' and officers' liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Companies Law. In addition, prior to the closing of this offering, we intend to enter into agreements with each of our office holders undertaking to indemnify them to the fullest extent permitted by the Companies Law, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by insurance.

Code of Ethics

Our board of directors will adopt a Code of Ethics to be effective upon the listing of our shares on NASDAQ applicable to all of our directors and employees, including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which is a "code of ethics" as defined in Item 16B of Form 20-F promulgated by the SEC. Upon the effectiveness of the registration statement of which this prospectus forms a part, the full text of the Code of Ethics will be posted on our website at www.collectbio.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus and is not incorporated by reference herein. If we make any amendment to the Code of Ethics or grant any waivers, including any implicit waiver, from a provision of the Code of Ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. Under Item 16B of the SEC's Form 20-F, if a waiver or amendment of the Code of Ethics applies to our principal executive officer, principal financial officer, principal accounting officer or controller and relates to standards promoting any of the values described in Item 16B(b) of Form 20-F, we are required to disclose such waiver or amendment on our website in accordance with the requirements of Instruction 4 to such Item 16B.

BENEFICIAL OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT

The following table sets forth certain information regarding the beneficial ownership of our ordinary shares as of April 5, 2016 and as adjusted to reflect the sale of the ADSs offered by us (assuming no exercise of the underwriters' over-allotment option), by:

- each of our directors and senior management;
- all of our directors and senior management as a group; and
- each person (or group of affiliated persons) known by us to be the beneficial owner of more than 5% of the outstanding ordinary shares.

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to ordinary shares. Ordinary shares issuable under share options, warrants or other conversion rights currently exercisable or that are exercisable within 60 days after April 5, 2016 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options, warrants or other conversion rights, but are not deemed outstanding for the purpose of computing the percentage ownership of any other person. Percentage of shares beneficially owned before this offering is based on 81,733,326 ordinary shares outstanding (which excludes 2,686,693 shares held in treasury) on April 5, 2016. The number of ordinary shares deemed outstanding after this offering includes the ordinary shares represented by the ADSs being offered for sale in this offering, and assumes no exercise of the underwriters' over-allotment option.

As of April 5, 2016, there were 5 shareholders of record of our ordinary shares. The number of record holders is not representative of the number of beneficial holders of our ordinary shares, as the shares of most our shareholders who hold ordinary shares that are traded on the TASE are recorded in the name of our Israeli share registrar, Bank Leumi Registration Company Ltd. As of April 5, 2016, there were no record holders of our ordinary shares in the United States.

None of our shareholders has different voting rights from other shareholders. To the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation or by any foreign government. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of us.

Except as otherwise indicated in the footnotes to this table, we believe the persons named in this table have sole voting and investment power with respect to all the ordinary shares indicated.

	<u>As of April 5, 2016</u>		<u>After Offering</u>	
	<u>Ordinary Shares</u>	<u>%</u>	<u>Ordinary Shares</u>	<u>%</u>
Directors and Senior Management				
Nuriel Chirich Kasbian	16,702,838 ⁽¹⁾	20.3%		
Dr. Shai Yarkoni	15,061,028 ⁽²⁾	18.3%		
Dr. Nadir Askenasy	13,861,795 ⁽³⁾	17.0%		
Ronen Twito	538,963 ⁽⁴⁾	*		
Amotz Nechushtan	13,333 ⁽⁵⁾	*		
Yaakov Goldman	18,000 ⁽⁶⁾	*		
Abraham Nahmias	18,000 ⁽⁷⁾	*		
Dr. Ruth Ben Yakar	68,000 ⁽⁸⁾	*		
Yuval Berman	18,000 ⁽⁹⁾	*		
David Grossman	18,000 ⁽¹⁰⁾	*		
Directors and Senior Management as a group (10 persons)	46,317,957	56.40%		
5% Shareholders				
Michael Ilan Management and Investments Ltd. ⁽¹¹⁾	17,394,608 ⁽¹²⁾	20.91%		

* Less than 1%

(1) Includes (i) 16,246,415 ordinary shares owned by Mr. Kasbian, (ii) options (Series 1) to purchase

TABLE OF CONTENTS

- 342,500 ordinary shares at an exercise price of NIS 1.85 per share and expiring on November 21, 2016, (iii) options (Series A) to purchase 95,923 ordinary shares at an exercise price of NIS 2.1 per share, and (iv) options to purchase 18,000 ordinary shares at an exercise price of NIS 1.90 per share and expiring on August 26, 2025. Excludes (i) options to purchase 54,000 ordinary shares that vest in more than 60 days from April 5, 2016, and (ii) 287,769 ordinary shares and options to purchase 95,923 ordinary shares at an exercise price of NIS 2.1 per share to be approved at the next shareholders' meeting.
- (2) Includes (i) 14,095,762 ordinary shares owned by Dr. Yarkoni, (ii) 277,266 ordinary shares owned by Dr. Yarkoni's ex-wife, over which Dr. Yarkoni may be deemed to have shared beneficial interest, (iii) options (Series 1) to purchase 70,000 ordinary shares at an exercise price of NIS 1.85 per share and expiring on November 21, 2016, (iv) options to purchase 600,000 ordinary shares, at an exercise price of NIS 1.40 per share and expiring on September 8, 2024, and (v) options to purchase 18,000 ordinary shares at an exercise price of NIS 1.90 per share and expiring on August 26, 2025. Excludes options to purchase 654,000 ordinary shares that vest in more than 60 days from April 5, 2016.
- (3) Represents 13,861,795 ordinary shares owned by Dr. Askenasy.
- (4) Includes (i) 71,942 ordinary shares owned by Mr. Twito, (ii) options to purchase 443,041 ordinary shares at an exercise price of NIS 1.286 per share and expiring on November 23, 2025, and (iii) options (Series A) to purchase 23,980 ordinary shares at an exercise price of NIS 2.1 per share. Excludes options to purchase 2,215,205 ordinary shares that vest in more than 60 days from April 5, 2016.
- (5) Represents options to purchase 13,333 ordinary shares at an exercise price of NIS 1.295 per share and expiring on November 28, 2025. Excludes options to purchase 66,667 ordinary shares that vest in more than 60 days from April 5, 2016.
- (6) Represents options to purchase 18,000 ordinary shares at an exercise price of NIS 1.90 per share and expiring on August 26, 2025. Excludes options to purchase 54,000 ordinary shares that vest in more than 60 days from April 5, 2016.
- (7) Represents options to purchase 18,000 ordinary shares at an exercise price of NIS 1.90 per share and expiring on August 26, 2025. Excludes options to purchase 54,000 ordinary shares that vest in more than 60 days from April 5, 2016.
- (8) Represents (i) options to purchase 50,000 ordinary shares at an exercise price of NIS 1.40 per share and expiring on September 28, 2024, and (ii) options to purchase 18,000 ordinary shares at an exercise price of NIS 1.90 per share and expiring on August 26, 2025. Excludes options to purchase 104,000 ordinary shares that vest in more than 60 days from April 5, 2016.
- (9) Represents options to purchase 18,000 ordinary shares at an exercise price of NIS 1.90 per share and expiring on August 26, 2025. Excludes options to purchase 54,000 ordinary shares that vest in more than 60 days from April 5, 2016.
- (10) Represents options to purchase 18,000 ordinary shares at an exercise price of NIS 1.90 per share and expiring on August 26, 2025. Excludes options to purchase 54,000 ordinary shares that vest in more than 60 days from April 5, 2016.
- (11) Based on information publically available from the Israeli Registrar of Companies, this entity is under control of, and affiliated with Mr. Michael Ilan and Pazit Ilan Berkowitz.
- (12) Includes (i) 15,949,724 ordinary shares owned by Michael Ilan Management and Investments Ltd., (ii) options (Series 1) to purchase 1,301,000 ordinary shares at an exercise price of NIS 1.85 per share and expiring on November 21, 2016, and (iii) options (Series A) to purchase 143,884 ordinary shares at an exercise price of NIS 2.1 per share.

RELATED PARTY TRANSACTIONS

The following is a description of some of the transactions with related parties to which we are party and which were in effect within the past three fiscal years. The descriptions provided below are summaries of the terms of such agreements and do not purport to be complete and are qualified in their entirety by the complete agreements.

We believe that we have executed all of our transactions with related parties on terms no less favorable to us than those we could have obtained from unaffiliated third parties. See “Management — Approval of Related Party Transactions under Israeli Law.”

Founders Agreement

On June 1, 2011, Nuriel Chirich Kasbian, our Chairman, Dr. Shai Yarkoni, our Chief Executive Officer and director, and Dr. Nadir Askenasy, our Chief Scientist entered into a founders agreement with respect to Collect Biotherapeutics, our subsidiary. Subsequently, on May 16, 2013, the parties to the founders agreement entered into an agreement pursuant to which it was agreed that the founders agreement will apply to the parties with respect to us following the merger which closed on July 1, 2013.

Under the founders agreement, each founder holding at least 30% of our share capital shall be entitled to recommend the appointment of one director (and remove any director so appointed). The founders agreement also provides pre-emptive rights, rights of first refusal, co-sale rights and bring along rights among the founders subject to certain permitted transfers. The pre-emptive rights are not triggered by the offer or sale of securities in this offering.

Kasbian Loans

In 2011, Nuriel Chirich Kasbian, our Chairman, lent to Collect Biotherapeutics, our subsidiary, \$140,000 bearing interest at 3% per annum and payable within 60 days upon written demand, but not earlier than April 2014. In May 2014, following our raise of NIS 15 million, we repaid the loan.

On December 11, 2012, Collect Biotherapeutics and Mr. Kasbian entered into a loan agreement pursuant to which Collect Biotherapeutics borrowed \$50,000 from Mr. Kasbian. The loan bore interest at Libor plus 3%. On April 30, 2013, Collect Biotherapeutics and Mr. Kasbian entered into an amendment to the loan agreement pursuant to which the loan was converted into 697,324 ordinary shares of Collect Biotherapeutics.

On February 7, 2013, Collect Biotherapeutics and Mr. Kasbian entered into a loan agreement pursuant to which Collect Biotherapeutics borrowed NIS 100,000 from Mr. Kasbian. The loan bore interest at Libor plus 3%. The loan was repaid during May 2013.

Yarkoni Loans

On February 7, 2013, Collect Biotherapeutics and G.A.S.R. Biotechnology Ltd., or G.A.S.R., a company controlled by Dr. Shai Yarkoni, our Chief Executive Officer and director, entered into a loan agreement pursuant to which Collect Biotherapeutics borrowed NIS 100,000 from G.A.S.R. The loan bore interest at Libor plus 3%. The loan was repaid during May 2013.

Michael Ilan

On May 13, 2014, Michael Ilan Management and Investments Ltd. (a private company wholly-owned by Mr. Michael Ilan), purchased 14,217,070 of our ordinary shares for NIS 15,000,000 in a private placement. As a result of this transaction, Michael Ilan became a related party.

Indemnification Agreements

Our articles of association permit us to exculpate, indemnify and insure our directors and officeholders to the fullest extent permitted by the Companies Law. We have obtained directors' and officers' insurance for each of our officers and directors. Prior to the closing of this offering, we intend to enter into indemnification and exculpation agreements with each of our current office holders and directors exculpating them to the fullest extent permitted by the law and our articles of association and undertaking to indemnify them to the fullest extent permitted by the law and our articles of association, including with respect to liabilities resulting from this offering, to the extent such liabilities are not covered by insurance. See “Management — Exculpation, Insurance and Indemnification of Directors and Officers.”

[TABLE OF CONTENTS](#)

Employment and Service Agreements

We have or have had employment, service or related agreements with each member of our senior management. See “Management — Executive Officers and Directors — Employment and Service Agreements.”

DESCRIPTION OF SHARE CAPITAL

The following description of our share capital is a summary of the material terms of our articles of association and Israeli corporate law regarding our shares and the holders thereof. This description contains all material information concerning our ordinary shares but does not purport to be complete. For a complete description, you should read our articles of association, a copy of which has been filed with the SEC as an exhibit to the registration statement on Form F-1 of which this prospectus forms a part. The following description is qualified in its entirety by reference to our articles of association and applicable law.

Ordinary Shares

As of April 5, 2016, our authorized share capital consists of 500,000,000 ordinary shares, no par value. As of April 5, 2016, there are 81,733,326 ordinary shares outstanding (which excludes 2,686,693 ordinary shares held in treasury). All of our outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights.

Pursuant to Israeli securities laws, a company whose shares are traded on the TASE may not have more than one class of shares for a period of one year following its registration, after which it is permitted to issue preferred shares (which shall bear a dividend preference and shall not have any voting rights), and all outstanding shares must be validly issued and fully paid. All outstanding shares must be registered for trading on the TASE which currently prohibits the issuance of more than one class of shares.

Options

As of April 5, 2016, the following number of options are outstanding:

- 5,443,758 ordinary shares issuable upon the exercise of 5,443,758 options at a weighted average exercise price of NIS 1.39 (\$0.36) per share issuable under the 2014 Collect Option Plan;
- 227,358 ordinary shares issuable upon the exercise of 227,358 options at exercise price of NIS 1.00 (\$0.26) per share issued to a consultant;
- 600,000 ordinary shares issuable upon the exercise of 600,000 options at exercise price of NIS 2.10 (\$0.56) per share issued to a consultant;
- 4,723,500 ordinary shares issuable upon the exercise of 4,723,500 options (Series 1) at an exercise price of NIS 1.85 (\$0.47) per share; and
- 1,927,801 ordinary shares issuable upon the exercise of 1,927,801 options (Series A) at an exercise price of NIS 2.11 (\$0.54) per share.

We maintain our 2014 Collect Option Plan, which was adopted by our board of directors in February 2014 and is scheduled to expire in 2024. The 2014 Collect Option Plan provides for the grant of options to our directors, officers, employees, consultants, advisers and service providers. As of April 5, 2016, 7,500,000 ordinary shares have been reserved for issuance under the 2014 Collect Option Plan. To date, an aggregate amount of 6,268,758 options to purchase 6,268,758 ordinary shares were granted, 225,000 were expired and 6,043,758 are currently outstanding. Of such outstanding options, options to purchase 1,701,199 ordinary shares were vested as of April 5, 2016, with a weighted average exercise price of NIS 1.41 per share, and will expire 10 years from the date of grant, during the years 2024 – 2026.

Articles of Association

The following are summaries of material provisions of our articles of association and the Companies Law insofar as they relate to the material terms of our ordinary shares.

Purposes and Objects of the Company

Our purpose is set forth in Section 2 of our articles of association and includes every lawful purpose.

Registration Number

Our number with the Israeli Registrar of Companies is 520036484.

TABLE OF CONTENTS

Voting Rights

Holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders at a shareholders meeting. Shareholders may vote at shareholders meetings either in person, by proxy or by written ballot. Israeli law does not allow public companies to adopt shareholder resolutions by means of written consent in lieu of a shareholders meeting. The board of directors shall determine and provide a record date for each shareholders meeting and all shareholders at such record date may vote. Unless stipulated differently in the Companies Law or in the articles of association, all shareholders' resolutions shall be approved by a simple majority vote. Except as otherwise disclosed herein, an amendment to our articles of association requires the prior approval of a simple majority of our shares represented and voting at a general meeting.

Transfer of Shares

Our ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our articles of association, unless the transfer is restricted or prohibited by applicable law or the rules of a stock exchange on which the shares are traded. See "Shares Eligible for Future Sale" with respect to the applicable U.S. law. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our articles of association or Israeli law, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel.

The Powers of the Directors

Our board of directors directs our policy and supervises the performance of our Chief Executive Officer. Pursuant to the Companies Law and our articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our articles of association to be exercised or taken by our shareholders.

Amendment of Share Capital

Our articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution duly passed by our shareholders at a general or special meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings and profits and an issuance of shares for less than their nominal value, require a resolution of our board of directors and court approval.

Dividends

Under Israeli law, we may declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according to our then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of distribution. In the event that we do not have retained earnings or earnings generated over the two most recent years legally available for distribution, we may seek the approval of the court in order to distribute a dividend. The court may approve our request if it determines that there is no reasonable concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.

Shareholders Meetings

Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year and in any event no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as special meetings. Our board of directors may call special meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law and our articles of association provide that our board of directors is required to convene a special meeting upon the written request of (1) any two of our

TABLE OF CONTENTS

directors or one quarter of the directors then in office; or (2) one or more shareholders holding, in the aggregate either (a) 5% of our issued share capital and 1% of our outstanding voting power, or (b) 5% of our outstanding voting power.

Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors. Furthermore, the Companies Law and our articles of association require that resolutions regarding the following matters must be passed at a general meeting of our shareholders:

- amendments to our articles of association;
- appointment or termination of our auditors;
- appointment and dismissal of directors and external directors;
- approval of acts and transactions requiring general meeting approval pursuant to the Companies Law;
- director compensation, indemnification and change of the principal executive officer;
- increases or reductions of our authorized share capital;
- a merger;
- the exercise of our board of directors' powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management; and
- authorizing the Chairman of the board of directors or his relative to act as the company's Chief Executive Officer or act with such authority; or authorize the company's Chief Executive Officer or his relative to act as the Chairman of the board of directors or act with such authority.

The Companies Law requires that a notice of any annual or special shareholders meeting be provided at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.

The Companies Law does not allow shareholders of publicly traded companies to approve corporate matters by written consent. Consequently, our articles of association do not allow shareholders to approve corporate matters by written consent.

Pursuant to our articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general meeting.

Quorum

The quorum required for our general meetings of shareholders consists of two or more shareholders present in person, by proxy or by other voting instrument in accordance with the Companies Law and our articles of association who hold or represent, in the aggregate, at least 33 1/3% of the total outstanding voting rights, within half an hour from the appointed time.

A meeting adjourned for lack of a quorum is adjourned to the same day in the following week at the same time and place or on a later date if so specified in the summons or notice of the meeting. At the reconvened meeting, and within half an hour from the appointed time, any number of our shareholders present in person or by proxy shall constitute a lawful quorum.

TABLE OF CONTENTS

Resolutions

Our articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by applicable law.

Israeli law provides that a shareholder of a public company may vote in a meeting and in a class meeting by means of a written ballot in which the shareholder indicates how he or she votes on resolutions relating to the following matters:

- an appointment or removal of directors;
- an approval of transactions with office holders or interested or related parties, that require shareholder approval;
- an approval of a merger;
- authorizing the Chairman of the board of directors or his relative to act as the company's Chief Executive Officer or act with such authority; or authorize the company's Chief Executive Officer or his relative to act as the Chairman of the board of directors or act with such authority;
- any other matter that is determined in the articles of association to be voted on by way of a written ballot. Our articles of association do not stipulate any additional matters; and
- other matters which may be prescribed by Israel's Minister of Justice.

The provision allowing the vote by written ballot does not apply where the voting power of the controlling shareholder is sufficient to determine the vote.

The Companies Law provides that a shareholder, in exercising his or her rights and performing his or her obligations toward the company and its other shareholders, must act in good faith and in a customary manner, and avoid abusing his or her power. This is required when voting at general meetings on matters such as changes to the articles of association, increasing the company's registered capital, mergers and approval of certain interested or related party transactions. A shareholder also has a general duty to refrain from depriving any other shareholder of its rights as a shareholder. In addition, any controlling shareholder, any shareholder who knows that its vote can determine the outcome of a shareholder vote and any shareholder who, under such company's articles of association, can appoint or prevent the appointment of an office holder or other power towards the company, is required to act with fairness towards the company. The Companies Law does not describe the substance of this duty except that the remedies generally available upon a breach of contract will also apply to a breach of the duty to act with fairness, and, to the best of our knowledge, there is no binding case law that addresses this subject directly.

Under the Companies Law, unless provided otherwise in a company's articles of association, a resolution at a shareholders meeting requires approval by a simple majority of the voting rights represented at the meeting, in person, by proxy or written ballot, and voting on the resolution. Generally, a resolution for the voluntary winding up of the company requires the approval of holders of 75% of the voting rights represented at the meeting, in person, by proxy or by written ballot and voting on the resolution.

In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.

Access to Corporate Records

Under the Companies Law, all shareholders of a company generally have the right to review minutes of the company's general meetings, its shareholders register and principal shareholders register, articles of association, financial statements and any document it is required by law to file publicly with the Israeli Companies Registrar and the ISA. Any of our shareholders may request to review any document in our possession that relates to any action or transaction with a related party, interested party or office holder that requires shareholder approval under the Companies Law. We may deny a request to review a document if we

TABLE OF CONTENTS

determine that the request was not made in good faith, that the document contains a commercial secret or a patent or that the document's disclosure may otherwise prejudice our interests.

Acquisitions under Israeli Law

Full Tender Offer

A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the target company's issued and outstanding share capital is required by the Companies Law to make a tender offer to all of the company's shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the same class for the purchase of all of the issued and outstanding shares of the same class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law (provided that a majority of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer except that if the total votes to reject the tender offer represent less than 2% of the company's issued and outstanding share capital, in the aggregate, approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender offer). However, a shareholder that had its shares so transferred may petition the court within six months from the date of acceptance of the full tender offer, whether or not such shareholder agreed to the tender or not, to determine whether the tender offer was for less than fair value and whether the fair value should be paid as determined by the court unless the acquirer stipulated in the tender offer that a shareholder that accepts the offer may not seek appraisal rights, so long as prior to the acceptance of the full tender offer, the acquirer and the company disclosed the information required by law in connection with the full tender offer. If the shareholders who did not accept the tender offer hold 5% or more of the issued and outstanding share capital of the company or of the applicable class, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company's issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer.

Special Tender Offer

The Companies Law provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company, unless one of the exemptions in the Companies Law is met. This rule does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a tender offer if as a result of the acquisition the purchaser would become a holder of 45% or more of the voting rights in the company, if there is no other shareholder of the company who holds 45% or more of the voting rights in the company, unless one of the exemptions in the Companies Law is met.

A special tender offer must be extended to all shareholders of a company, but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company's outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company's outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer.

If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.

Under regulations enacted pursuant to the Companies Law, the above special tender offer requirements may not apply to companies whose shares are listed for trading on a foreign stock exchange if, among other things, the relevant foreign laws or the rules of the stock exchange, include provisions limiting the percentage

TABLE OF CONTENTS

of control which may be acquired or that the purchaser is required to make a tender offer to the public. However, the ISA's opinion is that such leniency does not apply with respect to companies whose shares are listed for trading on stock exchanges in the United States, including NASDAQ, which do not provide for sufficient legal restrictions on obtaining control or an obligation to make a tender offer to the public, therefore the special tender offer requirements shall apply to such companies.

Merger

The Companies Law permits merger transactions if approved by each party's board of directors and, unless certain requirements described under the Companies Law are met, a majority of each party's shares voted on the proposed merger at a shareholders meeting called with at least 35 days' prior notice.

For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares represented at the shareholders meeting that are held by parties other than the other party to the merger, or by any person who holds 25% or more of the outstanding shares or the right to appoint 25% or more of the directors of the other party, vote against the merger. If the transaction would have been approved but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration offered to the shareholders.

Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors.

In addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and 30 days have passed from the date the merger was approved by the shareholders of each party.

Antitakeover Measures

The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights, distributions or other matters and shares having preemptive rights. As of the date of this prospectus, we do not have any authorized or issued shares other than our ordinary shares. In the future, if we do create and issue a class of shares other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization of a new class of shares will require an amendment to our articles of association which requires the prior approval of the holders of a majority of our shares at a general meeting. In addition, the rules and regulations of the TASE also limit the terms permitted with respect to a new class of shares and prohibit any such new class of shares from having voting rights. Shareholders voting in such meeting will be subject to the restrictions provided in the Companies Law as described above.

DESCRIPTION OF AMERICAN DEPOSITARY SHARES

American Depositary Shares

The Bank of New York Mellon, as depositary, will register and deliver ADSs. Each ADS will represent ten ordinary shares (or a right to receive [] ordinary shares) deposited with the principal Tel Aviv office of either of Bank Leumi or Bank Hapoalim, as custodian for the depositary. Each ADS will also represent any other securities, cash or other property which may be held by the depositary. The depositary's office at which the ADSs will be administered is located at 101 Barclay Street, New York, New York 10286. The Bank of New York Mellon's principal executive office is located at 225 Liberty Street, New York, New York 10286.

You may hold ADSs either (a) directly (1) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (2) by having uncertificated ADSs registered in your name, or (b) indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, also called DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.

Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.

As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder rights. The depositary will be the holder of the ordinary shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.

The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. For directions on how to obtain copies of those documents see "Where You Can Find More Information".

Dividends and Other Distributions

How will you receive dividends and other distributions on the shares?

The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent.

Cash. The depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest.

Before making a distribution, the depositary will deduct any withholding taxes, or other required governmental charges. See "Taxation" below. The depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.

TABLE OF CONTENTS

Shares. The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed ordinary shares (or ADSs representing those shares) sufficient to pay its fees and expenses in connection with that distribution.

Rights to purchase additional shares. If we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the depositary may (1) exercise those rights on behalf of ADS holders, (2) distribute those rights to ADS holders or (3) sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. In that case, you will receive no value for them. The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of ordinary shares, new ADSs representing the new ordinary shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.

Other Distributions. The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.

The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.

Deposit, Withdrawal and Cancellation

How are ADSs issued?

The depositary will deliver ADSs if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.

How can ADS holders withdraw the deposited securities?

You may surrender your ADSs for the purpose of withdrawal at the depositary's office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the ordinary shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities.

How do ADS holders interchange between certificated ADSs and uncertificated ADSs?

You may surrender your ADR to the depository for the purpose of exchanging your ADR for uncertificated ADSs. The depository will cancel that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depository of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depository will execute and deliver to the ADS holder an ADR evidencing those ADSs.

Voting Rights

How do you vote?

ADS holders may instruct the depository how to vote the number of deposited ordinary shares their ADSs represent. If we request the depository to solicit your voting instructions (and we are not required to do so), the depository will notify you of a shareholders' meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depository how to vote. For instructions to be valid, they must reach the depository by a date set by the depository.

The depository will try, as far as practical, subject to the laws of Israel and the provisions of our articles of association or similar documents, to vote or to have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders. If we do not request the depository to solicit your voting instructions, you can still send voting instructions, and, in that case, the depository may try to vote as you instruct, but it is not required to do so.

Except by instructing the depository as described above, you won't be able to exercise voting rights unless you surrender your ADSs and withdraw the ordinary shares. However, you may not know about the meeting enough in advance to withdraw the ordinary shares. In any event, the depository will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed.

We can not assure you that you will receive the voting materials in time to ensure that you can instruct the depository to vote your ordinary shares. In addition, the depository and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise voting rights and there may be nothing you can do if your ordinary shares are not voted as you requested.

In order to give you a reasonable opportunity to instruct the depository as to the exercise of voting rights relating to deposited securities, if we request the Depository to act, we agree to give the depository notice of any such meeting and details concerning the matters to be voted upon at least [] days in advance of the meeting date.

Fees and Expenses

<i>Persons depositing or withdrawing ordinary shares or ADS holders must pay:</i>	<i>For:</i>
\$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)	Issuance of ADSs, including issuances resulting from a distribution of ordinary shares or rights or other property Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
\$.05 (or less) per ADS	Any cash distribution to ADS holders
A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the ordinary shares had been deposited for issuance of ADSs	Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depository to ADS holders
\$.05 (or less) per ADS per calendar year	Depository services

TABLE OF CONTENTS

Registration or transfer fees	Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw ordinary shares
Expenses of the depositary	Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement); converting foreign currency to U.S. dollars
Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or ordinary shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes	As necessary
Any charges incurred by the depositary or its agents for servicing the deposited securities	As necessary

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.

The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary's obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.

Payment of Taxes

You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.

Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities

The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish.

TABLE OF CONTENTS

If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.

If there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs.

If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.

If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary may call for surrender of those ADSs or cancel those ADSs upon notice to the ADS holders.

Amendment and Termination

How may the deposit agreement be amended?

We may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.

How may the deposit agreement be terminated?

The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if

- 60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;
- we delist our ordinary shares from an exchange on which they were listed and do not list the ordinary shares on another exchange;
- we appear to be insolvent or enter insolvency proceedings all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;
- there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or
- there has been a replacement of deposited securities.

If the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.

TABLE OF CONTENTS

After the termination date and before the depository sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depository may refuse to accept a surrender for the purpose of withdrawing deposited securities if it would interfere with the selling process. The depository may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depository will continue to collect distributions on deposited securities, but, after the termination date, the depository is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph.

Limitations on Obligations and Liability

Limits on our Obligations and the Obligations of the Depository; Limits on Liability to Holders of ADSs

The deposit agreement expressly limits our obligations and the obligations of the depository. It also limits our liability and the liability of the depository. We and the depository:

- are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;
- are not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its obligations under the deposit agreement;
- are not liable if we or it exercises discretion permitted under the deposit agreement;
- are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;
- have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;
- are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and
- may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.

In the deposit agreement, we and the depository agree to indemnify each other under certain circumstances.

Requirements for Depository Actions

Before the depository will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depository may require:

- payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities;
- satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and
- compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.

The depository may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depository or our transfer books are closed or at any time if the depository or we think it advisable to do so.

Your Right to Receive the Ordinary Shares Underlying your ADSs

ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except:

- when temporary delays arise because: (1) the depository has closed its transfer books or we have closed our transfer books; (2) the transfer of ordinary shares is blocked to permit voting at a shareholders meeting; or (3) we are paying a dividend on our shares;
- when you owe money to pay fees, taxes and similar charges; or
- when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.

This right of withdrawal may not be limited by any other provision of the deposit agreement.

Pre-release of ADSs

The deposit agreement permits the depository to deliver ADSs before deposit of the underlying shares. This is called a pre-release of the ADSs. The depository may also deliver ordinary shares upon cancellation of pre-released ADSs (even if the ADSs are canceled before the pre-release transaction has been closed out). A pre-release is closed out as soon as the underlying ordinary shares are delivered to the depository. The depository may receive ADSs instead of ordinary shares to close out a pre-release. The depository may pre-release ADSs only under the following conditions: (1) before or at the time of the pre-release, the person to whom the pre-release is being made represents to the depository in writing that it or its customer owns the ordinary shares or ADSs to be deposited; (2) the pre-release is fully collateralized with cash or other collateral that the depository considers appropriate; and (3) the depository must be able to close out the pre-release on not more than five business days' notice. In addition, the depository will limit the number of ADSs that may be outstanding at any time as a result of pre-release, although the depository may disregard the limit from time to time if it thinks it is appropriate to do so.

Direct Registration System

In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered holdings of uncertificated ADSs and holdings of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of ADSs, to direct the depository to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depository of prior authorization from the ADS holder to register that transfer.

In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depository will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depository's reliance on and compliance with instructions received by the depository through the DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depository.

Shareholder communications; inspection of register of holders of ADSs

The depository will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depository will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.

SHARES ELIGIBLE FOR FUTURE SALE

Prior to this offering our ordinary shares have been traded only on the TASE. In connection with this offering, we intend to apply to list the ADSs listed on NASDAQ, under the symbol “[]”. No assurance can be given that our application will be approved. Sales of substantial amounts of our ordinary shares in the public market, or the perception that such sales could occur, could adversely affect prevailing market prices of our ordinary shares and ADSs. Upon completion of this offering, we will have outstanding ordinary shares (including those represented by ADSs), assuming the underwriters do not exercise their over-allotment option. All of the ADSs sold in this offering will be freely transferable without restriction or further registration under the Securities Act by persons other than by our affiliates.

Our ordinary shares will be held by our existing shareholders. Because all of these shares were sold outside the United States to persons residing outside the United States at the time, and are currently traded on the TASE, they will continue to be freely tradable on TASE without restriction or further registration, except for the restrictions described below, and except for the lock-up restrictions described under “Underwriting” below. Approximately []% of our outstanding shares will be subject to such lock-up agreements.

Lock-up Agreements

We and our executive officers, directors, and our 5% or more shareholders have agreed not to offer, sell, agree to sell, directly or indirectly, or otherwise dispose of any ordinary shares, ADSs or any other securities convertible into or exchangeable for ordinary shares except for the ordinary shares offered in this offering without the prior written consent of the representative for a period of [] months] after the consummation of this offering. After the expiration of such [] month] period, the ordinary shares held by our directors, executive officers or certain of our other existing shareholders may be sold outside of the United States subject to the restrictions under applicable Israeli securities laws or by means of registered public offerings.

Rule 144

In general, under Rule 144 under the Securities Act as in effect on the date hereof, beginning 90 days after the date hereof, a person who holds restricted ordinary shares (assuming there are any restricted shares) and is not one of our affiliates at any time during the three months preceding a sale, and who has beneficially owned these restricted shares for at least six months, would be entitled to sell an unlimited number of our ordinary shares, provided current public information about us is available. In addition, under Rule 144, a person who holds restricted shares in us and is not one of our affiliates at any time during the three months preceding a sale, and who has beneficially owned these restricted shares for at least one year, would be entitled to sell an unlimited number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. Beginning 90 days after the date hereof, our affiliates who have beneficially owned our ordinary shares for at least six months will be entitled to sell within any three month period a number of shares that does not exceed the greater of:

- 1% of the number of ordinary shares then outstanding; or
- the average weekly trading volume of our shares on NASDAQ during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; provided that current public information about us is available and the affiliate complies with the manner of sale requirements imposed by Rule 144.

Affiliates are also subject to additional restrictions on the manner of sales under Rule 144 and notice filing requirements.

We cannot estimate the number of our ordinary shares that our existing shareholders will elect to sell on the TASE.

Regulation S

Regulation S under the Securities Act provides that securities owned by any person may be sold without registration in the United States, provided that the sale is effected in an offshore transaction and no directed selling efforts are made in the United States (as these terms are defined in Regulation S), subject to certain other conditions. In general, this means that our ordinary shares may be sold in some manner outside the United States without requiring registration in the United States.

[TABLE OF CONTENTS](#)

Rule 701

In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory share plan or other written agreement executed prior to the completion of this offering is eligible to resell such ordinary shares in reliance on Rule 144, but without compliance with some of the restrictions, including the holding period, contained in Rule 144.

THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL SHARE TRANSFER RESTRICTION MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN LEGAL ADVISOR REGARDING THE PARTICULAR SECURITIES LAWS AND TRANSFER RESTRICTION CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF THE ADSS, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.

TAXATION

The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our ordinary shares or ADSs (both referred to below as the Shares). You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, including Israeli, or other taxing jurisdiction.

Israeli Tax Considerations and Government Programs

The following is a summary of the material Israeli income tax laws applicable to us. This section also contains a discussion of material Israeli income tax consequences concerning the ownership and disposition of our Shares. This summary does not discuss all the aspects of Israeli income tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. To the extent that the discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. This summary is based on laws and regulations in effect as of the date of this prospectus and does not take into account possible future amendments which may be under consideration.

General corporate tax structure in Israel

Israeli resident companies, such as us, are generally subject to corporate tax at the rate of 25% as of January 1, 2016.

Capital gains derived by an Israeli resident company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli tax legislation, a corporation will be considered as an “Israeli Resident” if it meets one of the following: (a) it was incorporated in Israel; or (b) the control and management of its business are exercised in Israel.

Law for the Encouragement of Industry (Taxes), 5729-1969

The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for “Industrial Companies.” Collect Biotherapeutics is currently qualified as an Industrial Company within the meaning of the Industry Encouragement Law.

The Industry Encouragement Law defines an “Industrial Company” as a company resident in Israel, of which 90% or more of its income in any tax year, other than income from defense loans, is derived from an “Industrial Enterprise” owned by it. An “Industrial Enterprise” is defined as an enterprise whose principal activity in a given tax year is industrial production.

The following corporate tax benefits, among others, are available to Industrial Companies:

- amortization over an eight-year period of the cost of purchased know-how and patents and rights to use a patent and know-how which are used for the development or advancement of the company; and
- under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies.

Eligibility for benefits under the Industry Encouragement Law is not contingent upon the approval of any governmental authority.

There can be no assurance that Collect Biotherapeutics will continue to qualify as an Industrial Company or that the benefits described above will be available in the future.

Law for the Encouragement of Capital Investments, 5719-1959

The Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets) by “Industrial Enterprises” (as defined under the Investment Law).

TABLE OF CONTENTS

The Investment Law was significantly amended effective as of January 1, 2011, or the 2011 Amendment.

The 2011 Amendment introduced benefits for income generated by a “Preferred Company” through its “Preferred Enterprise” (as such terms are defined in the Investment Law) as of January 1, 2011. Pursuant to the 2011 Amendment, a Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred Enterprise unless the Preferred Enterprise is located in a specified development zone (Collect Biotherapeutics is not), in which case the rate will be 9%. Under the 2011 Amendment, the corporate tax rate is 16% and 9% in 2014 and thereafter.

Tax benefits are available under the 2011 Amendment to production facilities (or other eligible facilities), which are generally required to derive more than 25% of their business income from export and meet additional criteria stipulated in the amendment.

Dividends paid out of income attributed to a Preferred Enterprise are generally subject to withholding tax at the rate of 20% or such lower rate as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required to be withheld (however, if afterward distributed to individuals or a non-Israeli company a withholding of 20%, or such lower rate as may be provided in an applicable tax treaty, will apply).

From time to time, the Israeli Government has discussed reducing the benefits available to companies under the Investment Law. The termination or substantial reduction of any of the benefits available under the Investment Law could materially increase our tax liabilities.

Currently, Collect Biotherapeutics is in a loss position for tax purposes and therefore does not implement the tax benefits according to the Investment Law. However, we believe that once Collect Biotherapeutics will have taxable income, it will be eligible for a reduced corporate tax rate according to the Investment Law.

Taxation of our Israeli individual shareholders on receipt of dividends

Israeli residents who are individuals are generally subject to Israeli income tax for dividends paid on our Shares (other than bonus shares or share dividends) at a rate of 25%, or 30% if the recipient of such dividend is a “substantial shareholder” (as defined below) at the time of distribution or at any time during the preceding 12-month period.

As of January 1, 2013, an additional income tax at a rate of 2% is imposed on high earners whose annual income or gain exceeds NIS 810,720.

A “substantial shareholder” is generally a person who alone, or together with his relative or another person who collaborates with him on a regular basis, holds, directly or indirectly, at least 10% of any of the “means of control” of the corporation. “Means of control” generally include the right to vote, receive profits, nominate a director or an officer, receive assets upon liquidation, or instruct someone who holds any of the aforesaid rights regarding the manner in which he or she is to exercise such right(s), and all regardless of the source of such right.

The term “Israeli resident” is generally defined under Israeli tax legislation with respect to individuals as a person whose center of life is in Israel. The Ordinance provides that in order to determine the center of life of an individual, account will be taken of the individual’s family, economic and social connections, including: (a) place of permanent home; (b) place of residential dwelling of the individual and the individual’s immediate family; (c) place of the individual’s regular or permanent occupation or the place of his permanent employment; (d) place of the individual’s active and substantial economic interests; (e) place of the individual’s activities in organizations, associations and other institutions. The center of life of an individual will be presumed to be in Israel if: (a) the individual was present in Israel for 183 days or more in the tax year; or (b) the individual was present in Israel for 30 days or more in the tax year, and the total period of the individual’s presence in Israel in that tax year and the two previous tax years is 425 days or more. The presumption in this paragraph may be rebutted either by the individual or by the assessing officer.

Taxation of Israeli Resident Corporations on Receipt of Dividends

Israeli resident corporations are generally exempt from Israeli corporate income tax with respect to dividends paid on our Shares.

TABLE OF CONTENTS

Capital Gains Taxes Applicable to Israeli Resident Shareholders

The income tax rate applicable to real capital gain (capital gain less the effect of inflation) derived by an Israeli individual from the sale of shares which had been purchased after January 1, 2012, whether listed on a stock exchange or not, is 25%. However, if such shareholder is considered a "Substantial Shareholder" (as defined above) at the time of sale or at any time during the preceding 12-month period, such gain will be taxed at the rate of 30%. As of January 1, 2013, an additional tax at a rate of 2% is imposed on high earners whose annual income or gains exceed NIS 810,720.

Moreover, capital gains derived by a shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable as ordinary business income, are taxed in Israel at ordinary income rates (26.5% as of 2015 for corporations and up to 50% for individuals).

Taxation of Non-Israeli Shareholders on Receipt of Dividends

Non-Israeli residents are generally subject to Israeli income tax on the receipt of dividends paid on our Shares at the rate of 25% or 30% if such recipient is a "substantial shareholder" at the time receiving the dividend or on any date in the 12 months preceding such date. If the Shares are held by a nominee company, the nominee company or the financial institution will withhold at the source a tax of 25% whether the recipient is a substantial shareholder or not. Otherwise, the withholding at the source will be 25% or 30% in accordance with the above, unless a lower tax rate is provided in a tax treaty between Israel and the shareholder's country of residence.

A non-Israeli resident who receives dividends from which tax was withheld is generally exempt from the duty to file returns in Israel in respect of such income; provided such income was not derived from a business conducted in Israel by the taxpayer, and the taxpayer has no other taxable sources of income in Israel.

For example, under the Convention Between the Government of the United States of America and the Government of Israel with Respect to Taxes on Income, as amended, Israeli withholding tax on dividends paid to a U.S. resident for treaty purposes may not, in general, exceed 25%, or 15% in the case of dividends paid out of the profits of a "Benefited Enterprise", subject to certain conditions. Where the recipient is a U.S. corporation owning 10% or more of the voting shares of the paying corporation during the part of the paying corporation's taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any) and the dividend is not paid from the profits of a Benefited Enterprise, and not more than 25% of the gross income of the paying corporation consists of interest or dividends (other than interest derived from the conduct of banking, insurance, or financing business or interest received from subsidiary corporations, 50% or more of the outstanding shares of the voting stock of which is owned by the paying corporation at the time such dividends or interest is received) the Israeli tax withheld may not exceed 12.5%, subject to certain conditions.

Capital gains income taxes applicable to non-Israeli shareholders.

Non-Israeli resident shareholders are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition of our Shares, provided that such gains were not derived from a permanent establishment or business activity of such shareholders in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemptions if Israeli residents (1) jointly have a controlling interest of more than 25% in such non-Israeli corporation or (2) are the beneficiaries of or are entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.

Regardless of whether shareholders may be liable for Israeli income tax on the sale of our Shares, the payment of the consideration may be subject to withholding of Israeli tax at the source. Accordingly, shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale.

TABLE OF CONTENTS

Estate and gift tax

Israeli law presently does not impose estate or gift taxes.

EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR ISRAELI TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR SHARES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.

U.S. Federal Income Tax Considerations

THE FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY SHARES AND AMERICAN DEPOSITORY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.

Subject to the limitations described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences to a “U.S. Holder” arising from the purchase, ownership and sale of the Ordinary Shares and ADSs. For this purpose, a “U.S. Holder” is a beneficial owner of Ordinary Shares or ADSs that is: (1) an individual citizen or resident of the United States, including an alien individual who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust; and (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury regulations.

This summary is for general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations that may be relevant to a decision to purchase our Ordinary Shares or ADSs. This summary generally considers only U.S. Holders that will own our Ordinary Shares or ADSs as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer’s status as a U.S. Holder. This summary is based on the provisions of the Code, final, temporary and proposed U.S. Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof, and the U.S./Israel Income Tax Treaty, all as in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to differing interpretations. We will not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment in our Ordinary Shares or ADSs by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.

This discussion does not address all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. Holder based on such holder’s particular circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer, state, local, excise or foreign tax considerations. In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank, life insurance company, regulated investment company, or other financial institution or “financial services entity”; (2) a broker or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares or ADSs in connection with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our Ordinary Shares or ADSs as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment trusts; (8) a U.S. Holder that expatriates out of the United States or a former long-term resident of the United States; or (9) a U.S. Holder having a functional currency other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, Ordinary

TABLE OF CONTENTS

Shares or ADSs representing 10% or more of our voting power. Additionally, the U.S. federal income tax treatment of persons who hold Ordinary Shares or ADSs through a partnership or other pass-through entity are not considered.

Each prospective investor is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing of our Ordinary Shares or ADSs, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.

Taxation of Dividends Paid on Ordinary Shares or ADSs

We do not intend to pay dividends in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under the heading “Passive Foreign Investment Companies” below, a U.S. Holder will be required to include in gross income as ordinary income the amount of any distribution paid on Ordinary Shares or ADSs (including the amount of any Israeli tax withheld on the date of the distribution), to the extent that such distribution does not exceed our current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our current and accumulated earnings and profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder’s tax basis for the Ordinary Shares or ADSs to the extent thereof, and then as capital gain. Corporate holders generally will not be allowed a deduction for dividends received.

In general, preferential tax rates for “qualified dividend income” and long-term capital gains are applicable for U.S. Holders that are individuals, estates or trusts. For this purpose, “qualified dividend income” means, inter alia, dividends received from a “qualified foreign corporation.” A “qualified foreign corporation” is a corporation that is entitled to the benefits of a comprehensive tax treaty with the United States which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty satisfies this requirement and we believe we are eligible for the benefits of that treaty.

In addition, our dividends will be qualified dividend income if our Ordinary Shares or ADSs are readily tradable on NASDAQ or another established securities market in the United States. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend is paid or in the prior year, as a PFIC, as described below under “Passive Foreign Investment Companies”. A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder has not held our Ordinary Shares or ADSs for at least 61 days of the 121 day period beginning on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make related payments on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our Ordinary Shares or ADSs are not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as “investment income” pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation.

The amount of a distribution with respect to our Ordinary Shares or ADSs will be measured by the amount of the fair market value of any property distributed, and for U.S. federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such U.S. dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of it, any subsequent gain or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.

Distributions paid by us will generally be foreign source income for U.S. foreign tax credit purposes and will generally be considered passive category income for such purposes. Subject to the limitations set forth in the Code, U.S. Holders may elect to claim a foreign tax credit against their U.S. federal income tax liability for Israeli income tax withheld from distributions received in respect of the Ordinary Shares or ADSs. The rules relating to the determination of the U.S. foreign tax credit are complex, and U.S. Holders should consult with their own tax advisors to determine whether, and to what extent, they are entitled to such credit. U.S. Holders that do not elect to claim a foreign tax credit may instead claim a deduction for Israeli income taxes withheld, provided such U.S. Holders itemize their deductions.

Taxation of the Disposition of Ordinary Shares or ADSs

Except as provided under the PFIC rules described below under “Passive Foreign Investment Companies,” upon the sale, exchange or other disposition of our Ordinary Shares or ADSs, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder’s tax basis for the Ordinary Shares or ADSs in U.S. dollars and the amount realized on the disposition in U.S. dollars (or its U.S. dollar equivalent determined by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). The gain or loss realized on the sale, exchange or other disposition of Ordinary Shares or ADSs will be long-term capital gain or loss if the U.S. Holder has a holding period of more than one year at the time of the disposition.

Gain realized by a U.S. Holder on a sale, exchange or other disposition of Ordinary Shares or ADSs will generally be treated as U.S. source income for U.S. foreign tax credit purposes. A loss realized by a U.S. Holder on the sale, exchange or other disposition of Ordinary Shares or ADSs is generally allocated to U.S. source income. The deductibility of a loss realized on the sale, exchange or other disposition of Ordinary Shares or ADSs is subject to limitations.

Passive Foreign Investment Companies

Special U.S. federal income tax laws apply to U.S. taxpayers who owns shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income tax purposes for any taxable year that either:

- 75% or more of our gross income (including our pro rata share of gross income for any company in which we are considered to own 25% or more of the shares by value) is passive; or
- at least 50% of our assets, averaged quarterly over the year (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) and generally determined based upon value (provided we were not considered a “controlled foreign corporation” prior to the public offering) are held for the production of, or produce, passive income.

For this purpose, passive income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from notional principal contracts. Cash is treated as generating passive income.

We believe we may be a PFIC during 2016 and although we have not determined whether we will be a PFIC in 2017, or in any subsequent year, our operating results for any such years may cause us to be a PFIC. The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value of our Ordinary Shares. Accordingly, there can be no assurance that we currently are not or will not become a PFIC.

If we currently are or become a PFIC, each U.S. Holder who has not elected to treat us as a qualified electing fund by making a “QEF election”, or who has not elected to mark the shares to market (as discussed below), will be subject to special rules with respect to (i) any “excess distribution” (generally, the portion of any distributions received by the non-electing U.S. Holder on the Ordinary Shares or ADSs in a taxable year in excess of 125% of the average annual distributions received by the non-electing U.S. Holder in the three preceding taxable years, or, if shorter, the non-electing U.S. Holder’s holding period for the Ordinary Shares or ADSs), and (ii) any gain realized on the sale or other disposition of such Ordinary Shares or ADSs. Under these rules:

- the excess distribution or gain would be allocated ratably over the non-electing U.S. Holder’s holding period for such Ordinary Shares or ADSs;
- the amount allocated to the current taxable year and any year prior to us becoming a PFIC would be taxed as ordinary income; and
- the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year.

TABLE OF CONTENTS

In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the tax basis of such shares would not receive a step-up to fair market value as of the date of the decedent's death, but instead would be equal to the decedent's basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also be subject to these special U.S. federal income tax rules.

The PFIC rules described above would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held the Ordinary Shares or ADSs while we were a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election is required for each taxable year that we are a PFIC to include in income such U.S. Holder's pro rata share of our ordinary earnings as ordinary income and such U.S. Holder's pro rata share of our net capital gains as long-term capital gain, regardless of whether we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain required information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the IRS. Although we have no obligation to do so, we intend to notify U.S. Holders if we believe we will be treated as a PFIC for any taxable year in order to enable U.S. Holders to consider whether to make a QEF election. In addition, we intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. U.S. Holders should consult with their own tax advisors regarding eligibility, manner and advisability of making a QEF election if we are treated as a PFIC.

In addition, the PFIC rules described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder of our Ordinary Shares or ADSs which are regularly traded on a qualifying exchange, including Nasdaq, can elect to mark the Ordinary Shares or ADSs to market annually, recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between the fair market value of the Ordinary Shares or ADSs and the U.S. Holder's adjusted tax basis in the Ordinary Shares or ADSs. Losses are allowed only to the extent of net mark-to-market gain previously included income by the U.S. Holder under the election for prior taxable years. Thus, a U.S. Holder may recognize taxable income without receiving any cash to pay its tax liability with respect to such income. The U.S. Holder would also be permitted an ordinary loss in respect of the excess, if any, of the U.S. Holder's adjusted tax basis in our Ordinary Shares or ADSs over their fair market value at the end of the taxable year, but only to the extent of the net amount previously included in income as a result of the mark-to-market election. A U.S. Holder's tax basis in our Ordinary Shares or ADSs would be adjusted to reflect any such income or loss amount. Gain realized on the sale, exchange or other disposition of our Ordinary Shares or ADSs would be treated as ordinary income, and any loss realized on the sale, exchange or other disposition of our Ordinary Shares or ADSs would be treated as ordinary loss to the extent that such loss does not exceed the net mark-to-market gains previously included in income by the U.S. Holder, and any loss in excess of such amount will be treated as capital loss. Amounts treated as ordinary income will not be eligible for the favorable tax rates applicable to qualified dividend income or long-term capital gains.

U.S. Holders who do not make a timely QEF election or a mark-to-market election, and who hold our Ordinary Shares or ADSs during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to our Ordinary Shares or ADSs in the event that we are a PFIC.

Tax on Investment Income

U.S. Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including dividends on and gains from the sale or other disposition of our Ordinary Shares and ADSs), or in the case of estates and trusts on their net investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder's total adjusted income exceeds applicable thresholds.

TABLE OF CONTENTS

Tax Consequences for Non-U.S. Holders of Ordinary Shares or ADSs

Except as provided below, an individual, corporation, estate or trust that is not a U.S. Holder, referred to below as a non-U.S. Holder, generally will not be subject to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our Ordinary Shares or ADSs.

A non-U.S. Holder may be subject to U.S. federal income tax on a dividend paid on our Ordinary Shares or ADSs or gain from the disposition of our Ordinary Shares or ADSs if: (1) such item is effectively connected with the conduct by the non-U.S. Holder of a trade or business in the United States, or, if required by an applicable income tax treaty is attributable to a permanent establishment or fixed place of business in the United States; or (2) in the case of a disposition of our Ordinary Shares or ADSs, the individual non-U.S. Holder is present in the United States for 183 days or more in the taxable year of the disposition and other specified conditions are met.

In general, non-U.S. Holders will not be subject to backup withholding with respect to the payment of dividends on our Ordinary Shares or ADSs if payment is made through a paying agent or office of a foreign broker outside the United States. However, if payment is made in the United States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides an applicable IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise establishes an exemption.

The amount of any backup withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder's U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.

Information Reporting and Withholding

A U.S. Holder may be subject to backup withholding at a rate of 28% with respect to dividends and proceeds from a disposition of Ordinary Shares or ADSs. In general, backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that the required information is timely furnished to the IRS.

A U.S. Holder with interests in "specified foreign financial assets" (including, among other assets, our Ordinary Shares or ADSs, unless such Ordinary Shares or ADSs are held on such U.S. Holder's behalf through a financial institution) may be required to file an information report with the IRS if the aggregate value of all such assets exceeds \$50,000 on the last day of the taxable year or \$75,000 at any time during the taxable year (or such higher dollar amount as may be prescribed by applicable IRS guidance). You should consult your own tax advisor as to the possible obligation to file such information reports in light of your particular circumstances.

TABLE OF CONTENTS

Discretionary Accounts. The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.

Lock-Up Agreements. Pursuant to certain “lock-up” agreements, our executive officers and directors have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of any ordinary shares or ADSs or securities convertible into or exchangeable or exercisable for any ordinary shares or ADSs, whether currently owned or subsequently acquired, without the prior written consent of [], for a period of [months] after the consummation of this offering.

Nasdaq Listing. We intend to apply to list the ADSs on Nasdaq under the symbol “.” No assurance can be given that our application will be approved.

Electronic Offer, Sale and Distribution of ADSs. A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representative may agree to allocate a number of ADSs to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.

Price Stabilization, Short Positions and Penalty Bids. In order to facilitate the offering of the ADSs, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the ADSs. In connection with the offering, the underwriters may purchase and sell the ADSs in the open market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of ADSs than they are required to purchase in the offering. “Covered” short sales are sales made in an amount not greater than the underwriters’ option to purchase additional ADSs in the offering. The underwriters may close out any covered short position by either exercising their over-allotment option or purchasing ADSs in the open market. In determining the source of ADSs to close out the covered short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase ADSs through the over-allotment option. “Naked” short sales are sales in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing ADSs in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of ADSs made by the underwriters in the open market prior to the completion of the offering.

Similar to other purchase transactions, the underwriters’ purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of the ADSs or preventing or retarding a decline in the market price of the ADSs. As result, the price of the ADSs may be higher than the price that might otherwise exist in the open market.

The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the ADSs, including the imposition of penalty bids. This means that if the representative of the underwriters purchases ADSs in the open market in stabilizing transactions or to cover short sales, the representative can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them.

The underwriters make no representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the ADSs. In addition, neither we nor the

TABLE OF CONTENTS

underwriters make any representation that the underwriters will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

From time to time, the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future.

Offer Restrictions Outside the United States

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

ENFORCEMENT OF FOREIGN JUDGMENTS

We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in the registration statement of which this prospectus forms a part, substantially all of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside of the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States.

We have been informed by our legal counsel in Israel, Doron Tikotzky Kantor Gutman Cederboun & Co., that it may be difficult to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law.

Subject to specified time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that among other things:

- the judgment is obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel;
- the judgment is final and is not subject to any right of appeal;
- the prevailing law of the foreign state in which the judgment was rendered allows for the enforcement of judgments of Israeli courts and the substance of the judgment is not contrary to public policy; and
- the judgment is executory in the state in which it was given.

Even if these conditions are met, an Israeli court will not declare a foreign civil judgment enforceable if:

- the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);
- the judgment was obtained by fraud;
- the possibility given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court;
- the judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel;
- the judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or
- at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel.

If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.

[TABLE OF CONTENTS](#)

EXPENSES RELATING TO THIS OFFERING

We estimate that the total expenses of this offering payable by us, excluding the underwriting discounts, commissions and expenses, will be approximately \$ [] as follows:

	<u>Amount</u>
SEC registration fee	\$ *
NASDAQ listing fee	*
FINRA filing fee	*
Printing and engraving expenses	*
Transfer Agent fees and expenses	*
Legal fees and expenses	*
Accountant fees and expenses	*
Miscellaneous costs	*
Total	\$ []

* To be completed

All amounts in the table are estimated except the SEC registration fee, NASDAQ listing fee and the FINRA filing fee.

LEGAL MATTERS

The validity of the ADSs, the ordinary shares represented by the ADSs being offered by this prospectus and other legal matters concerning this offering will be passed upon for us by Zysman, Aharoni, Gayer and Sullivan & Worcester LLP, New York, New York with respect to U.S. federal law and Doron Tikotzky Kantor Gutman Cederboun & Co., Israel with respect to Israeli law.

Certain legal matters in connection with this offering will be passed upon for the underwriter by [] with respect to U.S. federal law and [] with respect to Israeli law.

EXPERTS

The financial statements of the Company as of December 31, 2015 and 2014 and for each of the three years in the period ended December 31, 2015 appearing in this prospectus have been audited by Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, an independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of the ADSs. This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms.

You may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC's public reference room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC's website at <http://www.sec.gov>.

TABLE OF CONTENTS

Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements will file reports with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In addition, we will not be required under the Exchange Act to file annual or other reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. Instead, we will file with the SEC, within 120 days after the end of each fiscal year, or such other applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm. We also intend to furnish certain other material information to the SEC under cover of Form 6-K.

In addition, because our ordinary shares are traded on the TASE, we have filed Hebrew language periodic and immediate reports with, and furnish information to, the TASE and the ISA, as required under Chapter Six of the Israel Securities Law. Copies of our filings with the ISA can be retrieved electronically through the MAGNA distribution site of the ISA (www.magna.isa.gov.il) and the TASE website (www.maya.tase.co.il).

We maintain a corporate website at www.collectbio.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

[TABLE OF CONTENTS](#)

CELLECT BIOMED LTD.
CONSOLIDATED FINANCIAL STATEMENTS

AS OF DECEMBER 31, 2015

NIS IN THOUSANDS

INDEX

	<u>Page</u>
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets	F-3
Consolidated Statements of Comprehensive Loss	F-4
Statements of Changes in Equity	F-5
Consolidated Statements of Cash Flows	F-6 – F-7
Notes to Consolidated Financial Statements	F-8 – F-28



Kost Forer Gabbay & Kasierer
3 Aminadav St.
Tel-Aviv 6706703, Israel

Tel: +972-3-6232525
Fax: +972-3-5622555
ey.com

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

**To the Shareholders and
Board of Directors of**

Collect Biomed Ltd.

We have audited the accompanying consolidated balance sheets of Collect Biomed Ltd. (the “Company”) and its subsidiaries as of December 31, 2015 and 2014 and the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2015. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, based on our audits, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company and its subsidiaries as of December 31, 2015 and 2014 and the results of their operations, changes in equity and cash flows for each of the three years in the period ended December 31, 2015, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Without qualifying our above opinion, we draw attention to Note 1b to the consolidated financial statements. As discussed in Note 1b to the financial statements, the Company incurred losses totaling NIS 10,172 thousand during the year ended December 31, 2015, has not yet generated revenues from its operations and is dependent on external sources for financing its operations. These factors, among others discussed in Note 1b, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are discussed in Note 1b. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Tel-Aviv, Israel
March 31, 2016

/s/ KOST FORER GABBAY & KASIERER
A Member of Ernst & Young Global

CONSOLIDATED BALANCE SHEETS

In thousands, except share and per share data

	Note	December 31,		Convenience translation (Note 2d)
		2014	2015	December 31, 2015
		NIS		U.S. dollars
CURRENT ASSETS:				
Cash and cash equivalents	6	2,122	3,913	1,003
Marketable securities	7	11,257	7,829	2,006
Other receivables	8	161	412	106
		<u>13,540</u>	<u>12,154</u>	<u>3,115</u>
LONG-TERM ASSETS:				
Restricted cash	16c	20	20	5
Property, plant and equipment, net	9	234	1,187	304
		<u>254</u>	<u>1,207</u>	<u>309</u>
		<u>13,794</u>	<u>13,361</u>	<u>3,424</u>
CURRENT LIABILITIES:				
Trade payables	10	107	466	119
Other payables	11	728	2,394	614
		<u>835</u>	<u>2,860</u>	<u>733</u>
SHAREHOLDERS' EQUITY:				
Ordinary shares of no par value: Authorized: 500,000,000 shares as of December 31, 2014 and 2015, Issued and Outstanding: 71,085,351*) and 75,949,888*) shares as of December 31, 2014 and 2015, respectively	13	—	—	—
Share premium		30,723	36,544	9,365
Reserve from transaction with shareholder		181	181	46
Share-based payments	14	1,710	3,603	923
Treasury shares		(9,425)	(9,425)	(2,415)
Accumulated deficit		(10,230)	(20,402)	(5,228)
		<u>12,959</u>	<u>10,501</u>	<u>2,691</u>
		<u>13,794</u>	<u>13,361</u>	<u>3,424</u>

*) Net of 2,686,693 treasury shares of the Company, held by the Company.

The accompanying notes are an integral part of the consolidated financial statements.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

In thousands, except share and per share data

	Note	Year ended December 31,			Convenience translation (Note 2d)
		2013	2014	2015	Year ended December 31, 2015
		N I S			U.S. dollars
Research and development expenses	17a	1,062	3,058	5,893	1,510
General and administrative expenses	17b	2,425	2,491	4,204	1,077
Total operating expenses		3,487	5,549	10,097	2,587
Operating loss		3,487	5,549	10,097	2,587
Financial income		(11)	(37)	(4)	(1)
Financial expenses		202	39	79	20
Total comprehensive loss		3,678	5,551	10,172	2,606
Loss per share					
Basic and diluted loss per share	18	0.075	0.084	0.137	0.035
Weighted average number of shares outstanding used to compute basic and diluted loss per share		49,152,886	65,968,768	74,475,109	74,475,109

The accompanying notes are an integral part of the consolidated financial statements.

STATEMENTS OF CHANGES IN EQUITY

In thousands, except share and per share data

	Share capital	Share premium	Reserve from transaction with shareholder	Treasury shares	Share-based payments	Capital funds	Accumulated deficit	Total equity
	N I S							
<u>Balance as of January 1, 2013</u>	17,286	383	181	(9,425)	—	(7,861)	(1,001)	(437)
Issuance of share capital	—	4,258	—	—	—	—	—	4,258
Effect of merger with public shell company (see Note 5)	35,623	(1,236)	—	—	—	(31,870)	—	2,517
Effect of cancellation of par value per share	(52,909)	13,178	—	—	—	39,731	—	—
Share-based payment	—	—	—	—	583	—	—	583
Total comprehensive loss	—	—	—	—	—	—	(3,678)	(3,678)
<u>Balance as of December 31, 2013</u>	—	16,583	181	(9,425)	583	—	(4,679)	3,243
Issuance of share capital net of issue costs (see Note 13a6)	—	14,140	—	—	329	—	—	14,469
Share-based payment	—	—	—	—	798	—	—	798
Total comprehensive loss	—	—	—	—	—	—	(5,551)	(5,551)
<u>Balance as of December 31, 2014</u>	—	30,723	181	(9,425)	1,710	—	(10,230)	12,959
Issuance of share capital net of issue costs (see Note 13a8)	—	5,596	—	—	696	—	—	6,292
Share-based payment	—	—	—	—	1,318	—	—	1,318
Exercise of stock options	—	225	—	—	(121)	—	—	104
Total comprehensive loss	—	—	—	—	—	—	(10,172)	(10,172)
<u>Balance as of December 31, 2015</u>	—	36,544	181	(9,425)	3,603	—	(20,402)	10,501
Balance as of December 31, 2015 convenience translation (see Note 2d)	—	9,365	46	(2,415)	923	—	(5,228)	2,691

The accompanying notes are an integral part of the consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS
In thousands, except share and per share data

	Year ended December 31,			Convenience translation (Note 2d)
	2013	2014	2015	Year ended December 31, 2015
	N I S			U.S. dollars
<u>Cash Flows from Operating Activities:</u>				
Net loss	(3,678)	(5,551)	(10,172)	(2,606)
Adjustments to reconcile net loss to net cash used in operating activities:				
Adjustments to profit and loss items:				
Net financing expenses	3	3	69	18
Gain from revaluation of financial assets presented at fair value through profit and loss	—	(35)	(2)	(1)
Depreciation	7	24	71	18
Interest and indexation differences in respect of loans from shareholder, net	188	21	—	—
Share-based payment	583	798	1,318	338
Other (Appendix a)	(21)	—	—	—
	<u>760</u>	<u>811</u>	<u>1,456</u>	<u>373</u>
Changes in asset and liability items:				
Decrease (increase) in other receivables	(47)	104	(328)	(84)
Increase in other payables	338	235	1,333	342
	<u>291</u>	<u>339</u>	<u>1,005</u>	<u>258</u>
Cash paid and received during the year for:				
Interest paid	(6)	—	—	—
Interest received	3	2	1	*)
	<u>(3)</u>	<u>2</u>	<u>1</u>	<u>*)</u>
Net cash used in operating activities	<u>(2,630)</u>	<u>(4,399)</u>	<u>(7,710)</u>	<u>(1,975)</u>
<u>Cash Flows from Investing Activities:</u>				
Proceeds received from the sale of fixed assets	—	—	77	20
Investment in marketable securities measured at fair value through profit and loss	—	(14,022)	—	—
Sale of marketable securities measured at fair value through profit and loss	—	2,800	3,430	879
Sale of investment in subsidiary (Appendix a)	(68)	—	—	—
Increase in restricted cash	(20)	—	—	—
Purchase of property, plant and equipment	(21)	(229)	(332)	(85)
Net cash provided by (used in) investing activities	<u>(109)</u>	<u>(11,451)</u>	<u>3,175</u>	<u>814</u>

*) The amount is less than 1\$.

The accompanying notes are an integral part of the consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS – (Continued)

In thousands, except share and per share data

	Year ended December 31,			Convenience translation (Note 2d)
	2013	2014	2015	Year ended December 31, 2015
	N I S			U.S. dollars
Cash Flows from Financing Activities:				
Exercise of stock options	—	—	104	26
Receipt of loans from shareholders	200	—	—	—
Repayment of loans from shareholders	(200)	(536)	—	—
Effect of merger with public shell company	2,598	—	—	—
Issuance of share capital, net of issue costs (see note 13)	3,946	14,469	6,292	1,613
Net cash provided by financing activities	6,544	13,933	6,396	1,639
Exchange differences on balances of cash and cash equivalents				
	—	(5)	(70)	(18)
Increase (decrease) in cash and cash equivalents	3,805	(1,922)	1,791	459
Balance of cash and cash equivalents at the beginning of the year	239	4,044	2,122	544
Balance of cash and cash equivalents at the end of the year	4,044	2,122	3,913	1,003
a. Realization of investment in subsidiary				
Subsidiary's assets and liabilities as of date of sale:				
Working capital (except for cash and cash equivalents)	(89)	—	—	—
Other	21	—	—	—
	(68)	—	—	—
b. Non-cash activities				
Conversion of loan to share capital	312	—	—	—
Purchase of property, plant and equipment	—	—	692	177

The accompanying notes are an integral part of the consolidated financial statements.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 1:- GENERAL

- a. Collect Biomed Ltd. (the “Company”) is a public company whose shares are listed for trading on the Tel Aviv Stock Exchange. On September 3, 2013, the Company changed its name from T.R.F. Capital Ltd. to its present name due to the merger transaction from July, 2013 (See Note 5 below). Until July 1, 2013, the Company was a “public shell company” with no significant business activity. On June 30, 2013, the merger of the Company was approved by the Company’s general shareholders’ meeting, through an exchange of shares, with Collect Biotherapeutics Ltd. (renamed from “Collect Biotechnology Ltd” during 2016) (hereafter — “Collect”). Collect is engaged in the development of an innovative, unique technology that enables the biological filtering and commercialization of stem cells. The closing of the merger agreement took place on July 1, 2013, under the terms of which, the shareholders of Collect were issued 85% of the Company’s shares, and the Collect shares were transferred in their entirety to the Company’s ownership (also see Note 5).

As the shareholders of Collect obtained control of the Company, and since the Company was a non-operating shell company, the share exchange should reflect the substance of the transaction, which is a capital transaction, rather than a business combination. That is, the transaction is a recapitalization, equivalent to the issuance of shares by the private company (Collect) for the net monetary assets of the public shell company, accompanied by a recapitalization. The transaction is accounted for as a share-based payment transaction under International Financial Reporting Standards (“IFRS”) 2, whereby Collect is deemed to have issued shares in exchange for the cash and other net assets of the Company. The assets and liabilities of Collect are included at their carrying value and the assets and liabilities of the Company are included at fair value. Equity represents the authorized and issued number of shares of the Company (amount of shares prior to the closing of the merger was adjusted to reflect the ratio of the shares exchange) and additional paid-in capital and accumulated deficit of Collect (the legal subsidiary which is the ongoing operating company). In addition, the comparative data presented in these financial statements are those of Collect.

- b. Going Concern

The accompanying financial statements have been prepared in conformity with IFRS, assuming that the Company will continue to operate as a going concern. During the year ended December 31, 2015, the Company incurred a net loss of NIS 10,172 (\$2,606) and had an accumulated deficit of NIS 20,402 (\$5,228) at December 31, 2015. The Company’s management plans to seek additional equity financing. The Company believes its current capital resources are sufficient to support its operations through the end of the first half of 2017.

The Company’s activities since inception have consisted principally of raising capital and performing research and development activities. The Company is considered to be in the development stage as of December 31, 2015, as its principal commercial operations have not commenced. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations, if any, are dependent on future events, including, among other things, its ability to obtain marketing approval from regulatory authorities and access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 1:- GENERAL – (continued)

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities of the Company. To fund its capital needs, the Company plans to raise funds through equity or debt financings or other sources, such as strategic partnerships and alliance and licensing arrangements, and in the long term, from the proceeds from sales. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. These matters raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

The following accounting policies have been applied consistently in the consolidated financial statements for all periods presented, unless otherwise stated.

a. Basis of presentation of the financial statements:

These financial statements have been prepared in accordance with IFRS as issued by the International Accounting Standards Board ("IASB").

The Company's financial statements have been prepared on a cost basis, except for securities that are measured at fair value through profit or loss.

The Company has elected to present profit or loss items using the "function of expense" method. The Company's operating cycle is one year.

b. Consolidated financial statements:

The consolidated financial statements include the financial statements of companies that the Company controls (subsidiaries). Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such control ceases.

The financial statements of the Company and its subsidiaries (the "Group") are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group. Significant intercompany balances and transactions and gains or losses resulting from intercompany transactions are eliminated in full in the consolidated financial statements.

c. Functional currency, reporting currency and foreign currency:

1. Functional currency and reporting currency:

The reporting currency of the financial statements is the New Israeli Shekel ("NIS").

The Company determines the functional currency of each company in the group, used to measure the financial condition and results of operations of each company separately.

2. Transactions, assets and liabilities in foreign currency:

Transactions denominated in foreign currency are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES – (continued)

denominated in foreign currency are translated on each reporting date into the functional currency at the exchange rate at that date. Exchange rate differences are recognized in profit or loss.

d. Convenience translation into U.S. dollars:

The financial statements as of December 31, 2015 and for the year then ended have been translated into U.S. dollars using the exchange rate of the U.S. dollar as of December 31, 2015 (U.S. \$1.00 = NIS 3.902). The translation was made solely for convenience purposes.

The dollar amounts presented in these financial statements should not be construed as representing amounts that are receivable or payable in dollars or convertible into dollars, unless otherwise indicated.

e. Cash equivalents:

Cash equivalents are considered as highly liquid investments, including unrestricted short-term bank deposits with an original maturity of three months or less from the date of acquisition.

f. Taxes on income:

Tax results with respect to current or deferred taxes are recognized in profit or loss, unless they relate to items recognized in other comprehensive income or equity.

Current taxes

The liability for current taxes is determined using the tax rates and tax laws that were enacted or essentially enacted by the reporting date, as well as adjustments required in connection with the taxes payable in respect of prior years.

g. Property, plant and equipment:

Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation.

Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows:

	%
Computers	33
Vehicles	15
Leasehold improvements	(*)
Office furniture and equipment	7 – 15

(* Leasehold improvements are depreciated on a straight-line basis over the lease term or the estimated useful life of the improvement, according to the shorter period.

The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate.

Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized. An asset is derecognized on disposal or when no further economic benefits are expected from its use.

h. Research and development expenses, net of participations:

Research and development expenses are recognized in profit or loss when incurred. An intangible asset arising from a development project or from the development phase of an internal project is recognized, if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES – (continued)

available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development.

i. Financial instruments:

1. Financial assets:

Financial assets within the scope of International Accounting Standard ("IAS") 39, "*Financial Instruments: Recognition and Measurement*" ("IAS 39") are initially recognized at fair value plus directly attributable transaction costs, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.

After initial recognition, the accounting treatment of financial assets is based on their classification as follows:

Financial assets at fair value through profit or loss

This category includes financial assets designated upon initial recognition as at fair value through profit or loss.

Loans and receivables

Loans and receivables are investments with fixed or determinable payments that are not quoted in an active market. After initial recognition, loans are measured based on their terms at amortized cost plus directly attributable transaction costs using the effective interest method and less any impairment losses. Short-term borrowings are measured based on their terms, normally at face value.

2. Financial liabilities:

Financial liabilities within the scope of IAS 39 are initially measured at fair value.

After initial recognition, the accounting treatment of financial liabilities is based on their classification as follows:

Financial liabilities measured at amortized cost

After initial recognition, loans and other liabilities are measured according to their terms at amortized cost using the effective interest method, taking into account directly attributable transaction costs.

3. Offsetting financial instruments:

Financial assets and financial liabilities are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.

j. Onerous contract

The Company recognized a net provision for contractual future lease payment amounts greater than the future economic benefits expected from leased assets (expected income from sublease of the assets) as a result of discontinuing use of the assets, departure and transfer of activities carried out in them. This provision is presented at present value.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES – (continued)

k. Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

Fair value measurement is based on the assumption that the transaction will take place in the asset's or the liability's principal market, or in the absence of a principal market, in the most advantageous market.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

Fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement:

Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 — inputs other than quoted prices included within Level 1 that are observable directly or indirectly.

Level 3 — inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).

l. Treasury shares

The Company's shares held by the Company are measured at their acquisition cost and are presented as an offset against the Company's equity. Any gain or loss deriving from the purchase, sale, issuance or cancellation of treasury shares is recognized directly in equity.

m. Employee benefit liabilities:

The Group has several employee benefit plans:

1. Short-term employment benefits:

Short-term employee benefits are expected to be settled in full less than 12 months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. The liability for a cash bonus or profit-participating plan is recognized when the Company has a legal or constructive obligation to pay the said amount in respect of services rendered by the employee in the past and the amount may be reliably estimated.

2. Post-employment benefits:

Post-employment benefit plans are normally funded by contributions to insurance companies and are classified as defined contribution plans.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES – (continued)

The Company has defined contribution plans pursuant to Section 14 of the Israeli Severance Pay Law, into which the Company pays fixed contributions and has no legal or constructive obligation to pay further contributions on account of severance pay, even if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in current and prior periods.

Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee's services.

n. Share-based payment transactions:

From time to time the Company grants to its employees and other service providers remuneration in the form of equity-settled share-based instruments, such as options to purchase ordinary shares.

Equity-settled transactions:

The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model.

As for other service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured by reference to the fair value of the equity instruments granted.

The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period in which the performance or service conditions are satisfied, and ending on the date on which the relevant employees become fully entitled to the award (the "Vesting Period").

No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vested irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.

When the Company changes the conditions of the award of equity-settled instruments, an additional expense is recognized beyond the original expense, calculated in respect of a change that increases the total fair value of the remuneration granted or benefits the other service provider according to the fair value on date of change.

Cancellation of the award of equity-settled instruments is accounted for as having vested at the cancellation date and the expense not yet recognized in respect of the award is recognized immediately. However, if the cancelled grant is replaced by a new grant, and is intended as an alternate grant at the date awarded, the cancelled and new awards will both be accounted for as a change to the original award, as described above.

o. Loss per share:

Loss per share is calculated by dividing the net loss attributable to Company shareholders by the weighted number of outstanding ordinary shares during the period. Potential ordinary shares are only included in the computation of diluted loss per share when their conversion increases loss per share or decreases income per share. Potential ordinary shares that are converted during the period are included in diluted loss per share only until the conversion date and from that date in basic loss per share.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 3:- SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS

Estimates and assumptions:

The preparation of the financial statements requires management to make estimates and assumptions that have an effect on implementation of the accounting policies and on the reported amounts of assets, liabilities and expenses. Changes in accounting estimates are recognized in the period in which the estimate was changed.

Discussed below are the key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities in the subsequent financial year.

Determining the fair value of share-based transactions

The fair value of share-based transactions is determined upon initial recognition using acceptable option pricing models. The model is based on per-share price data and the exercise price and assumptions regarding expected volatility, expected life, expected dividend and risk-free interest rate.

NOTE 4:- DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION

a. Amendments to IAS 7, "Statement of Cash Flows", regarding additional disclosures of financial liabilities:

In January 2016, the IASB issued amendments to IAS 7, "Statement of Cash Flows", (the "Amendments") which require additional disclosures regarding financial liabilities. The Amendments require disclosure of the changes between the opening balance and the closing balance of financial liabilities, including changes from cash flows, changes arising from obtaining or losing control of subsidiaries, the effect of changes in foreign exchange rates and changes in fair value.

The Amendments are effective for annual periods beginning on or after January 1, 2017. Comparative information for periods prior to the effective date of the Amendments is not required. Early application is permitted.

The Company will include the necessary disclosures in the financial statements when applicable.

b. IFRS 16, "Leases":

In January 2016, the IASB issued IFRS 16, "Leases" (the "New Standard"). According to the New Standard, a lease is a contract, or part of a contract, that conveys the right to use an asset for a period of time in exchange for consideration.

According to the New Standard:

- Lessees are required to recognize an asset and a corresponding liability in the statement of financial position in respect of all leases (except in certain cases) similar to the accounting treatment of finance leases according to the existing IAS 17, "Leases".
- Lessees are required to initially recognize a lease liability for the obligation to make lease payments and a corresponding right-of-use asset. Lessees will also recognize interest and depreciation expenses separately.
- Variable lease payments that are not dependent on changes in the Consumer Price Index ("CPI") or interest rates, but are based on performance or use (such as a percentage of revenues) are recognized as an expense by the lessees as incurred and recognized as income by the lessors as earned.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 4:- DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION – (continued)

- In the event of a change in variable lease payments that are CPI-linked, lessees are required to remeasure the lease liability and the effect of the remeasurement is an adjustment to the carrying amount of the right-of-use asset.
- The New Standard includes two exceptions according to which lessees are permitted to elect to apply a method similar to the current accounting treatment for operating leases. These exceptions are leases for which the underlying asset is of low value and leases with a term of up to one year.
- The accounting treatment by lessors remains substantially unchanged, namely classification of a lease as a finance lease or an operating lease.

The New Standard is effective for annual periods beginning on or after January 1, 2019. Earlier application is permitted provided that IFRS 15, “Revenue from Contracts with Customers”, is applied concurrently.

For leases existing at the date of transition, the New Standard permits lessees to use either a full retrospective approach, or a modified retrospective approach, with certain transition relief whereby restatement of comparative data is not required.

The Company believes that the New Standard is not expected to have a material impact on the financial statements.

NOTE 5:- MERGER WITH CELLECT BIOTHERAPEUTICS LTD. (former “Collect Biotechnology Ltd”)

- a. The merger between the Company and Collect, a private company engaged in development of innovative, unique technology, enabling selection of biologically filtered stem cells and commercialization, closed on July 1, 2013. Under the terms of the agreement, 44,887,373 ordinary shares, NIS 1.00 par value each, of the Company, constituting 85% of its equity, were issued to shareholders of Collect, as well as an aggregate of 568,395 options (not listed for trading), each exercisable for one ordinary share of the Company, NIS 1.00 par value each, in consideration for the entire share capital of Collect and all of the existing options in Collect for the purchase of ordinary shares of Collect, such that following the merger, Collect became a wholly-owned subsidiary of the Company.

The terms of the options granted by the Company to the option holders of Collect under the terms of the agreement are as follows:

1. 227,358 Series 1 unlisted options — exercisable until April 30, 2018, at an exercise price of NIS 1.00 per option. At the date of exchange of these options with the options described in Note 13a, no additional benefit has been created for the option holders.
2. 341,037 Series 2 unlisted options — exercisable until the end of 24 months from the grant date, at an exercise price equal to the average price of the Company’s share in the first ten trading days after closing of the merger transaction (July 1, 2013), but not less than the par value of the underlying shares NIS 0.1 per option. On September 18, 2013, following cancellation of the par value of the Company’s shares, the Company revalued the options and recognized an expense for the incremental value created as a result of the said change in the amount of NIS 121 (valued using the Black — Scholes options pricing model assuming share price volatility of 64.3%, risk-free interest rate of 1.48% and a share price of NIS 0.959). In the second quarter of 2015, these options were exercised (see Note 13.a.8.)

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 5:- MERGER WITH CELLECT BIOTHERAPEUTICS LTD. (former “Collect Biotechnology Ltd”) – (continued)

Under the terms of the above-described transaction and change in control described below, the Company issued shares for the purpose of acquiring Collect, such that after the transaction, the prior shareholders of Collect held 85% of the Company’s share capital as of closing.

In accordance with the aforesaid, the said transaction was presented in the financial statements as an issuance of equity by Collect in consideration for the Company’s net assets.

Regarding the accounting treatment and presentation of comparative information, see Note 1a.

- b. See Note 16.b.2 and 16.b.3 for further details in respect of the change in the Company’s controlling shareholders and the signing of employment and service agreements with the Company’s Chairman of the Board and Chief Executive Officer (“CEO”).
- c. On July 15, 2013, as part of the merger, the Company sold its shares in Tagor Properties, a former subsidiary. As a result of the sale, the Company recognized a capital gain in the amount of NIS 21.

NOTE 6:- CASH AND CASH EQUIVALENTS

	<u>December 31,</u>		<u>Convenience</u>
	<u>2014</u>	<u>2015</u>	<u>translation</u>
	<u>N I S</u>		<u>(Note 2d)</u>
			<u>December 31,</u>
			<u>2015</u>
			<u>U.S. dollars</u>
Cash for immediate withdrawal	1,978	3,913	1,003
Cash equivalents (short-term deposits)	144	—	—
	<u>2,122</u>	<u>3,913</u>	<u>1,003</u>

NOTE 7:- MARKETABLE SECURITIES MEASURED AT FAIR VALUE THROUGH PROFIT AND LOSS

Marketable securities measured at fair value through profit and loss as of December 31, 2015 are comprised of NIS mutual funds that follow changes in short-term Bank of Israel interest.

NOTE 8:- OTHER RECEIVABLES

	<u>December 31,</u>		<u>Convenience</u>
	<u>2014</u>	<u>2015</u>	<u>translation</u>
	<u>N I S</u>		<u>(Note 2d)</u>
			<u>December 31,</u>
			<u>2015</u>
			<u>U.S. dollars</u>
Other receivables	77	—	—
Government authorities	67	187	48
Prepaid expenses	17	225	58
	<u>161</u>	<u>412</u>	<u>106</u>

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 9:- PROPERTY, PLANT AND EQUIPMENT, NET

Balance as of December 31, 2015:

	Laboratory equipment	Leasehold improvements*)	Vehicles	Office furniture and equipment	Computers	Total
Cost						
Balance as of January 1, 2015	—	—	176	16	76	268
Additions during the year:						
Purchases	687	244	—	20	73	1,024
Balance as of December 31, 2015	687	244	176	36	149	1,292
Accumulated Depreciation						
Balance as of January 1, 2015	—	—	11	6	17	34
Additions during the year:						
Depreciation	12	—*)	26	2	31	71
Balance as of December 31, 2015	12	—	37	8	48	105
Depreciated cost as of December 31, 2015	675	244	139	28	101	1,187
Depreciated cost as of December 31, 2015 (convenience translation into U.S. dollars (Note 2d))	172	62	37	7	26	304

*) The Company entered into new offices in early January 2016, and did not record depreciation expenses of the leasehold improvements during 2015.

Balance as of December 31, 2014:

	Vehicles	Office furniture and equipment	Computers	Total
Cost				
Balance as of January 1, 2014	—	9	30	39
Additions during the year:				
Purchases	176	7	46	229
Balance as of December 31, 2014	176	16	76	268
Accumulated Depreciation				
Balance as of January 1, 2014	—	5	5	10
Additions during the year:				
Depreciation	11	1	12	24
Balance as of December 31, 2014	11	6	17	34
Depreciated cost as of December 31, 2014	165	10	59	234

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 10:- TRADE PAYABLES

	December 31,		Convenience translation (Note 2d)
	2014	2015	December 31, 2015
	N I S		U.S. dollars
Service providers	70	182	47
Notes payable	37	284	72
	<u>107</u>	<u>466</u>	<u>119</u>

NOTE 11:- OTHER PAYABLES

	December 31,		Convenience translation (Note 2d)
	2014	2015	December 31, 2015
	N I S		U.S. dollars
Employees and payroll accruals*)	341	663	170
Accrued expenses	375	985	253
Payables for acquisition of property, plant and equipment	—	692	177
Other	12	54	14
	<u>728</u>	<u>2,394</u>	<u>614</u>

*) Balance includes related parties

NOTE 12:- FINANCIAL INSTRUMENTS

Financial liabilities

Management assessed that the balance of cash, other receivables trade accounts payable and other current liabilities approximates their fair value, due to the short maturities of these instruments.

- a. On December 11, 2012, a shareholder loaned \$50 to Collect. According to the loan's terms, the interest rate was Libor + 3% and would mature not before April 1, 2014. The loan may be converted into the Company's shares on the basis of a company value of \$2,500, on a fully diluted basis.

The fair value of the underlying shares, based on the value of the Company performed by an independent appraiser on the date the loan was made, was \$508. The fair value of the liability component, calculated as the present value of the expected cash flows of the loan at an interest rate of 24.9% was \$39 and is measured after initial recognition at amortized cost and accreted to its redemption amount using the effective interest method.

On April 30, 2013, Collect's board of directors ratified an amendment of the loan agreement and conversion of the loan on such date. The loan balance was converted to 697,324 ordinary shares. This number of shares was determined considering the offset intended to correct the number of shares issued to that shareholder in May 2012.

- b. On February 7, 2013, several shareholders loaned NIS 200 to Collect. According to the loans' terms, the interest rate was Libor + 3% and it would mature not before April 1, 2014. The loans may be converted into the Company's shares on the basis of a Company value of \$2,000 on a fully diluted basis.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 12:- FINANCIAL INSTRUMENTS – (continued)

On March 31, 2013, Collect's board of directors decided to prepay the loans prior to maturity. The loans were repaid during May 2013.

- c. As of December 31, 2013, Collect had a loan from a shareholder (prior to the merger) and founder, which at such date amounted to \$140. The loan bears interest at the annual rate of Libor + 3%, and its maturity date will not be earlier than April 1, 2014. The loan was initially recognized as a liability, at its fair value on the date received. The fair value was determined by discounting the loan's expected cash flows based on an annual interest rate of 24.9%, reflecting the Company's risk. The difference between the fair value upon receipt of the loan and the cash received was recognized as a capital reserve.

On May 16, 2013, the shareholder undertook that as long as the merger with the Company closed, payment of the loan would not be demanded, until after the completion of the merger and as from the merger date, the Company raised at least \$5,000. In addition, the shareholder agreed that as long as the Company would be unable to repay the loan, it would not institute liquidation proceedings due to non-payment of the loan. During 2014, the loan was repaid in full, after all of the conditions for its repayment were fulfilled (also see Note 13).

NOTE 13:- EQUITY

- a. Changes in share capital:

	Number of Shares
<u>Balance as of January 1, 2014</u>	56,868,281*)
Issuance of shares – see note 6 below	14,217,070
<u>Balance as of December 31, 2014</u>	71,085,351
Exercise of stock options – see note 8 below	341,037
Issuance of shares – see note 7 below	4,523,500
<u>Balance as of December 31, 2015</u>	<u>75,949,888*)</u>

*) Net of 2,686,693 treasury shares of the Company, held by the Company.

1. On April 30, 2013, Collect, issued 1,319,232 shares to three individuals (who were not shareholders prior to this issuance and not considered as related parties to the Company), in consideration for NIS 541, based on a Company value of \$5,000 post-issuance.
2. For the issuance of shares against the conversion of a shareholder loans, see Note 12 above.
3. On June 30, 2013, the Company's general meeting of the shareholders approved an increase of the Company's authorized capital, such that after the change, the Company's authorized share capital would be NIS 100,000,000, divided into 100,000,000 ordinary shares, NIS 1.00 par value each. In addition, on this date, the Company's general meeting of the shareholders approved, within the scope of approval of the merger (see Note 5 above), the issuance of 44,887,373 ordinary shares, NIS 1.00 par value each.
4. On August 14, 2013, the Company's board of directors approved a change in the equity structure, such that subsequently, the Company's shares will become shares without par value. The Company's general meeting of shareholders approved this change on September 18, 2013. Immediately following the change, the authorized share capital of the Company became NIS 100,000,000, divided into 100,000,000 ordinary shares, no par value, and the issued and outstanding share capital of the Company was 55,595,672 ordinary shares without par value.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 13:- EQUITY – (continued)

5. On October 10, 2013, the Company's board of directors approved a private placement of 3,959,302 ordinary shares of the Company, having no par value, to six investors, for consideration of NIS 3,405, reflecting a price of NIS 0.86 per share. On October 22, 2013, the Tel Aviv Stock Exchange approved the issuance.
6. On April 22, 2014, the Company's board of directors approved the Company entering into an investment agreement (the "Private Placement") with Michael Ilan Management and Investments Ltd., a private company wholly-owned by Mr. Michael Ilan (the "Investor"), whereby the Investor agreed to invest the sum of NIS 15,000 according to a pre-money company valuation of NIS 60,000, for consideration of 14,217,070 ordinary shares of the Company, representing, after issuance, 20% of the Company's issued and outstanding capital and 19.84% on a fully-diluted basis. On May 13, 2014, the Private Placement was completed.

Additionally, the Company entered into an agreement with a broker (the "Broker"), pursuant to which, the Company agreed that at the closing of the Private Placement, the Broker would be entitled to cash compensation of 3% of the amount of the investment (NIS 450), plus options that will be exercisable over three years from their grant date, in an amount equal to 3% of the share capital to be issued to investors. Following closing, a total of 426,512 options, exercisable into 426,512 ordinary shares, were granted to the Broker. The total benefit in respect of the grant calculated at the grant date was NIS 329.

7. On April 20, 2015, the Company published a shelf offering under the shelf prospectus dated November 25, 2014, pursuant to which the public was offered up to 4,500,000 shares and up to 4,500,000 options (Series 1), exercisable into 4,500,000 ordinary shares of the Company. The Company exercised its right for an over-allotment not to exceed 15% of the total securities offered through the shelf offering, such that in total, the Company issued 4,523,500 ordinary shares and 4,523,500 options (Series 1) of the Company. The total gross proceeds received by the Company in respect of the securities offered to the public according to the shelf offering totaled NIS 6,604 (proceeds net of issuance costs amounted to NIS 6,292).

Following the offering, the CEO and additional officers became entitled to a bonus, in accordance with the Company's compensation policy, totaling to NIS 172. The Company accrued this amount as an expense in the second quarter of 2015. Pursuant to the issuance of the share capital, the Company granted 200,000 options (Series 1) exercisable for 200,000 ordinary shares of the Company to a broker, representing 0.26% of the Company's issued and outstanding capital on a fully-diluted basis, at an exercise price of NIS 1.85 per share, in consideration for NIS 32, which was recorded in the second quarter of 2015, as deduction from the share premium.

8. During June 2015, 341,073 unlisted options were exercised for 341,073 shares of the Company, in consideration for a total of NIS 104.

b. Rights related to ordinary shares

All ordinary shares shall have equal rights and each ordinary share shall entitle the holder the following rights:

1. The right to receive notices of any general meeting of shareholders, to participate in meetings and vote on any matter raised in the meeting. Each ordinary share entitles its holder to one vote.
2. The right to participate in any distribution by the Company to its shareholders and receive dividends and/or bonus shares, if distributed in accordance with the Company's articles of association.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 13:- EQUITY – (continued)

3. The right to participate at the time of liquidation of the Company, in the distribution of the Company's assets permitted to be distributed in proportion to the number of shares allocated and the degree of repayment by the shareholders, if not fully paid, and subject to the provisions of the articles of association of the Company and without prejudice to existing rights of shareholders of any kind.

NOTE 14:- SHARE-BASED COMPENSATION

- a. Details on share options granted are provided below:

1. On April 30, 2013, Cellect granted to each of two service providers 113,679 fully vested options, for the purchase of 113,679 ordinary shares of the Company at an exercise price of NIS 0.01 per share. The options may be exercised within five years from the grant date. The fair value of the options was determined using the Black-Scholes options pricing model as described in Note 5.

The total benefit in respect of the grant calculated at the grant date was NIS 462, and was recorded as an expense on the date of grant. Under the terms of the options, upon the closing of the merger with a public company, the options that had been granted were exchanged for options for shares of the public company, according to the ratio for the exchange of shares in the merger. Regarding the new options received, see Note 5.1 above.

2. For the options granted to a relative of the Chairman of the Board, see Note 16.b.1.
3. On February 18, 2014, an option plan for employees and consultants of the Company was approved by the Company's board of directors.
4. On July 31, 2014, the Company's board of directors, following approval by the compensation committee, approved the following grants:

Grant of 1,226,512 unlisted options of the Company (including 426,512 options to the Broker for the private placement, see Note 13 above). Grant of 700,000 unlisted options to one employee, three senior officers and two consultants of the Company.

Concurrently, the Company's board of directors, following approval by the compensation committee, approved the grant of 1,200,000 unlisted options to the Company's Chief Executive Officer. The grant of the options was approved by the Company's general shareholders meeting on September 8, 2014.

On September 28, 2014, following approval by the compensation committee, a special general shareholders' meeting approved grant of 100,000 options to a consultant in the advisory board of the Company.

Based on the below data, the fair value of the options was determined as NIS 2,413 on the grant date, and was recognized as an expense during the Vesting Period, of up to three years.

5. On August 26, 2015, the Company's general shareholders' meeting approved a grant to each of the Company's directors, including the external directors, of 72,000 unlisted options, exercisable for 72,000 ordinary shares, no par value, and in total, 504,000 unlisted options exercisable for 504,000 ordinary shares, no par value, of the Company, representing 0.6% of the Company's issued and outstanding capital on a fully-diluted basis, at an exercise price of NIS 1.90 per share.
6. On October 19, 2015, the board of directors approved an increase to the unlisted option pool of 4,087,903 options. As a result, the Company has a total of 7,500,000 unlisted options.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 14:- SHARE-BASED COMPENSATION – (continued)

7. On October 15, 2015, the Company appointed Ronen Twito as the Deputy Chief Executive Officer and Chief Financial Officer (the “Deputy CEO and CFO”), effective November 3, 2015. On November 23, 2015, the Company’s general meeting of shareholders approved the Deputy CEO and CFO’s terms of service, including a grant of options, which is an exception from the Company’s compensation policy, as further described below. The terms of service included among others, a grant of 2,658,246 options, exercisable for 2,658,246 ordinary shares, no par value, of the Company at an exercise price of NIS 1.28 per share, representing 3.5% of the Company’s issued and outstanding capital. The total benefit in respect of the grant calculated at the grant date was NIS 3,033. The terms of service also included a bonus plan based on, among others, future capital raising by the Company.
8. On November 29, 2015, the Company’s board of directors approved the grant of 80,000 unlisted options to an officer exercisable for 80,000 ordinary shares. The fair value of the options at the grant in accordance with the Black-Scholes model estimated a total of about NIS 81, that will be recognized as an expense over the Vesting Period of the options (three years).
- c. Expense recognized in the financial statements:

The expense that was recognized for services received from employees, directors and service providers is as follows:

	Year ended December 31,			Convenience translation (Note 2d)
	2013	2014	2015	Year ended December 31, 2015
	NIS			U.S. dollars
Share-based payment settled by equity instruments	583	798	1,318	338
Total share-based compensation	583	798	1,318	338

- d. Activity during the year:

The table below includes the number of share options and the weighted average of their exercise prices:

	2014		2015	
	Number of options	Weighted Average Exercise price	Number of options	Weighted Average Exercise price
	NIS		NIS	
Outstanding at beginning of year	568,395	0.5952	2,994,907	1.2450
Options exercised for shares	—	—	(341,037)	0.3
Options forfeited	—	—	(131,250)	1.4
Granted	2,426,512	1.3972	3,242,246	1.382
Outstanding at end of year	2,994,907	1.2450	5,764,866	1.374

CELLECT BIOMED LTD.**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS****In thousands, except share and per share data****NOTE 14:- SHARE-BASED COMPENSATION – (continued)**e. Measuring the fair value of stock options settled by equity instruments:

The Company shares data which is useful for measuring the fair value of the options under the Black-Scholes model, for the years ended December 31, 2014 and 2015, is as follows:

	2014	2015
Dividend yield (%)	0	0
Expected volatility of the share prices (%)	96.1% – 101 %	85.8% – 87.5 %
Risk-free interest rate (%)	1.05% – 3.16%	2.26% – 2.33 %
Expected life of share options (years)	3 – 10	10

According to the data above, the fair value of options granted in the years 2014 – 2015 was set to NIS 6,020 at the grant date.

NOTE 15:- TAXES ON INCOME

a. Corporate tax rates in Israel:

Corporate tax rate in Israel in 2014 and 2015 is 26.5%.

On January 4, 2016, the Israeli Parliament approved by a second and third reading the Bill for Amending the Income Tax Ordinance (No. 217) (Reduction of Corporate Tax Rate), 2015, which consists of the reduction of the corporate tax rate from 26.5% to 25%.

b. Final tax assessments

The Company received final tax assessments through tax year 2010. Collect has no final tax assessments since its inception (year 2011).

c. Net operating carryforwards losses for tax purposes and other temporary differences:

As of December 31, 2015, the Company had carryforward operating losses amounting to approximately NIS 11,878.

The Company did not recognize deferred tax assets for carryforward operating and capital losses and other temporary differences because their utilization in the foreseeable future is not probable.

NOTE 16:- CONTINGENT LIABILITIES AND COMMITMENTS

a. Contingent liabilities

On November 26, 2013, the Company sent a letter in response to a letter of demand and warning before instituting legal proceedings (the "Letter"), which the Company received on November 5, 2013. It was alleged in the Letter that in early 2010, the Letter's sender entered into an agreement with the Company's Chief Executive Officer (in this note, the "CEO"), who is also a shareholder in the Company, pursuant to which it was agreed to establish a joint venture with the objective of developing stem cell products. It was further alleged that pursuant to the said agreement, the above business activity was carried out within the framework of Sticks Negev Ltd. ("Sticks"), in which the Letter's sender holds 18% of his shares. The Letter's sender alleged that the CEO transferred the activity of Sticks to the ownership of Collect. In the Letter, the sender proposed that the Company and the CEO would meet to try to reach a settlement in order to prevent the institution of legal proceedings on his part.

In the Company's letter of response, the Company rejected the Letter sender's allegations.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 16:- CONTINGENT LIABILITIES AND COMMITMENTS – (continued)

On April 13, 2014, the Company's representative received a statement of claim from Attorney Eliash, in which he brought a civil action against Dr. Shai Yarkoni, the Company's CEO, Dr. Nadir Askenasy, the Company's Chief Scientist, and the Company, claiming his entitlement to 1,386,328 of the Company's shares. The Company assesses, based, among other things, on the opinion of its legal counsel, that the chances of the claim being accepted were remote. On November 11, 2015, all the claims against the Company were dismissed.

b. Commitments

1. On April 30, 2013, Collect entered into two agreements to receive brokerage services in respect of the merger (with one of these agreements signed with a relative of a controlling shareholder and one of the founders of Collect (before the merger) (the "Relative"). Collect committed to pay, for the brokerage services it received from the Relative, after the closing of the merger, a sum equal to 2.5% of the net assets acquired, after deducting the merger expenses (but not less than NIS 50 for each service provider). The Company recognized an expense of NIS 100 for such brokerage services. Additionally, the Company granted the Relative the option to purchase 341,037 ordinary shares of Collect, exercisable for 24 months from the first day of trading after the closing of the merger, for shares of the merged company, according to the exchange ratio of the shares in the merger, at an exercise price per share equal to the average price of the merged company's shares in the first ten trading days following the merger, and in any case, at an exercise price that will not be less than NIS 0.1. Regarding the exchange of options granted upon the closing of the merger, see Note 5.
2. Within the scope of approval of the merger, as described in Note 5 and the change in the Company's controlling shareholder, a new Chairman of the board of directors was appointed for the Company on July 7, 2013. According to the terms of the agreement, the Chairman of the board of directors will be employed on a half-time basis, and will be entitled to a monthly salary as follows: until a cumulative investment of total of \$2,000 is raised — NIS 10; when an investment between \$2,000 to \$4,000 is raised — NIS 15 and once a cumulative total investment of more than \$4,000 is raised — NIS 20. He will also be entitled to a bonus for capital raised by the Company, whereby for the first \$2,000 raised, he will be entitled to a bonus of 0.75% of the amount raised, and for amounts exceeding \$2,000, he will be entitled to a bonus of 1% of the amount raised (exceeding the first \$2,000). The bonus in respect of the capital amounts raised is limited to NIS 200.

Further to the investment described in Note 13.a.6, during 2014, the Chairman of the board of directors received a bonus of NIS 166 and 34 NIS for the years 2014 and 2015, respectively, as a result of capital raised.

3. Within the scope of the approval of the merger, as described in Note 5 and the change in control, a new CEO was appointed to the Company on July 7, 2013. Under the terms of the agreement, the CEO will be entitled, through a company he owns, to monthly compensation of NIS 58.5, and after an investment of \$2,000 is raised, the monthly compensation will increase by 10%, and will increase by a further 10% when an additional cumulative total investment of \$2,000 will be raised. Commencing in January 2014, the CEO was paid as an employee rather than a contractor, with the Company's expense for his employment remaining unchanged. Following a \$15,000 investment in the Company in April 2014, the CEO's monthly gross salary was raised to NIS 54.5. The CEO is also entitled to social conditions, Company car and customary expenses of senior officers in the Company.

The CEO was entitled to a bonus of NIS 100 upon the closing of the merger. In July 2013, the CEO was paid a bonus of NIS 100 in respect of the merger.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 16:- CONTINGENT LIABILITIES AND COMMITMENTS – (continued)

In addition to the aforementioned compensation, the CEO will be entitled to a bonus as follows: for investment of \$1,000 — NIS 100, and additionally, for investments of between \$1,000 and \$2,000 — 0.75% of the cumulative amount raised; for investments that exceed \$2,000 — 1% of the amount exceeding \$2,000, up to a cumulative one-off payment of NIS 200. In December 2013, the CEO was paid a bonus for the amounts raised during 2013 of NIS 100.

Further to the investment described in Note 13, the CEO received a bonus totaling NIS 166 during 2014. In addition, the CEO received a bonus during 2015 in the amount of NIS 100 in respect of his performance in 2014.

Starting 2015, the CEO is eligible for grants under an objective plan set by the remuneration committee that replaces the terms of the grant mentioned above.

4. On May 6, 2015, the Company's general shareholders' meeting approved an updated compensation policy related to the additional payment of a NIS 100 bonus to the Company's CEO who is also a shareholder in respect of his activity during the year 2014. In addition, the Company's general shareholders' meeting approved the 2015 bonus plan of up to five times the CEO's monthly salary, depending on operational results. Bonus in 2014 was recorded as an expense in the second quarter of 2015.

Following the attainment of targets in 2015, the Company included provision for grant of four times the CEO's monthly salary.

5. On April 30, 2013, Cellect entered into an agreement to receive consulting services from its founder-shareholder, who also serves as its Chief Scientist, who, until that date, during 2013, provided consulting services for no consideration. Commencing on the merger closing date, as described in Note 5, the said shareholder will be entitled to a total of NIS 0.4 for each hour of service provided to the Company.
6. On October 15, 2015 the Company announced the appointment the Deputy CEO and CFO of the Company commencing November 3, 2015. In addition, the Company announced a special meeting to approve the terms of Mr. Ronen Twito, including private placement, in excess of the policy of remuneration of the Company. The terms of employment include the granting of options in an amount of about 3.5% of the issued capital of the Company at the date of the decision and determining program objectives bonuses conditioned upon, inter alia, future investments in the Company. On November 23, 2015, the general shareholders' meeting approved the above conditions. In connection with the granting of the options, see Note 14.a.7 above.
7. On May 28, 2014, the Company entered into a rental agreement for its offices, commencing June 1, 2014 through May 30, 2016. The Company has an option to extend the rental contract for 12 additional months. Under the terms of the agreement, the Company will pay monthly rental fees plus monthly management fees totaling NIS 6. The Company furnished a promissory note of NIS 35 to secure all of its obligations pursuant to the agreement.

Since the Company has remained committed to respect the agreement until May 30, 2016, the Company recognized a provision for future rental payments.

On September 1, 2015, the Company signed a new lease agreement for new offices. The aforementioned lease agreement is for a minimum period of 3 years from the date of signing the agreement. Under this agreement, the Company will pay a monthly rental fee plus an administration fee of NIS 30.

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 16:- CONTINGENT LIABILITIES AND COMMITMENTS – (continued)

8. The Company has entered into operating lease agreements for vehicles. These leases have an average life of three years with no option to extend the contract. The future minimum monthly lease payments as of December 31, 2015 are approximately NIS 7.
- c. Liens:
The Company provided a NIS 20 restricted bank deposit to secure credit card payments.

NOTE 17:- SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF COMPREHENSIVE LOSS

- a. Research and development expenses:

	Year ended December 31,			Convenience translation (Note 2d)
	2013	2014	2015	Year ended December 31, 2015
	NIS			U.S. dollars
Salaries and related expenses	729	1,555	2,739	702
Professional services	147	400	746	191
Patents	164	169	326	84
Subcontractors (*)	—	354	1,308	335
Share-based payment	—	512	523	134
Other research and development costs	22	68	251	64
	<u>1,062</u>	<u>3,058</u>	<u>5,893</u>	<u>1,510</u>

(*) Including lab materials for clinical experiments.

- b. General and administrative expenses:

	Year ended December 31,			Convenience translation (Note 2d)
	2013	2014	2015	Year ended December 31, 2015
	NIS			U.S. dollars
Salaries and related expenses	336	850	1,024	262
Directors' fees	188	269	358	92
Share-based payment	583	286	795	204
Professional services	1,048	762	1,366	350
Insurance	115	23	23	5
Travel abroad	25	—	201	52
Office expenses	22	161	235	60
Other	108	140	201	52
	<u>2,425</u>	<u>2,491</u>	<u>4,204</u>	<u>1,077</u>

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 18:- LOSS PER SHARE

	Year ended December 31,					
	2013		2014		2015	
	Weighted number of shares *)	Net loss attributed to Company's shareholders	Weighted number of shares	Net loss attributed to Company's shareholders	Weighted number of shares **)	Net loss attributed to Company's shareholders
	NIS		NIS		NIS	
Number of shares and loss for the purpose of calculating basic and diluted loss per share	49,152,886	(3,678,000)	65,968,768	(5,551,000)	74,475,109	(10,171,980)

*) The weighted number of shares is after the effect of the reverse acquisition, as discussed in Note 5.

**) Not included in the calculation are 4,723,500 Series 1 options and unregistered options mentioned in Note 13 above for anti-dilutive effect.

NOTE 19:- BALANCES AND TRANSACTIONS WITH RELATED PARTIES

a. Related party balances

	December 31				Year ended December 31, 2015		Convenience translation (Note 2d)
	2014		2015		December 31, 2015		
	Key management personnel	Other interested and related parties	Key management personnel	Other interested and related parties	Key management personnel	Other interested and related parties	
	NIS				U.S. Dollars		
Other payables	76	112	116	274	30	70	
	76	112	116	274	30	70	

b. The directors and senior managers of the Company are entitled, in addition to salary, to non-cash benefits (such as a car, medical insurance, etc.).

Benefits for employment of key management personnel (including directors) employed in the Company:

	Year ended December 31,						Convenience translation (Note 2d)
	2013		2014		2015		
	No. of people	Amount NIS	No. of people	Amount NIS	No. of people	Amount NIS	
Short-term employee benefits (includes Company's CEO in 2014 and 2015)	1	120	3	2,143	5	3,423	877

CELLECT BIOMED LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 19:- BALANCES AND TRANSACTIONS WITH RELATED PARTIES – (continued)

c. Benefits for employment of key management personnel (including directors) that are not employed in the Company:

	Year ended December 31,						Convenience translation (Note 2d)
	2013		2014		2015		Year ended December 31, 2015
	No. of people	Amount NIS	No. of people	Amount NIS	No. of people	Amount NIS	Amount U.S. dollars
Key management personnel and related parties (includes Company's CEO in 2013)	1	828	3	514	2	444	114
Directors' fees	3	217	5	248	5	477	122
	4	1,045	8	762	7	921	236

d. Transactions with related parties:

	Year ended December 31,						Convenience translation (Note 2d)	
	2013		2014		2015		Year ended December 31, 2015	
	Key management personnel	Related parties	Key management personnel	Related parties	Key management personnel	Related parties	Key management personnel	Related parties
Research and development expenses	—	621	533	1,023	713	1,422	183	364
General and administrative expenses	—	580	316	785	921	811	236	208
Financing expenses	—	188	—	22	—	—	—	—
	—	1,389	849	1,830	1,634	2,233	419	572

e. Commitments

Regarding commitments with a controlling shareholder, see Note 16.b

NOTE 20:- SUBSEQUENT EVENTS

- a. During February 2016, the Company raised an amount of approximately NIS 8,000 in a private placement (which also included the Company's executives and related parties). The Company issued 5,783,437 ordinary shares of the Company as well as 1,927,801 non-listed options series A for a period of 12 months at a ratio of 3 shares per option (1:3). The options are exercisable for a period of twelve months at an exercise price of NIS 2.1 per share. The Company's Chairman of the board of directors invested an amount of approximately NIS 400 as part of the investment, which will be submitted for approval at the next general shareholders' meeting.
- b. On March 31, 2016, the Company's board of directors approved the issuance of 600,000 unlisted options to a consultant at an exercise price of NIS 2.1 each. The options vest each quarter over a period of 24 months, pursuant to the Company's option plan. The approval of the grant is subject to signature of a consulting agreement, publication of the private placement on Tel Aviv Stock Exchange and a receipt of all relevant approvals.

American Depositary Shares

Representing Ordinary Shares



PROSPECTUS

Through and including _____, 2016 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligations to deliver a prospectus when acting as underwriter and with respect to their unsold allotments or subscriptions.

PART II

INFORMATION NOT REQUIRED IN THE PROSPECTUS

Item 6. Indemnification of Directors and Officers

Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our articles of association include such a provision. We may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.

Under the Companies Law and the Israeli Securities Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:

- financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator's award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company's activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;
- reasonable litigation expenses, including attorneys' fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; and
- reasonable litigation expenses, including attorneys' fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent.

Under the Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company's articles of association:

- a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;
- a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and
- a financial liability imposed on the office holder in favor of a third party.

Under our articles of association, we may insure an office holder against the aforementioned liabilities as well as the following liabilities:

- a breach of duty of care to the company or to a third party;
- any other action which is permitted by law to insure an office holder against;

TABLE OF CONTENTS

- expenses incurred and/or paid by the office holder in connection with an administrative enforcement procedure under any applicable law including the Efficiency of Enforcement Procedures and the Israeli Securities Law, which we refer to as an Administrative Enforcement Procedure, and including reasonable litigation expenses and attorney fees; and
- a financial liability in favor or a victim of a felony pursuant to Section 52ND of the Israeli Securities Law.

Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:

- a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;
- a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;
- an act or omission committed with intent to derive illegal personal benefit; or
- a fine or forfeit levied against the office holder.

Under the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders. See “Management — Approval of Related Party Transactions under Israeli Law.”

Our articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Companies Law and the Israeli Securities Law, including expenses incurred and/or paid by the office holder in connection with an Administrative Enforcement Procedure.

Prior to the closing of this offering, we intend to enter into indemnification agreements with our office holders to exculpate, indemnify and insure our office holders to the fullest extent permitted by our articles of association, the Companies Law and the Israeli Securities Law, including expenses incurred and/or paid by the office holder in connection with an Administrative Enforcement Procedure. The indemnification thereunder will be limited to events determined as foreseeable by the board of directors based on our activities, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.

The maximum indemnification amount set forth in such agreements is limited to an amount which shall not exceed 25% of our net assets based on our most recently audited or reviewed financial statements prior to actual payment of the indemnification amount. Such maximum amount is in addition to any amount paid (if paid) under insurance and/or by a third-party pursuant to an indemnification arrangement.

In the opinion of the SEC, indemnification of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and therefore unenforceable.

We have obtained directors’ and officers’ liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Companies Law.

Item 7. Recent Sales of Unregistered Securities

The following is a summary of transactions during the three years preceding this offering, involving offers and sales of our securities which took place outside the United States and were not registered under the Securities Act:

On April 30, 2013, Collect Biotherapeutics, our subsidiary, issued 1,319,232 ordinary shares to three unrelated parties in consideration for NIS 541,000.

On April 30, 2013, Collect Biotherapeutics, our subsidiary, issued 697,324 ordinary shares to a related party upon conversion of a related party loan in the principal amount of US\$50,000.

TABLE OF CONTENTS

On April 30, 2013, Collect Biotherapeutics, our subsidiary, granted to each of two service providers 113,679 fully vested options, for the purchase of 113,679 ordinary shares of Collect Biotherapeutics at an exercise price of NIS 0.01 per share. The options may be exercised within five years from the grant date and upon the closing of the merger on July 1, 2013, the options were exchanged for options according to the ratio for the exchange in the merger.

As a result of the merger with Collect Biotherapeutics, which closed on July 1, 2013, Collect Biotherapeutics became a fully owned subsidiary and we issued to shareholders of Collect Biotherapeutics 44,887,373 ordinary shares, options (Series 1) exercisable for 227,358 ordinary shares until April 30, 2018 and options (Series 2) exercisable for 341,037 ordinary shares exercisable until July 1, 2015, which constituted approximately 85% of our then outstanding share capital on a fully diluted basis.

On October 10, 2013, our board of directors approved a private placement of 3,959,302 of our ordinary shares to six investors, in consideration for NIS 3,405,000. On October 22, 2013, the TASE approved the issuance.

On May 13, 2014, Michael Ilan Management and Investments Ltd. (a private company wholly-owned by Mr. Michael Ilan) purchased 14,217,070 of our ordinary shares for NIS 15,000,000 in a private placement. In connection with the closing, a broker was granted a total of 426,512 options exercisable into 426,512 ordinary shares and paid cash of NIS 450,000.

On July 31, 2014, we granted options to purchase an aggregate of 1,226,512 ordinary shares (including 426,512 options to the broker for the above-referenced private placement.) to one employee, two senior officers and two consultants.

On September 8, 2014, we granted options to purchase 1,200,000 ordinary shares to our Chief Executive Officer and options to purchase 100,000 ordinary shares to a director.

On April 20, 2015, we published a shelf offering under the shelf prospectus dated November 25, 2014, pursuant to which the public was offered up to 4,500,000 shares and up to 4,500,000 options (Series 1), exercisable into 4,500,000 of our ordinary shares. We exercised our right for an over-allotment not to exceed 15% of the total securities offered through the shelf offering, such that in total, we issued 4,523,500 ordinary shares and 4,523,500 options (Series 1). The total gross proceeds we received in respect of the securities offered to the public according to the shelf offering totaled NIS 6,604,000. In connection with the offering, we granted 200,000 options (Series 1) exercisable for 200,000 ordinary shares to a broker at an exercise price of NIS 1.85 per share.

During June 2015, 341,073 options were exercised for 341,073 ordinary shares, in consideration for a total of NIS 104,000.

On August 26, 2015, we granted to each of our directors, including the external directors, options exercisable for 72,000 ordinary shares.

On December 7, 2015, we granted 2,658,246 options to purchase 2,658,246 ordinary shares to Mr Twito, our Deputy Chief Executive Officer and Chief Financial Officer. The options are exercisable at NIS 1.286 per share and expire on December 7, 2025.

On February 18, 2016, the Company completed a private placement of 5,783,437 of our ordinary shares to 28 investors, in consideration for NIS 8.0 million of which the issuance of 287,769 shares is subject to approval by our shareholders. As part of the private placement, we granted 1,927,801 options (Series 2/16) exercisable for 1,927,801 ordinary shares, at an exercise price of NIS 2.1 (\$0.54) per share of which the issuance of 95,923 options is subject to approval by our shareholders.

On March 31, 2016, we granted 600,000 options to purchase 600,000 of our ordinary shares to a consultant. The options are exercisable at NIS 2.1 per share.

None of the transactions after our initial public offering in Israel used the services of a U.S. underwriter.

[TABLE OF CONTENTS](#)

Item 8. Exhibits and Financial Statement Schedules

- (a) The “Exhibit Index” is hereby incorporated by reference herein.
- (b) Financial Statement Schedules

Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.

Item 9. Undertakings

- (a) The undersigned Registrant hereby undertakes:

- (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
 - i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
 - ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
 - iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.
- (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
- (4) To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.
- (5) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
 - i. If the registrant is relying on Rule 430B:
 - A. Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

TABLE OF CONTENTS

- B. Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness of the date of the first contract or sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date and underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or
- ii. If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
- (6) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell securities to such purchaser:
- i. Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
- ii. Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
- iii. The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
- iv. Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
- (b) The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.

TABLE OF CONTENTS

- (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
- (d) The undersigned registrant hereby undertakes that:
- i. For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.
 - ii. For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Nes Ziona, State of Israel on [], 2016.

Collect Biomed Ltd.

By: _____
Name: Dr. Shai Yarkoni
Title: Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned directors and officers of the registrant, an Israeli corporation, which is filing a registration statement on Form F-1 with the U.S. Securities and Exchange Commission, Washington, D.C. 20549 under the provisions of the Securities Act of 1933, as amended, hereby constitute and appoint Messrs. Dr. Shai Yarkoni and Ronen Twito and each of them, the individual's true and lawful attorneys-in-fact and agents, with full power to act separately and full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign such registration statement and any and all amendments (including post-effective amendments) to the registration statement, including a prospectus or an amended prospectus therein and any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or his or her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on [], 2016, in the capacities indicated:

<u>Name</u>	<u>Title</u>	<u>Date</u>
<u>/s/</u> Dr. Shai Yarkoni	Chief Executive Officer and Director (Principal Executive Officer)	[], 2016
<u>/s/</u> Ronen Twito	Deputy CEO and Chief Financial Officer (Principal Financial Officer & Principal Accounting Officer)	[], 2016
<u>/s/</u> Nuriel Chirich Kasbian	Chairman of the Board of Directors	[], 2016
<u>/s/</u> Dr. Nadir Askenasy	Director	[], 2016
<u>/s/</u> Yaakov Goldman	Director	[], 2016
<u>/s/</u> Abraham Nahmias	Director	[], 2016
<u>/s/</u> Dr. Ruth Ben Yakar	Director	[], 2016
<u>/s/</u> Yuval Berman	Director	[], 2016
<u>/s/</u> David Grossman	Director	[], 2016

AUTHORIZED REPRESENTATIVE

Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Collect Biomed Ltd. has signed this registration statement in the city of [], the State of [], on [], 2016.

Vcorp Services, LLC

By: _____

Name: _____

Title: Authorized Representative

[TABLE OF CONTENTS](#)

EXHIBIT INDEX

Exhibit No.	Exhibit Description
1.1*	Form of Underwriting Agreement.
3.1	Articles of Association of Collect Biomed Ltd. (unofficial English translation from Hebrew original).
4.1*	Form of Deposit Agreement between Collect Biomed Ltd., The Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued thereunder.
4.2*	Specimen American Depositary Receipt (included in Exhibit 4.1).
4.3*	Specimen Certificate for Ordinary Shares.
5.1*	Opinion of Doron Tikotzky Kantor Gutman Cederbaum & Co., Israeli counsel to Collect Biomed Ltd. (including consent).
10.1	Founders Agreement dated June 1, 2011 between Nuriel Chirich Kasbian, Dr. Shai Yarkoni, and Dr. Nadir Askenasy.
10.2	Chairman of the Board Agreement dated April 30, 2013 between Collect Biotechnology Ltd. and Nuriel Chirich Kasbian (unofficial English translation from Hebrew original).
10.3	Employment Agreement dated April 30, 2013 between Collect Biotechnology Ltd. and Dr. Shai Yarkoni (unofficial English translation from Hebrew original).
10.4	Employment Agreement dated October 14, 2015 between Collect Biomed Ltd. and Ronen Twito.
10.5	Consulting Agreement dated April 30, 2013 between Collect Biotechnology Ltd. and Dr. Nadir Askenasy (unofficial English translation from Hebrew original).
10.6	Collect Biomed Ltd. 2014 Global Incentive Option Scheme.
10.7	Joint Product Development Agreement dated June 17, 2015 between Collect Biomed Ltd. and Entegris Inc.
21.1	Subsidiaries of Collect Biomed Ltd.
23.1*	Consent of Kost Forer Gabbay & Kasierer, Certified Public Accountant (Isr.), a member of Ernst & Young Israel.
23.2*	Consent of Doron Tikotzky Kantor Gutman Cederbaum & Co., Israeli counsel to Collect Biomed Ltd. (included in Exhibit 5.1).
24.1	Power of Attorney (included on the signature pages of this registration statement).

* To be filed by amendment.

PUBLIC COMPANY
COMPANIES LAW, 5759 – 1999
A COMPANY LIMITED IN SHARES
ARTICLES OF ASSOCIATION
OF
CELLECT BIOMED LTD
(PUBLIC CORPORATION 52-003648-4)

Index

Part no.	Article no.	Subject	Page
Part One		<u>Preamble</u>	
	1.	Name of the company	5
	2.	Objectives of the company	5
	3.	Liability of shareholders	5
	4.	The Capital	5
Part Two		<u>General Provisions</u>	
	5.	Definitions and interpretations	5
	6.	Change of articles	7
Part Three		<u>Capital of the Company.</u>	
	7.	Ordinary shares	7
	8.	Redeemable securities	8
	9.	Company capital, increase of Registered capital and revocation	8
	10.	Issuance of securities	9
Part Four		<u>Shareholders</u>	
	11.	Shareholders and share certificates	10
	12.	Calls for payment	12
	13.	Forfeiture	13
Part Five		<u>Transfer of shares</u>	
	14.	Transfer of shares	15
	15.	Share transfer deed	15
	16.	Assignment of shares by law	16
	17.	Registration of share transfer	17
Part Six		<u>General Meetings</u>	
	18.	Annual General Meetings	18
	19.	Convening special meetings	18
	20.	Agenda	19
	21.	Notice of meeting	19
	22.	Quorum	20
	23.	Chairman of general meeting	21
	24.	Voting in a general meeting	21
	25.	Vote count and secret ballot	21
	26.	Vote by proxy; vote by corporation Partners	22
	27.	Voting instrument	24
	28.	Protocols	25

Part Seven		<u>The Board of Directors</u>	
	30.	Members of the Board	25
	31.	Restrictions on appointment Of directors	26
	32.	An outside director	27
	33.	A corporation as director	27
	34.	An alternate director and power Of attorney	27
	35.	Vacancy of office of director	28
	36.	Authorities of the Board	30
	37.	Assumption of authorities of the board	32
	38.	Rights of a director	32
	39.	Chairman of the Board	33
	40.	Convening a meeting of the Board	33
	41.	Agenda	34
	42.	Notice of meetings of the Board	35
	43.	Quorum	35
	44.	Voting in the Board of Directors	36
	45.	Protocols in meetings of the Board	37
	46.	Defects in convening the meeting	37
	47.	Committees of the Board	38
Part Eight		<u>Audit Committee</u>	
	48.	Appointment of members of Audit committee	38
	49.	Positions and work procedures of The Audit Committee	39
Part Nine		<u>Exemption, indemnification and liability insurance</u>	
	50.	Exemption and indemnification	40
	51.	Liability insurance	41
Part Ten		<u>General Manager</u>	
	52.	General Manager	42
	53.	Removal of Authorities of the general manager	43
Part Eleven		<u>Management of the company</u>	
	54.	Registered office	43
	55.	Shareholder register and Material shareholder register	44
	56.	Auditor	44
	57.	Expiration of service of auditor	44
	58.	Wages of auditor	45

59.	Authorities, obligations and Responsibility of auditor	46
60.	Internal auditor	46
Part Twelve	<u>Financial statements, accounts and signature</u>	
61.	Financial statements	47
62.	Stamp and signatory rights	47
Part Thirteen	<u>Dividends and bonus shares</u>	
63.	Dividends and bonus shares	47
Part Fourteen	<u>Notices and Dissolution</u>	
64.	Notices	49
65.	Dissolution	50

Part One: Preamble

1. **Name of the Company:** In Hebrew: סלקטד ביומד בע"מ
In English: Cellect Biomed Ltd.
2. **Objectives of the Company**
 - (a) To engage in any lawful business.
 - (b) The Company may donate from time to time reasonable sums for appropriate causes, even if the donations are not within the framework of the business considerations of the Company.
3. **Liability of the shareholders**
 - (a) The liability of a shareholder for the debts of the Company is limited to the payment of the unpaid portion which he undertook to pay for the share held by him in accordance with the terms of issuance of said share.
4. **The capital**

The registered share capital of the Company is 500,000,000 (five hundred million) ordinary shares without any nominal value each (hereinafter: **"Ordinary Share"**).

Part Two: General Provisions

5. **Definitions and interpretations**

- "Written"**: In writing or any other term with the same meaning including handwritten, engraved, printed, typewritten, photocopied, or copied in any other manner that is visible, including telex, fax, telegraph, by cable or any other duplication method through electronic means.
- "Shareholder"**: Under its definition in Article 11 herein.
- "The Board of Directors"**: The Board of Directors of the Company who was duly elected in accordance with the provisions of these articles.
- "The Company"**: Cellect Biomed Ltd., or any other name which it will be called, if its name is changed.
- "Law"**: Companies Law, the Companies Ordinance or any other Israeli law, which is valid, as warranted, from time to time including the provisions of any stock exchange that applies to the Company.

“Regular Resolution”:	A resolution adopted by a regular majority of shareholders, voting in the general meeting by a voting instrument (on topics for which according to these articles can be adopted through a voting instrument) on their own or through proxies.
“The Office”:	The registered office of the Company at such time in Israel about which the Company notified the Companies Registrar.
“The Articles”:	The articles of association of the Company, as they will be amended from time to time by the general meeting.
“Companies Law”:	Companies Law, 5759 – 1999, as amended from time to time, and any regulations that are promulgated thereunder.
“Securities Law”:	Securities Law, 5728 – 1968, as amended from time to time, and any regulations that are promulgated thereunder.
“Vote count”:	Vote count of those voters, in accordance with the voting rights established for the shares by virtue of which the shareholders participating in the general meeting are voting. In the count of all the votes of shareholders, abstentions shall not be taken into account.
“Shareholder Register”:	A shareholder register that must be kept in accordance with section 127 of the Companies Law.
“Register of Material Shareholders”:	A register of material shareholders that must be kept in accordance with section 128 of the Companies Law.
“Office holder”:	As the term “senior office holder” is defined in Part 6 of the Securities Law.
“Companies Ordinance”:	The Companies Ordinance [New Version], 5743 – 1983, as amended from time to time, and all the regulations that are promulgated thereunder.

(b) Interpretation

- (1) Each term in these articles that is not defined above, shall be attributed the meaning that is afforded it by law unless the context dictates otherwise.
- (2) References made in the singular shall include the plural and vice versa. Reference made in the masculine gender shall include the feminine (and vice versa), and words that connote persons shall include also corporations, unless the context dictates another interpretation.

- (3) The headings of the sections in these articles are for the purpose of convenience only and shall not be used as an accessory to interpret or for the interpretation of these articles.
- (4) The articles which may be stipulated in the Companies Law shall apply to the Company, insofar as there is no contradiction between them and the provisions of these articles.
- (5) In the case of a contradiction between the provisions of the law which may not be stipulated in bylaws and any of the provisions of these articles – the provisions of the law shall prevail in such case, without impairing from the remainder of the provisions of the articles.
- (6) These articles are the same as a contract between the Company and its shareholders and between the shareholders and themselves.

6. **Change of articles**

Subject to the provisions of relevant law, the Company may change these articles by a regular resolution adopted in the general meeting of the Company.

Part Three: Capital of the Company

7. **Ordinary shares**

- (a) All the ordinary shares shall have equal rights among them and each regular share shall confer upon its holder the following rights:
 - (1) The right to receive invitations or notices about all general meetings of the Company, to participate in the meetings and to vote in them on any matter that is raised in the meeting, where each ordinary share confers on its holder one vote on every vote on a resolution;
 - (2) The right to participate in any distribution that the Company makes to its shareholders, and to receive dividends and/or bonus shares, if they are distributed in accordance with the provisions of these articles and the provisions of the Companies Law, proportionate to the number of the shares allocated and the rate that they are paid up by the shareholders, if they are not are not fully paid up; and
 - (3) The right to participate in the dissolution of the Company, in the distribution of the assets of the Company, that remain to be distributed, after the Company meets all of its obligations and payment of all its debts in any case, proportionate to the number of the shares allocated and the rate that such shares are paid up by the shareholders, if they are not fully paid up, and subject to the provisions of these articles and without prejudicing existing rights of all the shareholders in the Company of any kind or class.

- (b) The Company may pay a person a commission for signing or underwriting, or agreement to sign or underwrite securities of the Company, conditional or otherwise, provided that the amount or the sum of the commission does not exceed the sum of the commission permitted by relevant law at the time of payment.

8. Redeemable securities

The Company is entitled, taking into account the provisions of relevant law, to issue redeemable shares and to redeem them. At the time of the redemption of the shares the Company will act in accordance with the provisions of the law.

9. Capital of the Company, increase of capital and its cancellation

- (a) The Company may have shares, bonds, or other securities, each with different rights.
- (b) The Company will not issue bearer shares or stock that state that their holder is a holder of bearer stock.
- (c) The Company is entitled from time to time by a regular resolution adopted in a general meeting:
 - (1) To increase the registered share capital of the Company by classes of shares, as determined;
 - (2) To cancel registered share capital that has not yet been allocated, provided that there is no commitment by the Company, including a conditional commitment, to allocate the shares;
 - (3) To consolidate and redistribute its share capital into shares of a nominal value;And
 - (5) To convert, from time to time, part of the allocated shares into shares with other rights.
- (d) Unless established otherwise in a resolution approving the change of share capital, the new shares shall be subject to the provisions of these articles regarding calls for payment, forfeiture, transfer, delivery etc., applicable to the shares of the original share capital.

- (e) Without derogating from the generality of the authority of the Board of Directors, if as a result of a consolidation or division of shares the shareholders are left with fractional shares, the Board may in its discretion, act as follows:
- (1) Allocate to each shareholder, whom the consolidation and/or division left him with a fractional share, shares of the class of shares that exists in the capital of the Company prior to the consolidation, in such number, that together with the fractional share will create one consolidated, complete share, and said allocation shall be considered as valid immediately prior to the consolidation or distribution, as warranted;
 - (2) Determine that holders of fractional shares shall not be entitled to receive a consolidated share for the fraction of a consolidated share.
 - (3) Allocate additional shares in the same number that would prevent the creation of fractional shares for consideration, as established by the Board of Directors; and
 - (4) Cause a transfer of shares between the shareholders for a fair price in order to efficiently prevent fractional shares. The Board is authorized to appoint a trustee to conduct such share transfer among the shareholders.

10. **Issuance of securities**

- (a) The Board may issue or allocate shares or other securities, that are convertible or may be exercised into shares (including bonds and warrants), until a limit of the registered share capital of the Company, under the terms, dates and for a specific sum or for a sum that is established according to an accepted formula; for this purpose convertible securities or securities which may be exercised into shares shall be deemed as if they were converted or exercised on the date of their issuance.
- (b) The authority of the Board as set forth in article 10(a) may be delegated as enumerated in articles 10(b)(1) or 10(b)(2) herein:
 - (1) To a committee of the Board – by an issuance or allocation of securities as part of a workers compensation plan or employment agreements or wage agreements between the Company and its employees, or between the Company and the employees of an affiliated Company to which its Board agreed in advance, provided that the issuance or allocation is according to a plan that includes detailed criteria, that is delineated and approved by the Board;

- (2) To a committee of the Board, to the general manager, to the secretary of the Company or a deputy of such position, or to another person whom the general manager recommends – in an allocation of shares following an exercise or conversion of securities of the Company.
- (c) The Board of Directors may decide to issue a series of bonds as part of its authority to borrow on behalf of the Company, within the limits set by said authority.
- (d) The provision of article 10(c) above does not negate the authority of the general manager or someone who is so authorized, to borrow on behalf of the Company, to issue individual bonds, promissory notes and bills of exchange, within the limits set by said authority.
- (e) The Company shall not allocate a share the consideration of which, in full or in part, is not paid in cash, unless the consideration for the share is specified in a written document.
- (f) If the Company decides to allocate shares with a nominal value insofar as there will be shares with a nominal value as part of the capital of the Company, for a lower amount than the nominal value, including bonus shares, it must change part of its profits into share capital (under such meaning in section 302(b) of the Companies Law), from a premium on shares, or from any other source included in its equity capital, that are listed in its last financial statements, for a sum equal to the differential between the nominal value and the amount.

Part Four: Shareholders

11. Shareholder and share certificates

- (a) A shareholder of the Company is any one of the following:
 - (1) A person in whose benefit a share is registered with a member of the stock exchange and said share is included among the shares registered in the shareholder register by the relevant nominee Company; and/or
 - (2) A person who is registered as a shareholder in the shareholder register.
- (b) Other than as stated in article 11(a) above, a person or legal entity shall not be recognized by the Company as having any right to a share, and the Company shall not be bound or recognize any benefit in equity or trust relationships or chose in action, planned or partial, but only the right of a shareholder, to a complete share, and all – unless a competent court of the law orders otherwise.
- (c) If two or more holders are registered as joint owners of a share:

- (1) In respect to a vote, giving proxies, and notices, the shareholder who is registered first in the shareholder register shall be considered as the sole shareholder, unless all the holders of the joint share give written notice to the Company that another person should be referred as sole shareholder.
 - (2) Each of the holders may give a valid receipt in respect to all the joint holders for each dividend, other money or property that is received from the Company for the share or in respect thereto, and the Company is entitled to pay a dividend, the other money or the property for the share to one or more shareholder of the joint holders of the share, as it chooses to do.
- (d) Subject to the provisions of relevant law, a shareholder who is a trustee shall be registered in the shareholder register, as a shareholder, with a statement concerning his trusteeship status. Without derogating from the foregoing, the Company will recognize the trustee as a shareholder, for all intents and purposes, and will not recognize another person, including the beneficiary, as holding any right to the share.
- (e) A shareholder registered in the shareholder register is entitled to receive from the Company one share certificate testifying to his ownership of the share.
- A shareholder registered in the shareholder register, shall be entitled to receive one share certificate for the shares registered in his name and fully paid up, or, if the Board approves (after payment of the amount that the Board establishes from time to time), a number of share certificates, for one or more of the shares. Each share certificate shall state the number of the shares for which it is issued.
- (f) Share certificates shall be issued with the stamp of the Company and with the signatures of two directors of the Company or in any other manner determined by the Board of Directors of the Company.
- (g) A share certificate in the name of two or more persons in the name of two or more persons, shall be delivered to the person whose name appears first in the shareholder register among the names of the joint holders.
- (h) A new share certificate may be issued in place of a share certificate that was destroyed, lost or ruined, for the payment and under the terms regarding evidence, indemnification, guarantee against damages and/or issuance of an affidavit, as determined by the Board of Directors in its sole discretion from time to time.
- (i) The Company shall keep a register of material shareholders in addition to the shareholder register. The material shareholder register shall contain reports that the Company received pursuant to the Securities Law about the holdings of the material shareholders in Company shares.

12. **Calls for payment**

- (a) A shareholder shall not be entitled to a dividend or participate in the allocation of bonus shares or exercise any right of a shareholder in the Company, unless he has paid up all the sums and calls for payment that he owes the Company until said time in respect to his shares in the Company.
- (b) The Board of Directors may, from time to time, in its discretion, make calls for payment on shareholders for any sums that have not been paid up in respect to shares held by each of the shareholders, and for which pursuant to the terms of the allocation of the shares are not payable at a fixed time, and each shareholder shall pay the amount of the call made upon him, at the time and place designated by the Board of Directors. The Board of Directors may instruct that a call for payment be made in installments.
- (c) Notice of a call for payment shall be given and shall specify the amount of payment (no less than 14 days from the date of the notice) and the place for payment provided that prior to the time of payment for the call for payment, the Board of Directors may, by written notice to the shareholders, cancel the call or extend the time for payment or payment for any part thereof.
- (d) Joint holders of a share shall be jointly and severally liable to pay all amounts and calls for payment in respect to such share held jointly. Without derogating from the aforesaid generality, a call for payment delivered to one of the holders shall be deemed as having been delivered to all the owners.
- (e) If pursuant to the terms of the issuance of a share or otherwise, an amount is made payable at a fixed time or in installments at fixed times, whether on account of the share capital or by way of premium, such amount or installment shall be payable at such time as if it were payable by virtue of a call duly made by the Board of Directors for which notice was duly given, and all the provisions of these Articles in respect to calls for payment shall be applicable to such amount or installment.
- (f) If a call for payment or an installment is not paid on the due date or prior to such time, then the person who at such time is the holder of the share for which the call for payment was made, or for which the installment is due, shall pay interest on such sum at the maximum amount practiced at such time in Bank Leumi of Israel Ltd for unauthorized overdrafts, or at a lower rate that the Board will determine from time to time, from the date designated for its payment until the actual payment thereof, however the Board may waive the payment of interest, in whole or in part.

The provisions of this article do not detract or impair from the remedies and relief available to the Company by these articles or by any relevant law or agreement.

- (g) The Board of Directors may decide to accept money from a shareholder who wishes to advance payments, in whole or in part, on account of shares which have not been fully paid up and in respect to which the time for their payment has not yet matured, and to pay interest on such sums for a period not to exceed the period between the date of payment and the date on which this sum was designated to be paid, at the rate agreed by the Board of Directors and the shareholder.

13. **Forfeiture**

- (a) A shareholder who has not fully paid up a sum for which a call has been made by the designated date, may be furnished with a written notice by the Board of Directors demanding that he pay the unpaid sum with interest and any expenses which the Company incurs due to the default in payment on the designated date for payment.
- (b) The notice shall specify another date for payment, which shall not be earlier than seven days after the notice, and it shall state that if the amount is not paid up by this date the share for which such notice is given may be forfeited.
- (c) If the demands in the notice are not satisfied, the Board of Directors may, so long as the sum is not paid up, including the interest and expenses, decide to forfeit the share. The forfeiture shall also apply to any dividends announced in respect to the forfeited shares (insofar as they are eligible for dividends) which were not actually paid out prior to the forfeiture.
- (d) A share that has been forfeited shall be deemed the property of the Company, and the Board of Directors may, taking into account the provisions of these articles, sell or transfer it or reallocate it in another manner, under such terms and manner as decided by the directors. A share so forfeited so long as it has not been sold, transferred or allocated again as stated, shall become a dormant share under such meaning in section 308 of the Companies Law which shall not confer any rights at all so long as it is owned by the Company.
- (e) Insofar as nothing has been done with the forfeited share, the Board of Directors may cancel the forfeiture under the terms that it establishes.
- (f) A shareholder whose shares have been forfeited:
 - (1) Shall cease being a shareholder in respect to the shares that were forfeited and upon the forfeiture all of his rights and obligations for the forfeited shares shall be revoked and any action and/or demand against the Company regarding the forfeited shares shall be cancelled, other than those rights and obligations which are excepted from this rule by these articles and/or which are imposed on the former shareholder by law; however

- (2) He shall continue to be obligated to pay the Company and will pay the Company, without delay, all the calls for payment, payment installments, interest and expenses owed on account of the forfeited shares or for them at the time of the forfeiture, together with interest on those sums from the date of the forfeiture until the date of actual payment, at the maximum rate permitted at that time by law, provided that if the shares that were forfeited are sold, transferred or reissued, the shareholder's debt will be reduced by the sum actually received by the Company (after the expenses of the sale), from their sale, transfer or reissuance, as warranted.
- (g) The provisions in these articles regarding forfeiture shall apply to the default of payment of any sum that is to be paid on a designated date according to the terms of issuance of the share, whether on account of the share or in the form of a premium, as if it was a sum that was meant to be defrayed by virtue of a call for payment and a duly delivered notice.
- (h) In the case of a sale after forfeiture, the Board of Directors may appoint a person to sign a transfer instrument of the share that was sold and to arrange (subject to the provisions of relevant law) so that the buyer will be registered in the shareholder register as the owner of the shares that were sold or which will be received by him in any other manner. The recipient of the share that was sold, transferred, allocated or sent shall not be responsible for how the consideration for the sale is used, if received, his right to the share shall not be harmed due to a defect or a disqualification in the forfeiture, sale, allocation or transfer process, and after he is registered in the register (subject to the provisions of relevant law) or he receives the share into his possession in any other manner, no such claim shall be raised, and the validity of the sale or the transfer shall not be appealed.
- (i) An affidavit duly made by a director of the Company that a certain share of the Company has been duly forfeited on the date specified in the affidavit shall serve as conclusive proof of its content against any person who asserts a claim to the share. The affidavit with a Company receipt for the consideration, if given, for the share, in its sale or transfer, shall confer a right to the share on the transferee.
- (j) The net proceeds of any sale following a forfeiture after the discharge of the sale expenses, shall be applied in discharging the debts and the fulfillment of the obligations of such shareholder (including the debts, obligations and agreements for which the date of discharge or maturity have not yet come due), and the balance (if any) shall be paid to him or to whoever is conferred a right to the shares following the death, bankruptcy or dissolution of the shareholder.

- (k) The provisions of this article shall not be construed as derogating from any other relief available to the Company against the debtor shareholder.

Part five: Transfer of shares in the shareholder register

14. **Transfer of shares**

- (a) Subject to the provisions of relevant law, the Board of Directors may stop the registration in the register of transfers of shares for a specific period of time, that will not exceed 30 days per year, provided that it will not do so during the 14 days prior to the determining date for ownership of a share to establish eligibility to the rights for the share (such as the determining date for eligibility to vote in a general meeting or to receive a dividend or other distribution from the Company).
- (b) Part of a share may not be transferred, but a share which is jointly held by a number of owners, each may transfer their right to the share.
- (c) In the case of a transfer of shares, the transferee shareholder shall have all the rights that were attached to the transferred shares and all the obligations related to them according to these articles, unless otherwise agreed in writing, between the transferor shareholder and the transferee shareholder.

15. **Share transfer deed**

- (a) A transfer of shares shall not be registered in the shareholder register unless a transfer instrument is delivered to the office. A share transfer deed in the Company shall be signed by the transferor and the transferee, and the transferor will be deemed the owner of the share until the name of the transferee is registered in the shareholder register in respect to the transferred share.
- (b) The instrument of transfer of a share shall be in the following form or as near thereto as possible, or in the usual or common form as the Board of Directors may approve:

Share transfer deed

I, _____ of _____ (hereinafter: **“the Transferor”**) do hereby transfer to _____ of _____ (hereinafter: **“the Transferee”**), in consideration of the amount of NIS _____ (in words _____ new shekels) paid to me - _____ shares of Collect Biomed Ltd. (Company no. 52-003648-4), and they shall belong to the transferee, the administrators of his estate and representatives, subject to the terms by which I/we held the same immediately before the execution of this deed; and I/we, the transferee(s), do hereby agree to accept the shares subject to these terms.

In witness whereof we set our hand this _____ day of _____ month _____ year _____.

Signature of transferor _____ Signature of transferee _____

Witness to signature _____ Witness to signature _____

- (c) A transfer deed shall be submitted to the office for registration, along with the share certificates that are being transferred (if there are certificates) and/or any other evidence required by the Board regarding the proprietary right of the transferor or in respect to his right to transfer the shares. Transfer deeds that are registered shall remain with the Company but any transfer deed in respect to which the Board refuses to register, shall be returned upon request, to the person who so delivered them, together with the share certificate (if delivered).

16. **Assignment of shares by law**

- (a) The Board of Directors may, at any time and subject to the provisions of relevant law, register as a shareholder a person who is entitled to a share by law, including an heir, executor of an estate, liquidator or a trustee in a bankruptcy, after the Company is presented with a probate order, a succession order or any other sufficient evidence, as the Board deems fit, demonstrating the right to the shares. An eligible person who is so registered as a shareholder in the Company, is entitled, subject to the provisions of these articles dealing with the transfer of shares and the provisions of relevant law, to transfer these shares to another. Without derogating from the above, the Board may refuse to perform such registration or may delay it, as it is entitled to do, as if the registered owner himself transferred the share, prior to the assignment of the right.
- (b) Subject to the provisions of the Companies Law and these articles:
- (1) The executors of an estate of a shareholder who died, or in the absence of an executor of estate or administrator of an estate, persons who have a right by virtue of being heirs of the shareholder who died, shall be the only ones to be recognized by the Company as right holders to the share. A share registered in the name of two or more persons and one died, the Company shall recognize only the shareholders who are alive as the persons with rights to the share or benefits to it. Nonetheless the aforesaid shall not be construed as releasing the estate of the joint shareholder who died from all the obligations for the shares.

- (2) A person who is entitled to a share by law but has yet to be registered in the shareholder register is not entitled: (1) to receive dividends or any other money and/or property paid for said share as if he was the registered owner of the share; and (2) by virtue of said share to benefit from all rights of a shareholder regarding notices about general meetings, to be present at them or to vote in them, or class meetings, as the case warrants, of the Company or to make use of any other right of shareholders.

17. **Registration of transfer of shares**

- (a) Subject to the provisions of relevant law, the Company shall change the registration of ownership in the shareholder register if each of the following is present:
- (1) The Company is delivered a transfer deed of the share with the signatures of the transferor and the transferee as stated in article 15 above, and the requirements of these articles are satisfied;
 - (2) The Company is delivered a court order to amend the register;
 - (3) It is proven to the Company that the conditions in the law to assign the right have been satisfied; or
 - (4) Another condition is satisfied which according to these articles is sufficient to that the change can be registered in the shareholder register.
- (b) The transferor of the shares shall be considered the shareholder until the registration of the share transfer in the shareholder register in the name of the transferee in respect to the transferred share.
- (c) The Company will keep all the registration in the shareholder register as stated in this article 17. The Company may destroy share transfer instruments and share certificates that were cancelled after the expiration of 7 years from the date of registration of the revision in the shareholder register, where there will be an absolute presumption that the destroyed documents as stated above were binding and valid and that the transfers, the revocations and the registrations, as warranted, were lawfully made.

Part Six: General Meetings

18. Annual general meetings

- (a) The Company shall convene an annual meeting each year but no later than 15 months after the previous annual meeting.
- (b) The agenda at the annual meeting shall include deliberation of the financial statements of the Company and may include appointment of directors, appointment of an auditor, or any other matter that is scheduled for the agenda as set forth in article 20 herein.

19. Convening special meetings

- (a) The Board of Directors must convene a special meeting by a resolution of the Board and must convene a special meeting upon the demand of each of the following:
 - (1) Two directors or a quarter of the directors then serving;
 - (2) One or more shareholders, who hold at least five percent (5%) of the issued capital and at least one percent of the voting rights in the Company or one or more shareholders who hold at least five percent (5%) of the voting rights in the Company.
 - (b) A Board of Directors that is requested to convene a special meeting will convene such a meeting within twenty one (21) days from the date that it received the demand to convene, and the provisions of section 63(c) of the Companies Law shall apply.
 - (c) If the Board of Directors omits to convene a special meeting as stated, the person demanding said meeting, and if shareholders – even some of them who have more than half of the voting rights, convene the meeting on his own, provided that it is not convened more than three months from the date such demand was submitted, and it shall be convened, insofar as possible, in the same manner that meetings are convened by the Board of Directors.
 - (d) Annual general meetings of shareholders shall be called "**annual meetings**" and all other meetings of the Company shall be called "**special meetings**".
 - (e) A flaw in the convening of a general meeting or in the management thereof, including a flaw resulting from the non-satisfaction of a provision or term that was fixed by the Companies Law or in these articles, shall not invalidate any resolution adopted by the general meeting and shall not render defective the discussions that took place in it.
-

- (f) The general meeting of the Company shall be convened in Israel, at a location to be established in the notice of the meeting.

20. **Agenda**

- (a) The agenda in a general meeting shall be set by the Board of Directors and shall include also topics for which a special meeting was demanded to be convened pursuant to article 29 above as well as any subject that is required as set forth in article 20(b) herein.
- (b) The general meeting shall adopt resolutions on subjects that are specified on the agenda only. Notwithstanding the above, it is understood that the general meeting, may, inter alia, adopt resolutions related to other subjects that were not included on the original agenda of the general meeting in respect to matters:
 - (1) Which the law permits to be raised even if they are not included on the original agenda of the general meeting; and –
 - (2) Which in light of the circumstances for which the general meeting is convened, the chairman of the general meeting believes is proper and correct to be discussed; or
 - (3) Which a shareholder as stated in article 19(a)(2) above, asked in writing, at least seven (7) days prior to the meeting, to raise and attached the language of the resolution, provided that the subject is appropriate to be discussed in a shareholder meeting.

21. **Notice of a meeting**

- (a) Prior notice of at least 14 days or, if required by law, at least 35 days (as warranted by the circumstances), other than the day on which the notice is delivered and inclusive of the day for which the notice is delivered, about the convening of a general meeting, shall be given in the manner set forth in section 69 of the Companies Law and shall include the details as stated in the provisions of the aforesaid section or the provisions of any other relevant law.
- (b) The notice shall be publicized in at least two daily newspapers with a broad readership, which are published in the Hebrew language. Other than such notice (and without derogating from the duty of reporting applicable to a company as a public company pursuant to the Securities Law), a notice or invitation to a meeting shall not be delivered to each of the shareholders of the Company, whether registered or not.
- (c) A shareholder who is interested in voting in a general meeting will prove to the Company that he owns the share in accordance with the Companies Law.

Subject to the provisions of the law, shareholders who are eligible to participate and vote in the general meeting are those who are holders of shares at the time of the resolution to convene a general meeting, or by virtue thereof, provided that this date is not more than twenty one (21) days prior to the date of the general meeting, and is not less than four (4) days prior to the meeting, and in a general meeting where a vote can be made by a voting instrument, the determining date will not be more than forty (40) days prior to the date of the general meeting and no less than twenty eight (28) days prior to the meeting.

- (d) A general meeting with a quorum present may decide to adjourn the meeting, the discussion or adoption of a resolution on a topic that is on the agenda to another time or place that it determines; at the adjourned meeting no subject shall be discussed other than a subject that was on the agenda and which was not resolved.

If a general meeting is adjourned for over twenty one (21) days, notices and invitations shall be delivered for the adjourned meeting as set forth in this article 21.

A general meeting that was adjourned to a date that is less than twenty one (21) days, an immediate report will be published regarding the new date, as soon as possible, but no later than seventy two (72) hours prior to the time of the adjourned general meeting.

22. **Quorum**

- (a) Proceedings in the general meeting shall not commence until a quorum is present at the start of the proceedings.
- (b) A quorum shall be the presence of at least two (2) shareholders who hold at least a third of the voting rights (including through a proxy or voting instrument) within one half hour from the time the meeting was designated to start.
- (c) If a quorum is not present after one half hour from the time the general meeting was designated to start, the meeting shall be adjourned for one week, to the same day, same time and place or to a later date if specified in the invitation to the general meeting or to another day and/or place as will be determined by the Board of Directors in a notice to shareholders who are eligible to vote.
- (d) If a quorum is not present at the adjourned meeting as set forth in article 22(c) above, after a half hour from the time designated for its start, the meeting shall take place with any number of participants, even if the general meeting was convened at the demand of shareholders as set forth article 19 above.

- (e) **“Presence”** – means the presence of the shareholder himself, through a voting instrument or proxy or a representative as set forth in article 26 herein.

23. **Chairman of the general meeting**

- (a) The chairman of the Board of Directors shall serve as chairman of each general meeting.
- (b) If the chairman of the Board of Directors is absent from the meeting within 15 minutes from the time designated for the meeting or if he refuses to sit as chair of the general meeting, the general meeting shall elect one of the shareholders present, to serve as chairman of the meeting.
- (c) The chairman of the general meeting shall conduct the general meeting.

24. **Voting in the general meeting**

- (a) Subject to the provisions of relevant law and unless established otherwise in these articles, a resolution shall be considered adopted by a regular majority of votes of shareholders present at the meeting and voting on the resolution.

A shareholder shall not be entitled to vote in the general meeting prior to paying all of the sums and calls for payment owed from him at such time to the Company for his shares in the Company.

- (b) The chairman of the general meeting shall not have an additional or conclusive vote.
- (c) A declaration by the chairman of the general meeting that a resolution was unanimously adopted or adopted by a specific majority, or that it was adjourned shall be conclusive evidence of the accuracy of the declaration and there will be no need to prove the number of votes or the votes that were given for or against the resolution.

25. **Vote count or secret ballot**

- (a) Any resolution put to a vote in a general meeting shall be decided by counting votes, unless at least one shareholder present on his own or through a proxy and who holds at least five percent (5%) of the voting rights in the Company, demands, a secret ballot.
- (b) If a demand is made for a secret ballot, the vote will take place in the same manner, time and place as the chairman of the general meeting instructs, whether immediately or after a recess or adjournment or in another manner and the results of the secret ballot shall be considered a resolution of the general meeting in which the secret ballot was demanded. Those demanding a secret ballot may cancel the demand at any time prior to the secret ballot.

A secret ballot regarding the selection of a chairman and adjournment of the general meeting shall take place without delay.

- (c) A demand for a secret ballot shall not prevent the continuation of the general meeting and discussion on any issue other than the one in respect to which the secret ballot was demanded.

26. **Vote by proxy; vote of a corporation; partners**

- (a) A shareholder may vote personally or by proxy, through an instrument appointing the proxy as set forth below, or in the case of a corporation – by a representative through an instrument of appointment as set forth below. Likewise a shareholder may vote by a voting instrument, as set forth in article 27 herein. A representative or proxy does not need to be a shareholder of the Company.
- (b) A corporation being a shareholder of the Company may, by a resolution of its Board of Directors, directors, or any other managing body competent under the bylaws of the corporation or in accordance with a resolution of its Board of Directors, give an instrument of appointment to a representative and empower such person whom it finds suitable to be its representative at every meeting of the Company.

A representative of the corporation as stated above shall be entitled to exercise on behalf of the corporation that he represents those powers that the corporation itself could have used if it was a shareholder of the Company who is not a corporation.

- (c) The instrument appointing a proxy shall be signed by the principal or his agent who is so authorized by a duly written instrument, and if the principal is a corporation – by the signature of the person authorized to issue an instrument of appointment for the corporation as set forth in article 26(b) above or by the signature of an authorized signatory of the corporation. An instrument of appointment of a representative or proxy in effect for a non-specified period, shall expire following 12 months from the date of the last signature on it.
- (d) The instrument to appoint a proxy or a copy certified by an attorney or certified in another manner to the satisfaction of the Company, and confirmation of the ownership of a share as set forth in section 71 of the Companies Law, shall be deposited in the office or in another location as the Board will establish from time to time in a general manner or for a specific case, no less than forty eight (48) hours prior to the date designated for the meeting or the adjourned meeting for which the instrument of proxy is written, or on a date established by the Board in its discretion, provided that it is received in the Company prior to the time set for the general meeting or the adjourned meeting in which the person mentioned in this document intends to vote. If it is not so deposited, the instrument shall not be valid for said general meeting or an adjourned general meeting.

- (e) Any document appointing a proxy for a particular meeting, or for a specific time frame, shall be written in the format below insofar as possible or in another format approved by the Company:

I _____ bearer of identity card no/company no./public company no. _____ from _____ a shareholder in Collect Biomed Ltd (public company 52-003648-4 hereby appoint _____ Mr./Ms. _____ of _____ as my proxy (and in the case of a corporation – as my representative) to vote as my proxy to vote in my name and on my behalf in a general (annual / special) meeting of the Company to be held on the date of _____ month of _____ year _____ and in any adjourned meeting.

In witness I set my hand on this day of _____ month _____ year ____

Signature

- (f) If the statement of appointment does not specify the number of shares for which it is given or it specifies a number of shares that is higher than the number of shares registered in the name of the shareholder (in the register or title certificate), the instrument of appointment shall be considered as if it was given for all of the shares registered in the name of the shareholder. If the instrument of appointment is given for a number of shares that are lower than the number of shares registered in the name of the shareholder, the shareholder shall be considered as abstaining from being present at the vote for the remainder of the shares which are registered in the name of the shareholder, and the instrument of appointment will be valid only for the number of the shares listed in it.
- (g) A vote in accordance with an instrument of appointment shall be lawful even if the instrument has a defect that is not immediately apparent and/or if prior to said vote the principal died or became legally incompetent and/or the instrument of appointment was revoked or the power of attorney by which the instrument was signed was revoked and/or the share in respect to which the instrument was given was transferred, unless a written notice was received in the office and/or by the chairman of the general meeting prior to the meeting of the defect, the death, disqualification, revocation or transfer.
- (h) Without derogating from the aforesaid, a shareholder holding more than one share shall be entitled to appoint more than one proxy or representative, subject to the following provisions:

- (1) Each instrument of appointment will specify the class of the shares and the number of shares for which it is given.
 - (2) If the total number of shares of any class listed in the instrument of appointment is greater than the number of shares of said class registered in the name of said shareholder, the entire instrument of appointment will be null in respect to the shares of said class that was given by the shareholder.
 - (3) A shareholder or proxy or representative for the vote, may vote by virtue of some of the shares that are in his possession or for which he is serving as a proxy or representative, and he may vote by virtue of these shares in one manner and by virtue of some shares in another manner.
- (i) In a vote by joint holders of a share an instrument of appointment to a proxy shall be signed by the person who is authorized to vote as set forth in article 11(c)(1) above.
 - (j) A shareholder who is incompetent may vote through his lawful guardians or another person appointed by a court, and they may vote for him through proxies or instruments of appointment as stated in the provisions of these articles.

27. **Voting instrument**

- (a) A shareholder may vote in the general meeting and in meetings of a class of shares through a voting instrument in which the shareholder will specify the manner of his vote, on resolutions on topics that the law permits voting on them through a voting instrument, and for any other subject with the Board of Directors decides that a vote in the general meeting on a specific subject may also be adopted by way of a voting instrument.
- (b) A voting instrument in which a shareholder indicates the manner of his vote and which he completes as required, which reaches the Company by the final time established for such in the invitation to the general meeting, shall be considered as a presence in the general meeting for purposes of a quorum as set forth in article 22 above and for the purpose of counting the votes.
- (c) A voting instrument that is received by the Company as set forth in article 27(b) above, for a specific matter for which a vote was not taken in the general meeting, shall be considered as abstaining on the vote in that general meeting on the resolution for an adjourned meeting pursuant to the provisions of section 74 of the Companies Law, and it will be counted in the adjourned meeting that will be held pursuant to the provisions of 74 or 79 of the Companies Law.

28. **Protocols**

- (a) The Company shall keep protocols of the proceedings in the general meeting, and shall keep them in the office, for a period of at least seven years from the date of the general meeting.
- (b) A protocol signed by the chairman of the general meeting, constitutes conclusive proof of the contents therein.

29. **Meetings of a class**

The provisions of articles 18 – 28 above shall apply, mutatis mutandis, on a meeting of shareholders of a class of shares, insofar as the Company must hold them.

Part Seven: The Board of Directors

30. **Members of the Board**

- (a) The number of directors in the Company, shall be determined from time to time by a resolution of the annual general meeting, provided that the number of directors (including outside directors) shall not be less than five (5) directors and no more than eight (8) directors.
- (b) The directors, other than outside directors and until their maximum number as set forth in subsection (a) above, shall be elected by a regular resolution of the general meeting, and shall function in their capacity until his office is vacated or another director is chosen in his stead. A member of the Board whose term of office has ended, may be reelected.
- (c) In the Company, in addition to the outside director with accounting and financial expertise, directors with accounting and financial expertise in such number as determined by the Board of Directors of the Company from time to time.
- (d) The office of a director shall begin from the date of his appointment or a later date if the resolution of his appointment establishes such.
- (e) The Board of Directors is entitled at any time and from time to time to appoint any person as a director, provided that the number of directors does not exceed at any time the maximum number as specified above. A director who is so appointed, shall serve insofar as his office is not vacated in accordance with the provisions of article 35 herein.

- (f) The Company will maintain in the office a register of directors and their alternates, if they have alternates pursuant to the provisions of article 34 herein, which will be open for inspection by any person.
- (g) Subject to the provisions of relevant law, all the activities and resolutions of the Board, a committee of the Board or a director who is acting by virtue of his office, as well as any act that is taken according to their instructions, shall be valid, even if it is discovered afterwards that there was a defect in the appointment of a director/directors or if all or one of them were unfit from serving as directors, as if each of them was appointed lawfully and as if they all had the necessary qualifications to be a member of the Board or committee.

31. **Restrictions on the appointment of directors**

- (a) A candidate for director must disclose to his appointer if he was convicted in a judgment of an offense as described below, and five years have not yet passed since the judgment of conviction was issued or – in respect to sub article (3) herein – the period that was established by the court according to that sub article:
 - (1) Offenses according to sections 290 to 297, 392, 415, 418 to 420 and 422 to 428, of the Penal Law, 5737 – 1977, and according to sections 52c, 52d, 53(a) and 54 of the Securities Law;
 - (2) A conviction in a foreign court for the offenses of bribery, fraud, corporate administrative offenses or insider trading; or
 - (3) A conviction for another offense which the court holds that due to its nature, severity or circumstances, he is not fit to serve as a director in a public company, for the period that the court determines which shall not exceed five years from the date of the judgment.
- (b) A candidate for director in the Company will disclose if the administrative enforcement Board imposed on him any enforcement measures that prevent him from serving as a director of a public company or a private company which is a bonds company, and the period established by the administrative enforcement board in its decision has not yet passed.
- (c) A person convicted by a judgment of an offense enumerated in article 31(a) above shall not be appointed as a director, unless the period stated in said article passed (unless a court establishes otherwise as stated in section 226(b) of the Companies Law), and a person shall not be appointed as director if the administrative enforcement board imposed on him enforcement measures prohibiting him from serving as a director in a company, for a period determined by the Board.

- (d) A director shall not be appointed if he is a minor, legally incompetent, or declared bankrupt so long as he has not been absolved.
- (e) A candidate for director who is one of the above in sub article (d) shall disclose this to the Company.

32. **Outside director**

- (a) Two outside directors shall serve in the Company, who satisfy the conditions set forth in the Companies Law, who will be appointed by the general meeting in accordance with the provisions of the Companies Law.
- (b) At least one outside director shall serve in each committee that is entitled to exercise one of the authorities of a director.
- (c) The terms of office of an outside director shall be three years, and the Company may appoint him for two additional terms of three years each.
- (d) An outside director shall not be removed and his term of office shall not be stopped except according to the provisions of the Companies Law.

33. **Revoked.**

34. **Alternate director**

- (a) Subject to the provisions of the Companies Law, each director may appoint another as an alternate director and may revoke his appointment.
- (b) An appointment of an alternate director and the revocation of his appointment shall be done by written notice to the Company by the appointing director or in another manner as decided by the Board of Directors. The appointment will enter into effect upon receipt of the notice by the Company or a later date as stated in the notice.
- (c) An alternate director is the same as a director.
- (d) The appointment of an alternate does not negate the liability of the director for whom he is serving as alternate, and it will apply taking into account the circumstances of the situation, including the appointment of the alternate director and the term of his office.
- (e) The alternate director shall have all the authorities belonging to the director for whom is serving as the alternate. It is understood that the authorities of the alternate director shall not prejudice his authorities as director.

- (f) An alternate director shall not be entitled to participate and vote in a meeting of the Board in which the director who appointed him participates.
- (g) An alternate director may be appointed as a member of the Board of Directors, who is already a director, provided that the candidate for alternate director for a member of a committee, does not serve on that same committee of the Board and if he is an alternate director for an outside director, the candidate must be an outside director with accounting and financial expertise or with professional ability, in accordance with the qualifications of the director for whom he is serving as an alternate.
- (h) The office of an alternate director or an attorney shall be vacated:
 - (1) Automatically if the office of the director, for whom he is serving as the alternate, is vacated for any reason;
 - (2) If the alternate director experiences any of the instances enumerated in article 35 herein or if for another reason established in the Companies Law he is not fit to serve as an alternate director; or
 - (3) His appointment as an alternate director is cancelled by the person who so appointed him.

35. **Dismissal of a director**

- (a) The office of director shall be automatically vacated upon the occurrence of each of the following instances:
 - (1) Upon his death;
 - (2) He is found to be legally or mentally incompetent or mentally ill.
 - (3) He is declared to be bankrupt;
 - (4) If he resigns by written notice to the Company as stated in article 35(b) herein;
 - (5) If he is dismissed by a resolution of the general meeting as set forth in article 35(c) herein or is dismissed as stated in article 35(d) herein;
 - (6) On the date of the issuance of the notice of a conviction for an offense as set forth in article 35(e) herein;
 - (7) According to a decision by a court pursuant to the provisions of section 233 of the Companies Law;

- (8) On the date of the notice about the imposition of enforcement measures by an administrative enforcement Board prohibiting him to serve as director of a public company or in the Company, as set forth in section 232a of the Companies Law; or
- (9) A condition needed pursuant to the Companies Law no longer exists in regard to the director in order for him to serve as director or a cause for the expiration of his term as director exists.
- (b) A director or an alternate director may resign by delivery of written notice to the Board of Directors, the chairman of the Board or the Company and his resignation shall enter into effect on the date the notice is delivered, unless another date is specified in the letter. A director or alternate director shall state the reasons for his resignation.
- A notice received of the resignation of a director or an alternate director, shall be brought before the Board and the protocol of the first meeting convened after the resignation, shall record the fact of the resignation and the reasons given for it.
- (c) The general meeting may at any time dismiss a director, by a regular resolution, provided that the director is given a reasonable opportunity to bring his position before the general meeting.
- (d) If the Company becomes aware that a director or an alternate director was appointed contrary to the provisions of article 31(d) above (namely section 227(a) of the Companies Law) or contrary to the provisions of article 31(c) above (namely sections 226(a) and (a1) and 226a of the Companies Law), or that the director violated the provisions of article 31(a) above (namely section 225 of the Companies Law), article 31(e) above (namely section 227(b) of the Companies Law), or the provisions of article 35€ herein (namely section 232 of the Companies Law), the Board must decide in the meeting of the Board convened right after it becomes aware of such, to end the service of said director, if it finds, that the stated conditions are present, and from the date of the resolution the service shall expire.
- (e) A director who is convicted of an offense as stated in articles 31(a) above shall notify the Company of such and his service will end on the date of the delivery of the notice, and he may not be re-appointed as director, unless the period in which the director may not serve has passed, as stated in article 31(c) above (namely section 226(a) and (a1) of the Companies Law). If the administrative enforcement Board decides to impose on a person enforcement measures which prohibit him to serve as director in any public company or the Company, he will notify the Company and his term will expire on the date of the delivery of the notice, and he may not be reappointed as director, unless the period of the prohibition has passed as set forth in article 31(c) above (namely section 226a of the Companies Law).

- (f) A director (including an outside director) who no longer meets a requirements pursuant to the Companies Law in order to serve as a director (including an outside director) or if a reason for his service as director to expire exists, he will notify of such immediately to the Company, and his service shall expire on the date of the delivery of said notice.
- (f) A director who violates the duty of disclosure pursuant to article 31(a) above (namely section 225 of the Companies Law), article 31(f) above (namely sections 227a and 245a of the Companies Law), article 31(e) above (namely section 227(b) of the Companies Law), or article 35(e) above (namely sections 232 and 232a of the Companies Law), shall be considered as someone who violated his fiduciary duty to the Company.

36. **Authorities of the Board of Directors**

- (a) The Board shall delineate the policy of the Company and supervise the performance of the general manager and his activities, including the authorities listed in section 92(a) of the Companies Law.
- (b) The authorities of the Board of Directors pursuant to article 36(a) above may not be delegated to the general manager other than as set forth in article 10(b) above.
- (c) Without derogating from the authorities conferred on the Board of Directors pursuant to article 36(a) above and the rest of the authorities conferred on it by these articles, and without restricting or reducing in any manner these or any of the authorities, the Board of Directors shall have the following authorities:
 - (1) To appoint a person or persons (incorporated or otherwise), to receive and hold in trust for the Company any property belonging to the Company or in which the Company has an interest, or for any other purpose, and to do or perform any activity, act or things needed in respect to any such trust, and to act to pay the salaries of the trustee or trustees;
 - (2) To establish the authorized signatories of the Company for bills of exchange, promissory notes, receipts, endorsements, checks, dividend certificates, releases, contracts and other documents of any kind;
 - (3) To appoint, and in its discretion, to remove or suspend a general manager, manager, secretary, clerk, employee or agent, whether if they are employed on a permanent or interim basis or for special services, as the Board of Directors sees fit from time to time, and to define their authorities and obligations and to set their salaries and wages and to demand guarantees, in the cases and in the amounts that the Board deems fit;

- (4) To establish local management for the management of any of the businesses of the Company in a specific place in Israel or abroad, and to appoint any persons to be local managers and to determine their wages or to dismiss any of these people from their service, and from time to time and at any time delegate to any person who is so appointed any powers or authorities or discretion that is conferred at such time on the Board, and to authorize the members at that time in any local committee, all or some, to fill any vacancy in it and to act notwithstanding the vacancies;

Any such appointment or delegation may be done under the same terms and subject to the same conditions that the Board deems proper in accordance with the Companies Law, and the Board may at any time cancel any appointment or delegation or change them. The Board may authorize the persons to whom powers, authorities or discretion were delegated and which are conferred on them at such time, to delegate them, all of some, with a secondary delegation;

- (5) Subject to the provisions of relevant law, to appoint by power of attorney any person or persons to be the attorney or attorneys of the Company for the purposes and with the powers, authorities and discretion (which shall not exceed those given or conferred for use by the Board according to these articles or by law) for a period of time and subject to the same terms as the Board deems proper from time to time, and any such appointment may be given (if the Board sees fit to do so) to any local manager, or any Company or its members, its directors, agents or managers of any Company or firm or a person who is established by any Company or firm. Any such power of attorney may contain in it authorities for the protection or convenience of persons who come into contact or these attorneys as the Board deems fit;
- (6) To open, manager, defend, compromise, or neglect any legal proceedings on behalf of or against the Company or against its officials or related in another manner to its affairs and to compromise or extend the time for payment or defrayal of any debt owed or actions or demands by the Company or against it;
- (7) To deliver for arbitration any action or demand of the Company or against it;
- (8) To appoint on behalf of the Company an attorney or attorneys in Israel or abroad to represent the Company before any court, legal and quasi legal bodies, government offices or bodies, municipal or otherwise in Israel or abroad and to confer on such attorney the authorities that the Board feels proper to give, including the authority to delegate his authorities, in whole or in part, to another or others;

- (9) Subject to the provisions of the law (including section 113 of the Companies Law) and these articles, to delegate to any person, firm, Company or group of persons as stated, the powers, authorities and discretion conferred on the Board of Directors;
- (10) The Board is entitled to exercise any authority of the Company which was not conferred by law or these articles to another organ of the Company.

37. **Assumption of authorities of the Board**

- (a) The general meeting may assume authorities given to the Board for a specific matter, or for a specific time frame, that does not exceed the time required under the circumstances. The assumption of authorities shall be done after the Company adopts a resolution about the assumption in the general meeting.
- (b) If the Board cannot exercise its authorities and the exercise of any of its authorities is essential for the proper management of the Company, the general meeting may exercise it in its stead, so long as the Board is prevented from doing so, provided that the general meeting establishes, that in fact the Board cannot do so and that the exercise of the authority is essential as stated.
- (c) If the general meeting assumes authorities conferred by law on the Board, the shareholders shall have the rights, duties and liability applicable to the directors for the matter of the exercise of those authorities, mutatis mutandis, and, the provisions of chapters three, four and five of the Sixth Part of the Companies Law shall apply to them, taking into account their holdings in the Company, their participation in the meeting and the manner of their vote.

38. **The rights of a director**

Subject to relevant law and the issuance of the required approvals, a director shall not be disqualified, because of his office, from holding another office in the Company or in any other company in which the Company is a shareholder, or in which it has another benefit or from entering into a contract with the Company, whether as a vendor or buyer or in another manner.

39. **Chairman of the Board**

- (a) The Board of Directors will choose, dismiss, with a normal majority of votes, one of the members of the Board to serve as chairman of the Board, and the provisions in articles 39(b) – (f) below will apply to him.
- (b) The term of service of the chairman of the Board shall be until a resolution of the Board of the termination of his service and appointment of another chairman in his stead. However, it is understood, that an outgoing chairman may be re-appointed as chairman.
- (c) If the service of a director is vacated for one of the instances listed in these articles and said director is the chairman of the Board, his appointment as chairman shall automatically expire, and another chairman shall be chosen in his stead.
- (d) The chairman of the Board shall set the agenda as set forth in article 41 herein and will preside over the meetings of the Board.
- (e) If the chairman of the Board of Directors is absent from a meeting 15 minutes from the designated time for the meeting or if he is unwilling to preside over the meeting, the Board of Directors shall elect one of its members to preside over the meeting and sign the protocol of the meeting. The chairman of the Board in such instance shall not have an extra or casting vote in any vote by the Board of Directors in the event of a tie vote.
- (f) The chairman of the Board may serve as the CEO of the Company, or exercise his authorities for periods that do not exceed three years each from the date of the resolution, subject to and in accordance with the provisions of section 121(c) of the Companies Law.

40. **Convening a meeting of the Board**

- (a) The Board of Directors will convene for meetings pursuant to the needs of the Company and at least once every three months.
- (b) The Board will be convened according to one of the following methods:
 - (1) The chairman is entitled to convene a meeting at any time.
 - (2) In the following instances, the chairman of the Board will convene the Board without delay:
 - 1. A notice or report by the general manager to the chairman of the Board about any irregular matter that is material for the Company that requires an act by the Board; and

2. Notice by the auditor of the Company to the chairman of the Board that he became aware during the audit of material deficiencies in the accounting audit of the Company.

(2) The chairman of the Board will convene the Board, at the demand of any of the directors at any time, including if a director becomes aware of a matter of the Company in which there may be an apparent violation of the law or may harm proper corporate governance, whereby he will act without delay to convene a meeting of the Board.

(c) If a meeting of the Board is not convened within seven days from the date of the notice or report by the general manager or the auditor as stated in article 40(b)(2) above or from the date of the demand as set forth in article 40(b)(2) above, each of those listed above, may convene a meeting of the Board to discuss the subject specified in the demand, notice or report, as the case warrants, within at least two business days prior to the date of the meeting.

(d) The Board may hold meetings through the use of any communications devices, provided that all the directors participating can hear each other simultaneously.

(e) The Board may adopt resolutions even without an actual meeting (such as in writing, fax or email), provided that all the directors who are entitled to participate in the meeting and vote on the matter brought for a resolution agree to do so.

(f) Resolutions adopted in the manner specified in subsection (e), shall be formalized in a protocol, including the resolution not to convene a meeting, and the protocol shall be signed by the chairman of the Board.

41. **Agenda**

The agenda of Board meetings shall be set by the chairman of the Board and shall include:

(a) Subjects set by the chairman of the Board;

(b) Subjects that were set as set forth in article 40 above; and

(c) Any subject that a director, the general manager and/or the auditor asks of the chairman of the Board, a reasonable time prior to the meeting, to include on the agenda.

42. **Notice of a meeting of the Board of Directors**

- (a) Notice of a meeting of the Board shall be delivered to all the directors at least seventy two (72) hours prior to the date designated for the meeting, unless all the directors gave prior written consent to convene the meeting within a shorter time frame, or in urgent cases – and with the consent of a majority of the directors – even without such notice.
- (b) Notice pursuant to article 42(a) above shall be delivered to the address of the director in Israel that was previously delivered to the Company by the director in writing and which shall state the date of the meeting and the location, and a reasonable description of all the subjects on the agenda. It is understood that the dispatch of such notice covers the liability of the Company and the director is solely responsible to update the Company about a change of his address for the purpose of the sending of such notices. A change of address of the director shall be done by him in writing provided that it is delivered a reasonable time prior to the date designated for a meeting of the Board of Directors.

43. **Quorum**

- (a) A quorum for discussion in meetings of the Board shall be determined, from time to time, by the general meeting and until decided otherwise it shall be at least the presence of half of the directors, who serve at the time of the meeting, on their own or through alternates. The quorum shall be established at the start of each meeting of the Board and shall constitute a quorum for the entire duration of the meeting, for all the resolutions that are on the agenda, even in the case or cases where a quorum is not present during the continuation of the meeting.
- (b) If a half hour passes from the time designated for the start of the meeting of the Board and a quorum is not present, the meeting shall be adjourned for twenty four (24) hours exactly (after the original time designated for the meeting) or to another time set by the chairman of the Board (but in any case no earlier than twenty four (24) hours). The quorum at an adjourned meeting shall be the presence of at least two directors, who are serving at the time of the meeting, on their own or through an alternate. If the Board cannot act due to the absence of a quorum at the adjourned meeting, the general meeting may exercise the authorities of the Board for the purpose/s for which the meeting of the Board was convened and the provisions of article 37 above will apply.
- (c) Each duly convened meeting of the Board of Directors, in which a quorum is present, shall have all the authorities, powers of attorney and discretion given to it at such time, according to the provisions of the Company, to the Board of Directors or those exercised by it in general.

- (d) If a specific member is not appointed to the Board or if the office of a director is vacated, the remaining directors may operate for all matters, so long as their number is not less than the minimum fixed in article 30(a) above. If the number is less than the minimum, they may not exercise their authorities according to these articles, except to convene a general meeting with an agenda to appoint additional directors or to establish a lower minimum of directors or to appoint additional directors themselves. The general meeting may decide not to approve acts of the directors when their number falls below the minimum number and to exercise on its own the authorities of the Board, until the number of directors again reaches the minimum as set forth in article 30(a) above.

44. **Voting on the Board**

- (a) Each director shall have one vote in each vote on a resolution.
- (b) Resolutions of the Board shall be adopted by a regular majority of those present participating in the vote.
- (c) If the votes are tied in a Board meeting, the proposed resolution shall be considered as rejected.
- (d) Notwithstanding the aforesaid, resolutions on the subjects listed below shall not be adopted unless the subjects were on the agenda of the meeting that was duly convened, and there was no objection to the resolution by two or more of the members of the Board who participated in the meeting:
 - (1) Entering into new fields of activity and the expansion of the geographical field of activity of the Company;
 - (2) Investments in the field of activity of the Company (namely, not including investments in equipment) and the exercise of such investments;
 - (3) The transfer of any of the subjects mentioned in sections (1) and (2) to the authority of committees of the Board;
 - (4) Acquisition of Company shares, as defined in section 1 of the Companies Law, in a manner in which following the acquisition the Company will no longer be a public company, insofar as this resolution is brought for approval of the Board of the Company in accordance with the provisions of relevant law.

This majority shall apply also for resolutions on those subjects by committees of the Board and resolutions in subsidiaries of the Company, and resolutions in the committees of the Board and subsidiaries (1) shall be sent for a resolution of the Board; or (2) will be adopted only if the composition of the committee of the Board of Directors of the subsidiary is identical to the composition of the Board of Directors.

- (e) A director (or alternate director) is entitled to vote on his own, in writing (inclusive of by fax or email) or verbally if the meeting takes place through means of communication where the directors who are participating can hear each other simultaneously.

45. **Protocols in a meeting of the Board**

- (a) The Company will keep protocols of the proceedings in meetings of the Board and its committees and will keep them and the resolutions adopted without actual meetings of the Board, in the office for a period of seven years from the date of the meeting or adoption of the resolution, as the case warrants.
- (b) A protocol approved and signed by the director who presided over the meeting, shall serve as prima facie proof of its contents.
- (c) An announcement by the chairman of the Board, that a resolution was adopted unanimously or by a specific majority, or was rejected and a notation recorded in this matter in the protocol of the meeting of the Board, shall serve as prima facie proof of the authenticity of its contents, and it is not necessary to prove how many votes there were or how many were for or against the resolution.

46. **Defects in the convening of a meeting**

- (a) A resolution adopted in a meeting of the Board that was convened without the prior conditions satisfied for its convening (hereinafter – **“Defect in the Convening”**) may be revoked at the demand of each of the following:
 - (1) A director who was present at the meeting, provided that he demanded that a resolution for which the defect was present not be adopted, prior to the adoption of the resolution; or
 - (2) A director who was entitled to be invited to a meeting but was not present, within a reasonable time after he was informed about the adoption of the resolution and no later than the first Board meeting that was held after he was informed of the resolution;

It is understood that if there was a defect in the convening of the meeting related to the notice about the location of the meeting or its time, a director who came to the meeting may not, notwithstanding said defect, demand the revocation of the resolution.

- (b) The provisions of article 46(a) above shall not impair from the validity of an act done for the Company which was retroactively approved by the Board or if the party with whom the act was done did not know or could not have known about the irregularity or lack of authorization.

47. **Committees of the Board**

- (a) Subject to the provisions of section 112 of the Companies Law which prohibits the delegation of authorities and the provisions of these articles (including article 44(d) above), the Board may establish committees of the Board and appoint members from among the Board only to them (hereinafter: “**Board Committee**”) and delegate all or some of its authorities to a Board committee. The Board may from time to time cancel the delegation of said authority,

Each committee that is so established must, when exercising its authorities, comply with all the regulations that are established by the Board of Directors.

- (b) A Board committee will report to the Board on a regular basis about its decisions or recommendations. Decisions or recommendations of a Board committee which requires the approval of the Board, will be brought to the attention of the directors a reasonable time prior to the deliberations on the Board.
- (c) The meetings of a Board committee and its management shall be in accordance with the provisions of procedures and management of meetings of the Board, as set forth in the provisions of these articles, mutatis mutandis, so long as they are appropriate and if they do not replace the instructions that are given by the Board according to this section.
- (d) A committee of the Board whose job is to provide counsel or recommendations to the Board can be comprised of a person who is not a member of the Board.
- (e) A resolution that is adopted or an act that is done by a committee of the Board, according to an authority that was delegated to it from the authorities of the Board, shall be the same as a resolution adopted or an act that was done by the Board. However, the Board may evoke any decision of a committee that it appointed, but such cancellation shall not harm the validity of a decision of a committee where the Company acted in accordance thereto with another person, who was not aware of the revocation.

Part Eight: Audit Committee

48. **Appointment of an audit committee**

- (a) The Board of the Company shall appoint among its members an audit committee. The number of members of the audit committee shall be determined by the Board, from time to time provided that it shall not be less than three members and that all the outside directors will be members of the committee. The chairman of the Board and any director who is employed by the Company or by a controlling holder or by a corporation under the control of a controlling holder, a director who provides services, on a regular basis, to the Company, to a controlling holder in it or to a corporation under the control of a controlling holder, as well as a director whose main income is on the controlling holder, shall not be members of the audit committee. Likewise, a controlling holder or a relative thereof shall not be members of the audit committee.

- (b) The audit committee shall choose one of its members who is an outside director to serve as chairman of the audit committee, by a resolution adopted by a regular majority of the audit committee present at such meeting.
- (c) The term of office of the chairman of the audit committee shall be until a resolution of the audit committee about the termination of his term and the appointment of a chairman for the audit committee in his stead. However, it is understood that a chairman of the audit committee who ended his term of service may be reappointed.

49. **Positions and work procedures of the audit committee**

- (a) Subject to relevant law, the positions of the audit committee shall be as described in section 117 of the Companies Law.
- (b) The internal auditor of the Company shall receive notices about meetings of the audit committee and may participate in them. The internal auditor may ask the chairman of the audit committee to convene the committee to discuss a subject that he describes in his request, and the chairman of the audit committee will convene the meeting within a reasonable time from the request, if he sees a reason to do so.
- (c) A notice of a meeting of the audit committee, in which a subject related to the audit of the financial statements is raised, shall be delivered to the internal auditor who is entitled to participate in it.
- (d) Subject to the provisions of the Companies Law (including section 116a dealing with a quorum to deliberate and adopt resolutions in the audit committee and section 115(e) dealing with presence in meetings of the audit committee), the procedures of the meetings and activities of the audit committee and its management shall be in accordance with the provisions of the procedures and management of meetings of the Board of Directors, as described in these articles, mutatis mutandis, insofar as they are appropriate and insofar as they do not replace instructions given by the Board pursuant to this section.

Part Nine: Exemption, indemnification and liability insurance

50. **Exemption and indemnification**

- (a) The Company is entitled to exempt in advance an office holder from his liability, in whole or in part, for damage due to a breach of the duty of care to the Company, other than a breach of the duty of care in a distribution.
- (b) The Company may indemnify an office holder for an obligation or expense as described in paragraphs (1) – (6) herein, imposed on him following an act that he did by virtue of his being an office holder:
 - (1) A monetary duty imposed on him or expended in favor of another person by a court judgment, including a judgment issued as a settlement or a ruling of an arbitrator that is ratified by a court;
 - (2) Reasonable litigation costs, including legal fees, expended by the office holder following an investigation or proceeding that was conducted against him by the competent authority to carry out an investigation or proceeding, and which concluded without the filing of an indictment against him and without having imposed on him a monetary obligation as an alternative to a criminal proceeding, or which ended without an indictment against him but with the imposition of a monetary obligation as an alternative to a criminal proceeding for an offense that does not require proof of criminal intent or in connection to a monetary sanction;

The terms “**conclusion of a proceeding without the filing of an indictment in a matter in which a criminal investigation was opened**” and – “**monetary obligation as an alternative to a criminal proceeding**”, in this article shall be attributed the meaning given to them by section 260(a)(1a) of the Companies Law.

- (3) Reasonable litigation costs, including legal fees that the officer expended or which he was charged to pay by a court, in a proceeding filed against him by the Company or on its behalf or by another person, or in a criminal indictment for which he was acquitted, or an indictment for which he was convicted of a crime that does not require proof of criminal intent.
- (4) Other expenses expended in respect to an administrative proceeding that was conducted on his case, including reasonable litigation costs, including legal fees.

For this purpose “**an Administrative Proceeding**” - a proceeding pursuant to Parts 8(3) (Imposition of a monetary sanction by the Securities Authority), 8(4) (Imposition of administrative enforcement measures by the Administrative Enforcement Committee), or 9(1) (An Arrangement to prevent proceedings or to halt proceedings that is predicated on conditions) of the Securities Law, as amended from time to time, and a proceeding according to Section D’ of Chapter Four in Part Nine of the Companies Law and subject to any relevant law, any similar proceeding to these, by whatever name it is called.

- (5) Payment to a person injured by a violation as stated in section 52(54)(a)(1)(a) of the Securities Law.
 - (6) Any other obligation or expense imposed on him or expended, following an act that he did by virtue of his being an officer in it, for which indemnification can be made according to the provisions of relevant law.
- (c) The Company may give indemnification in one of the following ways:
- (1) By giving an undertaking in advance to indemnify an office holder of the Company in each of the following (hereinafter: “**Undertaking to Indemnify**”):
 - (a) As set forth in article 50(b)(1) above, provided that the undertaking for indemnification for a monetary obligation is limited to events which according to the Board of Directors are foreseeable in light of the Company’s actual activity at the time of the giving of the undertaking for indemnification and for a sum or criteria that the Board of Directors establishes is reasonable under the circumstances, and where the undertaking for indemnification will state the events which the Board of Directors feel are foreseeable in light of the Company’s actual activity at the time of the giving of the undertaking as well as the sum or the criteria which the Board establishes are reasonable under the circumstances.
 - (b) As set forth in Articles 50(b)(2), 50(b)(3), 50(b)(4), 50(b)(5), and 50(b)(6).
 - (2) To indemnify the office holder of the Company retroactively.

51. **Liability insurance**

- (a) The Company may enter into a contract for liability insurance for an officer of the Company for a liability that will be imposed on said officer for an act taken by virtue of his being an officer in the Company, for each of the following:
 - (1) A breach of the duty of care towards the Company or another person;

- (2) Breach of a fiduciary duty against the Company provided that the officer acted in good faith and had reasonable grounds to assume that the action would not harm the welfare of the Company;
- (3) A monetary obligation that is imposed on him in favor of another person;
- (4) Other expenses expended by the office holder in respect to an administrative proceeding conducted in his case, including reasonable litigation expenses, including legal fees;

For this matter “**Administrative Proceeding**” – as defined in article 50(b)(4) above;

- (5) Payment to a victim of a breach as contemplated by section 52(54)(a)(1)(a) of the Securities Law;
 - (6) Any additional obligation that may be insured by law.
- (b) In any case where the insurance contract will have coverage for the Company itself, the office holder shall have the preemptive right instead of the Company in receiving insurance compensation.

Part Ten: General Manager

52. **General Manager**

- (a) A general manager of the Company will be appointed and dismissed according to a resolution adopted by the Board of Directors of the Company, and it may appoint more than one general manager, for a fixed period of time or without any time limitation, and it may from time to time dismiss or release him or them from their office and appoint another or others in his or their stead.
- (b) Subject to the provisions of an employment agreement between the general manager and the Company, the general manager is responsible for the ongoing management of the affairs of the Company as part of the policy set by the Board and subject to its instructions.

Subject to the provisions of the agreement between the general manager and the Company, the general manager will have all the authorities of management and implementation that were not conferred by law or these articles to another body of the Company, and he may be supervised by the Board, provided that if the general meeting enacts a new regulation it shall not be in his power to cancel or revoke the lawful validity of a deed done prior to such by the general meeting or in accordance with its instructions, which would have been valid if not for the new regulation that was enacted.

- (d) Subject to the provisions of the law and articles 36(a) and 36(b) above, the Board of Directors may from time to time deliver and confer on the general manager at such time, some of those authorities by which it acts according to these articles, as it deems fit to manage the ordinary business of the Company and it may confer authorities for a period of time, and for certain purposes and needs for those times and under such conditions and restrictions as it deems fit as stated above.
- (e) The general manager must notify the chairman of the Board of Directors about any irregular matter that is material to the Company; if the Company does not have a chairman of the Board or if he is prevented from serving in such capacity, the general manager will notify all the directors.
- (f) Office holders of the Company, other than directors and the general manager (namely, a chief business manager, deputy to the general manager, legal advisor, any replacement as stated in the Company even if his title is different, and another manager subject directly to the general manager) shall be appointed and dismissed by the general manager, without derogating from the provisions of the Companies Law dealing with the approval of the terms of service and employment of an office holder.

53. **Removal of authorities from the general manager**

The Board of Directors may instruct the general manager how to act for a specific matter; if the general manager does not satisfy the provision and/or the general manager is prevented from exercising his authorities, the Board of Directors may exercise the required authority to implement the instruction and/or to exercise his authorities in his stead.

Part Eleven: Management of the Company

54. **Registered office**

- (a) The Company will maintain an office in Israel, to which any notice to the Company can be sent. Without derogating from the provisions of any law, the Company will keep in its registered office documents as set forth in section 124 of the Companies Law.
- (b) Delivery of a document to the Company shall be to the office as it is registered with the Companies Registrar at the time it is sent to the Company by mail.
- (c) A person who is entitled to inspect documents, is entitled to receive a copy of them for a fee that the Board or the general manager establishes.

55. **Register of shareholders and register of material shareholders**

- (a) The Company shall keep a register of shareholders and a register of material shareholders and will update the changes to them as soon as possible after it becomes aware of them.
- (b) The shareholder register and the material shareholder register shall be open for inspection by any person.
- (c) The details enumerated in section 130(a) of the Companies Law shall be recorded in the shareholder register.
- (d) The material shareholder register shall contain reports that the Company received pursuant to the Securities Law about the holdings of the material shareholders in Company shares.
- (e) The Company will keep all the records that are recorded in the shareholder register as set forth in article 55(c) above.
- (f) The shareholder register will be prima facie proof of the contents recorded in it.
- (g) In the case of a contradiction between the shareholder register and a share certificate, the shareholder register shall have more evidentiary value than that of the share certificate.

56. **Auditor**

- (a) The Company will appoint an auditor who will audit the annual financial statements of the Company and give his opinion about them (hereinafter: "**Audit Activity**").
- (b) An auditor will be appointed at each annual meeting and shall serve in his capacity until the end of the following annual meeting; however, the general meeting may appoint an auditor who will serve in his position for a longer period of time, that shall not be longer than the end of the third annual meeting after the one in which he is appointed.
- (c) The Company may appoint a number of auditors to carry out the audit activity together.
- (d) If the office of the auditor is vacated and the Company does not have another auditor, the Board will convene a special meeting, as soon as possible, with the agenda of appointing an auditor.

57. **Expiration of the term of the auditor**

- (a) The general meeting may terminate the service of the auditor.

If the agenda of the Company includes the termination of the service of the auditor or the non-renewal of his service, the audit committee will bring its position before the general meeting, after affording the auditor a reasonable opportunity to bring his position before it.

- (b) If the Board becomes aware that there are dependent relationships pursuant to the provisions of section 160 of the Companies Law, it will notify the auditor without delay that he must act to cease such dependency immediately; if the dependency continues, the Board will convene a special meeting within a reasonable time period, with the agenda to terminate the service of the auditor.
- (c) The general meeting that is convened as set forth in article 57(b) above, shall decide on the termination of the service of the auditor; however, the general meeting may, after the auditor brings his position before it, decide not to accept the recommendation of the Board to end his service, if it finds that the auditor has no dependency in the Company.
- (d) The Board of Directors will give the auditor a reasonable opportunity to bring his position before the general meeting with the agenda of ending or not renewing his service, and for this purpose the auditor will be invited to participate in the general meeting.
- (e) If the auditor resigns for reasons that involve an interest for shareholders in the Company, the Board will notify the Company of such.
- (f) Without derogating from the provisions of relevant law, the Board of Directors will notify the shareholders about the reasons for the resignation of the auditor as it deems fit, and it may also give notice about its position in the matter.

58. **Wages of the auditor**

- (a) The salary of the auditor for the audit activity and for additional services, shall be set by the Board of Directors, in accordance with the extent of the work, the duration of his employment and any additional relevant term related to his employment.

The Board will notify the general meeting about the wages of the auditor, and all matters related to his salary for additional services – also about the terms of contract with the auditor, including payments and undertakings of the Company towards the auditor.

For the purpose of this section – an accountant auditor – including a partner, employee or relative of the accountant and including a corporation under his control.

- (b) The Company will not stipulate the payment of the fee of the auditor on terms that limit the manner of his performance of the audit activity or which make a connection between the results of the audit and his fees.
- (c) The Company or anyone on its behalf shall not indemnify, directly or indirectly, the auditor, for an obligation imposed on him due to a breach of his professional responsibility in providing services that must be provided by an accountant auditor by law, or following the violation of another duty imposed on him by law.

59. **Authorities, duties and responsibility of the accountant auditor**

- (a) The auditor may at any time inspect documents of the Company required by him to perform his job and receive explanations about them.
- (b) The auditor may participate in any general meeting in which financial statements are submitted for which he conducted audit activity and any meeting of the Board which deliberates the approval of the financial statements, in meetings of the committee to inspect the financial statements and in meetings of the Board convened pursuant to article 40(b)(2)2 above; the Board of Directors will notify the auditor of the place and time of the general meeting or the Board or committee meeting for the examination of the financial statements.
- (c) If the auditor becomes aware during his audit activity about material defects in the accounting audit of the Company, he will notify the chairman of the Board of such.

60. **Internal auditor**

- (a) The Board of Directors of the Company will appoint an internal auditor; the internal auditor will be appointed in accordance with the recommendation of the audit committee.

An internal auditor shall not be an interested party in the Company, an officer in the Company, a relative of any of the above, or the auditing accountant or his representative

- (b) The organizational supervisor over the internal auditor shall be the chairman of the Board, or whoever the Board of the Company determines from time to time.
- (c) The internal auditor will check, inter alia, the validity of the activities of the Company in respect to compliance with the law and proper corporate governance.
- (d) The term of service of the internal auditor shall not be terminated without his consent and he shall not be suspended, unless the Board decides on such after obtaining the position of the audit committee, and after giving the internal auditor a reasonable opportunity to state his position before the Board and before the audit committee.

For this purpose, the quorum for the opening of a meeting of the Board shall not be less than a majority of the directors.

Part Twelve: Financial statements and signature

61. Financial statements

The Company will keep accounts, and likewise will keep financial statements pursuant to the Securities Law.

62. Stamp and signatory right

- (a) The Company may establish a stamp or rubber stamps for sealing documents.
- (b) The Board will determine the person or persons (even if they are not directors) who are authorized to sign on behalf of the Company, and their signatures together with the stamp of the Company or its printed name shall bind the Company, provided that he or they acted and signed within their authority or authorities.

Part Thirteen: Dividends and Bonus Shares

63. Dividends and bonus shares

- (a) A resolution by the Company to distribute dividends or allocate bonus shares shall be adopted by the Board of Directors of the Company. The Board of the Company shall decide on the date for payment of the dividend.
- (b) In addition, the Board may, prior to offering a dividend, allocate from the profits of the Company, amounts, as it deems fit, as a reserve fund or funds as they establish, in the sole discretion of the Board of Directors, for unforeseeable needs or to equalize dividends with special dividends to correct, to improve or to maintain any property of the Company, and for many other types of purposes, as the Board, according to their absolute discretion, believes is beneficial for the affairs of the Company, and it may invest these allocated sums in investments that they feel are proper (other than in shares of the Company), and from time to time manage these investments or change them and use all or some of them for the benefit of the Company, and it may divide the reserve fund into special funds, as it deems fit, and use the fund or any part of it for the Company's business, without having to keep the monies separate from the rest of the assets of the Company.

- (c) A Board of Directors which announces the distribution of dividends may decide that this dividend be paid in full or in part by distribution of certain assets, in particular by the distribution of fully paid up shares, bonds or a series of bonds of any other company, or in one or more of these methods.
- (d) In order to validate a resolution of the Board (including according to article 63(c) above), the Board may:
- (1) Resolve any difficulty that may arise in respect to the distribution of a dividend and/or allocation of bonus shares as it deems fit;
 - (2) Issue partial certificates, including certificates for fractional shares or decide not to count fractions under a certain amount, or sell fractions and transfer their consideration to those eligible to receive them;
 - (3) To establish for the distribution of a dividend and/or allocation of bonus shares the value of any specific asset;
 - (4) To decide that payment in cash will be done for shareholders on the basis of the value that will be so established, or that parts the value of which are less than one shekel will not be taken into account in order to adjust the rights of all the parties;
 - (5) To deposit such monies or specific assets with trustees against securities, for persons eligible to receive dividends and/or bonus shares or to a fund that was converted into capital;
 - (6) If required, a proper contract will be drawn up and the Board may appoint a person to sign such contract on behalf of those eligible to receive dividends, bonus shares and/or fund converted into capital and such appointment will be valid; and/or
 - (7) To make any other arrangement (in respect to the distribution of dividends and/or allocation of bonus shares), as the Board of Directors deems fit according to its sole discretion.
- (e) The Board of Directors may deduct and offset from any dividend, bonus or other monies that are due to be paid for shares held by a shareholder, whether or not he is the sole owner or holds the share jointly with others, all sums of money owed from him which he must defray on his own or jointly with any other person to the Company on account of calls for payment etc.
- (f) A shareholder shall not be entitled to a dividend if he has not delivered by the date designated for such, a bank account into which the relevant sums are to be transferred. Further, a shareholder is not entitled to change the bank account number a reasonable time (to be set by the Board) prior to the date for the actual distribution of the dividend by the Company.

- (g) The Board may invest each dividend that is not claimed within one year from the announcement of its distribution or to use it in another manner for the benefit of the Company until it is claimed. The Company is not obligated to pay interest or linkage for an unclaimed dividend.
- (h) Shareholders entitled to a dividend, are shareholders as of the designated date for the distribution of the dividend as established in the resolution of the Board of Directors or by virtue thereof, and subject to the provisions of relevant law.

Part Fourteen: Notices and Dissolution

64. Notices

Subject to the provisions of article 21 above (to wit notice of a meeting), the arrangement set forth in article 21 above shall apply:

- (a) The Company is entitled to deliver notice to any shareholder by personal delivery, by fax, by email or by dispatch by mail in a letter, prepaid envelope or packaging intended for the shareholder, to the address as delivered to the Company at the time of the allocation of the shares or transfer of the shares, unless said shareholder gave written notice of a change of his address (hereinafter: “**Registered Address**”).
- (b) A shareholder whose registered address is outside of Israel may, from time to time, give written notice to the Company about an address in Israel, and that address will be considered as his address for the delivery of notices – as stated above.
- (c) All notices regarding shares, to which persons are jointly entitled, shall be delivered to the person who appears first in the shareholder register, unless they deliver other instructions, and a notice sent as stated shall serve as sufficient notice to all these shareholders.
- (d) Any notice sent to a shareholder to his registered address, by Israel post to an address in Israel shall be considered as having been delivered three (3) business days from the day dispatch of the letter or envelope or other packaging containing the letter was delivered to the post office properly bearing the registered address of the recipient and delivered to the post office. A written certificate signed by the secretary or manager or other official of the Company that the letter, envelope or packaging containing the notice with the registered address was delivered to the post office as stated, shall serve as prima facie proof of the fact. Any notice sent by fax shall be considered as having been delivered one (1) day from the day it was sent, provided that confirmation of the dispatch of the fax is presented, and if hand delivered – at the time of delivery.

- (e) A person who becomes eligible to a share by virtue of the law, a transfer or in any other manner, shall be copied on every notice for such share, that was duly delivered to the registered address of the shareholder (from whom the right to the share is derived) registered in the shareholder register.
- (f) Any notice or document sent by post to a shareholder or left at his registered address, then notwithstanding the fact that said shareholder died – and it does not matter if the Company knew of the death or not – shall be seen as having been duly delivered in respect to all the shares registered, whether if they were held by the same shareholder separately or jointly with other persons, until the other person will be registered in his place as the owner or the joint owner of the shares, and such delivery will be seen, for the purposes of these articles, as sufficient delivery of the notice or the document to the personal representative, or all persons, if any, jointly interested in the same shares. Without derogating from the foregoing generality, a notice to a shareholder shall be delivered also to persons who have a right to a share due to the death or bankruptcy of a shareholder or if the shareholder is a corporation – in the event of its receivership or dissolution, after the receiver or liquidator, as warranted, is registered as the shareholder in the shareholder register.

65. **Dissolution**

- (a) Without derogating from the authority of the liquidator pursuant to section 334 of the Companies Ordinance and subject to special conditions, benefits and restrictions attached to shares of the Company, shares of the Company shall have equal rights regarding the return of the capital and participation in the distribution of surplus assets of the Company whether if the Company winds up voluntarily or whether in any other manner, after defrayal of all the obligations of the Company, its assets shall be distributed, among all the shareholders, proportionate to the nominal value of their shares without taking into account any premium paid on them.
- (b) For the purpose of article 65(a) above, a person who is entitled to shares but have not yet been allocated the shares, shall be considered as if the shares to which he is entitled were allocated to him prior to the dissolution, and that the amount paid on account of the nominal value of the shares has been paid up. In this case one who is entitled to the shares, is entitled to payment of an equal sum to the amount that he would have received in a dissolution if he would have held the shares of the Company on the eve of the adoption of the resolution of the dissolution, with a deduction of the price of the exercise that he would have had to pay if he would have exercised his right to the shares of the Company on the eve of the resolution of the dissolution.

- (c) If the Company winds up and the property of the Company that is to be distributed among the members is not enough to return all the paid up capital, these assets will be distributed inasmuch as possible in a proportionate manner to the paid up capital, or which is considered paid up at the start of the dissolution, of the shares held by each of the members.

FOUNDERS AGREEMENT

This Founders Agreement (the "**Agreement**") is entered into as of June 1, 2011, by and between Shai Yarkoni, an individual bearing Israeli passport 55365860 and Nadir Ashkenazi, an individual bearing Israeli I.D. 14692909 and Kasian Nuriel Chirich, an individual bearing Israeli I.D. 55483143. (Each of the individuals shall be referred to as a "**Party**" or "**Shareholder**" and collectively, the "**Parties**" or "**Shareholders**").

WHEREAS the Parties wish to establish a new company for the purpose of operating the Business (as such term is defined hereunder),

WHEREAS The Parties wish to enter into this Agreement respecting the operation and management of the Company, their ownership of the Company's Shares and their mutual rights and obligations within the framework of the Company, all as written in this Agreement;

NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Shareholders agree as follows:

1. Formation of the Company

- 1.1. As soon as reasonably practicable after the signing of this Agreement, the Shareholders shall jointly establish and, register a new company under the laws of Israel (the "**Company**"), in accordance with the provisions set forth below
 - 1.2. The Articles of Association of the Company upon registration thereof are attached hereto as **Appendix A** shall reflect the provisions set forth herein in this Agreement (the "**Articles**"). In the event of any contradiction or inconsistency between the relevant provisions of this Agreement and the Articles, the provisions of this Agreement shall prevail, and - without limiting the generality of the aforesaid - the Parties shall take reasonable steps, including the execution of documents, to amend the Articles accordingly.
 - 1.3. The name of the Company shall be "SCElect Biotechnology", or such other name as shall be agreed between the Parties and approved by the Israeli Registrar of Companies.
 - 1.4. The authorized share capital of the Company shall consist of one class of shares (the "**Shares**"). All the Shares shall bear equal rights and obligations for all intents and purposes, including voting rights, rights to receive dividends and - upon liquidation of the Company - rights to receive a portion of the assets of the Company legally available for distribution to the shareholders of the Company
 - 1.5. The authorised and issued Share capital of the Company consists of 500,000 Shares of 0.01 NIS par value each, held by the Shareholders
As follows:
-

- 1.5.1. **Shai:** 50,000 of the issued and outstanding share capital of the Company.
- 1.5.2. **Nadir:** 50,000 of the issued and outstanding share capital of the Company.
- 1.5.3. **Chirich:** 50,000 of the issued and outstanding share capital of the Company.

2. Scope of the Business

- 2.1. The Company shall establish and operate a business and raise funds for the development and commercialization of that certain technology as described in **Appendix B** attached hereto (the “**Business**”). The Company may also engage in other business activities subject to unanimous resolutions of the Company’s board of directors (the “**Board**”).
- 2.2. The Parties shall use their best efforts to contribute to the overall success of the Business of the Company.
- 2.3. The Business of the Company shall be conducted in the best interests of the Company on sound commercial profit making principles, so as to generate the maximum profits for distribution of dividends to the Shareholders, subject to the terms and provisions set forth below.

3. Representations and Warranties

Each Party represents and warrants, individually, to the others, as follows:

- 3.1. He is free, and has all corporate/individual power and authority, to enter and execute this Agreement and there exist no agreement and/or any limitation and/or restriction, whatsoever, which may prevent such Shareholder from entering and executing this Agreement.
- 3.2. This Agreement constitutes valid, binding and enforceable obligations of such Shareholder.
- 3.3. There are no legal proceedings pending against him, which are likely to materially impact on its ability to perform its obligations under this Agreement.
- 3.4. He is fully aware that the operation of the Business and the Company involves a certain degree of risk.
- 3.5. He is experienced, skilled and has the knowledge necessary to perform its undertakings hereunder.

4. Contribution of the Parties

- 4.1. Shai Yarkoni and Nadir Ashkenazi agree to take all the necessary actions and execute any document or instrument in order to duly assign the patents set forth in **Appendix C** (the “**Patents**”) to the Company and to update all relevant authorities upon such transfer. The costs for patent maintenance paid by shai until now will be considered as a loan bearing same interest as the loan of Chirich (see below).
- 4.2. Chirich, by himself or through a controlled subsidiary company, shall contribute funds to ensure the operation of the Company pursuant to the Budget attached hereto as **Appendix D**. The said contribution shall be made by way of a loan bearing interest and payment terms as will be agreed between the Parties.

5. Books-keeping and Accounting

- 5.1. Proper books of account shall be kept by the Company and entries shall be made therein of all matters, terms, transactions and items as are usually written and entered into books of account in accordance with generally accepted Israeli accounting principles (“GAAP”). All the Shareholders shall have free and full access at all reasonable times to examine and copy them. The Company shall furnish to any Shareholder correct information, account and statements, pertaining to its business, without any concealment or suppression.
- 5.2. Immediately following the execution of this Agreement, the Shareholders shall vote in favor of appointing the auditors of the Company, and the auditors’ accountants shall, at the financial year end of the Company, namely December 31, provide their review of the books and accounts of the Company. For such purpose, the auditors shall have access to all books of account, records and all vouchers, cheques, papers and documents of or which may relate to the Company.
- 5.3. The Company shall deliver to the Shareholders as soon as practicable, but in any event within six (6) months after (he end of each fiscal year of the Company, a consolidated balance sheet of the Company as of the end of such year, and statements of income and statements of cash flow of the Company for such year, prepared in accordance with GAAP, audited by the Company’s auditors, and accompanied by an opinion of such firm which opinion shall state that such balance sheet and statements of income and cash flow have been prepared in accordance with GAAP applied on a basis consistent with that of the preceding fiscal year, and present fairly and accurately the financial position of the Company as of their date, and that the audit by such accountants in connection with such financial statements has been made in accordance with generally accepted auditing standards.

6. Bank Accounts & Signature Rights

- 6.1. The Company shall maintain a bank account at such bank or financial institution as the Board shall, from time to time, determine.

- 6.2. All bank accounts and/or accounts shall be kept in the name of the Company and all cheques, bills, notes, drafts or other instruments shall require signatures as approved by the Board.
- 6.3. All monies received from time to time for the account of the Company shall be paid immediately into those bank accounts for the time being in operation, in the same drafts, cheques, bills or cash in which they are received and all disbursements on account of the Company shall be made by cheque at such bank or trust company.

7. General Meetings of the Shareholders

- 7.1. The Shareholders' meetings shall be convened as provided under the applicable law or the Company's Articles of Association, but not less than once every Calendar Year.
- 7.2. Each Share shall entitle the holder thereof to one vote on matters brought for the vote of the Shareholders of the Company. A resolution shall be deemed adopted if a quorum is present and approved by the holders of a majority of the voting power presented at a meeting in person or by proxy and voting thereon.
- 7.3. A quorum for a General Meeting shall be the present of shareholders holding not less than 75% of the issued and outstanding share capital. Notwithstanding the aforesaid, if within 45 minutes of the time "arranged for the General Meeting no quorum is present, such meeting shall stand adjourned and the General Meeting shall hold the adjourned meeting after 96 hours of the original meeting. The shareholders shall receive notice of the adjourned meeting (including, by phone or email). At such adjourned meeting if no quorum is present, the shareholders attending at such meeting shall be deemed as a legal quorum.
- 7.4. A resolution in writing signed or agreed to in writing (including by facsimile) by all of the Shareholders shall be valid for every purpose as a resolution adopted at a general meeting that was duly convened and held.
- 7.5. Any or all of the Shareholders may participate in a general meeting by means of a conference telephone call or similar communications equipment by means of which all persons participating in the meeting can hear each other and such participation in a meeting shall constitute presence in person at such meeting. If decisions were adopted as said herein, then the Chairman of the Board shall write the minutes of the decision and attach to it his signature.
- 7.6. Any amendment of the Articles shall require a vote of 75% of the shareholders attending a meeting.

8. The Board

- 8.1. The Board shall manage the Company and have all powers and authorities as specified in the Company's Articles of Association.

- 8.2. The Board shall supervise the general manager of the Company (the “**General Manager**”) and his acts.
- 8.3. The Board shall consist of three (3) members. Each Shareholder holding at least 30% of the Company’s capital shares shall be entitled to recommend appointment of one (1) director (and to remove any director so appointed from office and to appoint another in the place of any director so removed).
- 8.4. Every appointment and removal by a Shareholder of a director pursuant to its entitlement shall be notified in writing to the other Shareholders and to the Company.
- 8.5. The legal quorum at any meeting of the Board shall be the presence of majority of the directors (the “**Quorum**”).
- 8.6. Notwithstanding the aforesaid, if within 45 minutes of the time arranged for the Board meeting no Quorum is present, such meeting shall stand adjourned and the Board shall hold the adjourned meeting after 24 hours of the original meeting. The members of the Board shall receive notice of the adjourned meeting (including, by phone or email). At such adjourned meeting if no Quorum is present, the member/s of the Board attending at such meeting shall be deemed as a legal quorum.
- 8.7. The Chairman of the Board shall be nominated by the Board and shall not have any additional or casting vote.
- 8.8. Members of the Board shall not be paid for performing their duties as such. Travel and accommodation expenses pertaining the Board meetings shall be reimbursed by the Company on the basis of bills, invoices and other documents.
- 8.9. The members of the Board may also vote in writing, by delivery to the Company, prior to a Board meeting a written notice stating their affirmative vote on an issue to be considered by such meeting.
- 8.10. A resolution in writing signed or agreed to in writing (including by facsimile) by all of the members of the Board shall be valid for every purpose as a resolution adopted at a Board meeting that was duly convened and held.
- 8.11. Any or all of the members of the Board may participate in a meeting of the Board by means of a conference telephone call or similar communications equipment by means of which all persons participating in the meeting can hear each other and such participation in a meeting shall constitute presence in person at such meeting. If decisions were adopted as said herein, then the Chairman of the Board shall write the minutes of the decision and attach to it his signature.
- 8.12. The Chairman of the Board is obligated to call a meeting of the Board pursuant to any request at any time made by any member of the Board, or in accordance with the provisions of applicable law obliging him to do so.

- 8.13. Subject to the provisions of applicable law, the Company will procure and maintain, on the Company's account, a sufficient insurance policy in order to insure the responsibility of the members of the Board, to the maximum extent permitted by applicable law, for any liability that will be imposed on any of them in consequence of an act which he Performed by virtue of being its officer, including with respect to any of the following:
- 8.13.1. A breach of the duty of care towards the Company or any other person;
 - 8.13.2. A breach of the fiduciary duty towards the Company, provided that such member of the Board acted in good faith;
 - 8.13.3. A monetary obligation imposed on such member of the Board, in favor of a third party, which obligation is due to or in connection with his position as a Board member.
- 8.14. Subject to the provisions of applicable law, the Company shall indemnify the members of the Board, to the maximum extent permitted by applicable law., in respect of an act performed by him by virtue of him being its officer, including with respect to any of the following:
- 8.14.1. A monetary liability imposed on him in favor of a third party in any judgment, including any settlement confirmed as judgment and an arbitrator's award which has been approved by the court;
 - 8.14.2. Reasonable litigation expenses, including legal fees paid for by such member of the Board, or which he is obligated to pay under a court order, in a civil proceeding brought against him, or in a criminal proceeding in which he is found innocent; or in a criminal proceeding in which he is convicted of an offense that does not require proof of criminal intent.
- 8.15. The Board members shall not be entitled to remuneration for their performance, save for coverage for actual expenses approved in advance by the Company.

9. OFFICERS

- 9.1. The General Manager (CEO) shall be nominated and removed from his office by the Board. The first General Manager (CEO) shall be Shai Yarkoni
- 9.2. The General Manager is responsible for the ongoing operation of the Company's affairs within the bounds of the policy determined by the Board and subject to its directions and supervision.
- 9.3. All others key officers (such as CTO, CFO, COO) shall be nominated by the CEO subject to the approval of the Board. The first CTO shall be Nadir Ashkenazi.

10. Signatory Rights

The signatory rights on behalf of the Company shall be defined and amended from time to time by the Board.

11. Preemptive Rights

The following provisions shall apply with respect to the preemptive rights of the Company:

- 11.1. If at any time, the Company proposes to issue and sell New Securities, as defined below, it shall enable each of the Shareholders (in this section to be referred to as “**Offerees**”) to maintain its proportionate holdings of the share capital of the Company. The Offeree’s pro rata share shall be the ratio of the number of the Company’s Shares then held by the Offeree as of the date of the Rights Notice (as defined in Section 12.3 below), to the sum of the total number of Shares issued as of such date. This preemptive right shall be subject to the following provisions:
- 11.2. “**New Securities**” shall mean any share capital of the Company, whether or not now authorized, and rights, options or warrants to purchase share capital and/or securities of any type whatsoever that are, or may become, convertible and/or exercisable into share capital; provided that the term “New Securities” shall not include (i) securities offered to the public in a public offering at an official stock exchange; (ii) securities issued pursuant to the acquisition of another corporation by the Company by merger, purchase of all or substantially all the assets of another corporation or any other reorganization whereby the Company shall own not less than 51% (fifty-one percent) of the voting power of such corporation; and (iii) securities issued pursuant to any share split or other kind of recapitalization, in a manner which does not effect the percentage of holdings of the Shareholders in the issued share capital of the Company.
- 11.3. If the Company proposes to issue New Securities, it shall give the Offerees a written notice (the “**Rights Notice**”) of its intention, describing the New Securities, the price, the general terms upon which the Company proposes to issue them, and the number of New Securities that the Offeree has the right to purchase under this Section 12. Each Offeree shall have 21 days from delivery of the Rights Notice to agree to purchase (i) all or any part of its pro-rata share of such New Securities and (ii) all or any part of the pro-rata share of the other Offerees entitled to such rights to the extent that such other Offerees do not elect to purchase their full pro-rata share, in each case for the price and upon the general terms specified in the Rights Notice, by giving written notice to the Company setting forth the quantity of New Securities to be purchased, provided that such Offerees shall be obligated to consummate the purchase of such New Securities only if the Company consummates the sale of the balance (if any) of the New Securities, pursuant to the terms described in the Rights Notice.

- 11.4. In the event that any Offeree fails to exercise in full its preemptive right within the period specified hereinbefore, the Company shall have 120 days after delivery of the Rights Notice to sell the unsold New Securities at a price and upon general terms no more favorable to the purchasers thereof than specified in the Rights Notice, provided that concurrently with such sale the Company shall sell the eligible New Securities to the Offeree/s which properly exercised their/its preemptive rights pursuant to section 12.3 above. If the Company has not sold the New Securities within said 120 days period, the Company shall not thereafter issue or sell any New Securities without complying again with the procedure set forth in this Section 12.

12. Transfer Restrictions

- 12.1. The transferability of the company's Shares to a third party shall be restricted in accordance with the provisions of sections 14-16 hereunder.
- 12.2. Any transfer of share that will not be done accordingly to sections 14-16 hereunder, shall not be valid.

13. Right of First Refusal

- 13.1. Any Shareholder who wishes to sell or transfer any or all of the Shares or other securities of the Company of any kind whatsoever owned by him, or any interest therein, including option to purchase Shares of the Company and securities convertible to Shares of the Company, which exist now or at any time hereafter, or contract to do any of the foregoing, whether directly or indirectly (the "Offeror" and the "Securities" respectively), pursuant to the terms of a bona fide offer received from any third party, shall submit a written offer (the "Offer") to transfer the Securities to the other Shareholders (the "Offerees") on terms and conditions, including price, identical to those proposed by such party (the terms of the Offer are referred to herein as the "Proposed Terms"). The Offer shall disclose the identity of the proposed purchaser or transferee, the Securities proposed to be sold or transferred and the Proposed Terms.
- 13.2. Within 14 days from the date of receipt of the Offer, each Offeree shall give written notice to the Offeror (the "Response Note") whether it wishes to purchase the Securities, pursuant to the Proposed Terms. If such Response Notice has not been given by any Offeree within the aforesaid time period, it shall be deemed to have refused to purchase the Offered Shares.
- 13.3. At the expiration of said 14 days: (i) if notices of Offerees who express their wish to purchase Securities have been received by the Offeror in respect of all of the Securities, the Securities shall be transferred by the Offeror to such Offerees pursuant to the Proposed Terms; (ii) in the event that the Offerees do not elect to purchase all of the Securities, but rather all or some of them express their consent to purchase part of the Securities, in accordance with their pro-rata holdings in the Company, and in accordance with the provisions of this section 14, then the Offeror shall transfer to those Offerees, which so elected to purchase some of the Securities, such quantity of these securities as indicated by them, in accordance with their pro-rata holdings in the Company, and the balance of the Securities shall be transferred to the third party identified in the Offer; (iii) in the event that the Offerees do not elect to purchase any of the Securities, then the Offeror shall be entitled at its own discretion to transfer the Securities to the party identified in the Offer.

- 13.4. Any such transfer shall be executed at not less than the price and upon other terms and conditions; if any, not more favorable to the purchaser than the Proposed Terms.
- 13.5. Any Securities not sold within 90 days period shall again be subject to the requirements of a prior offer and right of first refusal pursuant to this Section 14.
- 13.6. The rights of first refusal contained in this Section 14 shall not apply to a transfer to one of the following: (i) a corporation in which the transferor holds at least 51% of the voting power and/or (ii) one or more of the transferor's shareholders (hereafter "**Permitted Transferee**"); *provided however*, that with respect to each and every transfer of Securities, whether to a Permitted Transferee or otherwise, the transferee in such transfer agrees in writing, prior to or concurrently with such Transfer, to be bound by the terms of this Agreement.
- 13.7. Any transfer of Shares, by a Permitted Transferee is subject to this Section 14.

14. Tag-Along (Co-Sale)

The following provisions shall apply with respect to the tag-along rights regarding the Securities of the Company:

- 14.1. subject to the terms and provisions of section 14 above, it is agreed that should a Shareholder of the Company (the "**Selling Shareholder**") receive a bona fide offer (a "**Purchase Offer**"), from any person or entity (the "**Third Party**") to purchase from such Selling Shareholder any Securities (as defined in section 14 above) of the Company held by such Selling Shareholder (the "**Offered Securities**"), which Purchase Offer such Selling Shareholder intends to accept, the other Shareholders shall have the right to participate in such sale of the Offered Securities pursuant to the terms and conditions of such Purchase Offer. Upon receipt of a Purchase Offer, the Selling Shareholder shall promptly give written notice (the "**Purchase Notice**") thereof to the other Shareholders of the Company at least 21 days prior to the closing of such sale or transfer. The Purchase Notice shall describe in reasonable detail the proposed sale or transfer including, without limitation, the number of the Offered Securities to be sold or transferred, the nature of such sale or transfer, the consideration to be paid, and the name and address of the Third Party. Each other Shareholder of the Company shall be entitled, upon written notice to the Selling Shareholder within 14 days after receipt of the Purchase Notice (a "**Participation Notice**"), to sell to the Third Party up to that number of its Shares determined by multiplying the total number of the Offered Shares times a fraction the numerator of which is the number of the Shares owned by such Shareholder and the denominator of which is the total number of Shares owned by all the Shareholders of the Company, other than the Selling Shareholder. A Participation Notice shall indicate the number of Shares that such Shareholder intends to transfer to the Third Party. To the extent that a Shareholder exercises such right, the number of Offered Securities that the Selling Shareholder may sell pursuant to such Purchase Offer shall be correspondingly reduced. At the closing of the sale to the Third Party, the Selling Shareholder shall transfer its shares to the Third Party only if the Third Party concurrently therewith purchases, on the same terms and conditions specified in the Purchase Notice, all of the Securities as to which a Participation Notice has been delivered by the other Shareholders or any of them.

14.2. The rights of co-sale contained in this Section 15 shall not apply to a transfer to a Permitted Transferee; *provided however*, that with respect to each and every transfer of Securities, whether to a Permitted Transferee or otherwise, the transferee in such transfer agrees in writing, prior to or concurrently with such Transfer, to be bound by the terms of this Agreement.

14.3. Any transfer of Shares by a Permitted Transferee is subject to this Section 15.

15. **Bring Along**

In the event that a certain Shareholders shall elect to sell all of their Shares to a third party (the “**Proposing Shareholders**”), and such Proposing Shareholders hold in the aggregate at least 70% of the Company’s issued and outstanding share capital, the other Shareholder (the “**Remaining Shareholder**”) shall be required, if so demanded by the Proposing Shareholders, to sell all of its Shares in the Company to such third party at the same price per Share and upon the same terms and conditions as the Proposing Shareholders, provided that the consideration to be paid by said third party for the Shares of the Remaining Shareholder will reflect, at least, a 30% increase, per annum, on the total monetary financing provided to the Company by the Remaining Shareholder (i.e. the total monetary financing provided by the Remaining Shareholder plus 30% per each year: 30% at the end of the first year, 60% at the end of the second year, etc.).

16. **Confidentiality**

16.1. Each of the Shareholders shall at all times use all reasonable efforts to keep confidential (and to ensure that its employees and agents keep confidential) any confidential information which it may acquire in relation to the Company and/or the Business and shall not use or disclose such information except in the ordinary course of advancing and promoting the Business. The restriction in this Section 17 shall not apply to any information which is:

16.1.1. Publicly available or becomes publicly available through no fault of that Shareholder;

16.1.2. Disclosed to that Shareholder by a third party; or

16.1.3. Disclosed by that Shareholder in accordance with the requirements of law, any stock exchange regulation or any binding judgment, order or requirement of any court or other competent authority in Israel or any other country.

16.2. The provisions of this Section 17 shall survive any termination of this Agreement.

17. Miscellaneous

17.1. This Agreement, together with the appendices attached hereto, constitutes the entire agreement among the Shareholders in respect of the subject matter hereof and thereof, and shall supersede all other prior agreements and understandings, both written and oral, among the Shareholders in respect of the subject matter hereof and thereof.

17.2. The descriptive headings herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.

17.3. In this Agreement, words and expressions importing the singular shall include the plural and vice versa; words and expressions importing the masculine gender shall include the feminine gender and vice versa; and words and expressions importing persons shall include bodies corporate and vice versa.

17.4. Neither this Agreement nor any of the rights, interests, or obligations hereunder shall be assigned by a Shareholder, except (a) with the prior written consent of the other Shareholders, and provided always that such assignee shall undertake in writing to be subject to all obligations of the assignor under this Agreement, or (b) to a transferee of that Shareholder's Shares in the Company in accordance with Sections 13-16 above. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the Shareholders and their respective successors and permitted assigns.

17.5. Each of the Shareholders shall perform such further acts and execute such further documents as may reasonably be necessary to carry out and give full effect to the provisions of this Agreement.

17.6. Upon the incorporation of the Company, the Shareholders will procure that the Company is made fully aware of the terms and conditions of this Agreement, and that it will endorse the same by appropriate corporate action.

17.7. Any term of this Agreement may be amended, terminated or waived only with the written approval of all Shareholders.

17.8. This Agreement shall be exclusively governed by and construed according to the laws of the State of Israel.

- 17.9. In the event of a dispute, the Shareholders shall meet and attempt in good faith to resolve this dispute. This duty to resolve a dispute in good faith shall continue for at least 30 days after one Shareholder requests a meeting for the purpose of resolving a dispute. If after 30 days the Shareholders are unable to resolve their dispute amicably, then either Shareholder may submit to the others an arbitration demand. Any dispute will be solely and finally settled by arbitration in Tel-Aviv-Jaffa, Israel. Should the Shareholders fail to agree on an arbitrator within 14 days after the arbitration has been demanded, then the arbitrator shall be nominated by the chairman of the Israeli Bar (the “**Arbitrator**”). The Arbitrator shall be bound to the substantive laws of the state of Israel but shall not be bound by or subject to any laws of evidence or procedural law. The Arbitrator’s ruling shall be subject to each Shareholder’s right to appeal to an additional arbitrator (the “**Appealing Arbitrator**”). Should the Shareholders fail to agree on the Appealing Arbitrator within 14 days after the arbitration has been demanded, then the arbitrator shall be nominated by the chairman of the Israeli Bar. Any ruling or decision, whether as determined by the Arbitrator or by the Appealing Arbitrator, including interim, shall detail the merits upon which it was based,
- 17.10. All notices and other communications required or permitted hereunder to be given to any Shareholder shall be in writing and shall be sent by facsimile or by express courier or mailed by registered mail, or otherwise delivered by hand or by messenger, addressed to such Shareholder’s address as set forth above or at such other address as any Shareholder shall have furnished to the other Shareholder in writing in accordance with this provision.

Any notice sent in accordance with this Section 18.10 shall be effective (i) if mailed, 5 business days after mailing, (ii) if sent by express courier, 2 business days after mailing, and (iii) if sent via facsimile, on the first business day after transmission and electronic confirmation of receipt.

IN WITNESS WHEREOF the Shareholders have signed this Agreement as of the date first hereinabove set forth.

/s/ Shai Yarkoni

Shai Yarkoni

/s/ Nadir Askenasy

Nadir Askenasy

/s/ Kasbian Chirich

Kasbian Nuriel Chirich

Appendix A

[Articles of Association of Cellect Biotechnology Ltd.]

Appendix B - Technology

Selection of Hematopoietic progenitors for transplantation using intrinsic insensitivity to receptor-mediated apoptosis. This unique property of primitive stem and progenitor cells allows implementation of negative selection through elimination of other cell subsets, including malignant, immune and mature cells. These negative regulatory signals in somatic cells operate as independent tropic factors in primitive stem and progenitor cells, which synergize with other growth factors in activation. The two distinct differentiating factors are:

- a) Cells are identified according to functional characteristic rather than surface markers.
- b) Activation of tropic pathways concomitant with negative selection.

Products / applications with established proof of concept

A line of products will be developed for Bone Marrow Transplants according to indication (Hematopoietic malignancy, Autoimmune diseases such as SLE, MS, ALS etc...) and source of hematopoietic cells (umbilical cord, mobilized peripheral blood or bone marrow). We anticipate 5-8 products, each will have a different combination of death ligands that will best suit particular problems of the specific transplant setting: reduce toxicity, increase engraftment, reduce the Graft Vs Host disease (GvHD), reduce graft rejection or deplete malignant contaminants.

The proposed approach will reduce significantly the cost of cell preparation as compared to immunomagnetic-based progenitor isolation, and will activate tropic pathways to shorten the time to and improve the quality of engraftment. This is anticipated to cause an exponential increase in the use of Hematopoietic Stem cells Transplants currently held back by extreme toxicity and very high costs.

June 4, 2011

STATUS REPORT

METHOD OF INDUCING IMMUNE TOLERANCE VIA BLOOD/LYMPH FLOW-RESTRICTED BONE MARROW TRANSPLANTATION

<u>Our Ref</u>	<u>Country</u>	<u>Earliest Priority</u>	<u>Entry Date</u>	<u>Filing Date Application No.</u>	<u>Issue Date Patent No.</u>	<u>Next Action</u>	<u>Status</u>	<u>Owner</u>
24970	USA CIF	07-Sep-2001 60/317,447		09-Sep-2002 10/237,033	21-Nov-2006 7,138,144	Tax 7.5 21-May-2014	Granted	Styx LLC

METHODS OF SELECTING STEM CELLS AND USES THEREOF

<u>Our Ref</u>	<u>Country</u>	<u>Earliest Priority</u>	<u>Entry Date</u>	<u>Filing Date Application No.</u>	<u>Issue Date Patent No.</u>	<u>Next Action</u>	<u>Status</u>	<u>Owner</u>
39644	PCT	31-May-2006 60/809,390		31-May-2007 IL2007/000663	Publ. Date: 06-Dec-2007 Publ. #: W02007/138597		Expired	Styx LLC
49814	Canada NP	31-May-2006 60/809,390	28-Nov-2008	31-May-2007 2,653,881		Tax 6 + Request Examination Due 31-May-2012	Pending	Styx LLC
49815	Europe NP	31-May-2006 60/809,390	17-Dec-2008	31-May-2007 07736403.2		Tax 6 31-May-2012 DIV new rule due FINAL 23-Jul-2012	Pending	Styx LLC
49817	USA NP	31-May-2006 60/809,390	14-Oct-2009	31-May-2007 12/227,865			Pending	ASKENASY Nadir
49818	India NP	31-May-2006 60/809,390	30-Dec-2008	31-May-2007 2785/MUMNP/2008			Pending	Styx LLC
49820	Israel NP	31-May-2006 60/809,390	30-Nov-2008	31-May-2007 195608		Awaiting Publication of Grant	Allowed	Styx LLC
49813	Australia NP	31-May-2006 60/809,390	24-Dec-2008	31-May-2007 2007266565			Abandoned	Styx LLC
49816	Japan NP	31-May-2006 60/809,390	28-Nov-2008	31-May-2007 2009512772			Abandoned	Styx LLC
49819	China NP	31-May-2006 60/809,390		31-May-2007 200780028001.5			Abandoned	Styx LLC

REGULATORY IMMUNE CELLS WITH ENHANCED CELL DEATH DIRECT EFFECT

<u>Our Ref</u>	<u>Country</u>	<u>Earliest Priority</u>	<u>Entry Date</u>	<u>Filing Date</u> <u>Application No.</u>	<u>Issue Date</u> <u>Patent No.</u>	<u>Next Action</u>	<u>Status</u>	<u>Owner</u>
51138	USA PRO			22-Jul-2010 61/366545		Expires 22-Jul-2011	Filed	Styx LLC
51139	PCT	22-Jul-2010 61/366,545				PCT Application Due 22-Jul-2011	Open	YARKONI Shai

APPENDIX D

Budget:

SCT102 preclinical development	\$	1.2M
1 Pharmacology (large animals)		0.3
1 Toxicology (non human primates)		0.5
1 Manufacturing/CMC		0.4
Research	\$	0.2M
Salaries (2.0FTE for 24 months)	\$	0.3M
Corporate costs	\$	0.3M
Total	\$	2.0M

Chairman of the Board Agreement

Entered into on April 30, 2013

By and Between

Collect Biotechnology Ltd. a private company number 514625805
From 10 Hataas Street, Kfar Saba 4442510 (the Company)

The first party

And

Mr. Kasbian Nuriel Chirich ID number 055365860 from 21 Unizman Street Tel Aviv Jaffa
(the chairman or the employee)

The second party

- Whereas The chairman serves as the Company's chairman from its establishment date
- And whereas The Company's shareholders are about to perform a share exchange transaction under section 103t with a "shell company" (the public company) such that after the exchange the Company shall be a subsidiary wholly owned by the public company;
- And whereas The chairman is a candidate for serving after the transaction as the Company's chairman of the Board and as the chairman of the Board of the public company and the Company is interested in such employment (the position) as specified in this agreement and all according to the manner, conditions and consideration set forth in this agreement as follows;
- And whereas The chairman declares that he has the capability, skills, reliability, and the experience necessary for fulfilling the position;
- And whereas The chairman declares that there is no legal and/or contractual and/or other prevention for his employment in the position;
- And whereas The parties wish to settle the terms of the commitment with the chairman in the public company and the Company under this agreement as detailed below;

Now therefore, it was stated, agreed and stipulated by and between the parties as follows:

1. Preamble

The preamble to this agreement constitutes an integral part thereof.

The headings of the sections were purported for convenience only and shall not derogate from the provisions of the agreement and/or constitute interpretation tool.

2. The role and purpose of the agreement

- 2.1 This agreement is personal and unique and beyond what is stated in the agreement no other agreements shall apply to the parties.
- 2.2 The employee shall be employed by the Company as an active chairman of the board of the Company and the public company at a aggregate scope of 50% position.
- 2.3 The parties are aware that after the completion of the transaction, the chairman shall be employed as an employee of the public company and as such shall serve even as the chairman of the Company.

3. Employment commencement date

- 3.1 The agreement is valid from April 30, 2013.
- 3.2 This agreement is valid for 36 months and shall be renewed for additional periods of 36 months subject to obtaining the approvals required under the law.

4. The chairman's personal confidence and obligations

- 4.1 The chairman shall be meticulous about complying with the provisions of any law, with all the rules and provisions to be issued from time to time by the authorities that shall supervise and/or regulate the activity of the Company and its employees in connection with managing the Company's business affairs and shall comply with the Company's internal guidelines and procedures as shall be from time to time.
- 4.2 The chairman commits to fulfill his position in the Company diligently and loyally and devote in working for the Company all his knowledge, experience, business time and energy, and act, to the best of his ability, diligently, efficiently and loyally for promoting the Company, its benefits and success according to the Company's guidelines and procedures.
- 4.3 The chairman commits to attend and participate actively in the Company's Board meetings during the term of the agreement and be involved in the Company's activity and to be at its disposal according to the Company's guidelines and policy, as shall be from time to time.
- 4.4 During the term of this agreement, the chairman shall not receive, directly or indirectly, any payment or other benefit from any party who is directly or indirectly involved in working with the Company, including from customers or suppliers of the Company.

- 4.5 During the term of his employment in the Company, the chairman shall not be involved, directly or indirectly, in any other business, company, occupation, directly or indirectly, which may be in conflict of interests with the activity of the public company and/or the Company.
- 4.6 The chairman commits to notify the Company's management immediately and with no delay of any matter or issue for which him or his family members may have a personal interest or that may create a conflict of interests with his position in the Company.

5. Wages and conditions

- 5.1 In return for the chairman's work in the Company, the chairman shall be entitled to wages and conditions as specified in the "Summary of employment conditions" which is attached to this agreement as Appendix A and constituting an integral part thereof.
- 5.2 It is clarified that as the Company's chairman, the latter shall be at the disposal of the Company for the purpose of fulfilling his position at hours and days beyond the regular working hours and days, as necessary. The chairman warrants and represents that he is aware that his position is a management position that requires a unique measure of personal confidence and accordingly the work hours and rest law – 1951 shall not apply to him while working at the Company. The chairman shall not be entitled to payments or any additions for overtime and/or for surplus hours or rest days and his monthly wage, as specified in this section, as above, was calculated to include a full compensation for his work at any scope necessary, according to the work requirements.

6. Confidentiality

- 6.1 The chairman warrants and represents that he is aware and he agrees that in the course of his work and confidence relations he is exposed and shall be exposed to a valuable commercial-professional information in all that concerns the Company's business affairs as shall be from time to time (the Company's area of activity) and to various commercial contacts. This information is the exclusive property of the Company and its disclosure to any party or its use by the chairman may harm and damage severely the Company.
- 6.2 The chairman warrants and represents to keep in confidentiality and not disclose or deliver to any person or entity, including companies in which the chairman is active and not use, himself or on behalf of a third party, directly or indirectly – whether the secrets, information and the documents below came to his attention as a result of his work in the Company or otherwise, as long as those did not become a public domain:
- 6.3 Commercial secrets and/or other secrets of the Company, information directly or indirectly related to its property, business affairs, affairs, the Company's reputation, its customers and suppliers and of the people and/or the entities related to the Company, including information regarding the Company's area of activity and any information relating and/or concerning the aforesaid, including but without derogating from the generality of the foregoing – the Company's R&D subjects, manufacturing methods, processes, prices, calculations, terms of agreement with customers and suppliers, drawings, documents and secrets whether the above secrets and information came to the attention of the chairman due to his work in the Company or that came to him by any other manner (the secrets/the information, as the case may be) and any document, memo, record, report, summary, plans, letters or other documents of the Company including electronic documents and computer software and encrypted information and/or information saved in any media with respect to the above information and secrets, in whole or in part, whether prepared by him or by another (the documents).

- 6.4 Information - whether written or verbal and in any media used or that may be used by the Company in its business, and/or provides the Company with a commercial advantage over its competitors coming to the information of the Company's chairman and/or in the context and/or during the performance of his position in the Company.
- 6.5 The chairman approves that he is aware that all of the above secrets, information and documents – are vital business and proprietary information of the Company which is not a public domain and cannot be easily discovered by others, which its secrecy confers on the Company a commercial advantage over its competitors and the Company takes reasonable measures to maintain its secrecy.
- 6.6 The chairman warrants and represents that he shall keep in confidentiality the information, as defined in this section, of the Company or related companies or of the Company's customers, as detailed below, shall not deliver to any person and/or entity outside the Company and shall not use such information or disclose it, by deed or omission, without the Company's consent in advance and in writing unless the disclosure is necessary for fulfilling his position in the Company.
- 6.7 The above obligations shall be valid at any time after the employment period of the chairman until such secrets, information and documents become a public domain.

7. Intellectual property

- 7.1 The chairman commits that all know how and/or copyrights including without limiting moral rights and/or all intellectual property rights of any type, including any development and/or drawing and/or representations and/or advertising and/or review and/or other material, shall be the property of the Company and the chairman and/or anyone acting on its behalf shall not have any right, grievance, claim, demand of any type other than the consideration paid under the provisions of this agreement which constitutes the full and only consideration for the chairman services and the consideration fruits of any type.

8. Employment restrictions

- 8.1 For a period of 6 months from the end of the chairman employment period (the restriction period) for any reason whatsoever, the chairman shall not engage, directly or indirectly, as a salaried employee and/or partner and/or otherwise in a business competing with the Company's businesses as they were prior to the actual employment termination in the Company.
- 8.2 The chairman commits that for a year from the employment termination date in the Company he shall not maintain by himself and/or through anyone on its behalf any business or commercial contact whether on its own initiative or otherwise by a third party with those who were at the employment termination date and/or during the year preceding the termination date and/or are managers of the Company, with customers of the Company and any company/competitor of the Company, whether as employer, contractor, partner, advisor, manager and/or otherwise in all that relates to the Company's area of activity as was on the employment termination date.

8.3 The chairman commits not to offer, directly or indirectly, work or employment to the Company's employee and/or a former employee of the Company and/or not to accept such an offer from the Company's employee and/or a former employee of the Company and/or not to employ him in any business for any purpose and in any place and/or not to be in any business contact with him for a year from the termination of work relations between the chairman and the Company.

8.4 "The Company" for the purpose of this section - including corporations relating to the Company at present or in the past.

8.5 "Employee" and "former employee" for the purpose of this section – including corporations controlled by the Company.

9. Early notice and termination of work relations

9.1 Each party may terminate this agreement by an early notice to the other party of 6 months in advance and in writing.

9.2 In the cases listed below, the Company may discontinue immediately the employment of the chairman, with no early notice, and with no severance pay or any other payment:

9.2.1 In the circumstances set forth in the law of early notice for dismissal and resignation – 2001.

9.2.2 Had the chairman materially breached this agreement.

9.2.3 In case it was found out that the chairman acted dishonestly and disloyally towards the Company and/or maliciously harmed the Company and/or abused his position.

9.2.4 Had the chairman been arrested for suspicion of committing a criminal offense and/or was convicted of a disgraceful criminal offense or an offense which its circumstances are such that its continued employment shall damage the Company, as per the management, whether or not the offense is related to its work in the Company.

9.3 The chairman shall return to the Company the entire equipment, documents and information including the information saved by electronic means and/or otherwise.

9.4 The chairman shall return any other material coming to him in the course of his employment in the Company or that was prepared by him in connection with his work in the Company.

10. General provisions

- 10.1 In case of disputes between the parties concerning their obligations and/or the interpretation of a certain provision of the provisions of this agreement, the matter shall be decided exclusively by a court in Tel Aviv having subject matter jurisdiction.
- 10.2 In any event where the Company pays the chairman monies under circumstances conferring the right to receive refunds from the national insurance institute, the chairman shall produce to the Company the confirmations required so that the Company shall be able to claim due funds from the national insurance institute.
- 10.3 All of the amounts payable to the chairman or to his credit under the employment agreement and all the cash equivalent benefits granted to the chairman under this agreement, are gross amounts and are subject to deduction of taxes and other compulsory payments as required by law.
- 10.4 In a case where any party shall not use any right conferred upon him under this agreement or under any law, it shall not be deemed as a waiver of such right and he shall be entitled to reuse these rights. Delay or waiver claims shall not be available to the violating party.
- 10.5 Any change in the provisions of this agreement or a waiver of any party shall be in force and effect only if approved by that party in writing.
- 10.6 The addresses of the parties for the purpose of this agreement are as specified in the preamble of this agreement. Any notice sent by registered mail to the other party according to its address, as aforesaid, shall be deemed as if it was received by the addressee three days after its delivery to the post office and if it was hand delivered – upon its delivery.
- 10.7 Upon signing this agreement, all agreements, documents and understandings among the parties are null and void and any change of this agreement shall be made in writing only.
- 10.8 This agreement constitutes a written notice to the employee regarding his work conditions as required by the notice to employee law (work conditions) – 2002.

In witness whereof we executed this agreement

/s/ Collect Biotechnology Ltd.
Collect Biotechnology Ltd.

/s/ Kasbian Nuriel Chirich
Kasbian Nuriel Chirich

Appendix A – summary of employment conditions and monetary conditions

Name of employee: Kasbian Nuriel Chirich
Position: chairman of the Company's board
Employment commencement date: April 30, 2013

1. Scope of position: 1/2 time position

2. Wages:

- 2.1 Subject to the provisions of this agreement and the compliance with all of the chairman's obligations under this agreement, the chairman shall be entitled to NIS 10,000 per month effective from the date of consummating the merger transaction of the Company with TRF Capital Ltd. (the base wage).
- 2.2 Effective from the date on which the public company and the Company shall consummate a aggregate capital raising of over \$ 2 million (the investment event), the chairman shall be entitled to an additional wage of NIS 5,000 per month for each investment event and up to a cap of NIS 20,000 per month (the updated wage).
- 2.3 The base wage and the updated wage shall be called in Appendix A "the wage", as the case may be.
- 2.4 The wage shall be paid to the chairman until the ninth day for each calendar month for the previous calendar month provided that this day is a business day.
- 2.5 The wage shall represent the basis for calculating vacation, sick leave, severance pay, early notice, provisions to pension funds/ managers insurance, provident funds and advanced study funds.

3. Bonus:

- 3.1 in addition to the wage specified in the above section 2, in the event that the public company and the Company shall consummate a aggregate capital raising, the chairman shall be entitled to a bonus as detailed below:
 - 3.1.1 To the extent that the aggregate capital raising shall be between \$1 million to \$2 million, the chairman shall be entitled to a onetime bonus of 0.75% of the total aggregate capital raising.
 - 3.1.2 To the extent that the aggregate capital raising shall be in excess of \$2 million, the chairman shall be entitled to a onetime bonus of 1% of the total aggregate capital raising.

4. Reimbursement of travel expenses:

- 4.1 in addition to the wage specified in the above section 2, the chairman shall be entitled to reimbursement of travel expenses in the course of works in the Company. In the framework of foreign travel on behalf of the Company, the chairman shall be entitled to fly in business class (for trips further than Europe) and the accommodation expenses abroad shall be paid by the Company. The Company shall issue general insurance policy and full medical insurance for the chairman during his stay abroad.

5. Managers' insurance:

- 5.1 According to the wages, effective from the employment commencement date of the chairman and subject to directives to be provided from time to time by the income tax commission and the maximum deductible amount, the Company shall pay a recognized insurance company under the managers' insurance an amount equal to 8 1/3% for severance pay and 5% for compensation from wages. In addition, 5% of the wages shall be provided by the Company to the insurance company out of the total wages, as a participation of the chairman for the managers' insurance for compensation.
- 5.2 All of the Company's provisions at a rate of 8 1/3% including linkage differentials, interest and any other gain deriving therefrom, shall be on account and in lieu of severance pay for the chairman or his survivors if such entitlement is resulted according to the general approval granted by the minister of labor and welfare and pursuant to the provisions of section 14 of the severance pay law – 1963 Appendix B.
- 5.3 All amounts accumulated from the above provisions shall be fully owned by the manager from the date of the provision and the Company may not delay them in any way whatsoever unless the manager was dismissed under circumstances that do not entitle him to severance pay where then the Company may deny/reduce the severance pay amount according to the law.

6. Advanced study fund:

- 6.1 The chairman shall be entitled to advanced study fund, at his choice, effective from the commencement of his employment.
- 6.2 The Company shall provide every month 7.5% of the wages to the advanced study fund and deduct and provide 2.5% of the chairman's wages to such fund. The amounts provided shall be owned and in the name of the chairman from the provision date.
- 6.3 The above provisions shall be made from the portion of the wages up to the maximum allowed for tax purposes as shall be changed from time to time.

7. Annual vacation:

- 7.1 The chairman shall be entitled to paid annual vacation of 25 days every year.
- 7.2 The right to accumulate vacation shall not exceed the total vacation days accumulated in two years.

8. Sick leave:

8.1 The chairman shall be entitled to paid sick leave according to the law.

8.2 (forever young but there is a limit)

9. Recreation:

9.1 The chairman shall be entitled to paid recreation days according to the law.

In witness whereof we executed this document:

/s/ Collect Biotechnology Ltd.
Collect Biotechnology Ltd.

/s/ Kasbian Nuriel Chirich
Kasbian Nuriel Chirich

Appendix B

A general approval regarding employers' payments to a pension fund and insurance fund in lieu of severance pay

Under severance pay law – 1963

Pursuant to the authority vested in me under Section 14 of the Severance Pay Law, - 1963 (the "Law"), I hereby confirm that the payments paid by an employer effective with publication date of publication of this approval for his employees to a comprehensive pension in a provident fund that is not an insurance fund within the meaning of the Income Tax Regulations (rules on the approval and management of provident funds) - 1964 (the "Pension Fund"), or to managers' insurance including the possibility of an annuity or a combination of payments to annuity plan and to a plan that is not for a pension in such insurance fund (the "insurance fund"), including payments paid through a combination of payments to a pension and insurance funds, whether or not there is a pension plan in the insurance fund (the "Employer Payments"), will be in lieu of the severance pay due to the employee in respect of the salary from which said payments were made and for the period payments were made (Exempt wages) provided that all of the following were met:

1. Employer payments
 - a. To a pension fund, payments that are not less than 14 -1/3% of the exempt wages or 12% of the exempt wages if the employer pays for his employee payments in addition to supplement severance pay to the severance pay fund or to insurance fund in the name of employee at a rate of 2-1/3% of the exempt wages. If the employer does not pay in addition to 12% the 2-1/3% as above, the payments will be in lieu of only 72% of the employee's severance pay;
 - b. To an insurance fund, payments that are not less than one of the following:
 - 1) 13-1/3% of the exempt wages if the employer pays for his employee also payments to secure monthly income in the event of work disability in a plan approved by the commissioner of capital market and insurance and savings in the Ministry of Finance at a rate required to secure at least 75% of the exempt wages or 2.5% of the exempt wages, whichever is lower ("payment for work disability insurance");
 - 2) 11% of the exempt wages if the employer paid insurance payments for work disability insurance and in this case the employer payments will be in lieu of 72% of the severance pay of the employee provided that; the employer paid in addition to these payments also payments for supplementing the severance pay severance to severance pay fund or to an insurance fund in the name of the employee at the rate of 2-1/3% of the exempt wages, the employer payments will be in lieu of 100% of the employee's severance pay.

2. Not later than three months after making the employer payments, a written agreement entered into between the employer and the employee containing the following –
- a) the employee's consent to the arrangement according to this approval under the version specifying the payments of the employer and the pension fund and insurance fund, as the case may be; the agreement also shall include the version of this approval;
 - b) a waiver of the employer in advance of any right it may have for a refund of monies from his payments unless the employee's right to severance pay was denied in a ruling under sections 16 or 17 of the law and to the extent such right was denied, or in the event that the employee withdrew money from the pension fund or the insurance fund not due to a qualifying event; In this regard, "qualifying event" - death, disability, or retirement at age of sixty or more. This approval does not derogate from the employee's severance pay right under the law, collective agreement, expansion order or labor agreement in respect of wages in excess of the exempt wages.
3. This approval does not derogate from the employee's severance pay right under the law, collective agreement, expansion order or labor agreement in respect of wages in excess of the exempt wages.

/s/ Collect Biotechnology Ltd.
Collect Biotechnology Ltd.

/s/ Kasbian Nuriel Chirich
Kasbian Nuriel Chirich

Employment Agreement

Entered into on April 30, 2013

By and Between

Collect Biotechnology Ltd. a private company number 514625805 From 10 Hataas Street,
Kfar Saba, POB 2409, 44641 (the "Company")

The first party

And

Dr. Shai Yarkoni ID number 55365860 from 33 Halamed Hei Street Kfar Saba 44395 (the
"CEO" or the "Employee")

The second party

(the Company and Dr. Shai Yarkoni shall be collectively called: the "Parties")

- Whereas the Employee is interested in working in the Company and the Company is interested to employ the Employee as CEO and the Company's president as specified in this agreement and all according to the manner, conditions and consideration set forth in this agreement as follows;
- And whereas the Company's shareholders are about to perform a share exchange transaction under section 103t with a "shell company" (the "Public Company") such that after the exchange the Company shall be a subsidiary wholly owned by the Public Company;
- And whereas the Employee is a candidate for serving after the transaction as the Company's CEO of the Board and as the CEO of the Board of the Public Company and the Company is interested in such employment as specified in this agreement and all according to the manner, conditions and consideration set forth in this agreement as follows;
- And whereas the Employee declares that he has the capability, skills, reliability, and the experience necessary for fulfilling the position as defined in this agreement below;
- And whereas the Employee declares that there is no legal and/or contractual and/or other prevention for his employment in the position as defined below;
- And whereas the Parties wish to settle the employment conditions of the Employee in the Public Company and the Company under this agreement as detailed below;

Now therefore, it was stated, agreed and stipulated by and between the Parties as follows:

1. Preamble

- 1.1 The preamble to this agreement constitutes an integral part thereof.

1.2 The division of the agreement into sections and the headings of the sections were purported for convenience only and are not to be used as for interpretation purposes.

2. The role and purpose of the agreement

2.1 This agreement is personal and unique and beyond what is stated in the agreement no other agreements shall apply to the Parties.

2.2 The Employee shall be employed by the Company as the Company's CEO.

2.3 The CEO shall be subject to the Company's Board, shall act according to its guidelines and shall be accountable in all that concerns the fulfillment of his position.

2.4 The Parties are aware that after the completion of the transaction, the CEO shall be employed as an employee of the Public Company.

3. Unique agreement

3.1 It is agreed that the information and conditions of this agreement are personal and confidential.

3.2 The CEO commits to keep in absolute confidentiality the conditions of his employment and wages and not allow any party, whether internal or external an access to the agreement conditions and not deliver to another any information regarding the conditions of his employment and wages other than to parties that where the law the CEO is required to deliver such information. Keeping in confidentiality the conditions of this agreement is subject to the disclosure provisions under the securities law, 1968 and the provisions of the stock exchange.

3.3 The Parties declare that they are not contractually precluded from entering into this agreement.

4. The CEO's personal confidence and obligations

4.1 The CEO shall be meticulous about complying with the provisions of any law, with all the rules and provisions to be issued from time to time by the authorities that shall supervise and/or regulate the activity of the Company and its employees in connection with managing the Company's business affairs and shall comply with the Company's internal guidelines and procedures as shall be from time to time.

4.2 The CEO commits to fulfill his position in the Company diligently and loyally and devote in working for the Company all his knowledge, experience, business time and energy, and act, to the best of his ability, diligently, efficiently and loyally for promoting the Company, its benefits and success according to the Company's Board guidelines and work procedures.

- 4.3 During the term of his employment in the Company, the CEO shall not be involved, directly or indirectly, in any other business, company, occupation, directly or indirectly, which may be in conflict of interests with the activity of the Public Company and/or the Company and commits to devote its entire time and energy to the Company.
- 4.4 Notwithstanding the foregoing in section 4.2 as above, it is agreed that the CEO may devote from his business time and energy to public and other activities, as specified in Appendix A of this agreement which shall be updated from time to time. Other activities that are not listed in Appendix A shall be reported to the Company's Board and approved by the Board.
- 4.5 The CEO commits to abide by the law and according to the Company's procedures in all of its decisions concerning hiring or dismissing the Company's employees.
- 4.6 During the term of this agreement, the CEO shall not receive, directly or indirectly, any payment or other benefit from any party who is directly or indirectly involved in working with the Company, including from customers or suppliers of the Company.
- 4.7 The CEO commits to notify the Company's management immediately and with no delay of any matter or issue for which him or his family members may have a personal interest or that may create a conflict of interests with his position in the Company.

5. Wages and conditions

- 5.1 In return for the CEO's work in the Company, the CEO shall be entitled to wages and conditions as specified in the "Summary of employment conditions" which is attached to this agreement as Appendix B and constituting an integral part thereof.
- 5.2 It is clarified that as the Company's CEO, the latter shall be at the disposal of the Company for the purpose of fulfilling his position at hours and days beyond the regular working hours and days, as necessary. The CEO warrants and represents that he is aware that his position is a management position that requires a unique measure of personal confidence and accordingly the work hours and rest law – 1951 shall not apply to him while working at the Company. The CEO shall not be entitled to payments or any additions for overtime and/or for surplus hours or rest days and his monthly wage, as specified in this section, as above, was calculated to include a full compensation for his work at any scope necessary, according to the work requirements.

6. Confidentiality

- 6.1 The CEO warrants and represents that he is aware and he agrees that in the course of his work and confidence relations he is exposed and shall be exposed to a valuable commercial-professional information in all that concerns the Company's business affairs (the Company's area of activity) and to various commercial contacts. This information is the exclusive property of the Company and its disclosure to any party or its use by the CEO may harm and damage severely the Company.
- 6.2 The CEO warrants and represents to keep in confidentiality and not disclose or deliver to any person or entity, including companies in which the CEO is active and not use, himself or on behalf of a third party, directly or indirectly – whether the secrets, information and the documents below came to his attention as a result of his work in the Company or otherwise, as long as those did not become a public domain:

- 6.3 Commercial secrets and/or other secrets of the Company, information directly or indirectly related to its property, business affairs, affairs, the Company's reputation, its customers and suppliers and of the people and/or the entities related to the Company, including information regarding the Company's area of activity and any information relating and/or concerning the aforesaid, including but without derogating from the generality of the foregoing – the Company's R&D subjects, manufacturing methods, processes, prices, calculations, terms of agreement with customers and suppliers, drawings, documents and secrets whether the above secrets and information came to the CEO due to his work in the Company or that came to him by any other manner (the secrets/the information, as the case may be) and any document, memo, record, report, summary, plans, letters or other documents of the Company including electronic documents and computer software and encrypted information and/or information saved in any media with respect to the above information and secrets, in whole or in part, whether prepared by him or by another (the “Documents”).
- 6.4 Information - whether written or verbal and in any media used or that may be used by the Company in its business, and/or provides the Company with a commercial advantage over its competitors coming to the information of the Company's CEO and/or in the context and/or during the performance of his position in the Company.
- 6.5 The CEO approves that he is aware that all of the above secrets, Information and Documents – are vital business and proprietary information of the Company which is not a public domain and cannot be easily discovered by others, which its secrecy confers on the Company a commercial advantage over its competitors and the Company takes reasonable measures to maintain its secrecy.
- 6.6 The CEO warrants and represents that he shall keep in confidentiality the Information, as defined in this section, of the Company or related companies or of the Company's customers, as detailed below, shall not deliver to any person and/or entity outside the Company and shall not use such information or disclose it, by deed or omission, without the Company's consent in advance and in writing unless the disclosure is necessary for fulfilling his position in the Company.
- 6.7 The above obligations shall be valid at any time after the employment period of the CEO until such secrets, Information and Documents become a public domain.

7. Employment restrictions

- 7.1 For a period of 6 months from the end of the CEO employment period (the “Restriction Period”) for any reason whatsoever, the CEO shall not engage, directly or indirectly, as a salaried employee and/or partner and/or otherwise in a business competing with the Company's businesses as they were prior to the actual employment termination in the Company.

- 7.2 The CEO commits that for a year from the employment termination date in the Company he shall not maintain by himself and/or through anyone on his behalf any business or commercial contact whether on his own initiative or otherwise by a third party with those who were at the employment termination date and/or during the year preceding the termination date and/or are managers of the Company, with customers of the Company and any company/competitor of the Company, whether as employer, contractor, partner, advisor, manager and/or otherwise in all that relates to the Company's area of activity as was on the employment termination date.
- 7.3 The CEO commits not to offer, directly or indirectly, work or employment to a Company's employee and/or not to accept such an offer from a Company's employee and/or not to employ him in any business for any purpose and in any place and/or not to be in any business contact with him for a year from the termination of work relations between the CEO and the Company.
- 7.4 "The Company" for the purpose of this section - including corporations relating to the Company at present or in the past.
- 7.5 "Employee" for the purpose of this section – including corporations controlled by the Company.

8. Patents and inventions

- 8.1 All proprietary rights and copyrights for each invention, development, or patent relating to the Company or its businesses and/or deriving from the provision of services to be invented or developed by the CEO during his employment in the Company or that he shall be a partner in their creation even if the invention or development is completed by the Company after employment termination, shall be the exclusive property of the Company.
- 8.2 The Company may protect the invention and/or development and/or the patent by registration or by any other way in Israel or elsewhere and the CEO may not register the invention and/or development and/or patent or take any other course of action with respect to the above other than activities that are required to register or use the patent in the name of the Company or by the Company or for the Company.
- 8.3 The CEO shall cooperate with the Company with respect to registering its rights for each patent or invention which were invented by him for the Company during his employment in the Company also after employment termination.
- 8.4 The CEO shall notify in writing the Company's Board of any invention and/or development and/or patent immediately after their creation.
- 8.5 For the avoidance of doubt, the wages of the CEO under this agreement represent the full consideration for his work including for each invention and/or patent invented by him in the course of his employment period in the Company and that relates to the Company's area of activity and represents a fair value and full compensation in connection with the invention and/or patent. The CEO warrants and represents that he shall not be entitled to any compensation and/or increased wages in connection with inventions and/or any intellectual property in the course of his employment period other than the consideration specified in Appendix A of this agreement and the CEO hereby waives any claim and/or demand based on section 134 of the patent law – 1967.

9. The agreement's term

9.1 This agreement is valid for 36 months from its signing date (the "Agreement Term").

10. Early notice and termination of work relations

10.1 Each Party may terminate this agreement by an early notice to the other Party of 180 days in advance and in writing.

10.2 It is agreed that in the early notice period, the CEO shall be entitled to its full rights whether under the law and the employment agreement including motor vehicle whether or not the Company has waived his work in the early notice period, in whole or in part. If the Company terminates the work of the CEO immediately, the Company shall pay the CEO the full payments to which the CEO is entitled in the early notice period under the law and the employment agreement.

10.3 In the cases listed below, the Company may discontinue immediately the employment of the CEO, with no early notice, or payment for early notice fees and with no severance pay or any other payment:

10.3.1 In the circumstances set forth in the law of early notice for dismissal and resignation – 2001.

10.3.2 In case it was found out that the CEO acted dishonestly and disloyally towards the Company and/or maliciously harmed the Company and/or abused his position.

10.3.3 Had the CEO been arrested for suspicion of committing a criminal offense and/or was convicted of a disgraceful criminal offense or an offense which its circumstances are such that its continued employment shall damage the Company, as per the management, whether or not the offense is related to its work in the Company.

10.4 The CEO shall return to the Company the entire equipment, Documents and Information including the information saved by electronic means and/or otherwise.

11. General provisions

11.1 In case of disputes between the Parties concerning their obligations and/or the interpretation of a certain provision of the provisions of this agreement, the matter shall be decided exclusively by a court in Tel Aviv having subject matter jurisdiction.

11.2 In any event where the Company pays the CEO monies under circumstances conferring the right to receive refunds from the national insurance institute, the CEO shall produce to the Company the confirmations required so that the Company shall be able to claim due funds from the national insurance institute.

- 11.3 All of the amounts payable to the CEO or to his credit under the employment agreement and all the cash equivalent benefits granted to the CEO under this agreement, are gross amounts and are subject to deduction of taxes and other compulsory payments as required by law.
- 11.4 In a case where any Party shall not use any right conferred upon him under this agreement or under any law, it shall not be deemed as a waiver of such right and he shall be entitled to reuse these rights. Delay or waiver claims shall not be available to the violating Party.
- 11.5 Any change in the provisions of this agreement or a waiver of any Party shall be in force and effect only if approved by that Party in writing.
- 11.6 The addresses of the Parties for the purpose of this agreement are as specified in the preamble of this agreement. Any notice sent by registered mail to the other Party according to its address, as aforesaid, shall be deemed as if it was received by the addressee three days after its delivery to the post office and if it was hand delivered – upon its delivery.
- 11.7 Upon signing this agreement, all agreements, documents and understandings among the Parties are null and void and any change of this agreement shall be made in writing only.
- 11.8 This agreement constitutes a written notice to the Employee regarding his work conditions as required by the Notice to Employee Law (Work Conditions) – 2002.

In witness whereof we executed this agreement

/s/ Collect Biotechnology Ltd.
Collect Biotechnology Ltd.

/s/ Dr. Shai Yarkoni
Dr. Shai Yarkoni

Appendix A
Public and other activities

1. Activities to promote the biotechnology industry in Israel.
2. Activities in the framework of Bionegev Ltd.
3. Representing the State in the framework of OECD authorities.
4. Activity in the framework of Rosetta EP and/or Sneh with respect to intellectual property management and commercialization.

Appendix B – summary of employment conditions and monetary conditions

Name of employee: Dr. Shai Yarkoni

Position: CEO of the Company

Employment commencement date: May 1, 2013

1. Scope of position: full time position

2. Wages:

- 2.1 The Company shall pay the CEO gross wage of NIS 45,000 per month. The wage shall be updated according to the increase in the cost of living as paid to employees from time to time to employees (the "Base Wage").
- 2.2 The CEO shall be entitled to a onetime bonus of NIS 100,000 to be paid to the CEO upon consummating the share exchange transaction with the Public Company.
- 2.3 Effective from the date on which the Public Company and the Company shall consummate a aggregate capital raising of \$2 million (the "Investment Event"), the CEO shall be entitled to an increased Base Wage by 10% and to a further increase of the Base Wage by an additional 10% for consummating an additional Investment Event of \$2 million (the "Updated Wage").
- 2.4 The Base Wage and the Updated Wage shall be called in Appendix A the "Wage", as the case may be.
- 2.5 The Wage shall be paid to the CEO until the ninth day for each calendar month for the previous calendar month provided that this day is a business day.
- 2.6 The Wage shall represent the basis for calculating vacation, sick leave, severance pay, early notice, provisions to pension funds/managers insurance, provident funds and advanced study funds.

3. **Bonus**:

- 3.1 in addition to the Wage specified in the above section 2, in the event that the Public Company and the Company shall consummate an aggregate capital raising, the CEO shall be entitled to a bonus as detailed below:
 - 3.1.1 To the extent that the aggregate capital raising shall be between \$1 million to \$2 million, the CEO shall be entitled to an onetime bonus of 0.75% of the total aggregate capital raising.
 - 3.1.2 To the extent that the aggregate capital raising shall be in excess of \$2 million, the CEO shall be entitled to an onetime bonus of 1% of the total aggregate capital raising.

4. **Company car**:

- 4.1 The Company shall provide the CEO with a private car of group 4 and shall pay for the maintenance according to the law and gross up its value for tax purposes. It is agreed that the provision of the car releases the Company from the payment of the Company's participation for the CEO's travel expenses. The CEO shall be charged with the car use value as required by the income tax regulations.

4.2 The Company car shall be used by the CEO for work and for his personal needs where a preference shall be given to work over any other need.

5. Reimbursement of travel expenses:

5.1 in addition to the Wage specified in the above section 2, the CEO shall be entitled to reimbursement of travel expenses in the course of works in the Company. In the framework of foreign travel on behalf of the Company, the CEO shall be entitled to fly in business class and the accommodation expenses abroad shall be paid by the Company. The Company shall issue general insurance policy and full medical insurance for the CEO during his stay abroad.

6. Mobile phone

6.1 The Company shall provide the CEO with a mobile phone for the purpose of fulfilling his position and shall pay for all maintenance costs up to a maximum amount to be determined by the Company from time to time. The CEO shall return the phone to the Company upon the termination of his employment. The CEO shall be charged with the phone use value as required by the income tax regulations.

7. Managers' insurance:

7.1 According to the Wage, effective from the commencement date of the CEO's employment and subject to directives to be provided from time to time by the income tax commission and the maximum deductible amount, the Company shall pay a recognized insurance company under the managers' insurance an amount equal to 8 1/3% for severance pay and 5% for compensation from the Wage. In addition, 5% of the Wage shall be provided by the Company to the insurance company out of the total Wage, as a participation of the CEO for the managers' insurance for compensation.

7.2 All of the Company's provisions at a rate of 8 1/3% including linkage differentials, interest and any other gain deriving therefrom, shall be on account and in lieu of severance pay for the CEO or his survivors if such entitlement is resulted according to the general approval granted by the minister of labor and welfare and pursuant to the provisions of section 14 of the Severance Pay Law – 1963 Appendix B.

7.3 All amounts accumulated from the above provisions shall be fully owned by the manager from the date of the provision and the Company may not delay them in any way whatsoever unless the manager was dismissed under circumstances that do not entitle him to severance pay where then the Company may deny/reduce the severance pay amount according to the law.

8. Advanced study fund:

8.1 The CEO shall be entitled to advanced study fund, at his choice, effective from the commencement of his employment.

8.2 The Company shall provide every month 7.5% of the Wage to the advanced study fund and deduct and provide 2.5% of the CEO's Wage to such fund. The amounts provided shall be owned and in the name of the CEO from the provision date.

8.3 The above provisions shall be made from the portion of the Wage up to the maximum allowed for tax purposes as shall be changed from time to time.

9. Annual vacation:

9.1 The CEO shall be entitled to paid annual vacation of 25 days every year.

9.2 The right to accumulate vacation shall not exceed the total vacation days accumulated in two years.

10. Sick leave:

10.1 The CEO shall be entitled to paid sick leave according to the law.

11. Recreation:

11.1 The CEO shall be entitled to paid recreation days according to the law.

In witness whereof we executed this document:

/s/ Collect Biotechnology Ltd.
Collect Biotechnology Ltd.

/s/ Dr. Shai Yarkoni
Dr. Shai Yarkoni

Appendix C

A General Approval regarding Employers' Payments to a Pension Fund and Insurance Fund in lieu of Severance Pay

Under Severance Pay Law – 1963

Pursuant to the authority vested in me under Section 14 of the Severance Pay Law, - 1963 (the "Law"), I hereby confirm that the payments paid by an employer effective with publication date of publication of this approval for his employees to a comprehensive pension in a provident fund that is not an insurance fund within the meaning of the Income Tax Regulations (rules on the approval and management of provident funds) - 1964 (the "Pension Fund"), or to managers' insurance including the possibility of an annuity or a combination of payments to annuity plan and to a plan that is not for a pension in such insurance fund (the "insurance fund"), including payments paid through a combination of payments to a pension and insurance funds, whether or not there is a pension plan in the insurance fund (the "Employer Payments"), will be in lieu of the severance pay due to the employee in respect of the salary from which said payments were made and for the period payments were made (Exempt wages) provided that all of the following were met:

1. Employer payments
 - a. To a pension fund, payments that are not less than 14 -1/3% of the exempt wages or 12% of the exempt wages if the employer pays for his employee payments in addition to supplement severance pay to the severance pay fund or to insurance fund in the name of employee at a rate of 2-1/3% of the exempt wages. If the employer does not pay in addition to 12% the 2-1/3% as above, the payments will be in lieu of only 72% of the employee's severance pay;
 - b. To an insurance fund, payments that are not less than one of the following:
 - 1) 13-1/3% of the exempt wages if the employer pays for his employee also payments to secure monthly income in the event of work disability in a plan approved by the commissioner of capital market and insurance and savings in the Ministry of Finance at a rate required to secure at least 75% of the exempt wages or 2.5% of the exempt wages, whichever is lower ("payment for work disability insurance");
 - 2) 11% of the exempt wages if the employer paid insurance payments for work disability insurance and in this case the employer payments will be in lieu of 72% of the severance pay of the employee provided that; the employer paid in addition to these payments also payments for supplementing the severance pay severance to severance pay fund or to an insurance fund in the name of the employee at the rate of 2-1/3% of the exempt wages, the employer payments will be in lieu of 100% of the employee's severance pay.
2. Not later than three months after making the employer payments, a written agreement entered into between the employer and the employee containing the following –

- a) the employee's consent to the arrangement according to this approval under the version specifying the payments of the employer and the pension fund and insurance fund, as the case may be; the agreement also shall include the version of this approval;
 - b) a waiver of the employer in advance of any right it may have for a refund of monies from his payments unless the employee's right to severance pay was denied in a ruling under sections 16 or 17 of the law and to the extent such right was denied, or in the event that the employee withdrew money from the pension fund or the insurance fund not due to a qualifying event; In this regard, "qualifying event" - death, disability, or retirement at age of sixty or more. This approval does not derogate from the employee's severance pay right under the law, collective agreement, expansion order or labor agreement in respect of wages in excess of the exempt wages.
3. This approval does not derogate from the employee's severance pay right under the law, collective agreement, expansion order or labor agreement in respect of wages in excess of the exempt wages.

/s/ Collect Biotechnology Ltd.
Collect Biotechnology Ltd.

/s/ Dr. Shai Yarkoni
Dr. Shai Yarkoni

EMPLOYMENT AGREEMENT

This employment agreement (the “**Agreement**”) dated as of October 14, 2015, effective as of November 3, 2015 (the “**Effective Date**”), by and between Collect Biomed Ltd., an Israeli company, with offices at 20 Hataas St., Kfar Saba, Israel (hereinafter the “**Company**”), and Ronen Twito I.D. Number: 032161655, an individual whose address is Yehuda Hanassi 8a, Herzeliya, Israel (the “**Employee**”),

WITNESSETH:

WHEREAS, the Company desires to employ Employee as its Deputy Chief Executive Officer & Chief Financial Officer (the “**Position**”), and Employee desires to be employed by the Company in such capacity, on the terms and conditions set forth below:

NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants herein contained, the parties hereto agree as follows:

It is hereby agreed by and between the parties as follows:

1. **Preamble**

The preamble to this Agreement and any attachments thereto are an integral part of this Agreement.

2. **Job Description**

The Company hereby employs the Employee, and Employee hereby accepts employment, to serve in a position Deputy to the Chief Executive Officer & Chief Financial Officer of the Company. The Employee shall report directly to the Chief Executive Officer.

3. **Working Hours**

The Employee shall be employed by the Company on a full-time basis. The Employee agrees that his position is considered to be a management position as defined in the Hours of Work and Rest Law - 1951, which requires a special measure of personal trust. Accordingly, the provisions of the Hours of Work and Rest Law - 1951 shall not apply and the Employee shall not be entitled to receive any additional payment for his work other than those that are set forth in this Agreement.

4. **Term of Agreement**

This Agreement shall take effect from the Effective Date and shall remain in effect unless it is earlier terminated as hereinafter provided.

5. **Monthly Salary**

- 5.1 The Monthly gross salary of the Employee shall be NIS 52,000 (the “**Monthly Salary**”).
- 5.2 Upon (i) the successful completion of a financing round in an amount exceeding US\$ 7.5 million or (ii) successful completion of a transaction including among other; merger, acquisition, joint venture, in a valuation of at least US\$ 10 million, the Monthly Salary will increase to NIS 60,000.
- 5.3 The Monthly Salary shall be paid to the Employee not later than the 10th day of each month with respect to the preceding month.

6. **Annual Bonus**

- 6.4 The employee shall be entitled to an annual bonus of up to 5monthly salaries commencing as of Jan 1, 2016 subject to targets which will be determined by the Compensation Committee and Board for each year. In case of fundraising the bonus payment will be as following :
 - 6.4.1 Subject to successful completion of a financing round in an accumulated amount exceeding US\$ 4 million and up to US\$ 5 million, the Employee shall be entitled to an Annual Bonus of two (2) Monthly Salaries.
 - 6.4.2 Subject to successful completion of a financing round in an accumulated amount exceeding US\$ 5 million and up to US\$ 7.5 million, the Employee shall be entitled to an Annual Bonus of three (3) Monthly Salaries.
 - 6.4.3 Subject to successful completion of a financing round in an accumulated amount exceeding US\$ 7.5 million and up to US\$ 12 million, the Employee shall be entitled to an Annual Bonus of four (4) Monthly Salaries.
 - 6.4.4 Subject to successful completion of a financing round in an accumulated amount exceeding US\$ 12 million, the Employee shall be entitled to an Annual Bonus of five (5) Monthly Salaries.
- 6.5 The Annual Bonus will be paid to Employee subject to and upon successful completion of a financing round in an amount exceeding as described above.
- 6.6 The Employee shall not be entitled to receive from the Company any salary or payment of any kind other than the Monthly Salary & Annual Bonus and other payments specifically set forth in this Agreement or properly authorized by the Board of Directors.

7. **Other Terms of Employment**

7.1 **Pension Benefits and Severance Payments**

7.1.1 **Managers Insurance.** The Company shall pay an aggregate amount equal to 14-1/3 and/or 13-1/3% of the Employee's monthly installment of the Monthly Salary for the preceding month to a Managers Insurance (Bituach Menahalim) policy respectively (the "**Policy**") and/or a comprehensive pension plan ("**Pension Plan**") through an agency and with an insurance company or a pension fund, to be selected by the Employee, to be divided as follows: 8-1/3% towards Severance (the "**Company's Severance Contribution**"); 6% toward provident (pensions compensation) or 5% for management insurance ("ביטוח מנהלים") (all in accordance with Section 14 of the Severance Compensation Act, 1963), In addition to the 14-1/3 and or 13-1/3% mentioned above, at the beginning of each month the Company shall deduct from the monthly installment of the Monthly Salary of Employee an amount equal to 5.5% of the Employee's monthly installment of the Monthly Salary for the preceding month, and shall pay such amount as premium payable in respect of the provident pensions compensation component of Policy or 5% for management insurances (all in accordance with Section 14 of the Severance Compensation Act, 1963). In addition the Company shall also pay up to 2.5% of the Employee's monthly installment of the Monthly Salary towards loss of (working capacity) disability insurance (depending on the cost to the Company necessary to provide coverage). In the event the Employee elects to be insured under a Pension Plan, the allocations shall be modified in accordance with the Pension Plans policies, provided, in any event they do not exceed the amounts set forth above.

7.1.2 **Section 14 of the Severance Compensation Law - 1963.**

- (i) It is hereby agreed that upon termination of employment under this Agreement, the Company shall release to the Employee all amounts accrued in the Pensions and or Managers Insurance on account of both the Company's and Employee's contributions. It is hereby clearly agreed and understood that the amounts accrued in the Pensions and/or Managers Insurance on account the Company's contribution [i.e. 13.33%-14.33 of each monthly installment of the Monthly Salary payment] shall be in lieu and in full and final substitution of any severance pay the Employee shall be or become entitled to under any applicable Israeli law.
- (ii) The Company hereby waives in advance any right to any amounts accrued in the Pensions and/or Managers Insurance, unless the Employee is either not entitled to Severance Pay according to Section 17 of the Severance Compensation Act, 1963, or has withdrawn amounts from the Pensions and/or Managers Insurance not due or as a result of an "Entitling Event", as such term is defined in the General Approval of the Labor Minister, dated June 30, 1998, issued in accordance to the said Section 14 (the "**General Approval**").

(iii) Sub-Sections (i) and (ii) are in accordance with Section 14 of the Severance Compensation Act, 1963 and the General Approval, a copy of which is attached hereby as Exhibit A.

7.2 Continuing Education Fund:

7.2.1 The Employee shall be entitled to participate in the Company's continuing education fund (Keren Hishtalmut). The Company shall contribute an amount equal to seven and a half percent (7.5%) of the Employee's Monthly Salary and shall deduct two and a half percent (2.5%) of the Employee's Monthly Salary and transfer it as the Employee's contribution.

7.2.2 It is clarified that unless Employee instructs Company, in writing, to transfer Company contributions exceeding that recognized for such purpose by the tax authorities directly to Employee as part of the Salary, such contributions shall be transferred to the Study Fund. For the avoidance of doubt, any and all tax charges in connection with Company contributions shall be borne solely by Employee.

7.2.3 Upon termination of Employment, Company will remit to Employee all sums accumulated for Employee's benefit in the Study Fund. Notwithstanding, in the event of termination for Cause, Company's contribution to the Study Fund (principal + interest) shall not be remitted to Employee but rather returned to the Company.

7.3 Annual Vacation: The Employee shall be entitled to twenty-two (22) working days of paid annual Vacation each year. Any accrued and unused vacation days can be redeemed by the Employee in accordance with the provisions of the Annual Leave Law - 1951. The Employee may accumulate up to Forty four (44) Annual Vacation days. in accordance with the Company compensation plan as will be amended from time to time

7.4 Sick Leave: The employee shall be entitled to Sick Leave in accordance with the provisions of Sick Pay Law-1976.

7.5 Recreation Pay (Dmei Havra'ah): The Employee shall be entitled to Recreation Pay according to applicable law.

7.6 Cell-Phone Expenses: The Company shall provide and maintain for the Employee a cellular Smartphone for as long as the Employee is employed by the Company. It is agreed that the Employee may transfer his own current cellular phone number to the Company. Upon cessation of the Employee's employment with the Company for whatever reason, the Company agrees to return to the Employee his cellular phone number.

- 7.7 Business Flight: In the case that employee in his capacity will be required to travel abroad the company will buy him business class air ticket, in transatlantic flights.
- 7.8 Company Automobile: The Company will provide a leased, Group level up to a sum of NIS 175,000 (or equally priced) all in accordance with the Company compensation plan as will be amended from time to time, automobile to the Employee, and will place such automobile at the disposal of the Employee under the terms of the Company's general leasing plan (to be provided to the Employee upon provision of the automobile).The Company shall bear all of the fixed and variable maintenance costs and actual expenses incurred directly in connection with his use of such automobile, including licenses, insurance, gas, repairs, parking at the Company offices, etc. but excluding any fines ("**Aggregate Automobile Expenses**").Should Employee choose not to take a leased automobile from the Company, or to take a leased an automobile of Group lower than Group detailed above, the Company will pay the difference in Employer cost to Employee on a monthly basis; provided however that such amount shall not be part of the Employee's salary for calculation of severance pay, or any other social benefits under this Agreement or under law ("**Car Replacement Payment**").The Employee will be compensated for all taxes he will be liable to as a consequence ("gross-up") of the Aggregate Automobile Expenses/Car Replacement Payment of car of Employee under this Section. ((the "Car").
- 7.9 Expenses: The Employee shall be entitled to reimbursement of expenses in accordance with the Company's standard policy for senior executive management in effect from time to time.
- 7.10 Professional Fees: The Company shall pay on behalf of the Employee the annual accountant membership fees and the accountant association fees in Israel. Such payment shall not be taken into account with respect to severance or any other social payment that the Employee may be entitled to.
- 7.11 D&O Insurance: The Employee shall be included within the Directors & Officers Insurance Policy of the Company for the duration of his employment with the Company.
- 7.12 Indemnification Agreement:
- 7.12.1 Subject to the Israeli Companies Act - 1999, the Company shall defend and indemnify Employee in his capacity as Deputy Chief Executive Officer & Chief Financial Officer of the Company against any and all claims, judgments, damages, liabilities, costs and expenses (including reasonable attorney's fees) arising out of, based upon or related to Employee' performance of services hereof, except to the extent that such claims arise out of Employee' (i) willful misconduct, (ii) bad faith, (iii) gross negligence or (iv) reckless disregard of the duties involved in the conduct of Employee' position.

7.12.2 Subject to the Israeli Companies Act -1999, the Company shall take any steps which may be deemed necessary to establish a policy of indemnifying its officers and directors, including, but not limited to Employee, for all actions taken in good faith in pursuit of their duties and obligations to the Company. Such steps shall include, but shall not necessarily be limited to, the obtaining of an appropriate level of Directors and Officers Liability coverage and including such provisions in the Company's Articles of Association, as applicable and customary.

8. **Grant of Stock Options**

8.1.1 Subject to the approval of the board of directors of the Company (the "**Board**"), the Employee will be granted options to purchase 3.5% from the Company's issued & outstanding shares(the "**Options**").The exercise price of each Option will be equal the average of the company's shares in the 30 trading days preceding the date of approval of their grant by the Board, subject to any dilution and subject to the following conditions:

- (1) The Option shall vest and become exercisable on a quarterly basis over 3 years period upon grant for as long as Employee's employment with the Company has not terminated.
- (2) The option shall be grant according to the company ESOP plan and section 102 "capital gain".
- (3) In the case of termination of the agreement not due to a material breach as stated in Section 9.2 below, the Option shall vest on a monthly basis and will be exercisable for a period of 12 month from the date of termination.
- (4) The Options shall be granted in accordance with an Option Agreement to be signed between the Employee and the Company and shall be at all times subject to (i) all the terms of the Company's Share Option Plan, (ii) any terms and conditions as shall be determined and altered from time to time by the Board or any of its committees at their sole discretion, and (iii) any terms and conditions as provided in any agreement or arrangement the Company may enter from time to time including agreements and arrangements with Investment Banks or Underwriters.

However, any such alteration shall not derogate from the rights granted herein.

8.1.2 Notwithstanding the above and subject to any applicable law, in any Transaction as described in Option Plan of the Company including among other merger or change of control, the Vesting Dates shall be accelerated so that any unvested Option or any portion thereof shall be immediately vested as of the date which is 7 days prior to the effective date of the Transaction.

9. **Termination of Employment**

- 9.1 Either party may terminate the Employee's employment with the Company without cause at any time upon four(4) month's prior written notice (the "Notice Period"). The Company shall have the right, in its sole discretion, to require the Employee to continue working for the Company during the Notice Period.
- 9.2 Notwithstanding the above, the Company may terminate this Agreement at any Material breach by Employee of any provision of this Agreement.
- 9.3 Following two years as of the Effective Date, the Employee will entitled to provide the services according to this agreement via a fully owned company as a service provider or contractor.

10. **Taxes and Other Payments**

- 10.1 Unless otherwise specifically provided for in this Agreement, the Company shall not be liable for the payment of taxes or other payments for which the Employee is responsible as result of this Agreement or any other legal provision, and the Employee shall be personally liable for such taxes and other payments.
- 10.2 The Employee hereby agrees that the Company shall deduct from his Monthly Salary the Employee's national insurance fees, income tax and other amounts required by law or the terms of this Agreement. The Company shall provide the Employee with documentation of such deductions.

11. **The Obligations of the Employee**

- 11.1 The Employee agrees to devote his entire business time, energy, abilities and experience to the performance of his duties, effectively and in good faith.
- 11.2 Throughout the Term, the Employee shall not, directly or indirectly, be employed by and/or otherwise render services to any other person or organization without the prior written consent of the Board or the CEO, Except: Director position in companies that are not compete with the company business and as specified in **Exhibit B** to the agreement.
- 11.3 The Employee agrees to immediately inform the Company of any Company issue or transaction in which the Employee has a direct or indirect personal interest and/or where such issue or transaction could cause a conflict of interest for the Employee in the fulfillment of his responsibilities as an employee of the Company.

- 11.4 The Employee hereby gives irrevocable instructions and permission to the Company to deduct from any amounts owed to the Employee by the Company, including amounts payable as severance compensation, (a) any debt he has or will have to the Company; and/or (b) any amount that was wrongfully or mistakenly paid to him by the Company. Any such amounts to be deducted shall be calculated in real terms as of the date of the deduction, including linkage to cost of living index.
- 11.5 The Employee declares that the terms and conditions of his employment are personal and confidential and will not be disclosed by him.
- 11.6 The Employee declares that he is free to enter into this Agreement and that he has no obligations of any kind to any third party that would impair this Agreement, either as an employee or an independent contractor. The Employee further declares that as long as he remains an employee of the Company, he will not incur any such obligations.
- 11.7 The Employee agrees to keep confidential (a) all professional, scientific, commercial, and business information; and (b) any other information or document that comes to the Employee's knowledge in connection with the affairs of the Company (collectively, the "**Confidential Information**"), and agrees not to use or exploit the Confidential Information or to disclose it to any third party where such use, exploitation or disclosure is not directly related to the affairs of the Company, unless the Company gives prior written authorization of such disclosure.
- 11.8 The Employees agrees that during his employment by the Company and thereafter he (a) will not disseminate or otherwise make use of the Confidential Information or of other non-public information of which he learned while working for the Company, except where such dissemination or use is directly related to the affairs of the Company; (b) will maintain the confidentiality of the Confidential Information; and (c) will not in any way act to injure the reputation of the Company or any of its affiliated companies.
- 11.9 The Employee understands and recognizes that his services to the Company are special and unique. Therefore, he agrees that during the term of this Agreement and for six (6) months after the termination for any reason of his employment, he shall not be employed in or give any services to any business or third party that competes directly with the Company or whose activities conflict with the activities of the Company, unless the Chief Executive Officer has given his explicit written consent prior the commencement of such employment or the giving of such services.

11.10 Upon the Company any documents, information and/or materials that were given to him or which were created by him in connection with his employment.

12. **Intellectual Property Rights**

12.1 The Employee declares that he is aware that anything that is done by him in the Company or in connection with the Company, whether it be an invention, a discovery, or the development of an idea or a thing, all within the framework of the Company's business (the "Development") shall belong to and be controlled by the Company, unless the Board of Directors shall, in writing, direct otherwise.

12.2 The Company shall have the right to fully utilize and exploit the Development, as it sees fit, including changing it, registering part or all of it as a patent, whether in Israel or abroad, selling it, transferring it to a third party, all without being required to either receive the Employee's consent or pay the Employee any additional payment for such Development apart from any payment he receives pursuant to this Agreement.

12.3 The Development and any subsequent intellectual property arising therefrom shall remain the sole property of the Employer even after the Employee's employment terminates for any reason. The termination of this Agreement, whether due to its breach or its own terms, shall not impair the Company's exclusive rights in the Development. Notwithstanding the termination of this Agreement, the Board shall have the discretion to award the Employee a cash payment in accordance with the terms of Section 5 above, as a result of any Development or subsequent intellectual property arising therefrom developed primarily by the Employee.

12.4 The Employee may not do anything with the Development or any related materials without the knowledge and prior consent of the Company. The Employee declares that he neither has nor will have any rights in the Development or its fruits and that all rights to the Development and its fruits shall fully reside in the Company.

12.5 Even in the event that at the time of the termination of the Employee's employment for any reason the Development has not been completed, the Employee shall be prohibited from any continued activity in connection with the subject of the Development, alone or in concert with others, that is not explicitly allowed in writing by the Company. The Company alone will be the sole owner of the uncompleted Development and shall have the sole right to complete the Development or to take any other action in connection with the Development.

13. **General**

13.1 It is agreed that the provisions of this Agreement represent the full scope of the agreement between the parties and that neither side shall be bound by any promises, declarations, exhibits, agreements or obligations, oral or written, that are not included in this Agreement prior to its execution. Any changes or amendments to this Agreement must be in writing and signed by both parties.

- 13.2 This Agreement shall be governed by, and construed and interpreted under, the laws of the State of Israel. The parties agree that any legal claim lodged by one party against the other arising from the terms of this Agreement shall be adjudicated only by the appropriate court in Tel Aviv, Israel.
- 13.3 If any provision of this Agreement shall be declared by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced in whole or in part, the remaining conditions and provisions or portions thereof shall nevertheless remain in full force and effect and enforceable, and no provision shall be deemed dependent upon any other covenant or provision unless so expressed herein.
- 13.4 The rights, benefits, duties and obligations under this Agreement shall inure to, and be binding upon, the Company, its successors and assigns, and upon the Employee and his legal representatives. This Agreement constitutes a personal service agreement, and the performance of the Employee's obligations hereunder may not be transferred or assigned by the Employee.
- 13.5 The failure of either party to insist upon the strict performance of any of the terms, conditions and provisions of this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith or with any other term, condition or provision hereof, and said terms, conditions and provisions shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either party shall be effective or any purpose whatsoever unless such waiver is in writing and signed by such party.
- 13.6 The headings of Sections are inserted for convenience and shall not affect any interpretation of this Agreement.

14. **Notices**

- 14.1 A notice that is sent by registered mail to a party at its address as set forth in paragraph 12.2, below, shall be deemed received three (3) days after its posting, and the receipt stamped by the post office shall represent definitive evidence of the date of mailing.
- 14.2 The addresses of the parties for the purposes of this Agreement are:

Company
Collect Biomed Ltd.
20 Hataas St.,
Kfar Saba,
Israel

Employee
Ronen Twito
Yehuda Hannasi Sa,
Herzliya

IN WITNESS WHEREOF the parties have hereunto set their hands at the place and on the date first above written.

Collect Biomed Ltd.

By: /s/ Collect Biomed Ltd.
Title CFO
Date: _____

By: Ronen Twito
Date: /s/ Ronen Twito

Exhibit A

(Unofficial translation from Hebrew original)

A General Approval regarding Employers' Payments to a Pension Fund and Insurance Fund in lieu of Severance Pay

Under Severance Pay Law – 1963

Pursuant to the authority vested in me under Section 14 of the Severance Pay Law - 1963 (the "Law"), I hereby confirm that the payments paid by an employer effective with publication date of publication of this approval for his employees to a comprehensive pension in a provident fund that is not an insurance fund within the meaning of the Income Tax Regulations (rules on the approval and management of provident funds) - 1964 (the "Pension Fund"), or to managers' insurance including the possibility of an annuity or a combination of payments to annuity plan and to a plan that is not for a pension in such insurance fund (the "Insurance Fund"), including payments paid through a combination of payments to a pension and Insurance Funds, whether or not there is a pension plan in the Insurance Fund (the "Employer Payments"), will be in lieu of the severance pay due to the employee in respect of the salary from which said payments were made and for the period payments were made (the "Exempt Wage") provided that all of the following were met:

1. Employer Payments

- a. To a pension fund, payments that are not less than 14 1/3% of the Exempt Wage or 12% of the Exempt Wage if the employer pays for his employee payments in addition to supplement severance pay to the severance pay fund or to insurance fund in the name of employee at a rate of 2 1/3% of the Exempt Wage. If the employer does not pay in addition to 12% the 2 1/3% as above, the payments will be in lieu of only 72% of the employee's severance pay;
- b. To an insurance fund, payments that are not less than one of the following:
 - 1) 13 1/3% of the Exempt Wage if the employer pays for his employee also payments to secure monthly income in the event of work disability in a plan approved by the commissioner of capital market and insurance and savings in the Ministry of Finance at a rate required to secure at least 75% of the Exempt Wage or 2.5% of the Exempt Wage, whichever is lower ("Payment for Work Disability Insurance");
 - 2) 11% of the Exempt Wage if the employer paid insurance payments for work disability insurance and in this case the Employer Payments will be in lieu of 72% of the severance pay of the employee provided that; the employer paid in addition to these payments also payments for supplementing the severance pay severance to severance pay fund or to an insurance fund in the name of the employee at the rate of 2 1/3% of the Exempt Wage, the Employer Payments will be in lieu of 100% of the employee's severance pay.

2. Not later than three months after making the Employer Payments, a written agreement entered into between the employer and the employee containing the following –
 - a) the employee's consent to the arrangement according to this approval under the version specifying the payments of the employer and the pension fund and insurance fund, as the case may be; the agreement also shall include the version of this approval;
 - b) a waiver of the employer in advance of any right it may have for a refund of monies from his payments unless the employee's right to severance pay was denied in a ruling under section 17 of the Law and to the extent such right was denied, or in the event that the employee withdrew money from the pension fund or the insurance fund not due to a qualifying event; In this regard, "qualifying event" - death, disability, or retirement at age of sixty or more.
3. This approval does not derogate from the employee's severance pay right under the Law, collective agreement, expansion order or labor agreement in respect of wages in excess of the Exempt Wage.

June 9, 1998

Eliyahu Yishai

Minister of Labor and Social Welfare

Exhibit B

Other Activities - The Employee is currently engaged in the following activities: (i) the Employee is the owner of a family business specializing mainly in the importation, branding and marketing of children and baby goods in the regions of Israel and Latin America, (ii) The Employee serves as project manager-director of corporate finance for a real-estate property project. The Employee warrants and undertakes that none of its current or future other activities will affect his duties under this Agreement and further warrants and undertakes that in no event such activities will breach any of his obligations hereunder (including without limitation, non compete obligations).

Consulting Agreement

Entered into on April 30, 2013

By and Between

Cellect Biotechnology Ltd. a private company number 514625805
From 10 Hataas Street, Kfar Saba, POB 2409, 44641 (the Company)

The first party

And

Dr. Nadir Askenasy ID number 014692909 from 18 Arvei Nahal, Tel Aviv 67454 (the
Consultant)

The second party

(the Company the Consultant shall be collectively called: the parties)

Whereas The Company addressed the Consultant for receiving its services as the Company's chief scientist (the consulting services or the services);

And whereas The Consultant is interested in providing the Company, as an independent contractor, and the Company is interested in receiving from the Consultant, as an independent contractor the consulting services subject to the provisions of this agreement as follows;

And whereas The Consultant declares that he has the knowhow, means and the ability to provide the Company with the consulting services;

And whereas The parties wish to settle in this agreement the services to be provided by the Consultant, the conditions and the consideration to be paid for the services.

Now therefore, it was stated, agreed and stipulated by and between the parties as follows:

1. Preamble

- 1.1 The preamble to this agreement and its appendices constitute an integral part thereof.
- 1.2 The sections and the headings of the sections were purported for convenience only and are not to be used as for interpretation purposes estimate the opinion of the parties concerning the agreement.

2. The appointment

- 2.1 The Company hereby appoints the Consultant and the Consultant agrees and accepts to provide the Company with the consulting services.
- 2.2 The Consultant shall fulfill his position loyally and diligently as required by such position.

3. Warrants and representations of the Consultant

The Consultant warrants and represents as follows:

- 3.1 The Consultant warrants and represents that the consulting services under this agreement are clear to him and he has the knowhow, ability, experience, business contacts, reliability and skills required for rendering the services as per the Company's requirements.
- 3.2 The Consultant commits to be available to the Company as necessary according to the requirements of his position.
- 3.3 The Consultant warrants and represents that he is not precluded by any law and/or agreement and/or otherwise from entering into this agreement and provide the services and approval of a third party is not required for fulfilling the liabilities of the Consultant under this agreement whether by law or an agreement.
- 3.4 The Consultant warrants and represents that he is not in conflict of interests with the Company and commits to notify the Company immediately of any matter or issue for which him and/or anyone acting on its behalf may have a personal interest and/or may create a conflict of interests by rendering the services under this agreement.
- 3.5 The Consultant commits to comply with all of provisions regarding the rendering of the services as dictated by the Company. The Consultant shall meticulously comply with the provisions of law.
- 3.6 The Consultant commits to return to the Company upon its first demand and in any event no later than the services termination date, any information and/or documents and/or equipment coming to him in connection with the performance of this agreement. No copies of the equipment and/or information and/or documents as above shall remain with him or anyone acting on its behalf.

4. The consideration

- 4.1 In return for complying with all of the Consultant's obligations under this agreement, the Company commits to pay the Consultant for each actual consulting hour NIS 400 plus VAT (the consideration). The consulting hours are subject to the work order placed by the Company. The consideration shall be paid in 30 days from the approval date of the invoice to be submitted by the Consultant to the Company.

- 4.2 The Consultant shall furnish, upon signing this agreement, to the Company the dealer's and tax deduction confirmation and see that the Company is informed of any change or update in the this confirmations. The Company shall deduct from the consideration to be paid all mandatory deductions if the Consultant does not furnish to the Company tax deduction exemption.
- 4.3 The Consultant warrants and represents that he shall not receive an any other consideration and/or benefit, directly or indirectly from any party with respect to this agreement.
- 4.4 The consideration specified in the above 4.2, represents the final and absolute consideration for the Consultant's services and it includes all taxes and charges prevailing in Israel upon the date of signing this agreement and/or any other tax and charge that shall be in force upon the payment date and/or any other expense of the Consultant and/or anyone on its behalf in connection with the services. The Consultant and/or anyone on its behalf shall not be entitled to any payment and/or expense reimbursement from the Company and/or anyone on its behalf beyond the consideration specified in section 4.2 as above.

5. The agreement's term

- 5.1 This agreements shall be in force and effect for 12 months effective from the date of signing the agreement which shall be renewed automatically for an additional period of 12 months each time unless any party notified the other party of his will not to renew the agreement 60 days before the end of each agreement period.
- 5.2 Notwithstanding the foregoing, the Company may terminate the agreement at any time, without any reason, by providing the Consultant with a written notice 30 days in advance however, the termination of the agreement under these circumstances shall not absolve the Company of its obligation to pay the consideration to the Consultant to the extent that the consideration is due to him under the conditions of this agreement and section 4 in particular.
- 5.3 Notwithstanding the foregoing, the Company may terminate this agreement, at its exclusive discretion without a prior notice and without being obligated for any payment and/or compensation to the Consultant in any of the following cases representing a material breach of this agreement:
- 5.3.1 The Consultant violated or did comply with one or more of its obligations under this agreement and failed to cure the violation after receiving the warning from the Company and on the date contained in the warning;
- 5.3.2 The Company notified the Consultant that he fails to properly provide the services in a manner assuring the orderly performance and/or their progress and conclusion under this agreement and the Consultant failed to take the measures in the time specified in the Company's notice that assure the orderly performance and/or progress of such services;

- 5.3.3 In the event of appointing a receiver for the Consultant and/or in the event of the Consultant's inability to carry out any activities relating to complying with the provisions of this agreement;
 - 5.3.4 In the event of a reasonable suspicion that the Consultant committed a criminal offense;
 - 5.3.5 In the event that the Consultant assigned the agreement, in whole or in part without the Company's written approval.
- 5.4 The foregoing of this section does not derogate from any right and/or remedy available to the Company under this agreement and under any law, including the provisions of contract law (remedies for violating an agreement) – 1970 and it is addition to such right and/or remedy.
- 5.5 Throughout the term of the agreement until its termination, the Consultant shall not be entitled to any other payment, compensation or benefit in connection with the performance of this agreement or its termination beyond the consideration specified in section 4 as above including its subsections.

6. Lack of employer employee relations

- 6.1 The Consultant warrants and represents that he is an independent contractor who provides services and is not coming under employer employee relation with the Company and this agreement and any of its conditions do not create employer employee relation and/or agency relations and/or agency between the Consultant and the Company and/or its employees and/or anyone on its behalf and the Consultant may not engage and/or not authorized to carry out any deed and/or omission that may bind the Company towards third parties without the Company's prior written approval.
- 6.2 Therefore, the following provisions shall apply under the Consultant's obligations:
- 6.2.1 The Consultant shall pay the income tax and national insurance payments for himself and any tax and/or payment due from him resulting from the performance of his obligations and/or from the Consultant's revenues under this agreement.
 - 6.2.2 The Consultant commits to comply with the provisions of the national insurance law – 1955 and the related regulations, with any replacement amendment and/or legislation so that his obligations under this agreement are fulfilled.
 - 6.2.3 The Consultant shall take care of all social rights and insurances coupled with rendering the services as an independent contractor and as required by law or agreement and shall pay regularly any payment concerning the provision of such services.

- 6.3 The Consultant commits to compensate the Company for any damage caused to the Company if the Company shall be required to make any payment in respect of employer employee relations between the Company and the Consultant.
- 6.4 Without derogating from the foregoing, it is agreed that if despite of the agreement between the parties, it is ruled by a competent judicial instance that there are employer employee relations between the Company and the Consultant and/or anyone on its behalf and/or the Company is required to pay the Consultant any amounts for rights by virtue of labor laws and/or other rights that were not explicitly indicated in this agreement, all of the provisions specified below shall apply:
- 6.4.1 The Consultant's wages from the commencement date of providing such services under this agreement shall retroactively set on 60% of the consideration (the reduced wages).
- 6.4.2 A settling of accounts shall take place between the parties and the Consultant shall return to the Company surplus amount that he received in excess of the reduced wages as specified in section 6.4.1 plus full linkage differentials and an annual interest rate of 4% to be calculated from the date of making the payment to the Consultant until its actual return by the Consultant and all is based on the known CPI on the relevant date.
- 6.4.3 The Consultant grants the Company an irrevocable order to offset from any amount awarded that is due and/or from any amount that the right for receiving such amount was not explicitly indicated in this agreement, if it is ruled to that effect, the entire debt he has to the Company deriving from the above settling of accounts. This offset order does not release the Consultant from returning the debt if the offset does not cover the entire debt or if not performed.

7. Confidentiality

- 7.1 The Consultant warrants and represents that he shall keep in absolute secrecy and take reasonable measures to keep in secret and avoid the leakage of any information and/or knowhow and/or plans delivered to him directly and/or indirectly by the Company and/or anyone on its behalf and/or any of its customers during and/or due and/or in the framework and/or in connection with this agreement and/or any of the agreements and/or transactions and/or projects to be performed, not to use transfer to others or disclose it other than for complying with the Consultant's obligations under this agreement and the Company's directives to be delivered in writing. The Consultant shall deliver to the Company immediately upon its demand and/or immediately upon the termination of this agreement for any reason whatsoever, the entire information held by the Consultant and no information in any format whatsoever shall remain with the Consultant.

8. Intellectual property rights

- 8.1 All proprietary rights and copyrights for each invention, development, or patent relating to the Company or its businesses and/or deriving from the provision of services to be invented or developed by the Consultant under the provision of services to the Company or that he shall be a partner in their creation even if the invention or development is completed by the Company after employment termination, shall be the exclusive property of the Company.
- 8.2 The Company may protect the invention and/or development and/or the patent by registration or by any other way in Israel or elsewhere and the Consultant may not register the invention and/or development and/or patent or take any other course of action with respect to the above other than activities that are required to register or use the patent in the name of the Company or by the Company or for the Company.
- 8.3 The Consultant shall notify in writing the Company's Board of any invention and/or development and/or patent immediately after their creation.
- 8.4 The Consultant shall cooperate with the Company with respect to registering its rights for each patent or invention which were invented by him for the Company during the service provision period to the Company also after the termination of this consulting agreement.
- 8.5 For the avoidance of doubt, the consideration paid to the Consultant under this agreement represent the full consideration for the services provided by the Consultant to the Company including for each invention and/or patent invented by him in the course of the period of this agreement. The consideration represents a fair value and full compensation in connection with the invention and/or patent. The Consultant warrants and represents that he shall not be entitled to any compensation in connection with inventions and/or any intellectual property by virtue of providing consulting services to the Company other than the consideration specified in this agreement and the Consultant hereby waives any claim and/or demand based on section 134 of the patent law – 1967.

9. Accountability, indemnification and insurance

- 9.1 The Consultant warrants and represents that he shall be accountable for any damage or loss that may be caused to the property and/or person due to his own omission and/or the omissions of anyone acting on its behalf in the course and/or from the provision of such services.
- 9.2 The Consultant shall take all precautionary measures required by law towards a person for bodily injuries and/or damage to property relating directly and/or indirectly to the provision of services and/or to this agreement.
- 9.3 It is hereby clarified that the Company and anyone acting on its behalf are not accountable and shall not be responsible for any payment and/or expense and/or loss and/or damage of any type of for any reason whatsoever that may be caused to the Consultant or any third party who are directly and/or indirectly related to the provision of services under third agreement.

9.4 The Consultant commits to indemnify the Company for any amount the Company shall be charged in connection with damages to property and/or bodily injuries due to the omissions of the Consultant and/or its employees and/or anyone acting on its behalf including court and legal fees and all upon the first demand of the Company.

9.5 The Consultant commits to purchase, at his own expense, all personal and professional insurances in the acceptable coverage in the Consultant's area of activity that are required for providing the consulting services.

10. The agreement's assignment

The Consultant may not assign and/or transfer its obligations or rights under this agreement, or any part thereof whether or not for consideration without the prior and written consent of the Company.

11. Miscellaneous

11.1 This agreement shall be deemed as exhausting the rights and the obligations of the parties on any matter contained therein and any amendment or change or addition in the this agreement shall not have any effect unless were agreed upon in writing by the parties.

11.2 This agreement with its appendices includes all agreed issues among the parties and shall prevail over any agreement, arrangement, correspondence or agreements among the parties on issues contained therein. Any promise, obligation, consent, MOU, representation or conduct in the past, if were made prior to signing the agreement, whether in writing or verbally, are null and void and are not to be used against the Company or the parties.

11.3 Any delay and/or waiver and/or extension or the avoidance of any party to exercise its rights and/or demand the performance of any of the agreement's conditions and/or its consent to deviate from the agreement shall not be deemed as a precedent or a waiver or consent of the waiving party of its rights.

11.4 The provisions of this agreement shall bind the parties and their representatives and/or heirs and/or successors and/or their representatives of any type.

11.5 This agreement shall be subject to Israeli law. In case of disputes between the parties in connection with this agreement the competent court in Tel Aviv shall have exclusive jurisdiction.

11.6 Any notice sent by registered mail to the other party according to its address, as aforesaid, shall be deemed as if it was received by the addressee three days after its delivery to the post office and if it was delivered by facsimile, email or courier - upon its delivery.

In witness whereof we executed this agreement

/s/ Cellect Biotechnology Ltd.
Cellect Biotechnology Ltd.

/s/ Dr. Nadir Askenasy
Dr. Nadir Askenasy

Collect Biomed LTD.

THE 2014 GLOBAL INCENTIVE OPTION SCHEME

DEFINITIONS

For purposes of the Global Incentive Option Scheme and related documents, including without limited, the Grant Notification Letter, the following definitions shall apply:

- (a) **“Board”** - the Board of Directors of the Company.
- (b) **“Cause”** - any of the following:
 - (i) conviction of any felony involving moral turpitude or affecting the Company or any of its affiliates;
 - (ii) any refusal to carry out a reasonable directive of the chief executive officer, the Board or the Grantee’s direct supervisor, which involves the business of the Company or any of its affiliates and was capable of being lawfully performed;
 - (iii) embezzlement of funds of the Company or any of its affiliates;
 - (iv) any breach of the Grantee’s fiduciary duties or duties of care of the Company or any of its affiliates; including without limitation disclosure of confidential information of the Company or any of its affiliates;
 - (v) any conduct (other than conduct in good faith), including without limitation, any act or omission, reasonably determined by the Board to be materially detrimental to the Company or any of its affiliates; and/or
 - (vi) if and as such term is or may be defined under the Grantee’s employment agreement, service agreement or any other engagement agreement with the Company or any of its affiliates; and/or
 - (vii) should circumstances arise as a result of which the Grantees’ employment with the Company and/or any of its affiliates is or may be terminated without severance pay.

For the avoidance of any doubt, it is hereby clarified that in any event of conflict between the definition of the term “Cause” in this Scheme and the definition of the term “Cause” in a certain employment agreement, the definition in this Scheme shall prevail in connection with the Option, with the Grant Notification Letter and with this Scheme.

- (c) **“Chairman”** - the chairman of the Committee.
- (d) **“Committee”** - a compensation committee appointed by the Board, which shall consist of no fewer than two members of the Board.
- (e) **“Company”** -Collect Biomed Ltd., an Israeli company.
- (f) **“Date of Grant”** - the date of grant of an Option, as determined by the Board or the Committee and set forth in the Grantee’s Grant Notification Letter.

- (g) **“Employee”** - a person who is employed by the Company or any affiliate.
- (h) **“Expiration Date”** - the date upon which an Option shall expire, as set forth in Section 7.2 of the Scheme.
- (i) **“Fair Market Value”** - as of any date, the value of a Share determined as follows:
 - (i) If the Shares are listed on any established Share exchange or a national market system, including without limitation the Tel-Aviv Stock Exchange, the NYSE MKT system, the NASDAQ National Market system, or the NASDAQ SmallCap Market of the NASDAQ Share Market, the Fair Market Value shall be the closing sales price for such Shares (or the closing bid, if no sales were reported), as quoted on such exchange or system for the last market trading day prior to time of determination, as reported in the Wall Street Journal, or such other source as the Board deems reliable;
 - (ii) If the Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value shall be the mean between the high bid and low asked prices for the Shares on the last market trading day prior to the day of determination, or;
 - (iii) In the absence of an established market for the Shares, the Fair Market Value thereof shall be determined in good faith by the Board.
- (j) **“Grantee”** - a person who receives or holds an Option under the Scheme.
- (k) **“Grant Notification Letter”** - a document to be signed between the Company and a Grantee that sets out and informs the Grantee with respect to the terms and conditions of the grant of an Option.
- (l) **“Non-Employee”** - a director, consultant, advisor, service provider of the Company or any affiliate, or any other person who is not an Employee.
- (m) **“Option”** - an option to purchase one or more Shares of the Company pursuant to the Scheme.
- (n) **“Purchase Price”** - the price for each Share subject to an Option.
- (o) **“Scheme”** - this 2014 Global Incentive Option Scheme.
- (p) **“Share”** - the ordinary shares, without nominal value par value each, of the Company.
- (q) **“Successor Company”** - any entity the Company is merged to or is acquired by, in which the Company is not the surviving entity.
- (r) **“Transaction”** –

- (i) Merger, acquisition or reorganization of the Company with one or more other entities in which the Company is not the surviving entity;
 - (ii) A sale of all or substantially all of the assets of the Company.
- (s) **“Vested Option”** - any Option, which has already been vested according to the Vesting Dates.
- (t) **“Vesting Dates”** - as determined by the Board or by the Committee, the date as of which the Grantee shall be entitled to exercise the Options or part of the Options, as set forth in Section 10 of the Scheme and in the Grantee’s Grant Notification Letter.

THE SCHEME

This scheme, as amended from time to time, shall be known as Collect Biomed Ltd. 2014 Global Incentive Option Scheme.

1. PURPOSE OF THE SCHEME

The Scheme is intended to provide an incentive to retain, in the employ of the Company and its affiliates, persons of training, experience, and ability, to attract new employees, directors, consultants, service providers and any other entity which the Board shall decide their services are considered valuable to the Company, to encourage the sense of proprietorship of such persons, and to stimulate the active interest of such persons in the development and financial success of the Company by providing them with opportunities to purchase shares in the Company, pursuant to the Scheme.

Incentives under the Scheme shall only be issued to Grantees subject to the applicable law in their respective country of residence for tax purposes or any other purposes, as the case may be.

2. ADMINISTRATION OF THE SCHEME

- 2.1 The Board shall have the power to administer the Scheme either directly or upon the recommendation of the Committee, all as provided by applicable law and in the Company's Articles of Association. Notwithstanding the above, the Board shall automatically have residual authority if no Committee shall be constituted or if such Committee shall cease to operate for any reason.
- 2.2 The Committee shall select one of its members as its Chairman and shall hold its meetings at such times and places as the Chairman shall determine. The Committee shall keep records of its meetings and shall make such rules and regulations for the conduct of its business as it shall deem advisable.
- 2.3 The Board and/or the Committee, if applicable subject to the approval of the Board, to the extent required under applicable law (and subject further to applicable laws) shall have the full power and authority to:
 - (i) designate participants;
 - (ii) determine the terms and provisions of the respective Grant Notification Letters, including, but not limited to, the number of Options to be granted to each Grantee, the number of Shares to be covered by each Option, provisions concerning the time and the extent to which the Options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary;
 - (iii) determine the Fair Market Value of the Shares covered by each Option;

- (iv) designate the type of Options;
 - (v) alter any restrictions and conditions of any Options or Shares subject to any Options;
 - (vi) interpret the provisions and supervise the administration of the Scheme;
 - (vii) accelerate the right of a Grantee to exercise in whole or in part, any previously granted Option;
 - (viii) determine the Purchase Price of the Option;
 - (ix) prescribe, amend and rescind rules and regulations relating to the Scheme; and
 - (x) make all other determinations deemed necessary or advisable for the administration of the Scheme.
- 2.4 The Board or the Committee shall have the authority to grant, at its discretion, to the holder of an outstanding Option, in exchange for the surrender and cancellation of such Option, a new Option having a purchase price equal to, lower than or higher than the Purchase Price of the original Option so surrendered and canceled and containing such other terms and conditions, or to change the Purchase Price as the Board or the Committee may prescribe in accordance with the provisions of the Scheme.
- 2.5 Subject to the Company's Articles of Association, all decisions and selections made by the Board or the Committee pursuant to the provisions of the Scheme shall be made by a majority of its members except that no member of the Board or the Committee shall vote on, or be counted for quorum purposes, with respect to any proposed action of the Board or the Committee relating to any Option to be granted to that member. Any decision reduced to writing shall be executed in accordance with the provisions of the Company's Articles of Association, as the same may be in effect from time to time.
- 2.6 The interpretation and construction by the Committee of any provision of the Scheme or of any Grant Notification Letter there under shall be final and conclusive unless otherwise determined by the Board.
- 2.7 Subject to the Company's Articles of Association and the Company's decision, and to all approvals legally required, including, but not limited to the provisions of any applicable law, each member of the Board or the Committee shall be indemnified and held harmless by the Company against any cost or expense (including counsel fees) reasonably incurred by him, or any liability (including any sum paid in settlement of a claim with the approval of the Company) arising out of any act or omission to act in connection with the Scheme unless arising out of such member's own fraud or bad faith, to the extent permitted by applicable law. Such indemnification shall be in addition to any rights of indemnification the member may have as a director or otherwise under the Company's Articles of Association, any agreement, any vote of shareholders or disinterested directors, insurance policy or otherwise.

3. DESIGNATION OF PARTICIPANTS

The persons eligible for participation in the Scheme as Grantees shall include any Employees and/or Non-Employees of the Company or of any affiliate.

The grant of an Option hereunder shall neither entitle the Grantee to participate nor disqualify the Grantee from participating in, any other grant of Options pursuant to the Scheme or any other option or share plan of the Company or any of its affiliates.

4. SHARES RESERVED FOR THE SCHEME; RESTRICTION THEREON

4.1 The Company has reserved 3,412,097 authorized but unissued Shares, for the purposes of the Scheme and for the purposes of any other share option plans which may be adopted by the Company in the future, subject to adjustment as set forth in Section 6 below. Any Shares which remain unissued and which are not subject to the outstanding Options at the termination of the Scheme shall cease to be reserved for the purpose of the Scheme, but until termination of the Scheme the Company shall at all times reserve sufficient number of Shares to meet the requirements of the Scheme. Should any Option for any reason expire or be canceled prior to its exercise or relinquishment in full, the Shares subject to such Option may again be subjected to an Option under the Scheme or under the Company's other share option plans.

4.2 Each Option granted pursuant to the Scheme, shall be evidenced by a written Grant Notification Letter between the Company and the Grantee, in such form as the Board or the Committee shall from time to time approve. Each Grant Notification Letter shall state, among other matters, the number of Shares to which the Option relates, the type of Option granted thereunder, the Vesting Dates, the Purchase Price per share, the Expiration Date and such other terms and conditions as the Committee or the Board in its discretion may prescribe, provided that they are consistent with this Scheme.

5. PURCHASE PRICE

5.1 The Purchase Price of each Share subject to an Option shall be determined by the Board and/or the Committee in its sole and absolute discretion in accordance with applicable law, subject to any guidelines as may be determined by the Board from time to time. Each Grant Notification Letter will contain the Purchase Price determined for each Grantee.

5.2 Without derogating from the above and in addition thereto, the Purchase Price of each Share subject to an Option shall be payable upon the exercise of an Option in the following acceptable forms of payment:

- (i) cash, check or wire transfer;
- (ii) at the discretion of the Committee, through delivery of Share (including other Share subject to the Options being exercised) having a Fair Market Value equal as of the date of exercise to the Purchase Price of the Share purchased and acquired upon the exercise of the Option, or by a different form of cashless exercise method through a third party broker as approved by the Committee;
- (iii) at the discretion of the Committee, any combination of the methods of payment permitted by any paragraph of this Section 5.2.

5.3 The Purchase Price shall be denominated in the currency of the primary economic environment of, either the Company or the Grantee (that is the functional currency of the Company or the currency in which the Grantee is paid) as determined by the Company.

6. ADJUSTMENTS

Upon the occurrence of any of the following described events, Grantee's rights to purchase Shares under the Scheme shall be adjusted as hereafter provided:

- 6.1 In the event of Transaction, the unexercised Options then outstanding under the Scheme shall be assumed or substituted for an appropriate number of shares of each class of shares or other securities of the Successor Company (or a parent or subsidiary of the Successor Company) as were distributed to the shareholders of the Company in connection and with respect to the Transaction. In the case of such assumption and/or substitution of Options, appropriate adjustments shall be made to the Purchase Price so as to reflect such action and all other terms and conditions of the Grant Notification Letters shall remain unchanged, including but not limited to the vesting schedule, all subject to the determination of the Committee or the Board, which determination shall be in their sole discretion and final. The Company shall notify the Grantee of the Transaction in such form and method as it deems applicable at least 7 days prior to the effective date of such Transaction.
- 6.2 Notwithstanding the above and subject to any applicable law, the Board or the Committee shall have full power and authority to determine that in certain Grant Notification Letters there shall be a clause instructing that, if in any such Transaction as described in Section 6.1 above, the Successor Company (or parent or subsidiary of the Successor Company) does not agree to assume or substitute for the Options, the Vesting Dates shall be accelerated so that any unvested Option or any portion thereof shall be immediately vested as of the date which is 7 days prior to the effective date of the Transaction.

- 6.3 For the purposes of Section 6.1 above, an Option shall be considered assumed or substituted if, following the Transaction, the Option confers the right to purchase or receive, for each Share underlying an Option immediately prior to the Transaction, the consideration (whether shares, options, cash, or other securities or property) received in the Transaction by holders of shares held on the effective date of the Transaction (and if such holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares); provided, however, that if such consideration received in the Transaction is not solely ordinary shares (or their equivalent) of the Successor Company or its parent or subsidiary, the Committee may, with the consent of the Successor Company, provide for the consideration to be received upon the exercise of the Option to be solely ordinary shares (or their equivalent) of the Successor Company or its parent or subsidiary equal in Fair Market Value to the per Share consideration received by holders of a majority of the outstanding shares in the Transaction; and provided further that the Committee may determine, in its discretion, that in lieu of such assumption or substitution of Options for options of the Successor Company or its parent or subsidiary, such Options will be substituted for any other type of asset or property including cash which is fair under the circumstances.
- 6.4 The Board or the Committee shall have full power and authority to determine that in certain Grant Notification Letters there shall be a clause instructing that, if the Company is voluntarily liquidated or dissolved while unexercised Options remain outstanding under the Scheme, the Company shall immediately notify all unexercised Option holders of such liquidation, and the Option holders shall then have 7 days to exercise any unexercised Vested Option held by them at that time, in accordance with the exercise procedure set forth herein. Upon the expiration of such 7 days period, all remaining outstanding Options will terminate immediately.
- 6.5 If the outstanding shares of the Company shall at any time be changed or exchanged by declaration of a cash dividend, share dividend (bonus shares), distribution of subscription rights, share split, combination or exchange of shares, recapitalization, spin-off or any other like event by or of the Company, and as often as the same shall occur, then the number, class and kind of the Shares subject to the Scheme or subject to any Options therefore granted, and the Purchase Prices, shall be appropriately and equitably adjusted so as to maintain the proportionate number of Shares without changing the aggregate Purchase Price. Upon happening of any of the foregoing, the class and aggregate number of Shares issuable pursuant to the Scheme (as set forth in Section 6 hereof), in respect of which Options have not yet been exercised, shall be appropriately adjusted, all as will be determined by the Board whose determination shall be final.
- 6.6 Notwithstanding, according to the Tel-Aviv Stock Exchange regulations, exercise of Options shall not be executed on the record date for the distribution of bonus shares, offer by way of rights, dividend distribution, capital consolidation, split capital or capital decrease (all of the above shall be referred as “Company Event”), and such an exercise, shall be postponed to following trading day. Additionally, if the Ex-Date of a Company Event applies before the record date of the Company Event (as such terms are defined in the TASE Articles), no exercise of Options on the Ex-Date stated shall be executed and such an exercise shall be postponed to following trading day.

7. TERM AND EXERCISE OF OPTIONS

- 7.1 Options shall be exercised by the Grantee by giving written notice to the Company and/or to any third party designated by the Company (the: “**Representative**”), in such form and method as may be determined by the Company, which exercise shall be effective upon receipt of such notice by the Company and/or the Representative and the payment of the Purchase Price at the Company’s or the Representative’s principal office. The notice shall specify the number of Shares with respect to which the Option is being exercised.
- 7.2 Options, to the extent not previously exercised, shall terminate forthwith upon the earlier of: (i) the date set forth in the Grant Notification Letter; (ii) the expiration of any extended period in any of the events set forth in Section 7.5 below, or (iii) ten (10) years from their Date of Grant.
- 7.3 The Options may be exercised by the Grantee in whole at any time or in part from time to time, to the extent that the Options become vested and exercisable, prior to the Expiration Date, and provided that, subject to the provisions of Section 7.5 below, the Grantee is employed by or providing services to the Company or any of its affiliates, at all times during the period beginning with the granting of the Option and ending upon the date of exercise.
- 7.4 Subject to the provisions of Section 7.5 below, in the event of termination of Grantee’s employment or services, with the Company or any of its affiliates, all Options granted to such Grantee will immediately expire. A notice of termination of employment or service shall be deemed to constitute termination of employment or service. For the avoidance of doubt, in case of such termination of employment or service, the unvested portion of the Grantee’s Option shall not vest and shall not become exercisable and the Grantee shall have no claim against the Company and/or its affiliate that his/her Options were prevented from continuing to vest as of such termination. Notwithstanding anything to the contrary mentioned above, a Grantee shall not cease to be an Employee only due to the transfer of such Employee’s employment among the Company and its affiliates.
- 7.5 Notwithstanding anything to the contrary hereinabove and unless otherwise determined in the Grantee’s Grant Notification Letter, an Option may be exercised after the date of termination of Grantee’s employment or service with the Company or any affiliates during an additional period of time beyond the date of such termination, but only with respect to the number of Vested Options at the time of such termination according to the Vesting Dates, if:

- (i) termination is without Cause, in which event any Vested Option still in force and unexpired may be exercised within a period of ninety (90) days after the date of such termination; or-
- (ii) termination is the result of death or disability of the Grantee, in which event any Vested Option still in force and unexpired may be exercised within a period of twelve (12) months after the date of such termination; or-
- (iii) prior to the date of such termination, the Committee shall authorize an extension of the terms of all or part of the Vested Options beyond the date of such termination for a period not to exceed the period during which the Options by their terms would otherwise have been exercisable.

For avoidance of any doubt, if termination of employment or service is for Cause, any outstanding unexercised Option (whether vested or non-vested), will immediately expire and terminate, and the Grantee shall not have any right in connection to such outstanding Options.

- 7.6 Any form of Grant Notification Letter authorized by the Scheme may contain such other provisions as the Committee may, from time to time, deem advisable.
- 7.7 The Options and any underlying Shares are extraordinary, one-time benefits granted to the Grantee and are not and shall not be deemed a salary component for any purpose whatsoever, including in connection with calculating severance compensation under applicable law.
- 7.8 Neither the Grantee nor any other person, as the case may be, shall have any claim to be granted any Options, and there is no obligation by the Company for uniformity of treatment of Grantees or their beneficiaries (if applicable). The terms and conditions of the Options granted under this Scheme and any of the board's determinations and interpretations with respect thereto need not be the same with respect to each Grantee (whether or not such Grantees are similarly situated).

8. VESTING OF OPTIONS

- 8.1 Subject to the provisions of the Scheme, each Option shall vest following the Vesting Dates and for the number of Shares as shall be provided in the Grant Notification Letter. However, no Option shall be exercisable after the Expiration Date.
- 8.2 An Option may be subject to such other terms and conditions on the time or times when it may be exercised, as the Committee may deem appropriate. The vesting provisions of individual Options may vary.

9. DIVIDENDS

With respect to all Shares (but excluding, for avoidance of any doubt, any unexercised Options) allocated or issued upon the exercise of Options purchased by the Grantee and held by the Grantee or by the Trustee, as the case may be, the Grantee shall be entitled to receive dividends in accordance with the quantity of such Shares, subject to the provisions of the Company's Articles of Association (and all amendments thereto) and subject to any applicable taxation on distribution of dividends.

10. PURCHASE FOR INVESTMENT

The Company's obligation to issue or allocate Shares upon exercise of an Option granted under the Scheme is expressly conditioned upon:

- (i) the Company's completion of any registration or other qualifications of such Shares under all applicable laws, rules and regulations, or;
- (ii) representations and undertakings by the Grantee (or his legal representative, heir or legatee, in the event of the Grantee's death) to assure that the sale of the Shares complies with any registration exemption requirements which the Company in its sole discretion shall deem necessary or advisable.

Such required representations and undertakings may include representations and agreements that such Grantee (or his legal representative, heir, or legatee):

- (i) is purchasing such Shares for investment and not with any present intention of selling or otherwise disposing thereof; and;
- (ii) agrees to have placed upon the face and reverse of any certificates evidencing such Shares a legend setting forth (a) any representations and undertakings which such Grantee has given to the Company or a reference thereto, and (b) that, prior to effecting any sale or other disposition of any such Shares, the Grantee must furnish to the Company an opinion of counsel, satisfactory to the Company, that such sale or disposition will not violate the applicable laws, rules and regulations of the United States or any other state having jurisdiction over the Company and the Grantee.

11. RESTRICTIONS ON ASSIGNABILITY AND SALE OF OPTIONS

No Option or any right with respect thereto, purchasable hereunder, whether fully paid or not, shall be assignable, transferable or given as collateral or any right with respect to it given to any third party whatsoever, other than by will or by laws of decent and distribution, or as specifically otherwise allowed under the Scheme, except as specifically allowed under the Scheme, and during the lifetime of the Grantee each and all of such Grantee's rights to purchase Shares hereunder shall be exercisable only by the Grantee.

Any such action made directly or indirectly, for an immediate validation or for a future one, shall be void.

12. EFFECTIVE DATE, DURATION, AMENDMENTS OR TERMINATION OF THE SCHEME

- 12.1 The Scheme shall be effective as of the day it was adopted by the Board and shall terminate at the end of ten (10) years from such day of adoption (the: “**Termination Date**”).
- 12.2 The Company shall obtain the approval of the Company’s shareholders for the adoption of this Scheme and/or the Annexes thereto, or for any amendment to this Scheme and/or the Annexes thereto, if shareholders’ approval is required under any applicable law including without limitation the U.S. securities law or the securities laws of other jurisdiction applicable to Options granted to Grantees under this Scheme and/or the Annexes thereto, or if shareholders’ approval is required by any authority or by any governmental agencies or national securities exchanges including without limitation the U.S. Securities and Exchange Commission.
- 12.3 The Board may at any time, subject to the provisions of Section 12.2 above and all applicable law, amend, alter, suspend or terminate the Scheme, provided, however, that
- (i) the Board may not extend the term of the Scheme specified in Section 12.1 above and;
 - (ii) no amendment, alteration, suspension or termination of the Scheme shall impair the rights of any Grantee, unless mutually agreed otherwise by the Grantee and the Company, which agreement must be in writing and signed by the Grantee and the Company.

Earlier termination of the Scheme prior to the Termination Date shall not affect the Board’s ability to exercise the powers granted to it hereunder with respect to Options granted under the Scheme prior to the date of such earlier termination.

13. SHAREHOLDERS RIGHTS AND VOTING RIGHTS

- 13.1 **Rights as Shareholder:** Unless stated otherwise in the Scheme, the Grantee shall not have any rights as a shareholder in relation to Options granted to him under this Scheme, and that is until the registration of the Grantee, or the Trustee on behalf of the Grantee, as a shareholder in the register of shareholders of the Company.
- 13.2 **Voting Rights:** As long as the exercised Shares are held by the Trustee for the benefit of Grantee, the Grantee is entitled to vote with respect of the exercised Shares. The company will send notices of general meetings of the Company to the Trustee, and the Trustee shall transfer such notices to the Grantee. Grantee wishing to attend general meetings of the Company or to exercise his right to vote in respect to the exercised shares held on his behalf by the Trustee, the Grantee shall approach the Trustee in writing at least four days prior to the meeting, and the Trustee shall transfer to the Grantee the power of attorney to attend the general meeting and to vote in respect of the exercised Shares held for the benefit of the Grantee with the Trustee, all- subject to the mechanism established by the Company to all its shareholders.

14. GOVERNMENT REGULATIONS

The Scheme, and the granting and exercise of Options hereunder, and the obligation of the Company to sell and deliver Shares under such Options, shall be subject to all applicable laws, rules, and regulations, whether of the State of Israel or of the United States or any other State having jurisdiction over the Company and the Grantee, including the registration of the Shares under the United States Securities Act of 1933, and the Ordinance and to such approvals by any governmental agencies or national securities exchanges as may be required. Nothing herein shall be deemed to require the Company to register the Shares under the securities laws of any jurisdiction.

15. CONTINUANCE OF EMPLOYMENT OR HIRED SERVICES

Neither the Scheme nor the Grant Notification Letter with the Grantee shall impose any obligation on the Company or an Affiliate thereof, to continue any Grantee in its employ or service, and nothing in the Scheme or in any Option granted pursuant thereto shall confer upon any Grantee any right to continue in the employ or service of the Company or an Affiliate thereof or restrict the right of the Company or an Affiliate thereof to terminate such employment or service at any time.

16. GOVERNING LAW & JURISDICTION

The Scheme shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts of Tel-Aviv, Israel shall have sole Jurisdiction in any matters pertaining to the Scheme.

17. TAX CONSEQUENCES

17.1 Any tax consequences to any Grantee arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other event or act (of the Company and/or its affiliates, or the Grantee) hereunder shall be borne solely by the Grantee. The Company and/or its affiliates shall withhold taxes according to the requirements under the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Grantee shall agree to indemnify the Company and/or its affiliates and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Grantee.

17.2 The Company shall not be required to release any Share certificate to a Grantee until all required payments have been fully made.

18. NON-EXCLUSIVITY OF THE SCHEME

The adoption of the Scheme by the Board shall not be construed as amending, modifying or rescinding any previously approved incentive arrangements or as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including, without limitation, the granting of Options otherwise than under the Scheme, and such arrangements may be either applicable generally or only in specific cases.

For the avoidance of doubt, prior grant of options to Grantees of the Company under their employment agreements, and not in the framework of any previous option scheme, shall not be deemed an approved incentive arrangement for the purpose of this Section.

19. MULTIPLE AGREEMENTS

The terms of each Option may differ from other Options granted under the Scheme at the same time, or at any other time. The Board may also grant more than one Option to a given Grantee during the term of the Scheme, either in addition to, or in substitution for, one or more Options previously granted to that Grantee.

20. RULES PARTICULAR TO SPECIFIC COUNTRIES

Notwithstanding anything herein to the contrary, the terms and conditions of the Scheme may be adjusted with respect to a particular country by means of an addendum to the Scheme in the form of an annex (the: “**Annex**”), and to the extent that the terms and conditions set forth in the Annex conflict with any provisions of the Scheme, the provisions of the Annex shall govern. Terms and conditions set forth in the Annex shall apply only to Options issued to Grantees under the jurisdiction of the specific country that is subject of the Annex and shall not apply to Options issued to any other Grantee. The adoption of any such Annex shall be subject to the approval of the Board and if required the approval of the shareholders of the Company.

CELLECT BIOMED LTD.

ANNEX A – ISRAEL
TO THE 2014 GLOBAL INCENTIVE OPTION SCHEME

DEFINITIONS

For purposes of this Annex and the Grant Notification Letter, the following definitions shall apply:

- (a) **“Affiliate”** - any “employing company” within the meaning of Section 102(a) of the Ordinance.
- (b) **“Approved 102 Option”** - an Option granted pursuant to Section 102(b) of the Ordinance and held in trust by a Trustee for the benefit of the Grantee.
- (c) **“Capital Gain Option (CGO)”** - an Approved 102 Option elected and designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance.
- (d) **“Controlling Shareholder”** - shall have the meaning ascribed to it in Section 32(9) of the Ordinance,
- (e) **“Employee”** - a person who is employed by the Company or its Affiliates, including an individual who is serving as a director or an office holder, but excluding any Controlling Shareholder, all as determined in Section 102 of the Ordinance.
- (f) **“ITA”** - the Israeli Tax Authorities.
- (g) **“Non-Employee”** - a consultant, adviser, service provider, Controlling Shareholder or any other person who is not an Employee.
- (h) **“Ordinary Income Option (OIO)”** - an Approved 102 Option elected and designated by the Company to qualify under the ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) of the Ordinance.
- (i) **“102 Option”** - any Option granted to Employees pursuant to Section 102 of the Ordinance.
- (j) **“3(i) Option”** - all Option granted pursuant to Section 3(i) of the Ordinance to any person who is a Non-Employee.
- (k) **“Ordinance”** - the Israeli Income Tax Ordinance [New Version] 1961 as now in effect or as hereafter amended.
- (l) **“Section 102”** - Section 102 of the Ordinance and any regulations, rules, orders or procedures promulgated thereunder as now in effect or as hereafter amended.
- (m) **“Trustee”** - any individual or entity appointed by the Company to serve as a trustee and approved by the ITA, all in accordance with the provisions of Section 102(a) of the Ordinance.

(n) **“Unapproved 102 Option”** - an Option granted pursuant to Section 102(c) of the Ordinance and not held in trust by a Trustee.

For the avoidance of any doubt, it is hereby clarified that any capitalized terms not specifically defined in this Annex shall be construed according to the interpretation given to it in the Scheme.

ANNEX A - ISRAEL

1. GENERAL

- 1.1 This Annex (the: “**Annex**”) shall apply only to Grantees who are residents of the state of Israel at the Date of Grant or those who are deemed to be residents of the state of Israel for the payment of tax at the Date of Grant. The provisions specified hereunder shall form an integral part of the 2014 Global Incentive Option Scheme of Collect Riot/led Ltd. (hereinafter: the “**Scheme**”), which applies to the issuance of options to purchase Shares of Collect Biomed Ltd. (hereinafter: the “**Company**”). According to the Scheme, options to purchase the Company’s Shares may be issued to employees, directors, consultants and service provides of the Company or its affiliates.
- 1.2 This Annex is effective with respect to Options granted following Amendment no. 132 of the Ordinance, which entered into force on January 1, 2003.
- 1.3 This Annex is to be read as a continuation of the Scheme and only modifies options granted to Israeli Grantees so that they comply with the requirements set by the Israeli law in general, and in particular with the provisions of Section 102 (as specified herein), as may be amended or replaced from time to time. For the avoidance of doubt, this Annex does not add to or modify the Scheme in respect of any other category of Grantees.
- 1.4 The Scheme and this Annex are complimentary to each other and shall be deemed as one. In any case of contradiction, whether explicit or implied, between the provisions of this Annex and the Scheme, the provisions set out in the Annex shall prevail.

2. ISSUANCE OF OPTIONS

- 2.1 The persons eligible for participation in the Scheme as Grantees shall include any Employees and/or Non-Employees of the Company or of any Affiliate; provided, however, that (i) Employees may only be granted 102 Options; and (ii) Non-Employees and/or Controlling Shareholders may only be granted 3(i) Options.
- 2.2 The Company may designate Options granted to Employees pursuant to Section 102 as Unapproved 102 Options or Approved 102 Options.
- 2.3 The grant of Approved 102 Options shall be made tinder this Annex adopted by the Board, and shall be conditioned upon the approval of this Annex by the ITA.
- 2.4 Approved 102 Options may either be classified as Capital Gain Options (“**CGOs**”) or Ordinary income Options (“**OIOs**”).

- 2.5 No Approved 102 Options may be granted under this Annex to any eligible Employee, unless and until, the Company's election of the type of Approved 102 Options as CGO or 010 granted to Employees (the: "**Election**"), is appropriately filed with the ITA. Such Election shall become effective beginning the first date of grant of an Approved 102 Option under this Annex and shall remain in effect at least until the end of the year following the year during which the Company first granted Approved 102 Options. The Election shall obligate the Company to grant only the type of Approved 102 Option it has elected, and shall apply to all Grantees who were granted Approved 102 Options during the period indicated herein, all in accordance with the provisions of Section 102(g) of the Ordinance. For the avoidance of doubt, such Election shall not prevent the Company from granting Unapproved 102 Options simultaneously.
- 2.6 All Approved 102 Options must be held in trust by a Trustee, as described in Section 3 below.
- 2.7 For the avoidance of doubt, the designation of Unapproved 102 Options and Approved 102 Options shall be subject to the terms and conditions set forth in Section 102.
- 2.8 Implementation of the mechanisms set out in Sections 2.4 and 5.2(ii) of the Scheme shall require the obtaining of a tax ruling from ITA.

3. TRUSTEE

- 3.1 Approved 102 Options which shall be granted under this Annex and/or any Shares allocated or issued upon exercise of such Approved 102 Options and/or other shares received subsequently following any realization of rights, including without limitation bonus shares, shall be allocated or issued to the Trustee and held for the benefit of the Grantees for such period of time as required by Section 102 or any regulations, rules or orders or procedures promulgated thereunder (the: "**Holding Period**"). In the case the requirements for Approved 102 Options are not met, the Approved 102 Options may be regarded as Unapproved 102 Options, all in accordance with the provisions of Section 102.
- 3.2 Notwithstanding anything to the contrary, the Trustee shall not release any Shares allocated or issued upon exercise of Approved 102 Options prior to the full payment of the Grantee's tax liabilities arising from Approved 102 Options which were granted to him and/or any Shares allocated or issued upon exercise of such Options.
- 3.3 With respect to any Approved 102 Option, subject to the provisions of Section 102 and any rules or regulation or orders or procedures promulgated thereunder, a Grantee shall not sell or release from trust any Share received upon the exercise of an Approved 102 Option and/or any share received subsequently following any realization of rights, including without limitation, bonus shares, until the lapse of the Holding Period required under Section 102 of the Ordinance. Notwithstanding the above, if any such sale or release occurs during the Holding Period, the sanctions under Section 102 of the Ordinance and under any rules or regulation or orders or procedures promulgated thereunder shall apply to and shall be borne by such Grantee.

- 3.4 Upon receipt of Approved 102 Option, the Grantee will sign an undertaking in which he or she will give his or her consent to the grant of the Option under Section 102, and will undertake to comply with the terms of Section 102 and the trust agreement between the Company and the Trustee.

4. THE OPTIONS

The terms and conditions, upon which the Options shall be issued and exercised, shall be as specified in the Grant Notification Letter to be executed pursuant to the Scheme and to this Annex. Each Grant Notification Letter shall state, inter alia, the number of Shares to which the Option relates, the type of Option granted thereunder (whether a CGO, OIO, Unapproved 102 Option or a 3(i) Option), the vesting provisions and the Purchase Price.

5. FAIR MARKET VALUE

Without derogating from the definition of “**Fair Market Value**” enclosed in the Scheme and solely for the purpose of determining the tax liability pursuant to Section 102(b)(3) of the Ordinance, if at the date of grant the Company’s shares are listed on any established stock exchange or a national market system or if the Company’s shares will be registered for trading within ninety (90) days following the date of grant of the CGOs, the fair market value of the Shares at the date of grant shall be determined in accordance with the average value of the Company’s shares on the thirty (30) trading days preceding the date of grant or on the thirty (30) trading days following the date of registration for trading, as the case may be.

6. EXERCISE OF OPTIONS

- 6.1 Options shall be exercised by the Grantee by giving a written notice to the Company and/or to any third party designated by the Company (the: “**Representative**”), in such form and method as may be determined by the Company and, when applicable, by the Trustee, in accordance with the requirements of Section 102, which exercise shall be effective upon receipt of such notice by the Company and/or the Representative and the payment of the Purchase Price for the number of Shares with respect to which the option is being exercised, at the Company’s or the Representative’s principal office. The notice shall specify the number of Shares with respect to which the option is being exercised.
- 6.2 Without derogating from Section 4.2 of the Scheme, and in addition thereto, with respect to Approved 102 Options, any shares of Common Stock allocated or issued upon the exercise of an Approved 102 Option, shall be voted in accordance with the provisions of Section 102 and any rules, regulations or orders promulgated thereunder.

7. ASSIGNABILITY AND SALE OF OPTIONS

7.1 Notwithstanding any other provision of the Scheme, no Option or any right with respect thereto, purchasable hereunder, whether fully paid or not, shall be assignable, transferable or given as collateral or any right with respect to them given to any third party whatsoever, and during the lifetime of the Grantee each and all of such Grantee's rights to purchase Shares hereunder shall be exercisable only by the Grantee.

Any such action made directly or indirectly, for an immediate validation or for a future one, shall be void.

7.2 As long as Options or Shares purchased pursuant to thereto are held by the Trustee on behalf of the Grantee, all rights of the Grantee over the shares are personal, can not be transferred, assigned, pledged or mortgaged, other than by will or laws of descent and distribution.

8. INTEGRATION OF SECTION 102 AND TAX ASSESSING OFFICER'S PERMIT

8.1 With regards to Approved 102 Options, the provisions of the Scheme and/or the Annex and/or the Grant Notification Letter shall be subject to the provisions of Section 102 and the Tax Assessing Officer's permit, and the said provisions and permit shall be deemed an integral part of the Scheme and of the Annex and of the Grant Notification Letter.

8.2 Any provision of Section 102 and/or the said permit which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified in the Scheme or the Annex or the Grant Notification Letter, shall be considered binding upon the Company and the Grantees.

9. DIVIDEND

Subject to the Company's Articles of Association, with respect to all Shares (but excluding, for avoidance of any doubt, any unexercised options) allocated or issued upon the exercise of Options and held by the Grantee or by the Trustee as the case may be, the Grantee shall be entitled to receive dividends in accordance with the quantity of such shares, and subject to any applicable taxation on distribution of dividends, and when applicable subject to the provisions of Section 102 and the rules, regulations or orders promulgated thereunder.

10. TAX CONSEQUENCES

10.1 Any tax consequences arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other event or act (of the Company, and/or its Affiliates, and the Trustee or the Grantee), hereunder, shall be borne solely by the Grantee. The Company and/or its Affiliates, and/or the Trustee shall withhold taxes according to the requirements under the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Grantee shall agree to indemnify the Company and/or its Affiliates and/or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Grantee.

- 10.2 The Company and/or, when applicable, the Trustee shall not be required to release any share certificate to a Grantee until all required payments have been fully made.
- 10.3 With respect to Unapproved 102 Option, if the Grantee ceases to be employed by the Company or any Affiliate. The Grantee shall extend to the Company and/or its Affiliate a security or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102 and the rules, regulation or orders promulgated thereunder.

11. GOVERNING LAW & JURISDICTION

This Annex shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts of Tel-Aviv, Israel shall have sole jurisdiction in any matters pertaining to this Annex.

JOINT PRODUCT DEVELOPMENT AGREEMENT

THIS JOINT PRODUCT DEVELOPMENT AGREEMENT (“Agreement”), effective as of the 17th day of June, 2015 (“Effective Date”), is made and entered into by and between **CELLECT BIOMED LTD.**, an Israeli corporation with its principal office located at 10 Hataas Street, Kfar Saba, Israel (“*Cellect*”), and **ENTEGRIS, INC.**, a Delaware corporation with its principal office located at 129 Concord Road Billerica, MA 01821 (“*Entegris*”). Each of Cellect and Entegris are sometimes hereinafter referred to as a “*Party*” and collectively as the “*Parties*”.

Recitals

- A. Cellect has expertise in developing products that facilitate functional allocation, selection, and use of stem cells.
- B. Entegris has expertise in developing packaging solutions for a variety of industries, including the pharmaceutical industry.
- C. Cellect and Entegris have signed a Letter of Intent dated _____ (the “*LOI*”) to perform a preliminary analysis to focus on selection of a polymer film that ultimately will be used in a medical device.
- D. Cellect and Entegris now wish to collaborate in a joint development program (“*Program*”) for development of a medical device and the Parties wish to document the requirements, deliverables and remaining milestones for accomplishing the Program objectives with respect to such medical device, on the terms and subject to the conditions set forth herein.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties intending to be legally bound hereby agree as follows:

Agreement

1. **DEFINITIONS.** As used in this Agreement, the following capitalized terms shall have the following meanings:

1.1 “*Affiliate*” means, with respect to a Party, any person or entity that controls, is controlled by, or is under common control with such Party, where “control” means the possession, directly or indirectly, through one or more intermediaries, of the power to direct or cause the direction of the management or policies of a person or entity, whether by ownership, agreement, or otherwise. For purposes of this definition, a person shall be deemed to “control” any Party if it owns or controls a sufficient interest in the voting equity (or other comparable ownership if the Party is not a corporation) such that it can direct, order or control the actions of such Party and the ownership of 50% or more of the voting equity (or other comparable ownership if the Party is not a corporation) shall be conclusive evidence of control.

1.2 “*Background Intellectual Property*” or “*BIP*” means, with respect to a Party, any IP that is (i) pre-existing IP that is owned or controlled by such Party as of the date of this Agreement, (ii) created, conceived or first reduced to practice by such Party alone or in conjunction with any third party (i.e., any party other than the other Party), without inventive contribution from the other Party, or (iii) created, conceived or first reduced to practice by such Party other than in the course of the work performed under this Agreement.

1.3 “*Change in Control*” means, with respect to a Party, the occurrence of either one of the following events: (i) any one person, entity or more than one person or entity acting as a group, in each case, acquires an ownership interest in such Party that, together with the ownership interest already owned, directly or indirectly, by such person, entity or group, constitutes more than fifty percent (50%) of the total fair market value or total voting power of all of the outstanding shares, units of ownership or equity interests of such Party; or (ii) the sale, transfer or exchange of substantially all of the assets of a Party to any one person, entity or more than one person or entity acting as a group within any twelve (12) month period ending on the date of the most recent acquisition of such Party assets by such person, entity or group.

1.4 “*Deliverables*” means the specific work product defined in a Statement of Work.

1.5 “*Foreground IP*” means all Intellectual Property created, conceived or first reduced to practice during the course or as a result of the work performed under the Program, including without limitation all such Foreground IP embodied at any time in any Product and all improvements, enhancements or modifications made to a Product which are regarded as IP.

1.6 “*Intellectual Property*” or “*IP*” means all intellectual property rights throughout the world, whether existing now or in the future, including without limitation: (i) all patent rights and other rights in useful inventions and ornamental designs; (ii) all copyrights and other rights in works of authorship, software, mask works, databases, compilations, and collections of information; (iii) all rights in know-how and trade secrets, but excluding (iv) all rights in trademarks, service marks, and other proprietary trade designations.

1.7 “*Mutual Confidentiality Agreement*” means that certain Non-Disclosure Agreement dated as of October 29, 2013 between Collect and Entegris.

1.8 “*Product*” means a medical device for the treatment of disease which is anticipated to utilize selective apoptosis of mature cells and that is developed under the Program.

1.9 “*Specifications*” means the functional specifications in the form attached to the applicable SOW, as such specifications may be amended from time to time as herein provided.

1.10 “*Territory*” means North America (USA and Canada).

2. **JOINT DEVELOPMENT PROGRAM.**

2.1 **Statement of Work.** The Parties mutually agree pursuant to this Agreement to complete one or more Statements of Work (“*Statement of Work*” or “*SOW*”) in the form attached hereto as Exhibit A. Each SOW shall set forth the terms for undertaking the applicable project phase of the Program, including the scope and objectives, estimated timetable, key activities and work streams, responsibilities of each Party, Milestones and Deliverables, and the cost and time estimates for each Milestone. Each SOW, when signed by both Parties, shall automatically, without any further action by the Parties be deemed to be incorporated herein by reference and be made a part of this Agreement. Neither Party shall have any obligation to commence work on any project phase of the Program unless and until the Parties have completed and executed a corresponding SOW. With respect to each SOW that is entered into, Collect and Entegris shall use reasonable commercial efforts to perform their respective tasks and responsibilities in accordance with this Agreement.

2.2 **Fees and Expenses.** Except as otherwise expressly provided herein or in the applicable SOW, Entegris will bear all costs related to the development, design, engineering, and manufacture of polymer systems which enable attachment of the active chemistry to enable the Product. Except as otherwise expressly provided herein or in the applicable SOW, Collect will bear all remaining costs related to the pre-clinical development of the Product including the testing of the biological activity of the products through the development stages.

2.3 **Technical Representative.** Each Party shall designate a single technical representative for the purpose of this Agreement (the “*Technical Representative*”). The Technical Representative shall act as the main contact person and project administrator for his/her respective Party, responsible for overseeing and directing the execution of each project phase and monitoring overall progress toward achievement of project objectives. Either Party may appoint a different Technical Representative by providing written notice to the other Party. The initial Technical Representatives shall be:

- (a) Collect Technical Representative: [Tal Almog]
Office phone: +972 9 9741 444
Mobile phone: +972 54 318 7538
E-mail: tal@cellectbio.com

- (b) Entegris Technical Representative: [Eric Isberg]
Office phone: +1 952 556 1817
Mobile phone: +1 612 910 7918
E-mail: eric_isberg@entegris.com

In the event that during the course of performing a SOW either Party believes that the SOW, as written, needs to be modified as a result of a change in scope, Specifications, or performance objectives, the Parties shall negotiate reasonable modifications to the SOW, including, for example, changes in the estimated time and/or development costs. A modification to the SOW shall only be effective if it is in writing and signed by both Parties.

2.4 Cooperation. During the performance of the development work hereunder, each Party shall cooperate and proactively provide the other Party with such technical information as the providing Party may deem to be necessary for the other Party's performance of its responsibilities under this Agreement and each SOW, subject to Section 5 (Confidentiality) hereof; and provided, however that the other Party shall be excused in meeting any Milestones under the applicable SOW based on any delay attributable to the providing Party's failure or delay in providing such technical information. Each of the Parties agrees to make available its facilities and equipment, subject to Section 5 (Confidentiality) hereof, as reasonably necessary for the performance of the work in accordance with each SOW.

2.5 Review of Deliverables. At such time as a Party believes it has completed a milestone set forth in the SOW (each, a "Milestone"), such Party will deliver to the receiving Party the corresponding Deliverable under the SOW. As soon as reasonably possible after receiving each Deliverable from such Party, the receiving Party shall promptly review and evaluate such Deliverable to determine whether it meets the applicable requirements in the SOW (the "Deliverable Requirements"). If the receiving Party believes that the Deliverable does not comply in all material respects with the applicable Deliverable Requirements, the receiving Party shall promptly notify the delivering Party in writing of such objection (each, an "Objection Notice") describing in reasonable detail the reasons therefore, and the delivering Party shall attempt to modify the Deliverable so as to comply with the applicable Deliverable Requirements. If the receiving Party fails to deliver an Objection Notice to the delivering Party within ten (10) days after receiving the Deliverable, then the receiving Party shall be deemed to have approved such Deliverable.

2.6 Production of the Product. Following the successful development of the Product under the Program, the Parties shall perform economic and feasibility tests in order to examine, in good faith, possible manufacture of the Product by Entegris, and following such tests, enter into good faith negotiations for the exclusive manufacturing of the Product by Entegris.

3. **INTELLECTUAL PROPERTY.**

3.1 Ownership and Control of Background IP.

- (a) Notwithstanding anything herein to the contrary, (i) Collect shall continue to exclusively own and retain all right, title and interest in and to, and to control, all Collect BIP, without the need to account to or obtain consent from Entegris, including but not limited to the right and sole discretion of using patent counsel of its choice to (x) prepare, file, prosecute, and maintain throughout the world patent, copyright, trade secret and/or other protection for Collect BIP, (y) retain, license, sell, or otherwise dispose of or exploit Collect BIP, and (z) enforce or defend any rights in Collect BIP; and (ii) Entegris shall continue to exclusively own and retain all right, title and interest in and to, and to control, all Entegris BIP, without the need to account to or obtain consent from Collect, including but not limited to the right and sole discretion of using patent counsel of its choice to (xx) prepare, file, prosecute, and/or maintain throughout the world patent, copyright, trade secret or other protection for Entegris BIP, (w) retain, license, sell, or otherwise dispose of or exploit Entegris BIP, and (zz) enforce or defend any rights in Entegris BIP.

- (b) Each Party agrees to grant and does hereby grant to the other Party during the term of this Agreement, solely for development in accordance with the Program and not for commercial purposes, a non-exclusive, nontransferable, royalty-free license to use its respective BIP for the sole purpose of enabling, and only to the extent necessary to enable, the other Party to perform its responsibilities under each Statement of Work. The foregoing licenses shall terminate automatically upon the termination or expiration of the applicable SOW or this Agreement. Except as expressly provided in this Section 3.1(b), neither Party acquires any rights nor licenses, express or implied, under the BIP of the other Party.

3.2 Ownership and Control of Foreground IP. Regardless of inventorship, the Parties mutually agree to jointly own all Foreground IP developed under the Program. Except as otherwise provided in this Section 3.2, the Parties shall mutually agree on all decisions relating to the prosecution, maintenance, defense and enforcement of Foreground IP.

- (a) The Parties shall consult with each other regarding whether an application or applications for patent or other IP rights should be filed, prosecuted, and/or maintained for any Foreground IP. If both Parties wish to take part in such applications, the applications shall be prepared and prosecuted by a mutually acceptable patent attorney and the legal fees, costs and expenses of preparation, prosecution and maintenance shall be shared equally between the Parties. If either Party elects not to participate in the preparation, filing, prosecution, and/or maintenance of an application and any resulting patents by contributing half of such legal fees, costs and expenses (the “*Non-Prosecuting Party*”), the other Party (the “*Prosecuting Party*”) shall have the right (but not the obligation) to prosecute, file and maintain such application and any resulting patents using counsel of its choice and shall control the process at its own expense and sole discretion and in the name of the Non-Prosecuting Party, and the ownership and the rights of the Parties in such application or patent shall remain unchanged. However, if the Non-Prosecuting Party elects not to participate in any country in the world, then the Non-Prosecuting Party shall assign its rights to the patent or patent application, as the case may be, to the Prosecuting Party. The Non-Prosecuting Party, though not actively participating in the process, shall provide all information and assistance reasonably requested by the Prosecuting Party in connection with the preparation, filing, prosecution and maintenance of such application and any resulting patents. Regardless of the participation of either Party, each Party shall be afforded the right to review all patent applications being prepared to ensure that no Confidential Information of that Party has been included in such patent applications. If Confidential Information of a Party has been revealed within any patent application, the Party owning such Confidential Information shall have the right to prohibit filing of such patent application until such Confidential Information is removed.

- (b) In the event that any Foreground IP is infringed or misappropriated by a third party or is subject to a declaratory judgment action, or is the subject of an interference, derivation, re-examination, reissue, post-grant review, inter parties review, or opposition proceeding, the Party becoming aware thereof shall promptly notify the other Party. The Parties shall consult with each other and if both Parties wish to take part in the enforcement of such Foreground IP or the defense of any the foregoing claims or actions, the Parties shall engage a mutually acceptable patent attorney for that purpose. The Parties shall cooperate in good faith with respect to the defense or enforcement of Foreground IP, including voluntarily joining as a party to such suit or defense where necessary or desirable. The costs of the foregoing proceedings shall be paid first with any amounts recovered, with the remaining costs being shared equally by the Parties, unless otherwise agreed by the Parties in writing. In the event that a Party elects not to take part in the defense or enforcement, as applicable, of the Foreground IP, the other Party shall have the right (but not the obligation) to enforce or defend, as the case may be, the Foreground IP at the enforcing Party's sole expense using counsel of its choice, including sole control over all litigation and settlement discussions and shall be entitled to all damages awarded and other payment received in connection therewith. In that case, the non-enforcing Party shall cooperate in good faith and provide all information and assistance reasonably requested by the enforcing Party in connection with the defense or enforcement action or proceeding, at the enforcing Party's sole expense. Upon the enforcing Party's request, the non-enforcing Party shall voluntarily join as a party to such suit or defense where necessary or desirable, unless the non-enforcing Party has a reasonable business justification for not cooperating (e.g., the alleged infringer is a customer or competitor of such Party).
- (c) Each Party agrees to grant and does hereby grant to the other Party, a non-exclusive, transferable, royalty-free license to use its respective rights under the Foreground BIP for the sole purpose of enabling, and only to the extent necessary to enable, the other Party to develop, sell, market, manufacture or otherwise commercialize the Product developed under the Program. Except as expressly provided in this Section 3.1(c), neither Party acquires any rights nor licenses, express or implied, under the Foreground BIP of the other Party.

4. **TERM AND TERMINATION.**

4.1 **Term.** Unless earlier terminated in accordance with the provisions hereof, the term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years (the “*Initial Term*”), and thereafter, shall automatically renew on a yearly basis (each, a “*Renewal Term*”). The Initial Term and any Renewal Terms are referred to collectively as the “*Term*”.

4.2 **Termination for Cause.** A Party may terminate this Agreement and/or any or all SOW’s upon written notice to the other Party if the other Party materially breaches this Agreement and/or the SOW and fails to cure such breach within thirty (30) days after receiving written notice of the breach from the non-breaching Party, provided that with respect to monetary breaches, the cure period shall be ten (10) days. Any such notice of breach shall describe the breach in reasonable detail as well as the steps reasonably requested to be taken to cure such breach, if curable.

4.3 **Termination Upon Bankruptcy or Insolvency.** Either Party may terminate this Agreement and/or any or all of the SOW’s immediately upon written notice to the other Party if the Other Party becomes unable to pay its debts in the ordinary course as they become due, becomes or is declared insolvent, makes a general assignment for the benefit of creditors, suffers a receiver to be appointed for it, enters into an agreement for the composition, extension, or readjustment of all or substantially all of its obligations, files a voluntary petition in bankruptcy, or has an involuntary petition in bankruptcy filed against it, which petition is not dismissed with prejudice within sixty (60) days after the filing thereof.

4.4 **Effects of Termination.** Upon the expiration or termination of this Agreement for any reason, (a) all amounts not disputed in good faith that are owed by terminating Party to the other Party under a Statement of Work which accrued before such expiration or termination will be immediately due and payable, and (b) each Party shall return or destroy, as requested, the other Party’s Confidential Information in accordance with the provisions of Section 5.6.

4.5 **Survival.** Sections 1 (Definitions), 2.6 (Consideration), 3 (Intellectual Property), 4 (Term and Termination), 5 (Confidentiality), 6 (Limitations on Liability) and 7.1 (Default) and any provisions of an SOW which by their terms or nature are intended or expressly stated to survive the expiration or termination of this Agreement and/or the SOW shall survive the expiration or termination of this Agreement and/or the SOW for any reason, and shall bind the parties, their successors and permitted assigns.

5. **CONFIDENTIALITY.**

5.1 **Confidential Information.** Subject to the exceptions set forth in Section 5.2 for purposes of this Agreement, the “Confidential Information” of a Party (“*Disclosing Party*”) shall mean any and all information and materials of such Party disclosed to or accessed, received or observed by the other Party (“*Receiving Party*”) in connection with this Agreement, including without limitation all business, financial, technical, sales and marketing information, all contracts, financial statements, business plans and assets, all trade secrets, know-how, ideas, and inventions (whether or not patentable), all customer and employee information, including customer lists, and all other information that a reasonable person familiar with Disclosing Party’s business and industry would consider confidential or proprietary under the circumstances, in each case regardless of whether received from Disclosing Party, its Affiliates, or any other source, whether in oral, written, visual, electronic or other form, and regardless of whether marked or identified as “confidential” or “proprietary” at the time of disclosure.

5.2 **Exceptions.** Any particular item of information shall not be considered Confidential Information for purposes of this Agreement at such time, and to the extent, such information: (i) was known to Receiving Party prior to any disclosure by or on behalf of Disclosing Party, as evidenced by documents predating the time of disclosure; (ii) is rightfully acquired by Receiving Party on a non-confidential basis from a third party that is legally entitled to disclose such information; (iii) is independently developed by Receiving Party, without reference to or reliance on the Confidential Information of Disclosing Party; or (iv) is or becomes generally available to the public through no wrongful act or fault of Receiving Party. For purposes of this Agreement, the Confidential Information of Disclosing Party shall not be deemed generally available to the public merely because it may be embraced by more general disclosures, or may be derived from combinations of disclosures that are in the public domain, but nonetheless shall be deemed confidential if collected and combined in a form which is not generally available to the public.

5.3 **Restrictions on Disclosure and Use.** Receiving Party shall at all times during the Term of this Agreement and for a period of five (5) years thereafter (or in the case of trade secrets, the longer of 5 years or for so long as such Confidential information constitutes a trade secret under applicable law) hold the Confidential Information of Disclosing Party in trust and in confidence, and shall protect such Confidential Information with at least the same degree of care, but no less than reasonable care, which Receiving Party uses to protect its own Confidential Information of a similar nature. Except as expressly authorized in writing by the other Party, neither Party shall access, use or disclose any Confidential Information of the other Party for any purpose whatsoever, whether for its own benefit or the benefit of any third party, other than for the limited purpose of exercising its rights and performing its obligations under this Agreement.

5.4 **Permitted Disclosures.** Except as expressly authorized in writing by Disclosing Party, or for the agreed-to purpose and in the course of pursuing, maintaining or enforcing Foreground IP in accordance with Section 3, Receiving Party shall not disclose or otherwise reveal any Confidential Information of Disclosing Party to any person or entity other than its directors, officers, employees, agents, subcontractors, Affiliates, auditors and financial and legal advisers having a need to know the Confidential Information and, in each case, who are under a duty of confidentiality and nondisclosure with respect to such Confidential Information consistent with the provisions of this Section 5. Each Party will ensure that any of its directors, officers, employees, agents, Affiliates, auditors and financial and legal advisers who have access to any Confidential Information of the other Party received under this Agreement are aware of, understand, and abide by this Agreement.

5.5 Legally Required Disclosures. If Receiving Party is requested to disclose any Confidential Information of Disclosing Party under applicable law or in any judicial or administrative proceeding, then, except as otherwise required to comply with applicable law, Receiving Party shall promptly notify Disclosing Party of such request, describing in reasonable detail the Confidential Information to be disclosed, so that Disclosing Party may resist such disclosure or seek an appropriate protective order, and shall provide all information and assistance reasonably requested by Disclosing Party in connection therewith. If Receiving Party is nonetheless compelled to disclose any Confidential Information of Disclosing Party, Receiving Party shall limit its disclosure to that which is required under applicable law or by the relevant judicial or administrative body.

5.6 Return or Destruction. Upon the expiration or termination of this Agreement for any reason, or Disclosing Party's earlier demand, Receiving Party shall, at the election of Disclosing Party, promptly return or destroy all Confidential Information of Disclosing Party (including copies and summaries thereof), and upon Disclosing Party's request, promptly certify to Disclosing Party that it has purged its records and files of and no longer has access to such Confidential Information. Receiving Party's confidentiality obligations under this Agreement, and rights and remedies related thereto, shall survive the expiration or termination of this Agreement for any reason.

6. **LIMITATIONS ON LIABILITY.** IN NO EVENT SHALL EITHER PARTY OR ITS AFFILIATES BE LIABLE FOR ANY INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, SPECIAL, INDIRECT, OR SIMILAR DAMAGES (INCLUDING LOST REVENUE OR PROFITS) ARISING OUT OF OR RELATED TO THIS AGREEMENT. THE LIMITATIONS ON LIABILITY IN THIS SECTION SHALL APPLY TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, REGARDLESS OF THE CAUSE OF ACTION OR BASIS OF LIABILITY (WHETHER IN CONTRACT, TORT, OR OTHERWISE). THESE LIMITATIONS ON LIABILITY ARE AN ESSENTIAL PART OF THIS AGREEMENT AND SHALL BE VALID AND BINDING EVEN IF ANY REMEDY IS DEEMED TO FAIL OF ITS ESSENTIAL PURPOSE. EACH OF THE PARTIES IS PROVIDING THE CONFIDENTIAL INFORMATION AND DELIVERABLES AND OTHER WORK PRODUCT TO THE OTHER PARTY UNDER THIS AGREEMENT "AS IS" WITHOUT ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE USEFULNESS, ACCURACY, NON-INFRINGEMENT OR COMPLETENESS THEREOF.

7. **MISCELLANEOUS.**

7.1 Default. Following the successful development of the Product under the Program, Entegris shall supply the polymer systems of the Product to Collect in amounts and price/profit margin that shall be agreed between the Parties at such time. If Entegris defaults on this obligation, Collect may find an alternate party for manufacturing the polymer systems in which case Entegris would receive a royalty of five percent (5%) of the Product final sales, payable by Collect on a quarterly basis, until the aggregate amount payable hereunder is equal to the amounts paid by Entegris on account of the Collaboration and Exclusivity Payment. If mutually agreed, Entegris or its supply chain partners may manufacture the Product in addition to the polymer systems.

7.2 Terms and Conditions of Sale. The supply of polymer systems of the Product and of any other products sold to Collect shall be upon the commercial terms and conditions specified on Appendix A attached hereto, which terms and conditions shall prevail over any inconsistent or conflicting terms which may be set forth on purchase orders or other forms.

7.3 Governing Law. This Agreement shall be governed and interpreted for all purposes by the laws of England and Wales, without giving effect to any conflict of laws principles that would require the application of the laws of a different jurisdiction, and with respect to the intellectual property matters contained herein, in accordance with the federal patent statute and other intellectual property laws of the USA. Notwithstanding the foregoing, questions affecting the construction and effect of any patent claim shall be determined by the law of the country in which the patent shall have, been granted.

7.4 Notices. All notices under this Agreement shall be in writing, and shall be delivered personally, by certified mail or via express courier service, return receipt requested. Notice shall be directed to the addresses set forth below the signature block, and shall be deemed effective upon receipt (or if delivery is refused, on the date of such refusal). Either Party may change its address for notices from time to time by providing written notice of such change to the other Party.

7.5 Assignment. Neither Party may assign or otherwise transfer this Agreement or delegate any of its rights or obligations hereunder, in whole or in part, by operation of law or otherwise, without the prior written consent of the other Party. Any attempted assignment, delegation or transfer in violation of the foregoing shall be null and void from the beginning and without effect. Notwithstanding the foregoing, either Party may assign this Agreement, without the prior consent of the other Party, to an Affiliate. For the purposes of this provision, any form of Change in Control of a Party shall be deemed an impermissible transfer, whether or not such Change in Control would otherwise be deemed a transfer under applicable law, and shall be null and void from the beginning and without effect.

7.6 Equitable Relief. Each Party acknowledges, on behalf of itself and its Affiliates, that a Party's breach of its confidentiality obligations under Section 5 would cause irreparable harm to the other Party, the extent of which is difficult to quantify, and that monetary damages would of be an adequate remedy for such breach. Therefore, in addition to recovery of monetary damage and all other rights and remedies available at law or in equity, in the event of any such breach by a Party, the other Party shall be entitled to seek injunctive and other equitable relief in any court of competent jurisdiction, without the necessity for posting bond or first proving actual damages.

7.7 Relationship. The Parties hereto are independent contractors and each will conduct its business hereunder as a principal for its own account. Nothing in this Agreement shall create any agency, employment, partnership, fiduciary or joint venture relationship between the Parties. Neither Party is or shall be construed to be an employee of the other Party under the meaning or application of any applicable law. Neither Party shall have, nor shall it represent to any third party that it has, the power or authority to represent, act for, bind or otherwise create or assume any obligation for or on behalf of the other Party.

7.8 Amendment; Waiver. No amendment to or waiver of the provisions of this Agreement shall be effective unless in writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party. Any waiver on one occasion shall not constitute a waiver of any other or subsequent duty or breach.

7.9 Severability. If any provision of this Agreement is determined to be invalid or unenforceable under applicable law, the provision shall be amended and interpreted by a court of competent jurisdiction to accomplish the objectives of such provision to the greatest extent possible under applicable law, and the remaining provisions of this Agreement shall continue in full force and effect.

7.10 Construction. The Section headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement. The term “including” as used herein means “including without limitation.” The terms “herein” and “hereunder” refer to this Agreement as a whole, rather than to any particular Section.

7.11 Entire Agreement. This Agreement, including all of the Exhibits and Appendices and each Statement of Work that is entered into between the Parties sets forth the entire agreement of the parties with regard to the subject matter hereof, and supersedes all prior and contemporaneous negotiations and agreements, written or oral. For the avoidance of doubt, this Agreement is not intended and shall not be construed to rescind the Mutual Confidentiality Agreement. The terms of this Agreement shall govern any Confidential Information disclosed pursuant to this Agreement, and the Mutual Confidentiality Agreement shall continue to govern Confidential Information (as defined therein) that was disclosed prior to the Effective Date under the Mutual Confidentiality Agreement. This Agreement, and any amendment hereto or waiver hereof, may be signed in counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument. Any signature may be delivered by facsimile or .pdf, which shall have the same effect as an original signature.

[The Next Page Is The Signature Page]

IN WITNESS WHEREOF, the Parties, intending to be legally bound, have executed this Joint Product Development Agreement as of the Effective Date by the undersigned duly authorized representatives.

Cellect Biomed Ltd.

Entegris, Inc.

By: /s/ Shai Yarkni
Name: Shai Yarkoni
Title: CEO

By: /s/ James O'Neil
Name: James O'Neil
Title: Chief Technology Officer

Address for Notices:
Cellect Biomed Ltd.
Attn:
10 Hataas Street
Kfar Saba
Israel

Address for Notices:
Entegris, Inc.
Attn: General Counsel
129 Concord Road
Billerica, MA 01821
United States of America

Exhibit A

Statement of Work

THIS STATEMENT OF WORK (“*Statement of Work*”) is entered into as of the [17] day of [June], 2015, between **Collect Biomed Ltd.** (“*Collect*”) and Entegris, Inc. (“*Entegris*”) pursuant and subject to the terms and conditions of that certain Joint Product Development Agreement (“*Agreement*”) dated as of [June 17th], 2015 between Collect and Entegris. The terms and conditions of the Agreement are incorporated herein by reference. All capitalized terms used in this Statement of Work but not otherwise defined herein shall have the meaning given to such terms in the Agreement.

The statement of work is attached as Attachment A (PDF).

IN WITNESS WHEREOF, the parties hereto have caused this Statement of Work to and year first above written.

Collect Biomed Ltd.

Entegris, Inc.

By: /s/ Shai Yarkoni
Name: _____
Title: _____

By: _____
Name: _____
Title: _____

Attachment A

ID	WBS	Task name	Duration	Start	Predecessors	2014	15	16	17	18
1	1	Design input - assess market needs	45 days	03/08/15						
2	1.1	Preliminary needs	5 days	03/08/15						
3	1.2	Get feedback from BMT technicians	20 days	10/08/15	2					
4	1.3	Prepare a design input document	20 days	07/09/15	3					
5	1.4	Preliminary needs document	0 days	02/10/15	4					
6	2	Design specification	21 days	05/10/15	1					
7	2.1	Preparation	21 days	05/10/15						
8	2.2	Design spec document	0 days	02/11/15	7					
9	3	Prepare a statutory strategy	40 days	03/11/15	6					
10	3.1	Regulatory strategy	40 days	03/11/15						
11	3.2	Sterilization plan	10 days	03/11/15						
12	3.3	Biocompatibility plan	10 days	03/11/15						
13	3.4	Shelf life plan	10 days	17/11/15	11					
14	3.5	Packaging & Labeling plan	10 days	03/11/15						
15	3.6	Document	0 days	28/12/15	10,11,12					
16	4	Preliminary design with a few alternatives	20 days	29/12/15	9					
17	4.1	Design alternatives	20 days	29/12/15						
18	4.2	Risk analysis	10 days	29/12/15						
19	4.3	Documents	0 days	25/01/16	17,18					
20	5	Preliminary manufacturing processes	30 days	26/01/16	16					
21	5.1	Preparation process plans	30 days	26/01/16						
22	5.2	Preliminary manufacturing processes document	0 days	07/03/16	21					
23	6	Define optimal binding method of Fast. to polystyrene	47 days	08/03/16	20					
24	6.1	Selecting a few binding methods	5 days	08/03/16						

H.S

Project: SOW_BIRD_130415
Date: 18/06/15

Task	Inactive Milestone	Finish-only
Split	Inactive Summary	External Tasks
Milestone	Manual Task	External Milestone
Summary	Duration-only	Deadline
Project Summary	Manual Summary Rollup	Progress
Inactive Task	Manual Summary	Manual Progress
	Start-only	

ID	WBS	Task name	Duration	Start	Predecessors
25	6.2	Production of selected polymer coated with binding methods	30 days	15/03/16	24
26	6.3	ELISA for binding	12 days	26/04/16	25
27	6.4	Cell assay for apoptosis	12 days	26/04/16	25
28	6.5	Binding method selected	0 days	11/05/16	27,26
29	7	Define the optimal polymer for binding Fast	55 days	12/05/16	23
30	7.1	Selecting 3 polymers	5 days	12/05/16	
31	7.2	Production of selected polymer coated with selected binding method	30 days	19/05/16	30
32	7.3	ELISA for binding	20 days	30/06/16	31
33	7.4	Cell assay for apoptosis	20 days	30/06/16	31
34	7.5	Polymer selected	0 days	27/07/16	32,33
35	8	Produce alpha prototype	195 day	29/12/15	
36	8.1	Production of CGMP FastL (subcontractor)	180 day	29/12/15	9
37	8.2	Production of bags	20 days	28/07/16	29
38	8.3	Attachment of FastL	15 days	06/09/16	37,36
39	8.4	Ready prototype	0 days	26/09/16	38
40	9	Verification bench testing of alpha prototype	45 days	27/09/16	35
41	9.1	Bench tests - preliminary in vitro studies	30 days	27/09/16	
42	9.2	Preliminary sterilization study	14 days	27/09/16	
43	9.3	Preliminary biocompatibility study	45 days	27/09/16	
44	9.4	Preliminary shelf life study	30 days	27/09/16	
45	9.5	Preliminary animal study	45 days	27/09/16	
46	9.6	Verification ended	0 days	28/11/16	41,42,43

Project: SOW_BIRD_130415
Date: 18/06/15

Task	Inactive Milestone	Finish-only
Split	Inactive Summary	External Tasks
Milestone	Manual Task	External Milestone
Summary	Duration-only	Deadline
Project Summary	Manual Summary Rollup	Progress
Inactive Task	Manual Summary	Manual Progress
	Start-only	קריטי

ID	WBS	Task name	Duration	Start	Predecessor	2014	'14	'15	'16	'17	'18
47	10	Produce and test a beta prototype	140 day	29/11/16	40						
48	10.1	Sterilization studies	105 day	29/11/16							
49	10.1.1	Develop protocol	5 days	29/11/16							
50	10.1.2	Execute and test sterilization	90 days	06/12/16	49						
51	10.1.3	Sterilization validation report	10 days	11/04/17	50						
52	10.1.4	Sterilization milestone	0 days	24/04/17	51					24/04	
53	10.2	Biocompatibility studies	90 days	29/11/16	42						
54	10.3	Packaging studies	90 days	29/11/16	42						
55	10.4	shelf life studies	140 day	29/11/16							
56	10.4.1	Time "0" baseline	21 days	04/04/17	54						
57	10.4.2	T1 accelerated	50 days	29/11/16							
58	10.4.3	Packaging integrity and Efficacy test	20 days	07/02/17	57						
59	10.4.4	T1 realtime	120 day	29/11/16							
60	10.4.5	Packaging integrity and Efficacy test	20 days	16/05/17	59						
61	10.4.6	Bench tests - in vitro studies	50 days	29/11/16							
62	10.4.7	Animal studies	90 days	29/11/16							
63	11	Develop Batch release criteria	15 days	13/06/17	47						
64	11.1	Cell assay for apoptosis	15 days	13/06/17							
65	12	Production of a clinical batch	95 days	04/04/17							
66	12.1	Technology transfer & prep for subcontractor	60 days	04/04/17	54						
67	12.1	Bag production	20 days	04/07/17	63						
68	12.2	FasL attachment	10 days	01/08/17	66,67						
69	12.3	Clinical batch	0 days	14/08/17	68,67					14/08	

Project: SOW_BIRD_130415
Date: 18/06/15

פינול קריטי	Inactive Milestone	Finish-only
Task	Inactive Summary	External Tasks
Split	Manual Task	External Milestone
Milestone	Duration-only	Deadline
Summary	Manual Summary Rollup	Progress
Project Summary	Manual Summary	Manual Progress
Inactive Task	Start-only	קריטי

Appendix A

Entegris Standard Sales Terms and Conditions

These Terms and Conditions May Change

Entegris reserves the right to update or modify these Terms and Conditions at any time without prior notice.

Governing Terms

All products and services offered for sale by Entegris, Inc. ("Entegris") are sold subject to the terms and conditions stated herein. These terms and conditions shall apply to the sale of the products and/or services described in the Entegris Quotation Sales Order, Invoice, or other contract documentation to which these terms and conditions are attached or incorporated by reference. Except as expressly agreed by an authorized representative of Entegris in writing, no other terms and conditions, including any terms and conditions attached to, or contained within, Buyer's request for quotation, acknowledgment, purchase order or other contract documentation shall apply. Buyer's acceptance of the products or services delivered by Entegris shall constitute an affirmation by Buyer that the terms and conditions set forth herein govern the purchase and sale of the goods or services. **THE TERMS OF THESE TERMS AND CONDITIONS SHALL SUPERSEDE ANY ADDITIONAL, DIFFERENT OR CONFLICTING TERMS PROPOSED BY BUYER OR CONTAINED ON BUYER'S PURCHASE ORDER OR ANY DOCUMENT OR INSTRUMENT SUBMITTED BY BUYER.**

Prices, Taxes and Payment

All prices are firm unless otherwise agreed to in writing. Entegris reserves the right to change the prices and specifications of its products at any time without notice. Any tax, duty, custom or other fee of any nature imposed upon this transaction by any federal, state or local governmental authority shall be paid by Buyer in addition to the price quoted or invoiced. In the event Entegris is required to prepay any such tax, Buyer will reimburse Entegris. Payment terms shall be net 30 days after shipment by Entegris. An interest charge equal to 1½% per month (18% per year) will be added to invoices outstanding beyond 30 days after shipment. In addition Entegris reserves the right to require pre-paid payment terms from any Buyer whose account is overdue for a period of more than 60 days or who has an unsatisfactory credit or payment record. Entegris may also refuse to sell to any person until overdue accounts are paid in full.

Delivery and Shipment

Entegris will make every effort to ship the products or provide the services hereunder in accordance with the requested delivery date, provided that Entegris accepts no liability for any losses or for general, special or consequential damages arising out of delays in delivery. All shipment costs shall be paid by Buyer, and if prepaid by Entegris, the amount thereof shall be reimbursed to Entegris.

Title

Title to the products shall remain with Entegris until the occurrence of the following events: a) when the point of origin of the shipment is within the country of destination, upon the shipment of the products from the Entegris facility; b) when the point of origin of the shipment is not within the country of destination, upon the arrival of the products at the Port of Entry of the destination country.

Risk of Loss

The risk of loss or damage to the products shall be assumed by Buyer upon the occurrence of the following events: a) when the point of origin of the shipment is within the country of destination, upon the shipment of the products from the Entegris facility; b) when the point of origin of the shipment is not within the country of destination, upon the arrival of the products at the Port of Entry of the destination country.

Inspection

Buyer shall be responsible for inspecting all products shipped hereunder prior to acceptance, provided, that if, Buyer shall not have given Entegris written notice of rejection within 30 days following shipment to Buyer, the products shall be deemed to have been accepted by Buyer.

Disclaimer of Express and Implied Warranties

The products shall be covered by the applicable Entegris standard warranty. **NO OTHER EXPRESS OR IMPLIED WARRANTY IS MADE WITH RESPECT TO THE PRODUCTS. ENTEGRIS EXPRESSLY EXCLUDES THE IMPLIED WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE.** Any model or sample furnished to the Buyer is merely illustrative of the general type and quality of goods and does not represent that the products will conform to the model or sample. Buyer's remedies under Entegris' warranty shall be limited to repair or replacement of the product or component thereof which failed to conform to Entegris' warranty.

Returned Goods

No products shipped under these Terms and Conditions may be returned without the express prior authorization of Entegris. All returns of products are subject to a restocking charge. No returns will be authorized after 60 days following shipment to Buyer.

Technical Advice

Entegris may, at Buyer's request, furnish technical assistance, advice and information with respect to the products, if and to the extent that such advice, assistance and information is conveniently available. It is expressly agreed that there is no obligation to provide such information which is provided without charge at the Buyer's risk, and which is provided subject to the disclaimers set forth in paragraph 7 above.

Agents, etc.

No agent, employee or other representative has the right to modify or expand Entegris' standard warranty applicable to the product(s) or to make any representations as to the product(s) other than those set forth in Entegris' product literature and any such affirmation, representation or warranty, if made, should not be relied upon by Buyer and shall not form a part of these Terms and Conditions.

Exports

Buyer represents that it will not knowingly export, either directly or indirectly, any product or service to any country for which approval is required, without the prior written approval of the office of Export Administration of the U.S. Dept. of Commerce or any other applicable U.S. Government Agency.

Equal Employment Opportunity

Entegris is an Equal Opportunity Employer. It does not discriminate in any phase of the employment process against any person because of race, color, creed, religion, national origin, sex, age, veteran or handicapped status. The Entegris Equal Opportunity Certificate, which is mailed annually to all vendors and vendees, is incorporated into this contract by reference.

Modifications, Waiver, Termination

This Contract may be modified, and any breach hereunder may be waived only by a writing signed by the party against whom enforcement thereof is sought.

Governing Law

This Contract shall be governed by and construed in accordance with the laws (other than those relating to conflict of laws questions) of the State of Delaware. The United Nations Convention on Contracts for the International sale of Goods shall not apply to these Terms and Conditions, and is hereby specifically excluded.

Arbitration

Any and all disputes or controversies arising under, out of or in connection with these terms and Conditions or the sale or performance of the products or services shall be resolved by final and binding arbitration in Boston, Massachusetts under the rules of the American Arbitration Association then obtaining. The arbitrators shall have no power to add to, subtract from or modify any of the terms or conditions of these Terms and Conditions. Any award rendered in such arbitration may be enforced by either party in either the courts of the Commonwealth of Massachusetts or in the United States District Court for the Eastern District of Massachusetts, to whose jurisdiction for such purposes Entegris and Buyer each hereby irrevocably consent and submit.

Limitation Of Liability

In no event shall Entegris (including its affiliates and subsidiaries) be liable for anticipated or lost profits or for special, punitive, indirect, incidental, or consequential damages. Entegris' total liability on any claim of any kind for any loss or damage whatsoever arising out of or in connection with or resulting from these Terms and Conditions or from the performance or breach thereof shall in no case exceed the price allocable to the products or services or units thereof which gives rise to the claim.

Assignment

Buyer shall not assign its rights or its obligations under these Terms and Conditions without the written consent of Entegris.

Cancellation Prior to Shipment

In the event Buyer requests that an order for products or services which it has placed with Entegris be cancelled prior to shipment, and with which request Entegris agrees, Buyer shall be liable to Entegris for all costs incurred by Entegris as a result of such cancellation, including but not limited to, cancellation costs to suppliers and unreimbursed advances on goods, if any, together with any specifically identifiable incidental and consequential expenses.

Performance

Unless otherwise agreed to in writing, Entegris reserves the right to make design changes which Entegris believes will improve its products. Entegris may also satisfy customer purchase orders by shipping 90-105% of ordered quantities for nonstandard products depending on actual yield from such nonstandard product runs. Entegris shall only charge Buyer for actual quantities shipped. Entegris' performance shall be excused in the event of strikes, accidents, fires, unavailability of materials and all other causes beyond the control of Entegris.

Tool Ownership

All tools, dies, and patterns produced by or at the request of Entegris, or otherwise utilized by Entegris in the production of any products sold to Buyer, shall remain the exclusive property of Entegris. Entegris reserves the right to advertise and/or sell any of the foregoing items and any of its products produced therewith, unless otherwise specifically agreed to in writing by an authorized representative of Entegris.

General Provisions

The failure of Entegris to enforce at any time any of the provisions of these Terms and Conditions, to exercise any election or option provided herein, or to require at any time performance by Buyer of any of the provisions herewith shall in no way be construed to be a waiver of any such provisions, or the right of Entegris thereafter to enforce each and every such provision. These Terms and Conditions contains the complete and exclusive statement of the agreement between the parties in connection with the subject products and/or services and supersedes any previous understandings, communications, commitments, or agreements, oral or written. Buyer warrants that it has not offered or given and will not offer or give to any employee, agent or representative of Entegris any gratuity with a view toward influencing such person with respect to the terms, conditions or performance of these Terms and Conditions or any contracts with Entegris. Entegris and Buyer are independent contractors: neither is an agent or employee of the other or has any authority to assume or create any obligation or liability of any kind on behalf of the other. Any provision of these Terms and Conditions that is invalid or unenforceable under applicable laws with respect to a particular party or circumstance will be severed from this Contract with respect to such party or circumstance without invalidating the remainder of these Terms and Conditions or the application of such provision to other persons or circumstances. The headings used in these Terms and Conditions have no legal effect.

Subsidiaries of Collect Biomed Ltd.

Collect Biotechnology Ltd. – Incorporated in the State of Israel
